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GENERAL INTRODUCTION 
INTRODUCTION  
Oral and Maxillofacial Surgery and its branches 
Oral and Maxillofacial surgery is a multidisciplinary field involving plastic, orthopaedic, 
general, ENT and neurosurgery. It deals with minor and major surgeries including simple and 
complicated extractions of teeth, treatment of cysts and tumours, management of maxillary 
sinuses disorders or traumatic injuries of orofacial soft and hard tissues, temporomandibular 
joint disorders, salivary gland diseases, dentofacial deformities and infections, pre-prosthetic 
surgical procedures, reconstruction of soft and hard tissues defects and management of facial 
neuropathy [1].  
Type of defects in Oral and Maxillofacial Surgery 
Severe maxillofacial bone defects secondary to trauma, congenital anomalies, ischemic 
diseases as osteoradionecrosis, infectious diseases as osteomyelitis, tumours, surgical 
resection or cranioplasty, odontogenic cysts lead to aesthetic deformities and functional 
damage greatly influencing the quality of life of patients with psychological consequences. 
These defects may vary from few millimetres to critical-sized large segmental defects. The 
vast majority of the small defects heal spontaneously under suitable physiological 
environmental conditions due to the regeneration ability of bone. However, the healing 
process of bone defect is slow and time consuming. Large defects are difficult to heal due to 
the size of defects or unstable biomechanical properties, unfavourable wound environment, 
suboptimal surgical technique, metabolic factors, hormones, nutrition and applied stress 
resulting in complex three-dimensional structure difficult to restore complicated with the 
absence of the overlying periosteum and soft tissues [2-5]. 
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Reconstruction of maxillofacial bone defects 
Reconstruction of maxillofacial bone defects is challenging for the oral and maxillofacial 
surgeons due to the potential exposure of grafted tissue to infection complicated by the direct 
contact with the mouth, sinuses, nasal passages and external environment characterized by 
high moisture content, significant bacterial populations and physiological functional loads as 
chewing. In addition to contaminated wound sites, tissue constructs may be exposed to 
complicated mechanical loads [6, 7]. 
The standard approaches widely used for reconstructive surgery including distraction 
osteogenesis or bone grafts [8] have significant limitations as shortage of availability, donor 
site morbidity, post-operative pain, hypersensitivity, infection, inflammation and resorption of 
the implanted bone. Although alternatives as the use of allografts or synthetic grafting 
materials overcome these limitations, both alternatives are also limited by immunorejection or 
lack of osteoinduction [9]. 
Exposed bone as a problem faced by Oral and Maxillofacial (OMFS) Clinicians  
One of the most common problems OMFS clinicians face is the presence of exposed necrotic 
bone in the oral cavity. Various pathological conditions have been attributed to this condition 
as osteomyelitis (OM), osteoradionecrosis (ORN), medication-related osteonecrosis of the 
jaws (MRONJ) which are presented with similar signs, symptoms and radiographic findings. 
However, each condition is a separate entity with different treatment approaches [10]. 
Osteomyelitis as a common infection of the maxillofacial region 
Osteomyelitis of the jaw is one of the most important oral and maxillofacial severe bone 
infections. It is a debilitating disease [11] with severe bone infection leading to dysfunction, 
progressive inflammatory destruction, [12] marked bone resorption at sites of infection and 
proximal abnormal bone formation [13]. It occurs more frequently in the mandible than in the 
maxilla originating from dental infection of root canal, periodontal ligament or extraction of a 
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tooth, fracture site, soft tissue wound or surgical site [14]. Many mechanisms of bone loss in 
osteomyelitis have been proposed in the literature [15-17]. During infection, localized pH 
reduction is manifested [18] with accumulation of an inflammatory exudate causing 
compression of the blood supply to the bone. Necrotic tissue promotes the proliferation of 
bacteria resulting in incomplete healing [19]. Furthermore, increased formation and activity of 
osteoclasts is noticed and elimination of osteoblasts responsible for new bone matrix 
deposition [20]. 
Some studies have proved that bacteria, such as, staphylococcus aureus create an acidic 
environment during proliferation under static culture conditions attributed to the metabolic 
production of acidic substances like lactic acid [21]. Secondly, the human immune system is 
notable for its ability to combat infectious microorganism by eliciting inflammatory responses 
[22]. During this process, local acidosis occurs due to massive infiltration of neutrophils and 
macrophages [23] to the site of infection. These pathological conditions can decrease the pH 
to 5.5–7.0 [24]. Infection interferes with the process of bone healing and regeneration by 
excessive bone resorption as well as impaired bone formation [25, 26]. 
Medication-related osteonecrosis of jaw (MRONJ) as an emerging disease 
Recently, another common disease associated with exposed necrotic bone is medication-
related osteonecrosis of the jaw (MRONJ). It is a devastating complication of anti-resorptive 
(ARD) drugs used globally to treat bone disorders as osteoporosis, skeletal complications 
associated with osseous metastasis and multiple myeloma [27, 28]. The American Association 
of Oral and Maxillofacial Surgeons (AAOMS) had changed the nomenclature of 
bisphosphonate-related osteonecrosis of the jaw (BRONJ) to medication-related osteonecrosis 
of the jaw (MRONJ) due to the rise in the number of osteonecrosis cases involving the 
maxilla and mandible associated with other anti-resorptive (Denosumab) and antiangiogenic 
therapies [29]. Multiple factors had played role in MRONJ pathogenesis. However, none of 
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them had been proved to be the exclusive reason. Some main theories had been proposed for 
MRONJ as over-suppression of bone turnover rate, anti-angiogenic properties of ARD 
leading to necrosis, constant micro-trauma, soft tissue toxicity and inflammation or infection. 
However, the presence of infection was almost always an initiating role rather than bone 
turnover [30, 31]. 
The unique structure of the maxillofacial region and certain bacterial infection has been 
suggested as key factors for the pathogenesis and progression of MRONJ. The oral cavity 
comprises of more than 750 bacterial species existing as mixed biofilm communities [32]. 
The mandible and maxilla are covered by thin layer of mucosa in close proximity to the 
external environment. After invasive dental procedures, oral trauma or soft tissue infection, 
microbial biofilms in the mouth and saliva gain access to the exposed jaw bone and play a 
significant role in the necrosis of the bone, inhibition of oral wound healing and facilitating 
bacterial colonization on bone surface [33, 34]. 
Management of exposed necrotic bone 
Management of exposed necrotic bone is controversial and difficult to perform due to the 
increased potential of bacterial adhesion to the exposed surface with high risk of resistance to 
the antibiotics. For decades, classical methods for treatment of necrotic bone have been used 
ranging from simple treatment as administration of antibiotics, oral antibacterial mouth rinses, 
pain control, surgical debridement and removal of sequestrum to aggressive surgical 
interventions as debridement of large area of bone to include a segmental mandibulectomy 
and partial maxillectomy, mandibular reconstruction and covering the exposed areas with 
tissue flaps. However, new treatments have been studied recently as therapeutic tools as 
hyperbaric oxygen (HBO), fluorescence-guided bone surgery, low-intensity laser therapy and 
the use of ozone in combination with antibiotics and surgery [35, 36]. 
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Tissue engineering paradigm in Maxillofacial Surgery 
A new paradigm is emerging in the field of oral and maxillofacial surgery in the recent years 
due to the advances in technology in both materials and methods used had led to refining the 
surgical procedures and achieving precision with minimally invasive techniques. In the 
maxillofacial region, nearly all disorders have become research subjects of regenerative 
medicine which is considered to be advantageous because the weight load is smaller than in 
the long bones and the amount of tissue needed for reconstruction is generally small with its 
increasing ability to replace, repair or regenerate damaged and injured tissues and restore their 
physiological function by means of stem cell-based technologies [37, 38]. 
Bone tissue engineering raised as an alternative to the conventional surgical techniques to 
regenerate oral and maxillofacial defects by combining the principles of orthopaedic surgery 
with knowledge from biology, physics, materials science and engineering [8, 39]. As tissue 
engineering becomes more of a clinical reality through the ongoing bench to bedside 
transition, nowadays, research in this field focus on addressing relevant clinical situations. 
While most in-vivo work in the area of bone tissue engineering focuses on bone regeneration 
within sterile, surgically created defects, there is a growing need for investigation of bone 
tissue engineering approaches within contaminated or scarred wound beds, such as those that 
may be encountered following traumatic injury or during delayed reconstruction/regeneration 
[40]. 
Gene therapy as a recent therapeutic technique in Maxillofacial Surgery 
Recently, progress of genome sciences and molecular biology has enabled to analyse 
biological phenomena genetically and promote basic research of gene biology and medicine 
in which genes can be used as a medicine by curing a wide range of serious diseases or 
healing of defects [41, 42]. Gene therapy has emerged as a new and promising tool for 
delivery of additional gene or removal of defective gene for the purposes of treating a disease 
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process or regenerating tissues and hence the improvement of the clinical status of the patient 
[43-45]. 
In contrast to traditional replacement gene therapy, craniofacial regeneration via gene therapy 
has been somewhat different in seeking to transfer the gene encoding desired growth factor or 
recombinant protein into cells for osteoinduction, tissue growth and repair [46]. This 
application of gene therapy does not replace a defective gene but rather delivers specific 
genetic information to cells to start synthesis and secretion of a gene product resulting in 
higher and more constant levels of protein production for gene therapy-directed osteogenesis. 
Since the effect is within a local environment for craniofacial bone regeneration, systemic 
administration is not necessary [2].  
General Introduction 
Page 7 
OBJECTIVES OF THE THESIS 
The main objectives of this thesis were to: 
1) Determine the effect of pH on viability and proliferation of human mesenchymal stem 
cells (hMSCs) and investigate the role of the pH on hMSCs mediated osteogenesis, 
expression of osteoblast markers and matrix mineralization that may contribute for 
understanding how changing pH modulates biological and biochemical processes 
during bone healing in osteomyelitis. 
2) Examine the success rate of fluorescence-guided surgery in MRONJ patients in terms 
of postoperative mucosal integrity and absence of bone exposure with monitoring 
pain, infection rates as well as disturbances of sensitivity. 
3) Identify the bacterial profiles that colonize MRONJ bone samples determined by 
polymerase chain reactions (PCR) and culture approach with clinical features of 
patients. This line of investigation could provide rationale in the future for MRONJ 
therapeutics and targeted antimicrobial therapy. 
4) Determine the treatment strategies available for BRONJ by performing a systematic 
review describing the outcome variables measured for each treatment modality and the 
success of the treatment expressed by the outcome. 
5) Outline the efforts done in gene therapy worldwide in the field of oral and 
maxillofacial surgery by conducting a systematic review and meta-analysis. 
6) Address the pathogenesis of anti-resorptive drug-related osteonecrosis of the jaw. 
7) Determine the new and innovative treatment strategies for medication-related 
osteonecrosis of the jaw. 
 
 
 
Publication I:MSCs and pH 
Page 8 
1. PUBLICATION I 
MESENCHYMAL STEM CELLS (MSCS) PROLIFERATION AND 
MINERALIZATION BUT NOT OSTEOGENIC DIFFERENTIATION ARE 
STRONGLY AFFECTED BY EXTRACELLULAR PH. 
Riham Fliefel, Cvetan Popov, Matthias Tröltzsch, Jan Kühnisch, Michael 
Ehrenfeld, Sven Otto. J of Craniomaxillofacial Surgery 2016;44(6):715–24. 
ABSTRACT  
Background: Osteomyelitis is a serious complication in oral and maxillofacial surgery 
affecting bone healing. Bone remodelling is not only controlled by cellular components but 
also by ionic and molecular composition of the extracellular fluids in which calcium 
phosphate salts are precipitated in a pH dependent manner. Objective: To determine the effect 
of pH on self-renewal, osteogenic differentiation and matrix mineralization of mesenchymal 
stem cells (MSCs). Methods: We selected three different pH values; acidic (6.3, 6.7), 
physiological (7.0-8.0) and severe alkaline (8.5). MSCs were cultured at different pH ranges, 
cell viability measured by WST-1, apoptosis detected by JC-1, senescence was analysed by β-
galactosidase whereas mineralization was detected by Alizarin Red and osteogenic 
differentiation analysed by Real-time PCR. Results: Self-renewal was affected by pH as well 
as matrix mineralization in which pH other than physiologic inhibited the deposition of 
extracellular matrix but did not affect MSCs differentiation as osteoblast markers were 
upregulated. The expression of osteocalcin and alkaline phosphatase activity was upregulated 
whereas osteopontin was downregulated under acidic pH. Conclusion: pH affected MSCs 
self-renewal and mineralization without influencing osteogenic differentiation. Thus, future 
therapies, based on shifting acid-base balance toward the alkaline direction might be 
beneficial for prevention or treatment of osteomyelitis  
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INTRODUCTION 
Osteomyelitis (OM) of the jaw is a debilitating disease [11] in which severe bone infection 
leads to dysfunction, progressive inflammatory destruction, marked bone resorption at sites of 
infection and abnormal bone formation [12, 13]. It occurs more frequently in the mandible 
than in the maxilla [14] with staphylococcus aureus creating an acidic environment decreasing 
the pH to 5.5–7.0 [24] caused by massive infiltration of neutrophils and macrophages [18, 19, 
21, 23, 47, 48]. It is well known that infection and inflammation interfere with the process of 
bone healing and regeneration by excessive bone resorption as well as impaired bone 
formation by activation of several cell populations producing inflammatory cytokines having 
an impact on bone remodelling [25, 26, 49, 50]. 
Bone remodelling is not only controlled by osteoblasts and osteoclasts [51] but also by the 
ionic and molecular composition of the extracellular fluids in which calcium phosphate salts 
are precipitated in a pH dependent manner [52-54]. Osteoblasts are the most affected cells by 
pH and acidity of the extracellular microenvironment [52, 55-57]. On a cellular level, even 
modest reduction in extracellular pH have an effect on osteoblast mineralization and energy 
metabolism as it was suggested that changes in acid-base balance in the extracellular 
microenvironment can direct bone formation and resorption [52, 55, 58, 59]. It was shown 
that alkaline pH enhance mineralization of osteoblasts and decrease the activity of osteoclasts 
while acidic surroundings can activate osteoclasts as well as impair osteoblast differentiation 
and in severe cases can cause osteoblast death [60-62]. 
MSCs are adult stem cells originating from the mesoderm possessing self-renewal ability and 
multi-lineage differentiation into mesoderm lineages, as chondrocytes, osteocytes and 
adipocytes, also ectodermic cells and endodermic cells [63] and existing in almost all tissues 
including bone marrow, adipose tissue, synovium, periosteum, perichondrium as well as 
cartilage [64]. They have the ability to migrate into sites of injury releasing trophic and 
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growth factors and differentiated towards terminally-committed cells making them prime 
candidates for use in regenerative medicine [65-69]. Recently, MSCs showed great potential 
in clinical practice upon activation by biological or pharmacological means leading to 
improvement in bone healing by modulating their differentiation into osteoblasts [70, 71]. The 
chemical and physical environment of MSCs has a strong influence on their behaviour in 
which matrix acidity is a crucial factor [72, 73]. The effect of the pH of the tissue 
microenvironment on bone mineralization and repair has been previously reported [74-76]. 
However, the insight into the mechanism underlying pH-related destruction of bone in 
osteomyelitis and osteogenic differentiation of human mesenchymal stem cells under various 
pH conditions have not been discussed. As tissue engineering becomes more of a clinical 
reality through the ongoing bench to bedside transition, research in this field must focus on 
addressing relevant clinical situations. While most in vivo work in the area of bone tissue 
engineering focuses on bone regeneration within sterile, surgically created defects, there is a 
growing need for investigation of bone tissue engineering approaches within contaminated or 
scarred wound beds, such as those that may be encountered following traumatic injury or 
during delayed reconstruction/regeneration [40]. Our study is novel and of importance when 
considering bone infections as it might be used in future clinical applications for prevention 
and treatment of some bone infections or diseases. It explains what happens in bone 
microenvironment during pH changes which could be a key study not only for bone 
infection/disease but also adds an important facet to the linkage between pH and other hard 
tissues mineralization. Thus, in the present study, we aimed to 1) determine the effect of pH 
on viability and proliferation of hMSCs, 2) investigate the role of the pH on hMSCs mediated 
osteogenesis, expression of osteoblast markers and matrix mineralization that may contribute 
for understanding how changing pH modulates biological and biochemical processes during 
bone healing in osteomyelitis.  
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MATERIALS AND METHODS 
Cell culture 
All experiments were performed with commercially available human MSCs (hMSCs; Lonza, 
Basel, Switzerland). Cells were cultured in high glucose Dulbecco’s modified eagle medium 
(DMEM; Life Technologies, California, USA), supplemented with 10 % fetal bovine serum 
(FBS; Life Technologies, California, USA), 1% penicillin/streptomycin (GE Healthcare, 
Little Chalfont, UK) at 37°C in a humidified atmosphere of 5% CO2. Cells between passages 
5 and 10 were used from three donors for the experiments.  
Preparation of pH culture media 
The pH of the culture medium was adjusted to one of six values: 6.3, 6.7, 7.0, 7.4, 8.0 and 8.5 
by adding an appropriate amount of 6M HCl or 10M NaOH to the supplemented DMEM. 
Before resuspending the cells, the culture media were kept in the incubator for 24 hours under 
culture conditions to allow the desired pH value to equilibrate (CO2-dependent). After 
incubation, a small adjustment in pH was occasionally required to create the desired final pH. 
The pH was monitored with a pH meter (Mettler Toledo GmbH, Giessen, Germany). The pH 
media were filtered using a syringe driven through a 0.22 µm sterile filter and stored at 4°C to 
be used later. For pH experiments, normal medium was replaced with various pH media 24 
hours upon cell plating and was kept through the experiment. 
Self-renewal analysis and WST-1 assay 
Long-term cell growth was evaluated by calculation of increased cell number as described 
previously [77]. The effect of pH on hMSCs proliferation in monolayer culture was evaluated 
over a five day time course. Cells were plated into 35 mm dishes at a density of 3.0× 104 and 
incubated in different pH media. At each time point, cell yield was divided by the number of 
cells plated at the start of the experiment to obtain a fold-change in cell number. The 
experiment was repeated twice. 
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Cell viability was assessed with WST-1 assay (Roche Diagnostics, Risch-Rotkreuz, 
Switzerland) as previously described [78]. Cells were seeded at a density of 1.7 ×103 
cells/well in 96-well plates and incubated with different pH media for 3 days. The WST-1 was 
mixed with the fresh complete medium, added to the wells and incubated for 4 hours at 37°C 
in 5% CO2. WST-1 was quantified by measuring the absorbance at 450 nm using Multiskan 
FC microplate plate reader (Thermo Scientific, Massachusetts, USA). Each experiment was 
repeated at least twice with two different donors to obtain the mean values. 
JC-1 staining for apoptosis detection  
One of the hallmarks of apoptosis is mitochondrial disruption, which is characterized by 
changes in the mitochondrial membrane potential. These changes were detected by using the 
fluorescent dye 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylimidacarbocyanine iodide (JC-1; Life 
Technologies, California, USA), a membrane-permeable dye which accumulates in 
mitochondria in a membrane potential-dependent manner. To ascertain whether pH induced 
apoptosis, slides were coated with collagen, hMSCs (7.0 × 103 cell) were cultured in different 
pH media for 24 hours. They were stained with JC-1 at 37 °C for 60 min and Hoechst 33342 
(Thermo Scientific, Massachusetts, USA) was used as the counterstain [79]. Cells were 
mounted on slides and pictured with Axio-Observer.Z1 fluorescence microscope (Zeiss, 
Oberkochen, Germany). Positive control was cells treated with hydrogen peroxide for 5 
minutes and negative control was cells cultured in normal media.  
Detection and Quantification of Senescent Cells  
Senescence-associated β-galactosidase (SA β-Gal; Sigma Aldrich, Missouri, USA) staining 
was used to detect senescent cells as previously described [78]. Cells were seeded at a density 
of 3.0× 104 in 35 mm dishes and cultured at different pH media for 72 hours. Fresh staining 
mixture was added and incubated at 37 °C overnight. The cells were observed under Axiovert 
40 CFL microscope (Zeiss, Oberkochen, Germany). The percentage of blue cells expressing 
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β-galactosidase (senescent cells) was calculated. The proportion of cells positive for SA-βgal 
activity was determined by counting the number of blue cells in the total population.  
Osteogenic differentiation of hMSCs 
Osteogenic differentiation was performed [77]. Shortly, cells were counted and plated at 
density of 3.2 × 104 on 35 mm dishes. After 24 hrs, normal media were replaced with pH 
adjusted osteogenic media with cells being cultured for 21 days. The osteogenic media 
consisted of DMEM supplemented with 100 nM dexamethasone, 10 mM β-glycerophosphate 
and 150 μM ascorbic-2-phosphates (Sigma Aldrich, Missouri, USA). Media were changed 
twice per week. As a control, hMSCs were cultured at different pH media without osteogenic 
reagents.  
Alizarin red staining (ARS) was performed on day 21. Mineralized nodules were visualized 
and photographed with Axiovert 40 CFL microscope (Zeiss, Oberkochen, Germany). 
Osteogenic quantification kit was used for quantification of the staining (Merck Millipore, 
Darmstadt, Germany). The osteogenic differentiation was calculated versus standard curve 
and the absorbance was measured at 405 nm using Multiskan FC microplate reader plate 
reader (ThermoScientific, Massachusetts, USA). 
Alkaline Phosphatase (ALP) activity and mineralization 
The differentiation of cells to osteoblasts was evaluated as a function of ALP activity. The 
ALP assay was performed on day 0, 2, 5, 7, 10 and 14 of culture. For this, cells were seeded 
in 35 mm dishes and cultured at different pH media. The media were changed twice per week. 
ALP released from the cells was measured with a commercially available ALP assay kit 
(StemTAG; Cell Biolabs, California, USA). The amount of enzyme released by the cells was 
quantified by comparison with a standard curve. The experiment was repeated twice with two 
different donors. The enzyme activities expressed as nmol protein. 
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RT-PCR analysis of osteogenic genes  
RT-PCR was used to evaluate the osteogenic differentiation at different pH after 21 days. 
RNA was isolated as previously described [77] by QIAzol reagent (Qiagen, Hilden, 
Germany). RNA concentration and quality was analysed by NanoDrop (ThermoScientific, 
Massachusetts, USA). Reverse transcription of RNA into complementary DNA (cDNA) was 
done using Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland). RT-
PCR was used to analyse the expression of the osteogenic genes. The primers for the target 
genes used and PCR conditions are shown in Table  1.1. The gel electrophoresis was 
visualized and photographed using gel imager (Vilber Lourmat, Eberhardzell, Germany). 
Bands were quantitatively analysed by ImageJ (http://imagej.nih.gov/ij/). Gene expression 
was calculated as the ratio to the housekeeping gene (GAPDH). 
Table  1.1: Sequences of the PCR primers with the annealing temperatures and the 
expected sizes of the amplified products. 
Gene Name Primer Sequence (F, R, 5'-3') Tannealing (°C) Product  
size (bp) 
GAPDH Glyceraldehyde 3 phosphate 
dehydrogenase 
F: CAA CTA CAT GGT TTA CAT GTT C 
R: GCC AGT GGA CTC CAC GAC 
50°C 181 
RUNX2 Runt-related transcription 
factor 2 
F: TCT TCA CAAATC CTC CCC 
R: TGG ATT AAA AGG ACT TGG TG 
55°C 230 
OCN Osteocalcin F: GGC ACA AAG AAG CCG TAC TC 
R: CAC TGG GCA GAC AGT CAG AA 
56°C 242 
OPN Osteopontin F: CTG ATG AAC TGG TCA CTG ATT TTC 
R: CCG CTT ATA TAA TCT GGA CTG CTT 
60°C 347 
Col1α1 Collagen 1α 1 F: AGG GCT CCA ACG AGA TCG AGA TCC G 
R: TAC AGG AAG CAG ACA GGG CCA ACG TCG 
54°C  223 
 
 
Statistical Analysis  
All the experiments were repeated at least two times with 3 different donors each and the 
results were expressed as means ± standard deviations. Statistical analysis was performed by 
using GraphPad Prism (GraphPad, California, USA) using one way ANOVA, followed by 
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Tukey test to determine the statistical significance among the different groups. Levels of 
significance were indicated at *P < 0.05, **P < 0.01, ***P < 0.0001. 
RESULTS 
hMSCs self-renewal under different pH conditions  
First, we analysed self-renewal by examining the effect of pH on the cell proliferation and 
viability. For this, we cultured hMSCs in the six different pH conditions for 5 days. We found 
that the exposure of hMSCs to pH (6.3, 6.7 and 8.5) had a negative effect on proliferation 
capability in comparison to physiologic pH (7.0, 7.4 and 8.0 ) indicating that the latter pHs are 
optimal for cell growth (Figure  1.1A). Then we analysed cell activity by measuring the 
enzymatic catabolism of formazan to WST-1. Our results showed that similarly to 
proliferation, the viability of hMSCs was influenced by pH and more viable cells were 
observed at physiologic pH (7.0, 7.4 and 8.0) while cell viability at pH (6.3, 6.7 and 8.5) 
decreased (Figure  1.1B). 
These findings suggested that the physiological pH (7.0, 7.4 and 8.0) was suitable for hMSCs 
growth. Since the cell viability at pH 8.5 was severely decreased, this result indicated that 
alkaline environment up to a certain limit was advantageous for cell growth.  
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Figure  1.1: Effect of pH on proliferation and viability of hMSCs. 
A) Proliferation of human bone marrow stem cells (hMSCs) in different pH media 
from day 0 to day 5. hMSCs grown in pH (7.0, 7.4 and 8.0) showed the highest 
proliferation rate compared with those grown in pH (6.3, 6.7 and 8.5); B) Effect of 
pH on viability of hMSCs cultured at different pH for 3 days was measured at the 
indicated time points using WST-1 assay and expressed as optical density at 450 
nm (A450) as described in Materials and Methods. Error bars represent standard 
deviations (n=2). 
pH effect on hMSCs apoptosis and senescence 
Observing the fact that pH (6.3, 6.7 and 8.5) resulted in less self-renewal of hMSCs, we next 
investigated the reasons behind. We checked whether the cells had undergone apoptosis or 
senescence. Apoptosis was inspected using JC-1 staining that shows the loss of the 
mitochondrial membrane potential. In healthy cells, the dye stains the mitochondria bright red 
while in apoptotic cells, the mitochondrial membrane potential collapses and JC-1 stained the 
cells green. The results showed that cells cultured in different pH media appeared orange-red 
and the only green cells were the positive control suggesting that pH did not induce apoptosis 
in cells (Figure  1.2A). 
Besides, we tested if different pH triggered senescence. We found that treatment of hMSCs 
with different pH media for 3 days resulted in senescent cells in cultures. Cells incubated at 
pH (6.3, 6.7 and 8.5) appeared flattened and were more positive for β-gal staining while at 
physiologic pH (7.0, 7.4 and 8.0), cells maintained their spindle shape and only few stained 
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blue (Fig.2B). Quantification of β-gal staining demonstrated that the staining frequency of 
hMSCs was approximately 58% blue-positive at pH 6.3, 56% at pH 6.7 and 25% for pH 8.5. 
In contrast, the frequency for pH 7.0 was 30% whereas at pH 7.4, it was 18% and at pH 8.0, it 
was about 15% which nearly lacked detectable β-gal activity (Figure  1.2B). 
 
Figure  1.2: Apoptosis and Senescence of hMSCs at different pH. 
A) Morphological observation of JC-1 and Hoechst 33342 staining of 
cells treated at different pH examined with fluorescence microscope at 
10× magnification, scale bar represents 100 μm. The experiments 
were performed on two different donors. Cells at different pH 
appeared orange red while for positive control (hydrogen peroxide 
treated cells), showed strong green fluorescence and indicated typical 
apoptotic morphology; B) hMSCS senescence at different pH 
condition measured by SA ß-Gal activity assay. The nuclei of 
senescent cells are surrounded by cyan dye and a significant increase 
in cell size was detected at pH (6.3, 6.7 and 8.5). Staining was 
quantified by positive cell count. Error bars represent the means ± SD, 
n = 2; (P < 0.0001). 
Osteogenic differentiation of hMSCs and Mineralization Assay 
We performed osteogenic differentiation of hMSCs in different pH osteogenic media (OD) or 
control media. At day 21, alizarin red staining (ARS) confirmed osteogenic differentiation 
and matrix mineralization of hMSCs. Cells grown in OD exhibited red staining at pH (7.0, 7.4 
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and 8.0), among them pH 8.0 showed the strongest staining. At pH other than physiologic, the 
cells showed weaker or no mineralization (Figure  1.3A&B). 
 
Figure  1.3: Osteogenic differentiation of hMSCs and 
quantification of ARS. 
A) Osteogenic differentiation of hMSCs stained with 
ARS, scale bars represent 1 cm; B) Morphology of 
hMSCs grown in control or osteogenic medium (OD) at 
different pH (magnification 10×, scale bars = 100 µm). 
Cells were incubated for 21 days in DMEM containing 
10% FBS and observed under phase contrast 
microscope with ARS quantification. Osteogenic 
differentiation showed significant difference of the 
amount of soluble alizarin red. The average absorbance 
value at 405 nm. Error bars represent standard 
deviations (n=2) (P < 0.0001). 
Quantitative estimation of alkaline phosphatase (ALP) activity and RT-PCR of 
osteogenic genes 
In order to validate the defected mineralization under various pH conditions, we first 
investigated the changes in ALP activity. Our results showed no significant differences at 
different pH conditions at day 0, 2, 5 and 7. However, from day 10-14, ALP activity showed 
significant difference as its activity increased proportionally at lower pH (6.3 and 6.7) 
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(Figure  1.4A). Additionally, our RT-PCR analysis showed that all the important osteogenic 
markers were expressed by the cells in comparison to control media. From the assessed genes, 
pH media had an effect on OPN and OCN while Col1α1 and Runx2 was pH independent. 
OPN increased gradually with increasing the pH of the media till pH 8.0 and then down 
regulated at pH 8.5. The expression of OPN in osteogenic differentiated cells was always 
higher compared to control media. In contrast to OPN, OCN had an opposite correlation 
where pH (6.3 And 6.7) showed higher expression followed by pH 8.5 and then the 
physiologic pHs (Figure  1.4B).  
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Figure  1.4: ALP activity of osteogenic differentiated 
MSCs at different pH with expression level of bone-
related markers (OPN, OCN, Runx2 and Col1A1) in 
control and osteogenic media. 
A) ALP activity was measured during the course of 
osteogenic differentiation from day 0 to day 14 showing 
that it was inversely proportional to the pH: when the pH 
increased, the ALP activity increased and vice versa; B) 
RT-PCR data of OPN, OCN, Runx2 and Col1α1 
representative of 3 independent experiments from three 
different donors were combined together and analysed. 
Runx2 code for major osteogenic transcription factors; 
Col1α1 is an early marker of osteogenic differentiation; 
OCN and OPN are markers of late stages of 
osteogenesis. GAPDH was used as the control 
Housekeeping gene for this study. Graphs representing 
mean values of relative optical densities of PCR results 
are shown in the mRNA expression patterns of 
osteogenic marker genes in cells at day 21 and the results 
are expressed as the fold change relative to the respective 
control. 
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DISCUSSION 
In this study, we confirmed that hMSCs are sensitive to pH as their self-renewal and 
mineralization were significantly affected. Our study provides new insight into the 
mechanism underlying pH-related bone destruction and adds an important facet to the linkage 
between pH and bone infections which might be used clinically in the future to treat 
osteomyelitis of the jaw. We have selected the used pH values in accordance to their 
relevance in vivo as follows: pH 6.3-6.7 is common in infection [18] and in cultures with high 
cell numbers but limited nutrients [80]; pH 7.0-7.4 are commonly used conditions in cell 
culture [81] and typical value in blood stream [82]; pH 8.0-8.5 are recommended pH for 
stronger ability for production of osteocytes [83]. An in-vitro approach was used to disclose 
several clinical important questions: What is the effect of pH on self-renewal and 
differentiation; how can we make use of this knowledge to be directed for preventing or 
treating osteomyelitis of the jaw?  
Osteomyelitis is prevalent in the facial skeleton associated with abnormal bone remodelling 
and massive bone resorption. It also presents a major complication ensuing orthopaedic and 
maxillofacial surgeries as well as routine dental extractions [84]. There is increased formation 
and activity of osteoclasts in osteomyelitis together with the elimination of the osteoblasts 
responsible for new bone matrix deposition following infection [20]. Infection causes some 
essential changes in the extracellular milieu. On these occasions, the pH of the bone tissue 
environment often falls below pH 7.0, whereas in healthy tissues this pH value varies in the 
range 7.35 to 7.45 [85]. 
During early embryonic development, pH regulation is critical for cell metabolism, 
intracellular ionic signalling, differentiation, quiescence and proliferation [86, 87]. pH 
controlled self-renewal (proliferation and viability) as well as expression of extracellular 
matrix proteins not only in fibroblasts but also several cell types by affecting the cytoskeleton 
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and cell adhesion molecules in addition to arrested cell cycle at the G1 phase [88-90]. Our 
results demonstrated that changes of pH other than the physiologic can negatively influence 
cell proliferation and viability of MSCs which might be caused by several factors as apoptosis 
or senescence. 
It is not clear what determines whether cells undergo senescence or apoptosis. One 
determinant is cell type; for example, damaged fibroblasts and epithelial cells tend to senesce, 
whereas damaged lymphocytes tend to undergo apoptosis [91]. While it is well known that pH 
regulates many vital cell functions [92], the effect of pH on apoptotic signalling is poorly 
defined. Loss of the mitochondrial membrane potential is a hallmark of intrinsic apoptosis, 
because it is associated with the release of pro-apoptotic proteins into the cytosol [93]. Some 
studies demonstrated that severe extracellular acidification or alkalization induced pro-
apoptotic effect [94, 95] in addition others revealed a link between acidosis and apoptosis [96, 
97] while different study showed that pH had no effect on mitochondria-mediated apoptosis in 
hMSCs [98]. Even though viability test revealed a pH dependency, it was difficult to make 
conclusions about apoptotic processes. Comparing the apoptotic events in our experiment, we 
did not find increased apoptosis throughout the different pH conditions. It is possible that this 
may represent a time-dependent phenomenon and that 7 days or more may be required to 
observe an enhancement in hMSCs apoptosis. Cellular senescence occurs in response to 
various cellular stresses with the loss of proliferative capacity, despite continued viability and 
metabolic activity [99]. From our results, we saw that the strongest senescence occurred under 
the acidic pH (6.3 and 6.7). Taken together, we found that the effect of pH on proliferation or 
viability is modulated through increased senescence.  
MSCs are characterized not only by the capacity for self-renewal but also by the ability to 
differentiate into osteoblasts and deposition of matrix minerals in which pH plays a regulatory 
role in the process of mineralization and bone repair [52, 100]. Poor mineralization at alkaline 
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conditions beyond pH 8.0 affected the solubility of calcium and magnesium pyrophosphate 
with no longer beneficial effect on bone mineralization [101]. It was also suggested that acidic 
pH reduce bone mineralization via increased hydroxyapatite solubility and systemic alkali 
therapy can be used to treat osteomalacia and the bone pain associated with it [98, 102, 103]. 
The physicochemical mechanism play also role in matrix mineralization based on the fact that 
low pH decreases calcium and phosphate tissue deposition because it increases their solubility 
[53, 64]. The most effective ways to destroy the ability of the nucleation core to induce 
mineral formation is exposure to acidic citrate buffer [104]. Also the nucleation activity and 
core is operative only within a very narrow pH range between 7.4–7.8 [105]. Either below or 
above this range, its ability to nucleate mineral formation was very reduced but in the studies 
by Wu et al [106], the pH range in which rapid mineral formation occurred was broader (pH 
7.4– 8.0) indicating that at pH 8.0, the nucleation core is highly stable and insoluble. In 
accordance to this data, our results showed that a slight elevation in pH from 7.4 to 8.0 
significantly increases the mineralization and the rise of pH to 8.5 does not further drive 
differentiation. This implies that small pH fluctuations will facilitate bone formation by 
elevating the phosphate ratio at least in the very narrow pH zone where the nucleation core is 
operative, up to a maximum of pH 8.0. 
Since we have found defective mineralization at certain pH conditions, a question regarding 
the reason for the defective mineralization remained. It occurred due to impairment of 
osteogenic differentiation or due to the change in the extracellular environment. So we 
performed PCR to analyse the key osteogenic markers for differentiation and mineralization. 
From our results, PCR was different from the alizarin red staining where late markers of 
osteogenesis were expressed on the PCR with the lack of mineralization in the staining. 
Osteoblasts arise from mesenchymal stem cells and determine the formation and structural 
organization of bone extracellular matrix and its mineralization [107]. Alkaline phosphatase is 
Publication I:MSCs and pH 
Page 24 
synthesized by the osteoblasts and is presumed to be involved in the calcification of bone 
matrix [108]. Some researchers showed that pH 8.5 was optimum for ALP activity toward 
inorganic pyrophosphate during bone formation, while the activity was retained at the pH 7.3-
7.4 [109, 110]. It was reported that decreasing the extracellular pH reduced the amount of 
collagen and alkaline phosphatase activity in mesenchymal stem cells, while others reported 
that alkaline pH decreased the alkaline phosphatase activity and could delay the 
differentiation of MSCs [54, 111]. It was shown in the literature that a higher calcium 
concentration inhibits the ALP activity but stimulates the expression of OPN associated with 
the osteogenic differentiation [112]. ALP activity appeared to decrease during mineralization 
[113]. In another study, it was also reported that a consistent marked loss of ALP activity 
occurs during mineralization. The time of onset and the extent of decline in ALP activity were 
found to mirror almost exactly the time of onset and the extent of calcium accumulation by 
the matrix vesicles (MV) [114]. Our results showed that ALP was decreased at higher pH 
indicating that mineralization down regulated the ALP activity.  
In parallel, we also investigated the changes of the expression levels of several key osteogenic 
genes like Runx2, collagen I (Col1α1), OPN and OCN. We reported that among the analysed 
genes only OPN and OCN have been slightly influenced by the different pH values. In body, 
OPN is normally linked to mineralization of the tissues [115 ] and similarly to our data was 
found to be sensitive to pH [98, 116]. The highest expression we observed under pH 8.0, 
while the least was detected at acidic pH (6.3 and 6.7). The other osteogenic marker, OCN is 
linked to terminally differentiated osteoblast; however, its role in bone mineralization remains 
unclear since in OCN-deficient mice, it was discovered that osteocalcin does not necessarily 
ensure normal osteoblast function [117]. The trend in OCN expression in our hMSCs showed 
increased levels under lower and higher pH values (different to physiologic). Analysis of the 
other two osteogenic markers, collagen I and Runx2, showed no significant changes upon pH 
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treatment. Throughout all different pH conditions during differentiation, we found strong 
upregulation of both genes. Collagen I is the main building protein of bone, while Runx2 is 
the master regulator of osteoblast lineage [118-120] that control expression of several 
osteogenic genes among which is collagen I [121]. Expression of Runx2 and collagen I can be 
affected by the pH was depending on the MSC donor [98, 116, 122, 123]. 
The difference between the osteogenic markers expression and the matrix mineralization can 
be explained by initiation of matrix vesicle-mediated mineralization followed by collagen-
mediated mineralization. The matrix vesicle mineralization is characterized by an initial 
formation of apatite or primary nucleation intracellularly within matrix vesicles (MV) that 
transport hydroxyapatite (HA) crystals outside of the cells [124-127]. During collagen-
mediated mineralization (secondary nucleation), MV membranes break down and exposure of 
preformed HA to the extracellular fluid, allowing for propagation of HA deposition onto the 
collagenous ECM [125, 127] leading to mineralization by physicochemical and biochemical 
processes [128]. At low pH, calcium and phosphate tissue deposition decreases by increasing 
HA solubility with 10-fold for each unit decrease in pH [53, 64, 129]. According to our data, 
pH had an effect on hMSCs mineralization potential where induction of mineralization was 
more efficient at physiologic pH (7.0, 7.4 and 8.0) and much less at pH (6.3, 6.7 and 8.5). 
Taken together, our study demonstrated that different pH conditions can strongly affect both 
cell self-renewal and mineralization. However, the same pH did not affect cell osteogenic 
potential since the main lineage–specific markers were expressed. 
A number of limitations of this study needed to be considered. For instance, one question still 
not answered is whether comparison to diseased tissue would have been advantageous to 
determine cell responses to alterations in the physicochemical environment. Direct 
comparison can often be complicated due to inherent heterogeneity of both normal and 
diseased tissue and the difficulty in obtaining bone samples. Another thing is that cells from 
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different lots or donors were used resulting in the variability of the results represented by big 
means and standard deviations. Despite these limitations the effect of pH on the gene 
expression is preserved. 
CONCLUSION 
Within this study, it was proven that MSCs were highly sensitive to small shifts in external 
pH as their viability, proliferation and mineralization were affected. However, the osteogenic 
differentiation was not affected by pH. Thus, we think that in the injured sites, MSCs 
behaviour could be altered by the extracellular pH. The results of our study indicate that 
changing the pH of culture medium from normal to alkaline medium could improve the 
differentiation of MSCs to osteoblasts. There are currently various treatments clinically 
available and used for treating osteomyelitis of the jaw due to the complex nature of the 
infection, including the presence of microorganisms and change in pH. Future therapies for 
treating osteomyelitis could be based on shifting the pH of the local environment in the 
alkaline direction in order to overcome the acidic inflammatory exudates released during 
infection.
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2. PUBLICATION II 
FLUORESCENCE-GUIDED SURGERY FOR THE TREATMENT OF 
MEDICATION-RELATED OSTEONECROSIS OF THE JAW: A PROSPECTIVE 
COHORT STUDY 
Sven Otto, Oliver Ristow, Christoph Pache, Matthias Troeltzsch, Riham Fliefel, 
Michael Ehrenfeld, Christoph Pautke. J of Craniomaxillofacial Surgery 2016. In 
Press Accepted Manuscript. 
ABSTRACT 
Introduction: The delineation of the necrotic bone is a crucial step in the surgical treatment of 
Medication-related osteonecrosis of the jaw (MRONJ). Several different approaches have 
been described including the innovative technique of fluorescence-guided surgery. However, 
until now there is a lack of data regarding the outcome. Therefore, the aim of the present 
study is to investigate the long-term success rates of fluorescence-guided surgery in the 
treatment of MRONJ. Patients and Methods: 54 Patients were prospectively assigned for 
surgical treatment of medication-related osteonecrosis of the jaw using fluorescence-guided 
surgery. Patients received doxycycline 100 mg twice a day for at least seven days 
preoperatively. Surgical treatment of MRONJ included complete removal of necrotic bone, 
which was monitored using the visual enhanced lesion scope (Velscope), followed by 
smoothening sharp bony edges and meticulous wound closure. Procedure success was 
assessed as postoperative maintenance of full mucosal coverage without pain, infection or 
bone exposure during regular follow-up. Results: The study included a total of 54 patients (32 
female and 22 male, mean age of 71.4 ±9.2 years). In the last follow-up an intact mucosa and 
absence of exposed bone, pain or signs of infection was identified in 47 of 54 patients (87%) 
and 56 of 65 lesions (86.2%) after first surgery using fluorescence-guidance. In 4 patients 
with 6 lesions a second fluorescence-guided surgery was necessary to achieve complete 
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mucosal closure. Respectively, including the case with second surgical attempt 51 of 54 
patients (94.4%) and 62 of 65 lesions (95.4%) showed complete mucosal healing. 
Conclusion: The study shows that fluorescence-guided surgery is a safe and successful 
treatment option which can be considered for all stages of MRONJ. The technique seems also 
promising for MRONJ cases under Denosumab.  
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INTRODUCTION 
There is an ongoing debate on treatment strategies for medication-related osteonecrosis of the 
jaw (MRONJ): namely non-surgical (conservative) versus surgical treatment. The success 
rates for surgical strategies in MRONJ cases under bisphosphonates are significantly higher 
[130-133] than conservative treatment regimens [134-139] even though a direct prospective 
comparison between surgical and non-surgical treatment is missing till date. 
MRONJ is currently diagnosed by the presence of exposed jawbone for a period that exceeds 
8 weeks [140, 141]. Consequently, a successful therapy should aim for absence of bone 
exposure and restoration of mucosal integrity [133, 142]. Due to the fact that the infected 
necrotic and exposed bone will not be revitalized and resurrected, MRONJ should be removed 
even if only small bone areas are affected. Thus, the aim of the surgical therapy should be a 
complete removal of the necrotic bone. But even among those who favour surgical therapy 
there is an uncertainty as to which surgical technique is more effective. Indeed, the challenge 
as well as the limitations of the MRONJ therapy is that the margins of the osteonecrosis 
cannot be exactly determined, and therefore a clear demarcation of the necrotic bone is 
difficult if not impossible [140, 143]. The complete removal of necrotic bone is of crucial 
importance because otherwise there is the risk of disease recurrence or progression [133, 144]. 
Furthermore, it must be avoided to unintentionally and unnecessarily remove healthy bone 
without signs of osteonecrosis. Still, surgical experiences supported by various imaging 
modalities are used to remove only as much as necessary and as less as possible of necrotic 
bone [145-148]. Therefore, surgical therapy is dependent on the surgeon and can neither be 
comparable nor reproducibly objectified.  
Fluorescence-guided bone surgery has shown promising results in the surgical MRONJ 
management [149-151]. Providing a controllable therapeutic approach, this technique may 
help to define the transitions between necrotic and non-necrotic bone during the surgical 
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procedure. Due to the fact that this surgical approach is easy to apply and reproducible, it may 
help to objectify surgical MRONJ therapy auguring an improvement of the treatment. 
Therefore, the aim of this study is to examine the success rate of fluorescence-guided surgery 
in MRONJ patients in in terms of postoperative mucosal integrity and absence of bone 
exposure. Furthermore, pain, infection rates as well as disturbances of sensitivity are 
monitored. 
PATIENTS AND METHODS 
Patients 
Over a period of 5 years (2010-2014), 54 patients were recruited and prospectively included 
in our monocentric cohort study (Department of Oral and Maxillofacial Surgery, Ludwig-
Maximilians-University, Munich, Germany). 32 female and 22 male patients were enrolled 
with a mean age of 71.4 (standard deviation ±9.2 years; age range, 45-91 years). Inclusion 
criteria were: Exposed necrotic jawbone over a period of more than 8 weeks; with a history of 
antiresorptive drug treatment (bisphosphonates and / or Denosumab) in the absence of 
radiotherapy to the head and neck region according AAOMS [29, 141]. Exclusion criteria 
were a history of head and neck irradiation, metastatic bone disease of the maxillofacial 
region and contradictions for surgery under general anaesthesia. After obtaining the approval 
of the institutional ethics committee (LMU 189/10), patients were informed about all 
treatment options and provided written informed consent. 
Surgical procedure 
All surgical procedures were performed by the same board-certified and specialized Oral and 
Maxillofacial Surgeons (SO) under general anaesthesia using a nasal intubation. The surgeries 
were performed under sterile conditions following a standardized operation protocol [130]. 
All patients received 100 mg doxycycline twice a day for at least 7 days preoperatively. 
Surgical procedures were performed as the fluorescence guided surgery technique described 
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previously by our group using the VELscope® system (LED Dental, White Rock, British 
Columbia, Canada) to induce and visualize fluorescence of the jaw bone [130, 143, 151, 152]. 
After surgical bone exposure was performed the bone fluorescence showed viable bone in a 
bright greenish fluorescence and necrotic bone areas showed none or only pale fluorescence. 
Reddish fluorescence was considered as a bacterial colonization or infection of necrotic bone 
parts and the respective areas were removed. Necrotic bone was removed using a burr a 
homogenous greenish bone fluorescence was observed as described in previous studies [130, 
143, 149, 153, 154]. It should be stressed that only necrotic and infected bone parts were 
removed and the surrounding vital bone was preserved which means that no resections 
including safety margins have been performed. Thereafter, sharp bony edges were 
smoothened using burrs and diamante burrs. A tension free wound closure was achieved using 
mucoperiosteal flaps and simple as well as back stiches (Serafit 3-0, SERAG-Wiesner GmbH 
Germany). In extensive cases of the maxillary molar and premolar region (stage 2 and 3) a 
second layer of wound closure was achieved using the buccal fat pad before mucoperiosteal 
closure. 
All patients stayed in hospital for at least 48 hours after surgery. Patients received the routine 
postoperative instructions and routine postoperative analgesic drug therapy; antibiotic 
treatment was continued using Augmentin 2.2 g or Unacid 3g intravenously three times per 
day for 3-5 days. In case of a penicillin allergy clindamycin 600 mg was used. In cases of 
severe infection (mainly stage 2 and 3) metronidazole 500 mg (1-0-1) was administered 
additionally. In cases of renal function disturbances the doses were adjusted accordingly. The 
antibiotic treatment was continued orally after discharge from hospital for 2-4 weeks orally. 
Measurements  
Regular clinical examinations were performed daily during in-patient treatment, weekly 
during the first month and monthly during first year of out-patient treatment. The surgical 
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treatment was only considered a success if full mucosal coverage without signs of residual 
infection or exposed bone was achieved at the time of last follow-up. Furthermore, all patients 
were asked for pain and were examined for signs of sinusitis and checked for oro-antral fistula 
in cases of upper jaw lesions and checked for sensitivity in the lower lip area in cases of 
MRONJ of the lower jaw. 
Statistical analysis 
Descriptive statistics were computed using SPSS version 16. Results are expressed as 
percentages or as mean values including standard deviation and range. Means were compared 
by statistical testing (students t-test), where p < 0.05 was considered to be significant. 
RESULTS 
Base line characteristics 
54 patients (32 female and 22 male) patients with a mean age of 71.4 years (standard 
deviation 9.2 years) were included in the study. The mean age of the female patients was 70.4 
years (standard deviation 7.6 years); the mean age of all male patients was 72.9 years 
(standard deviation 7.0 years). Respectively, there was no significant difference (Figure  2.1).  
 
Figure  2.1: Age range of patients with 
MRONJ. 
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45 of the patients (83.3%) suffered from an underlying malignant disease, specifically breast 
cancer (n=20; 37%), prostate cancer (n=16; 29.6%), and multiple myeloma (n=4; 7.4%). 
There were also cases of metastatic thyroid cancer (n=2), squamous cell carcinoma (n=1), 
bronchial cancer (n=1), and endometrial cancer (n=1) in the study cohort. In the remaining 9 
(16.7%) patients osteoporosis was the cause of the antiresorptive treatment. An overview is 
given in (Figure  2.2). 
 
Figure  2.2: Overview of primary cause of MRONJ. 
Overview of the underlying diseases leading to anti-resorptive 
treatment with bisphosphonates and Denosumab in patients 
suffering from MRONJ. 
Of the 54 patients included, 47 were treated with nitrogen-containing bisphosphonates (87%), 
3 had a history of Denosumab intake (5.5%) and the remaining 4 patients (7.4%) reported a 
sequential intake of bisphosphonates and Denosumab. The most common anti-resorptive 
drugs within the cohort were Zoledronate (n=40; 74.1%), Alendronate (n=5; 9.3%), 
Ibandronate (n=2; 3.7%) and Denosumab (n=3; 5.5%) or the combination of bisphosphonate 
and Denosumab (n=4; 7.4%). The mean duration of intake of the anti-resorptive drugs was 
46.3 months (SD 31.8 months). 
The 54 patients revealed 65 MRONJ lesions. 40 of the lesions (61.5%) were located in the 
mandible and 25 (38.5%) were located in the maxilla. The majority of the lesions referred to 
stage 2 (n=42; 64.6%) and stage 3 (n=8; 12.3%) according to AAOMS 2014 (Ruggiero et al., 
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2014a). It is worth mentioning that also stage 1 lesions were included (n=14; 21.5) and even a 
singular case of stage 0 (n=1; 1.5%). The mean follow-up of the patients was 12.9 months 
(median 11 months; range 1-39 months). 
Results of fluorescence-guided bone surgery 
The first surgical intervention using fluorescence-guided bone surgery resulted in complete 
mucosal healing in 47/54 of the evaluated patients (87%) and 56/65 lesions (86.2%) without 
any kind of bone exposure and without complaints at the time of last follow-up. Typical cases 
are illustrated in Figure  2.3 and Figure  2.4.  
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Figure  2.3: 58-years old female presented with MRONJ. 
Illustration of a 58-year old female patient suffering from 
breast cancer who received 56 months zoledronate and 
developed a medication-related osteonecrosis of the jaw in 
her left mandible (region 37/38 mainly lingual aspect). 
The illustration depicts the clinical intraoral situation prior 
to (a) and 3 months after surgery (b). The intraoperative 
clinical and fluorescence view prior to removal of the 
necrotic bone (c and d) and after the removal of necrotic 
bone and smoothening of sharp bony edges (e and f) are 
also illustrated. Note the weak green fluorescence in the 
lingual aspect region 37/38 corresponding to the necrotic 
bone area (d) as well as the reddish fluorescence in this 
area corresponding to the bacterial infection of this region 
prior to removal of the necrotic and infected bone parts as 
well as the homogenous greenish fluorescence after the 
removal and the absence of red fluorescence after the 
removal of necrotic bone parts. 
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Figure  2.4: 74-year old male presented with MRONJ. 
Illustration of a 74-year old male patient suffering from 
prostate cancer who has received intravenous treatment 
with zoledronate over 2 years and exposed necrotic 
bone and putrid exudation of the right mandible (region 
47/48) according to a medication-related osteonecrosis 
of the jaw (region 47/48) prior to (a) and one year after 
fluorescence-guided surgery (b). During surgery there 
was necrotic bone with diminished fluorescence in the 
lingual aspect of the mandible (c and d). After complete 
removal of the necrotic bone parts and smoothening of 
sharp bony edges the fluorescence was homogenously 
green (e and f). 
2/54 (3.7%) patients were also free of complaints and had no bone exposure and a complete 
mucosal coverage of the bone. However, in these patients the lesions in the maxilla were that 
extensive (AAOMS stage 3) that oro-antral fistula persisted. Both patients preferred an 
obturator prosthesis instead of another surgical approach to close the oro-antral fistula. One of 
these two cases is illustrated in Figure  2.5. 
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Figure  2.5: 62-year old female presented with MRONJ. 
The patient suffered from metastatic breast cancer who 
received zoledronate intravenously (4mg every 4 weeks) 
for more than 3 years and developed an extremely 
extended stage III MRONJ in her right maxilla with bone 
exposure suppuration which was also extremely painful on 
palpation (a). After antibiotic pre-treatment the patient was 
treated surgically. After exposure (b) the whole extent of 
the MRONJ lesion became visible which included parts of 
the hard palate and parts of the facial wall of the maxillary 
sinus. After removal of parts of the necrotic bone (c and d) 
it became obvious that the whole alveolar process of the 
right maxilla was necrotic and infected. The necrotic bone 
was completely removed using fluorescence-guided 
surgery (e) and a double-layered plastic wound closure 
was performed using the buccal fat pad and 
mucoperiosteum. In the postoperative course the patient 
was free of pain but developed a wound healing 
disturbance and an oro-antral fistula. After complete 
healing there was no bone exposure but the oro-antral 
fistula persisted (f). As the patient was free of complaints 
she did want to go for another surgery to close the oro-
antral fistula. So she was treated using an obturator 
prosthesis as described in detail elsewhere [155]. 
5/54 patients (9.3%) with 7/65 lesions (10.8%) showed stage improvement and were free of 
pain after first surgery but still had bone exposure present. 4 of these patients (with 6 of the 7 
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lesions) underwent a second surgery using fluorescence-guided bone surgery, which in all 4 
patients and all 6 lesions resulted in complete mucosal healing. An overview of the treatment 
outcome after first surgery and including the 4 cases with second surgery is provided in 
Table  2.1. 
Table  2.1: Overview of the treatment outcome after first surgery including the 4 cases 
with second surgery 
 Pre-operative 
total n=54 (65) 
After first surgery 
total n=54 (65) 
After second surgery in 
n=4 (6); total 54 (65) 
Bone exposure 53 (63) 5 (7) 1 (1)* 
Pain / complaints 43 (51) 1 (1) 1(1)**a 
Impaired sensitivity N. V3 7 (7) 1 (1) 1 (1)**b 
Sinusitis/ oro-antral fistula 7 (8) 2 (2) 2 (2)**b 
Pathological fracture 0 0 0 
*change due to complete mucosal healing in 4 patients with 6 lesions who underwent second surgery, **no 
change as none of the affected patients was treated surgically again, a  due to worsening of underlying malignant 
disease, b due to patients wish and no need for second surgery  
Only in one single patient (1 lesion) the bone exposure persisted and was subsequently treated 
conservatively as the patients systemic condition had worsened over time caused by the 
underlying malignant disease. The initial stage improvement (stage 2 prior to surgery and 
stage 1 after surgery) gradually worsened over time back to the initial stage 2. 
Taken together the results of the first and second surgery 51/ 54 patients (94.4%) and 62 / 65 
lesions (95.4%) showed complete mucosal healing and no bone exposure. Two further 
patients were free of complaints and had no bone exposure but developed oro-antral 
communication. Only one patient with a single lesion showed persistent bone exposure which 
could not be addressed by a second surgery due to the worsened general condition of the 
patient. 
It is worth mentioning that no continuity resection had to be performed in the mandible, 
whereas the removal of MRONJ in the maxilla resulted in resection-like defects in 4 cases. 
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Two of those cases developed a persistent oro-antral fistula. None of the patients showed a 
recurrence of MRONJ in the respective area after complete mucosal healing in the further 
postoperative course. None of the patients developed a pathological fracture of the mandible. 
DISCUSSION 
There is an ongoing debate and certainly no consensus yet regarding the management of 
patients with MRONJ. Moreover, there is not even consensus regarding the main treatment 
aim and the optimal outcome measures.  
While some authors recommend conservative treatment protocols mainly aiming in relief of 
pain and control of infection, a number of papers have suggested that in patients with a good 
performance status the primary aim of treatment should be mucosal healing as this is the 
physiological status, rather than bone exposure without symptoms [130, 133, 149, 156, 157]. 
Conservative treatment cannot achieve this aim, neither considering the frequency nor the 
predictability especially in oncological patients who have received long term intravenous 
courses of nitrogen-containing bisphosphonates. In this respect, Hoff et al.[135] reported 23% 
healing (3/13 patients) and similarly Nicolatou-Galitis et al.[158] reported mucosal healing in 
only 14.9% of BRONJ cases (7/47) managed conservatively, notably after a median time of 8 
months (range 2-36 months, mean 14.7 months), while pain subsided in 80.9% (38/47). It is 
also worth mentioning that 4 of the 7 patients who showed complete healing referred to stage 
0 according to the AAOMS definition [29, 141]. This in turn means that the outcome results 
for cases with bone exposure are even less convincing. Regardless of the type of definition or 
staging system applied, the vast majority of patients with BRONJ (especially oncological 
patients) cannot be cured using conservative measurements and have long lasting jaw bone 
exposure which can not only affect their quality of life [159], but may also limit the 
oncological treatment options including immuno- or chemotherapy and possibly further anti-
resorptive treatment with bisphosphonates or Denosumab [160, 161]. Conservative treatment 
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might be adequate if the aim of treatment is to slow down or stop disease progression and to 
alleviate pain and superinfection of the exposed bone, while there is increasing evidence 
supporting surgical protocols if the aim of treatment is mucosal healing. 
In this respect our study showed that fluorescence-guided bone surgery is a reliable and 
promising treatment option for patients suffering from MRONJ. 
This is in line with the recent literature where Carlson et al. reported mucosal integrity of 92% 
after surgical resection in a case series of 95 patients [133]. Likewise, other authors stated a 
healing rate up to 89% (12 month follow up; n=50) [131] as well as 88 % (60 weeks follow 
up; n=24) after surgical treatment. Prospective case series further support the benefit of a 
surgical treatment of BRONJ: Bedogni et al. 2011 [162] (n = 30) surgical treatment: 90 % 
healing 6 months follow up, Schubert et al., 2012 [163] (n = 54) surgical treatment: 89 % 
healing (min. 3 months follow up), Jacobsen et al., 2012 [164]. (n = 64 surgical treatments: 78 
% healing (7 years follow up). It is however hard to compare the different studies because the 
underlying study cohorts were composed of different populations regarding the proportion of 
oncological and osteoporotic patients, regarding the surgical protocol applied (e.g. only 
removal of necrotic bone versus resection) and regarding the outcome evaluation and 
postoperative follow-up but the bottom line of all of the above mentioned studies was that 
patients suffering from MRONJ can successfully be treated using surgical treatment 
protocols. 
Comparative studies also seem to substantiate these findings. The multivariate analysis of 
Mücke and co-workers showed a lower recurrence rate for surgically-treated ONJ patients 
when compared to conservative treatment (n=108) [144], as well as the multivariate analysis 
of Graziani et al., 2013 [165] (n = 347) confirmed significantly more mucosal healing for 
surgical treatment versus conservative protocols. Finally, a 2014 systematic review by Rupel 
et al. [166], and another very recent systematic review meeting PRISMA guidelines [167] 
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which analysed data from 97 studies and 4,867 patients suggest that surgical treatment 
protocols are superior to conservative management [139]. 
The most important parts for a successful surgical treatment of MRONJ include pre- and 
postoperative antibiotic treatment, complete removal of the necrotic and often infected bone 
parts, smoothening of sharp bony edges and a complete and reliable plastic wound closure. 
The aim of the preoperative antibiotic treatment is to stop disease progression and to reduce 
infection in order to provide optimal conditions for the surgical treatment. The complete 
removal of necrotic bone is essential to provide the conditions for bone and soft tissue healing 
and in order to avoid reinfection of necrotic bone parts. Fluorescence-guidance might be a 
tool to optimize the completeness of removal of necrotic bone parts. Smoothening of sharp 
bony edges is of special importance because of the remodelling suppression caused by anti-
resorptive drugs and seems therefore even more important when the anti-resorptive activity is 
high (e.g. after multiple years of intravenous bisphosphonate intake or shortly after the last 
application of anti-resorptive drugs with short half-life e.g. Denosumab). The aim of the 
plastic wound closure is to ensure that the delayed and endangered healing of the jaw bone 
treated with anti-resorptive drugs can take place in an undisturbed manner. In the experience 
of the authors of this article safe and reliable mucoperiostal flaps closed with multiple back 
stiches seems sufficient. However, it is recommended to perform double layered wound 
closure whenever possible. In this respect for example the use of the buccal fat pad in cases of 
MRONJ of the molar and premolar region of the maxilla and the use of the mylohyoid flap in 
the mandibular molar region might have advantages. The postoperative antibiotic treatment 
should protect the wound healing period and avoid reinfection of the bone. A prolonged 
antibiotic treatment seems to have advantages. 
According to several guidelines including the AAOMS position paper and the ASBMR expert 
panel recommendation early stages of MRONJ should be treated conservatively and surgical 
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treatment should only be applied to stages 2 and 3 [29, 168, 169]. The authors of this paper 
disagree with these opinions especially in patients receiving intravenous administrations of 
bisphosphonates in the oncological setting [157]. In fact treatment of all stage 0 and 1 lesions 
resulted in complete mucosal healing with minimal morbidity and a predictable and 
reasonable time frame. Furthermore, after complete mucosal healing the respective patients 
had no restrictions regarding their further oncological or osteological treatment including 
further anti-resorptive treatment. Actually, surgical treatment of early MRONJ lesions offers a 
lot of advantages including the usually smaller extent of the lesions leading to less extended 
surgical removal of bone and minor functional impairments. Besides that lack of infection 
usually offers better conditions for surgical treatment. Therefore, the authors of this paper call 
for a re-evaluation of concepts and aim for a change of paradigms. Instead of long lasting, 
unpredictable conservative treatment approaches usually resulting in improvements of 
symptoms but rarely leading to complete mucosal healing should be replaced by early surgical 
interventions aiming in complete mucosal healing in a predictable timeframe and resulting in 
optimized functional outcomes as respective surgeries which frequently occur after 
unsuccessful conservative treatment approaches can be avoided. Indeed, it is worth 
mentioning that after changing our treatment concept to early surgical intervention we did not 
experience MRONJ cases, in which we had to perform continuity resections of the mandible 
and no microvascular reconstructions were necessary any more, which we experienced during 
the timeframe where we applied a more conservative treatment approach in early stages. So in 
fact so called conservative treatment protocols might lead to the necessity of more aggressive 
and large resections including all functional impairments over the long run [169]. The authors 
of this paper do not doubt that ablative surgery including continuity resections of the 
mandible and microvascular reconstructions are necessary in selected cases of MRONJ 
whereas a lot more cases of osteoradionecrosis require this radical treatment. We think that 
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the progression of MRONJ cases presenting in early stages can be avoided when treated 
adequately. However, conservative treatment approaches and the role of drug holidays might 
well be different in MRONJ cases under Denosumab especially in cases without prior 
bisphosphonate treatment because of the much shorter half-life of Denosumab (26 days) when 
compared to bisphosphonates in bone [157]. 
Regarding the specific technique of fluorescence-guided bone resection it needs to be 
mentioned that it is not yet certain what exactly causes the intraoperative fluorescence. Recent 
reports suggest that there is an auto-fluorescence without tetracycline bone labelling, leading 
to similar bone fluorescence of tetracycline-exposed tissue [170, 171]. Indeed, it is well 
known that not only tetracycline but also components of the extracellular matrix e.g. calcified 
tissues (bone or teeth) have fluorescence properties [130, 154]. A combination of these 
components might contribute to the fluorescence effects that can be used in the treatment of 
MRONJ. Therefore, further basic and clinical research is needed in order to investigate the 
fluorescence properties and their differences. Once the causes for fluorescence-guided 
surgical approaches might be suitable not only for MRONJ but also for osteoradionecrosis 
and osteomyelitis [154]. 
Limitations of the present study include the inhomogeneous recall intervals of some of the 
patients which were mainly due to their underlying diseases and respective oncological 
treatment protocols. Furthermore there were only very few cases of MRONJ due to 
Denosumab intake. Given the much shorter half-life of Denosumab when compared to 
nitrogen-containing bisphosphonates there might be a different and more important role of 
conservative treatment protocols especially when there is no pre-treatment with 
bisphosphonates and no further necessity of anti-resorptive treatment. However, up to now 
there is no study which directly compares the outcome of conservative and surgical treatment 
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and there is also no study comparing conventional surgical treatment versus fluorescence-
guided surgery. 
The available data might not yet be robust enough to inform guidelines on the treatment of 
MRONJ, especially as there is hardly any data on how to manage patients exposed to 
Denosumab where conservative treatment might theoretically play a different role due to its 
much shorter half-life. There is an urgent need of prospective randomized trials comparing 
surgical and non-surgical treatment of MRONJ and including patient-centred outcome 
measures like quality of life before, during and after treatment. Ultimately, the clinical 
decision making will always be based on individual risk assessment, especially as most 
patients with MRONJ have multiple comorbidities, which require knowledge about the 
predictable efficacy and limitations of the all treatment options. 
CONCLUSION 
We conclude that fluorescence-guided bone resection is a reliable surgical treatment option 
for patients suffering from medication-related osteonecrosis of the jaw. 
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3. PUBLICATION III 
ROLE OF MICROBIOLOGICAL CULTURE AND PCR IN MEDICATION- 
RELATED OSTEONECROSIS OF THE JAW (MRONJ)  
Sappasith Panya, Riham Fliefel, Florian Probst, Matthias Tröltzsch, Michael 
Ehrenfeld, Sören Schubert, Sven Otto. Under review in J of Craniomaxillofacial 
Surgery 2016. 
ABSTRACT 
We hypothesized that local infection plays a critical role in the pathogenesis of medication-
related osteonecrosis of the jaw (MRONJ). Recent developments in molecular methods have 
revolutionized new approaches for the rapid detection of microorganisms including those 
difficult to culture. The aim of our study is to identify the bacterial profiles in MRONJ by 
microbiological culture and polymerase chain reactions (PCR). A retrospective analysis was 
performed on MRONJ patients from 2008 to 2014. The bacterial profile from MRONJ bone 
samples was determined using microbiological culture and PCR. Ninety five patients fulfilled 
the inclusion criteria with mean age of 69.85 ± 8.71 years. A female predilection was 
detected. The mandible was more commonly affected than maxilla. Tooth extraction was the 
frequent triggering factor. Breast cancer was the primary cause for administration and 
intravenous bisphosphonates were the most commonly administrated anti-resorptive drugs. 
The majority of patients were classified as stage 2. Posterior teeth were most commonly 
affected. Based on bone culture results, the most common microorganism were both 
actinomyces and mixed flora. PCR confirmed the presence of actinomyces in 55 patients. Our 
data suggest that PCR might be an innovative method for detection of microorganisms 
difficult to culture using traditional microbiological techniques.  
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INTRODUCTION 
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially devastating 
complication of anti-resorptive drugs used globally to treat bone disorders as osteoporosis, 
skeletal complications associated with osseous metastasis and multiple myeloma [27, 28]. 
Nowadays, the pathophysiology of MRONJ is not clearly understood. Numerous theories 
have been proposed, neither of which can provide an adequate explanation of the disease. 
MRONJ was perceived as a type of avascular necrosis due altered bone turnover or direct 
toxicity to the soft tissue, infection, inflammation, inhibition of angiogenesis or suppression 
of innate or acquired immunity have been identified as possible explanations of the disease 
process [172].  
Bacterial infection to the maxillofacial region has been suggested as key factor for the 
pathogenesis and progression of MRONJ [18, 173]. The oral cavity comprises of more than 
750 bacterial species existing as mixed biofilm communities [32]. The mandible and maxilla 
are covered by thin layer of mucosa in close proximity to the external environment. After 
invasive dental procedures, oral trauma or soft tissue infection, microbial biofilms in the 
mouth and saliva gain access to the exposed jaw bone and play a significant role in the 
necrosis of the bone, inhibition of oral wound healing and facilitating bacterial colonization 
on bone surface [33, 34]. Actinomyces were regularly found in MRONJ suggesting a latent 
role of infection in the pathogenesis [174-176]. Actinomyces are filamentous gram-positive 
anaerobic bacteria that usually can be found in calculus, periodontal pockets, carious lesions 
and oral mucosal surfaces, in addition to the upper respiratory, gastrointestinal tracts and 
vagina. They are common saprophyte bacteria of low virulence in nature causing no disease 
as long as they stay on the surface of the mucosa but in certain conditions where the integrity 
of the mucosal barrier is compromised, the bacteria may be pathogenic and gain access to the 
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oral tissues or jawbones initiating a prolonged chronic inflammatory process, creating a 
tumour-like mass, tissue destruction, osteolysis and multiple sinus tracts [177-179]. 
MRONJ lesions are usually colonized by oral bacteria and the use of systemic antibiotics 
failed to restrict the bacterial colonization and effective healing of the lesion. It is important to 
identify the bacterial species colonizing jaw bone associated with the disease to delineate the 
pathogenesis. Moreover, it is not well understood whether the bacteria involved in MRONJ is 
similar or different to other biofilm associated bone infections in the oral cavity [180]. 
Recently, bone abnormalities were studied by various modalities but none proved to be 
reliable in describing the infectious nature of the disease. Recent advances using biomolecular 
profiling to describe MRONJ flora have decreased this gap [181]. 
Here, we identify the bacterial profiles that colonize MRONJ bone samples determined by 
culture approaches and polymerase chain reactions (PCR) with clinical features of patients. 
This line of investigation could provide rationale in the future for MRONJ therapeutics and 
targeted antimicrobial therapy. 
33BPATIENTS AND METHODS 
75BStudy design 
This is a retrospective study of MRONJ patients treated at the Department of Oral and 
Maxillofacial Surgery, Ludwig-Maximillians-University Clinic, Munich from January 2008 to 
December 2014. Inclusion criteria were based on the American association of oral and 
maxillofacial surgery (AAOMS) Position paper [30]. Patients missing clinical, radiographic 
or follow-up data were excluded or if they had a history of head and neck radiation. 
Appropriate Institutional Review Board approval was obtained. 
76BData collection 
Clinical data relevant to the study were extracted and entered into an excel datasheet with a 
detailed history concerning: age, gender, location and teeth involved in the lesion, primary 
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cause of the disease, comorbidities, clinical presentation, MRONJ clinical staging, type of 
anti-resorptive drug, route of administration and pathological/microbiological findings of 
bone samples. Bone samples were obtained from bone resection surgeries and were sent for 
microbiological investigations and PCR. Due to high likelihood of false positive culture from 
environmental exposure, we considered only at least strongly positive culture result (+2) as 
positive culture. One bone sample from each MRONJ patient was cut into fragments and 
prepared for microbiological analysis as described below. 
Microbiological culture of bone samples from MRONJ 
Bone samples have been introduced in classical bacterial diagnostics. For this, aerobic 
cultures were prepared on Columbia blood-agar, MacConckey-agar and Columbia-CAN-agar, 
anaerobic cultures on Schaedler-agar and Schaedler-KV-agar (all agar plates from BD, 
Heidelberg, Germany). Besides, the swabs were cultivated in thioglycolate broth. All aerobe 
cultures have been read after 24h, 48h and 72h, the anaerobic cultures after 2d, 5d and 7d. The 
bacterial counts have been enumerated semi-quantitative and bacterial colonies were objected 
to MALDI-TOF MS for further species identification. 
Samples were evaluated by the use of Microflex LT mass spectrometer (Bruker Daltonik 
GmbH, Bremen, Germany) in linear positive-ion mode across the m/z range of 2,000 to 
20,000 Da. Each spot was measured by using 240 laser shots at 60 Hz in groups of 40 shots 
per sampling area of the spot. Spectra were analysed by using MALDI Biotyper software (v 
3.1 – Build 65). Sample preparation included either the “direct transfer method”, the 
“Extended Direct Transfer method (EDT)” or the “ethanol/formic acid extract method” as 
previously described [40]. Resulting spectra were compared against reference spectra using 
Bruker MALDI-TOF Biotyper software to obtain identification with a confidence score. For 
most isolates, the MSP (Main Spectral Projection) reference spectra were those contained in 
the Bruker database of 2013 (database version V 3.3.1.2) containing 364 genera, 2185 species 
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and 4613 individual MSP. Results with score values >2 were considered as correct species 
identification, results displaying values of 1.5≤ and ≤2 were accepted as correct genus 
identification. 
PCR of Actinomyces 
Identification of bacteria by sequencing of 16S rDNA has been performed as described 
previously with some modifications [182]. In brief, crude bacterial lysates were prepared 
directly from culture plates by suspending bacteria from a clonal culture in 100 μl of RT-PCR 
grade water (approximately McFarland Standard 2.0) and placed in a hot block at 100 °C for 
10 min. A ~800 bp-fragment of 16S rDNA was amplified using the universal primer pair FD1 
5′-AGAGTTTGATCCTGGCTCAG-3′ and 800r 5′-GAGTACCAGGGTATCTAATCC-3′. 
Resulting PCR amplicons were sequenced using the same primers and standard sequencing 
methods. Data from both strands was aligned in SeqMan (DNASTAR Lasergene 8 Suite) to 
generate a contig of around 800 bp. The consensus sequences were then used to compare with 
online databases (NCBI BLAST—http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the Ribosomal 
Database Project (http://rdp.cme.msu.edu/). Identification criteria of 99% sequence identity 
for identification to species level were applied [183] where matches had to be to the species 
type strain. The identities of type strains, as well as accession numbers in NCBI for equivalent 
16S rDNA sequences, are available at http://www.bacterio.cict.fr/ for all validly published 
bacterial species. 
Statistical analysis 
Descriptive statistics were computed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). 
Results are expressed as mean values including standard error of the mean and range. Means 
were compared by statistical testing (Student's t-test), where P< 0.05 was considered to be 
significant. 
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RESULTS 
A total of 150 patients were diagnosed with MRONJ from 2008 to 2014. However, 95 
patients satisfied the inclusion criteria and form the basis of this study. Flow chart of the 
number of patients included in the study is illustrated in (Figure  3.1). 
 
Figure  3.1: Flow chart. 
Flow chart of the number of patients included in the 
study. 
The mean age of the patients was 69.9 ± 8.7 years; with a male to female ratio of 1:1.4 (39 
males and 56 females). Breast cancer was the primary cause for the administration of 
antiresorptive drugs (n=35; 36.8%), followed by prostate cancer (n=24; 25.3%) and 
osteoporosis (n=13; 13.7%) in addition to multiple myeloma (n=10; 10.5%), lung cancer 
(n=4; 4.2%) and finally other cancers (n=9; 9.5%). The relevant comorbidities identified 
included: diabetes mellitus (n=17; 17.9%), cardiovascular diseases (n=29; 30.5%), 
chemotherapy (n=57; 60%), irradiation other than head and neck (n=51; 53.7%), steroid 
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intake (n=28; 29.5%), anti-angiogenic drugs (n=2; 2.1%) and smoking (n=28; 29.5%). The 
most commonly administrated anti-resorptive drugs (ARD) were bisphosphonates (BPs) in 85 
patients (89.5%) of which, zoledronate in 58 (61.1%), pamidronate in 3 (3.2%), ibandronate 
in 2 (2.1%), combination of BPs in 22 (23.1%). Only ten patients received Denosumab 
(10.5%). Among the ARD groups, 79 patients (83.2%) had intravenous ARD, 6 patients 
(6.3%) with oral and 10 patients (10.5%) had subcutaneous injection. The baseline 
characteristics of the patients included in the study are listed in (Table  3.1). 
Table  3.1: Characteristics of patients diagnosed with MRONJ. 
Variable Category Number of patients (%) 
(n=95) 
Age (years) Mean 69.9 ± 8.7 years 
Gender    
 Male 39 (41.1) 
 Female 56 (58.9) 
Primary cause    
 Breast cancer 35 (36.8) 
 Prostate cancer 24 (25.3) 
 Multiple myeloma 10 (10.5) 
 Osteoporosis 13 (13.7) 
 Lung cancer 4 (4.2) 
 Other (Colon, Systemic 
Mastocytosis, Renal, 
Bladder, Thyroid, 
Endometrium) 
9 (9.5) 
Comorbidities   
 Diabetes Mellitus 17 (17.9) 
 Cardiovascular disease 29 (30.5) 
 Chemotherapy 57 (60) 
 Irradiation (body) 51 (53.7) 
 Steroid intake 28 (29.5) 
 Antiangiogenic drugs 2 (2.1) 
 Smoking 28 (29.5) 
Antiresorptive drug 
(ARD) 
  
Bisphosphonate:  85 (89.5) 
 Zoledronate 58 (61.1) 
 Pamidronate 3 (3.2) 
 Ibandronate 2 (2.1) 
 Combination 22 (23.1) 
Denosumab  10 (10.5) 
Route of 
administration  
  
 Intravenous 79 (83.2) 
 Oral 6 (6.3) 
 Subcutaneous 10 (10.5) 
 
 
Publication III: Microbiology and PCR for MRONJ 
Page 52 
Initial presentation of the lesion was only one case referred to stage 0 (1.1%) with no bone 
exposure but non-specific signs and symptoms of MRONJ. Fifteen patients (15.8%) were 
categorized as stage 1 where bone was exposed in the absence of pain and clinical signs of 
infection. The majority of cases (n=59; 62.1%),) were classified as stage 2 based on exposed 
necrotic bone in the maxillofacial region accompanied by pain or signs of infection. Twenty 
patients (21.1%). were presented with stage 3 lesions with complications such as pathological 
fracture, extra-oral fistula formation, extension of the lesion to the inferior border of the 
mandible or to the floor of the maxillary sinus. Most of MRONJ lesions were located in the 
mandible (n=55; 57.9%), 25 patients (26.3%) had maxillary lesions and 15 patients (15.8%) 
had involvement of the maxilla and mandible. Characteristics of MRONJ lesions are 
presented in (Table  3.2). 
Table  3.2: Characteristics of MRONJ lesions. 
Characteristics Number of patients (%) 
Staging of MRONJ  
Stage 0 1 (1.1) 
Stage 1 15 (15.8) 
Stage 2 59 (62.1) 
Stage 3 20 (21.1) 
Clinical presentation  
Pain 81 (85.3) 
Exposed bone 70 (73.7) 
Disturbance in wound healing 55 (57.9) 
Inflammation 54 (56.8) 
Pus 39 (41.1) 
Pathological fracture 9 (9.5) 
Swelling 55 (57.9) 
Fistula 35 (36.8) 
Sinus involvement 13 (13.7) 
Histopathological Features  
Necrotic bone 94(98.9) 
Inflammatory infiltrate 87(91.6) 
Bacterial colonization 67(70.5) 
Location  
Mandible 55 (57.9) 
Maxilla 25 (26.3) 
Both 15 (15.8) 
Triggering events  
Extractions 56 (58.9) 
Dentoalveolar surgery 15 (15.8) 
Denture sore 4 (4.2) 
Periodontal treatment 7 (7.4) 
Spontaneous 13 (13.7) 
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The posterior teeth specially the first and second molars were the most affected teeth by 
MRONJ than the anterior teeth. The frequency of MRONJ in teeth of each quadrant is 
represented in (Figure  3.2). 
 
Figure  3.2: Distribution of teeth involved in MRONJ. 
Distribution of teeth involved in MRONJ at the different 
quadrants of maxilla and mandible where n is the number 
of teeth involved in each quadrant. 
Regarding the onset of MRONJ, the most frequent signs and symptoms were: pain in 81 
patients (85.3%), exposed bone in 70 patients (73.7%), disturbance in wound healing in 55 
patients (57.9%), inflammation in 54 patients (56.8%), pus in 39 patients (41.1%), 
pathological fracture in 9 patients (9.5%), swelling in 55 patients (57.9%), fistula in 35 
patients (36.8%) and sinus involvement in 13 patients (13.7%). The lesions were stratified 
into lesions with a known triggering event or spontaneous development of MRONJ. The most 
common events prior to the development of MRONJ lesions were extraction in 56 patients 
(58.9%), dentoalveolar surgery in 15 patients (15.8%), denture sores in 4 patients (4.2%), 
periodontal treatment in 7 patients (7.4%) and lesions developed spontaneously in 13 patients 
(13.7%). Histopathological examination of the bone specimens revealed typical picture of 
MRONJ lesions where nearly all the patients showed an active inflammatory process with 
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necrotic bone (n=94, 98.9%), inflammatory cell infiltrate (n=87, 91.6%) and bacterial 
colonization (n=67, 70.5%). The characteristics of MRONJ lesions are illustrated in Table 2. 
Ninety five patients had undergone microbiological culture tests. However, only 55 patients 
had undergone PCR for actinomyces. Based on bone culture results, the most common 
microorganism were both actinomyces and mixed oral flora (n=23, 24.2%) each then 
enterobacter group (n=19, 20%), streptococci (n=18, 18.9%), miscellaneous microorganisms 
(n=13, 13.6%), candida (n=9, 9.4%) and finally enterococcus (n=5, 5.2%) (Figure  3.3). 
 
Figure  3.3: Pie-chart of micro-organisms in MRONJ. 
Pie charts showing distribution of microorganism in bone 
sample of MRONJ lesions from 2008 to 2014. 
As actinomyces were the most commonly found microorganisms, we therefore performed 
PCR to confirm the presence of actinomyces. Of the 55 patients, 53 (96.4%) were PCR and 
culture positive and 35 (63.6%) were positive only for PCR but negative for actinomyces 
culture. The results are shown in (Table  3.3). 
Table  3.3: PCR results of MRONJ bone samples. 
 
Culture 
(n=55) 
PCR (n, %) 
Positive Negative 
Positive 18(32.7) 0(0) 
Negative 35(63.6) 2(3.6) 
Total  53(96.4) 2(3.6) 
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DISCUSSION 
The main objective of this study was to identify microorganisms manifested in MRONJ with 
special attention to actinomyces using microbiological cultures and PCR which might be 
useful in assisting surgeons in making proper decisions on the treatment modality of the 
disease based on the hypothesis that infection maybe the most important factor negatively 
influencing the onset and progression of MRONJ.  
MRONJ can reduce the patient's quality of life and may produce significant morbidity due to 
impairment of chewing, swallowing and speaking as well as deterioration of facial aesthetics. 
Thus, it is of tremendous importance to treat those patients to adequately eliminate pain, 
control infection of soft and hard tissue and eradicate bone exposure [184]. 
From the results of our study, it was proved that actinomyces were highly prevalent in 
MRONJ patients by microbiological culture which was consistent with an earlier study on 
MRONJ bone samples [174]. A previous study on a pathological specimen of MRONJ lesion 
showed that the lesions were composed of areas with active inflammatory cells with acellular 
necrotic debris and bone resorption [185]. The histopathological findings of the bone samples 
in our study were similar.  
The terminology MRONJ had been well recognised worldwide nowadays due to the increase 
in the prevalence of the disease. The pathogenesis of the disease raised many questions 
regarding the potential mechanisms underlying the pathophysiology [186]. Several 
mechanisms had also been proposed as: i) over suppression of bone turnover, ii) a response to 
infection, iii) immunomodulation, iv) ischemia due to the antiangiogenetic effects of BPs, v) 
soft tissue toxicity. Arguably, all theories could play a role in the pathogenesis of BRONJ. 
However, none of them was able to explain why the jawbone is the exclusive target [18, 173]. 
However, microbial infection in the pathogenesis of MRONJ is debatable and is not fully 
elucidated with few publications referring to the importance of infection as a prime 
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component in the multifactorial disease [31, 173, 181]. In our study, we have confirmed the 
presence of actinomyces in the bone samples but it is not clearly known whether 
osteonecrosis occurs first and then infection of the necrotic lesion or infected lesion 
undergoes osteonecrosis [187, 188]. There are some evidences showing that infection is 
necessary for osteonecrosis with formation of a bacterial biofilm in the lesion [18, 189, 190] 
as the oral cavity is occupied by hundreds of bacterial species existing as mixed biofilm. 
When the patient immunity is decreased, those microorganisms show opportunistic infection 
as actinomyces which are dominant pathogenic microorganisms detected at MRONJ by 
histopathological studies [191].  
From our results, we confirmed that PCR using 16S rRNA was useful in identifying 
actinomyces directly from bone samples. PCR targeting the 16S rRNA gene of the 
actinomyces is highly conserved within species of the same genus and is thus considered the 
new standard for classification and identification of bacteria as well as a reliable method for 
the distinction of species that are difficult to cultivate [192, 193]. PCR is superior to 
microbiological cultures in diagnosis of oral actinomyces as being highly sensitive and 
rapidly detecting actinomyces either dead or alive. Another advantage is that it quantifies 
DNA rather than viable organisms. However, culturing methods cannot detect non-viable 
bacteria [194]. Previous studies have used different molecular methodologies to identify and 
differentiate actinomyces from oral samples after anaerobic cultivation, including PCR-RFLP, 
chromosomal DNA fingerprinting, 16S rRNA gene sequencing and oligonucleotide–DNA 
hybridization using universal primers or oligonucleotide probes [195-197].  
Fifty-three (96.4%) of the 55 bone samples reacted positively with the universal primer pair 
designed for actinomyces suggesting their presence. These results show that PCR targeting 
the 16S rRNA region can be used to detect actinomyces in MRONJ bone samples.  
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Microbiological cultures were used as a traditional technique to identify actinomyces from 
bone samples. Anaerobic culturing was done in all 95 samples. However, these results were 
confirmed by PCR for 55 bone samples. The positive PCR results of the bone samples that 
were negative to culture were attributed to the high sensitivity of the PCR compared to culture 
methods, the way of transporting the specimens to the laboratory, death of some actinomyces 
during culturing and the inhibition of growth of actinomyces by the presence of other 
organisms affecting their ability to grow in culture. However, DNA from dead organisms can 
still be detected by PCR as explained by another study [194]. 
From our results, MRONJ occurred in the mandible twice as likely to be affected as in the 
maxilla which was in agreement with previous studies [198, 199]. Age older than 65 years 
was found to be a risk factor for MRONJ. Some studies recognized no statistically significant 
correlation between ageing and MRONJ [200] whereas others have included advanced age as 
a potential co-factor [201]. Correlations between MRONJ and comorbidities as diabetes 
mellitus, cardiovascular disease, chemotherapy or steroid intake have been discussed. These 
comorbidities affect bone remodelling by microvascular ischemia and compromised wound 
healing as well as impaired osteoblastic differentiation and function  and the additional 
immunosuppressive and antiangiogenic effects [35, 202]. The great majority of MRONJ 
occur in females. The reason for the female dominance seems to be due to the higher number 
of breast cancer patients compared with prostate cancer patients and the greater prevalence of 
osteoporosis in females than in men [201]. MRONJ has been reported in patients with 
malignancies, particularly in those with breast and prostate cancer. [203] The profile of 
patients affected by this complication seems to show a similar pattern in our study. The 
majority of patients presented with MRONJ were at stages II which is comparable to findings 
in other studies [137, 151]. The classic clinical presentation of MRONJ is bone exposure with 
signs of infection, swelling and a purulent discharge [204]. Our study has corroborated that 
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MRONJ is more frequent in subjects on intravenous bisphosphonates as reported elsewhere 
[140, 161]. The cumulative risk of developing MRONJ was significantly greater in patients 
receiving zoledronic acid.  
Although no consensus has been reached regarding the mechanism of MRONJ, in the present 
study, MRONJ developed either spontaneously or due to dentoalveolar reasons as tooth 
extraction, periodontal disease and denture trauma. Previous studies had shown that dental 
treatment is a risk factor for developing MRONJ [135]. In contrast, some studies had proved 
that tooth extraction and dentoalveolar surgical procedures aimed at treating and curing local 
infections leading to decreased risk for the development of MRONJ [205-207]. local 
infections were treated and overcome by the removal of infected teeth and suspicious bony 
lesions, and by antibiotic treatment and mucosal coverage of the extraction wounds, 
protecting the extraction sockets from bacterial ingrowth after extraction [206]. 
One limitation of this study was that there was no control group of untreated MRONJ 
patients. In addition, no non-MRONJ patients were characterized for bacterial species. The 
number of patients was reduced from 150 to 95 due to the incomplete records or absence of 
histopathological, microbiological or PCR diagnosis.  
CONCLUSION 
The pathogenesis of MRONJ had raised many questions regarding the potential mechanisms 
underlying the pathophysiology with special attention to the role of microbial infection. 
Actinomyces were the most frequent microorganisms in the disease. However, this does not 
necessarily lead to the pathogenic role. PCR was found to be the most reliable method for the 
detection of these microorganisms. 
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4. PUBLICATION IV 
TREATMENT STRATEGIES AND OUTCOMES OF BISPHOSPHONATE 
RELATED OSTEONECROSIS OF JAW (BRONJ) WITH CHARACTERIZATION 
OF PATIENTS: A SYSTEMATIC REVIEW 
Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Int J Oral Maxillofac 
Surg. 2015;44(5):568-85. 
ABSTRACT 
The aim of this systematic review was to answer the question: What are the treatments 
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their outcomes? 
A literature search of PubMed, Cochrane Library, and Web of Science databases was 
conducted in accordance with the PRISMA statement, search phrases were (‘jaw 
osteonecrosis’ OR ‘bisphosphonate-related osteonecrosis’ OR ‘bisphosphonate 
osteonecrosis’) AND (‘treatment’ OR ‘outcomes’). Ninety-seven articles published between 
2003 and February 2014 were reviewed. The studies reported 4879 cases of BRONJ. The 
mean age of the patients was 66.5±4.7 years. The male to female ratio was 1:2. The mean 
duration of bisphosphonate (BP) administration was 38.2±15.7 months. The quality of the 
publications was good, with some moderate and poor. Minimally invasive surgical treatment 
was the treatment most used. Medical treatment was also used. Adjunctive treatments 
included laser, growth factors, hyperbaric oxygen and ozone. The articles provided a broad 
range of outcome variables to assess the treatment of BRONJ and the outcomes of each 
treatment. Considerable heterogeneity was found regarding study design, sample size, and 
treatment modalities. Clinical trials with larger samples are required to provide sufficient 
information for each treatment modality to predict the outcomes of each treatment.  
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INTRODUCTION 
Bisphosphonates (BPs) are a class of drugs [208] used across a wide range of disciplines 
including endocrinology, oncology, orthopaedics and dentistry [209]. They are commonly 
prescribed for bone diseases[208] as in osteoporosis, Paget’s disease of bone, hypercalcemia 
of malignancy, osteolytic bone metastases and osteolytic lesions of multiple myeloma [210, 
211]. Their use has resulted in a statistically significant reduction in skeletal complications, 
including pathologic fractures, spinal cord compression, hypercalcemia of malignant disease 
and the need for subsequent radiotherapy or surgery to bone [212-214]. 
BPs are synthetic analogues of the naturally occurring pyrophosphate molecule that may be 
broadly classified on the basis of whether or not they contain a nitrogen atom, with nitrogen-
containing bisphosphonates (N-BPs) being more potent than non-N-BPs [215]. They differ 
one from another in the substitution of the active side chains on their phosphorous-carbon 
phosphorous structural backbone.  
BPs mechanism of action is the inhibition of bone resorption by suppressing osteoclast 
activation and inducing osteoclast apoptosis [216, 217]. The efficacy of BP has been 
established in several studies [218-221]. However, the use of bisphosphonates may have side 
effects[222].Bisphosphonate related osteonecrosis of the Jaw (BRONJ) has been 
characterized as a main side effect of bisphosphonate therapy [223-225].The first descriptions 
of BRONJ were in 2003 [226-228]. Since then, numerous reports have been published for the 
development of osteonecrosis of the jaw in patients treated with bisphosphonates [134, 229-
240]. 
BRONJ lesions may remain silent till the occurrence of outcoming events such as [241] 
invasive dental procedures, infections, mechanical trauma to the jawbone as well as 
concomitant use of immunosuppressive and chemotherapy drugs [242, 243]. According to 
recent position paper by the American association of Oral and Maxillofacial Surgeons 
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(AAOMS) , risk factors for the development of BRONJ can be grouped as drug-related, local, 
demographic and systematic, genetic and preventive [29]. The clinical manifestation of 
BRONJ may vary from having necrotic bone exposure ranging from a few millimetres to 
larger areas, which can be asymptomatic for weeks, months, or years [244],simple swellings 
of soft tissues, abscesses to more complex cases presenting with fistulas and diffuse pain 
[245]. 
There are two major theories regarding the pathophysiology of BRONJ. One is the osteoclast-
based, ‘‘inside-out,’’ theory, in which inhibition of osteoclastic activity and marked 
suppression of bone turnover, together with spread of physiologic micro-damage and possibly 
local infection, leads to bone death within the jaw, with subsequent exposure. As such, the 
bone exposure would be a late event. The second, ‘‘outside-in,’’ theory suggests a break in 
the oral mucosa leads to ingress of bacteria and local infection which, coupled with poor bone 
remodelling leads to bone death. BRONJ may result from a combination of these two 
mechanisms and hypovascularity also may play an important role [246, 247]. Although there 
have been reports with no obvious co-morbidity factors. It is reasonable to believe that co-
factors play a relevant role in the development of these lesions [230, 248]. 
Management of BRONJ has centred on efforts to eliminate or reduce severity of symptoms, to 
slow or prevent the progression of disease and to eradicate diseased bone[249]. There is 
currently no gold standard for the treatment of BRONJ. Several treatment options have been 
described in relation to the AAOMS staging of (BRONJ) [250]. No agreement on a surgical 
versus non-surgical approach to therapy has been reached in the treatment of BRONJ[136, 
251-253]. Some recommendations focus on prevention and a conservative approach [134, 
226, 232, 254]. 
Treatment strategies are administering antibiotics, oral antibacterial mouth rinse, stop of BPs 
if possible, pain control, surgical debridement or resection for long-term palliation of 
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infection and pain[230, 254] , sequential removal of sequestra and extensive involvement may 
necessitate large area of debridement to include  segmental mandibulectomy and partial 
maxillectomy [230], mandibular reconstruction with the fibula flap [255], cover the exposed 
areas with tissue flaps [226].  Hyperbaric oxygen therapy, fluorescence-guided bone 
resection, and low-intensity laser therapy have been also studied as therapeutic tools [143, 
253, 256, 257].  
Other treatment modalities that increase bone wound healing using growth and differentiation 
factors are being studied [258, 259], or transplantation of intralesional autologous bone 
marrow stem cell [260]. Recently, Teriparatide (N-terminal 34 amino acids of recombinant 
human parathyroid hormone) was reported for medical treatment of BRONJ[261]. 
Pentoxifylline and α-tocopherol in addition to antimicrobial therapy decreased area of bone 
exposure and symptoms in BRONJ patients [262]. The use of ozone in combination with 
antibiotics and surgery for patients with exposed bone lesions was also subject to clinical 
investigation and found to resolve pain, secretions, and halitosis [263]. 
Therefore, the main objective of this study were to conduct systematic review of literature to 
determine  (a) available treatment strategies for BRONJ describing (b) the outcome variables 
measured by each treatment modality,(c) success of the treatment expressed by the outcome. 
MATERIALS AND METHODS 
All the included studies were subjected to a Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [264]. PRISMA consists of a 27 item 
checklist and a four-phase flow diagram that relates to the title, abstract, introduction, 
methods, results, and discussion sections of articles and funding. They were developed based 
on recommendations on what should be included in an accurate and complete report of 
systematic reviews and meta-analyses. 
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The systematic search included the time period 2003, the year of the initial description of 
BRONJ to 28th of February 2014. All publications identified in the literature search were 
retrieved from online journals and selected on the basis of the inclusion criteria. 
Inclusion Criteria 
(a) Academic publications; the review included any published studies (cross-sectional 
surveys, cohort and case-control studies), clinical trials, case series and retrospective studies 
(b) in English language confirming diagnosis of BRONJ by AAOMS (American Association 
of Oral and Maxillofacial Surgeons) or ASBMR (American Society of Bone and Mineral 
Research); (c) studies on humans ;(d) Participants of any age and gender with clinical 
diagnosis of BRONJ; (e) any form of treatment; (f) outcomes variables should be mentioned 
in the publication; (g) outcome of the treatment. 
Exclusion Criteria 
(a) Single case reports of BRONJ (b) Experimental laboratory studies (c) Case series with less 
than 5 patients (d) literature reviews, Letters, editorials, PhD theses and abstracts were 
excluded. 
Disease Definition 
The disease definition as proposed by AAOMS and ASBMR   included the persistence of 
exposed necrotic bone in the oral cavity for 8 weeks, despite adequate treatment, in a patient 
with current or previous history of bisphosphonate use, without local evidence of malignancy 
and no prior radiotherapy to the affected region [140, 231, 245, 265] . 
A clinical staging system has been proposed to classify patients with established BRONJ with 
appropriate treatment for each stage [231, 245, 265, 266] (Table  4.1). 
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Table  4.1: Staging and treatment of bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) according to AAOMS 
 
 
BRONJ Stage 
 
Clinical Conditions 
 
Treatment Strategies 
At risk No apparent necrotic bone in patients who have been 
treated with either oral or IV bisphosphonates. 
No treatment indicated. 
Patient education. 
Stage 0 No clinical evidence of necrotic bone, but non-
specific clinical findings and symptoms. 
Systemic management, including the 
use of pain medication and antibiotics. 
Stage 1 Exposed and necrotic bone in asymptomatic 
patients without evidence of infection 
Oral anti-bacterial mouth rinse. 
Clinical follow-up on a quarterly basis. 
Patient education and review of 
indications for continued BP use. 
Stage 2 Exposed and necrotic bone associated with infection 
as evidenced by pain and erythema in region of 
exposed bone with or without purulent drainage. 
Symptomatic treatment with oral 
antibiotics 
Oral anti-bacterial mouth rinse 
Pain control 
Superficial debridement to relieve soft 
tissue irritation 
Stage 3 Exposed necrotic bone in patients with pain and 
erythema and one or more of the following: exposed 
and necrotic bone extending beyond the region of 
alveolar bone, such as inferior border and ramus in 
the mandible, maxillary sinus or zygoma in the 
maxilla, resulting in pathologic fracture, extra-oral fi- 
stula, oral antral/oral nasal communication, or 
osteolysis extending to the inferior border of the 
mandible or to the maxillary sinus floor 
Oral anti-bacterial mouth rinse 
Antibiotic therapy and pain control 
Debridement/surgical resection for 
prolonged relieve of pain and infection 
 
Electronic database search:  
Three databases – PubMed, Cochrane Library, and Web of Science– were electronically 
searched. The heading sequence (“jaw osteonecrosis” OR “bisphosphonate-related 
osteonecrosis” OR “bisphosphonate osteonecrosis”) AND (“treatment” OR “outcomes”) were 
searched as text word. The results of the database searches were combined and duplicate 
articles were excluded. All references were gathered and screened for eligibility.  
First round search 
Abstracts were reviewed and all articles containing the keywords were retained. Articles that 
were not in English were excluded. Complete versions were then obtained for all the articles 
that that met the inclusion criteria. 
Second round search and evaluation 
A manual search was done of the reference lists of all the articles retained after the first round 
for appropriate studies relevant to the review topic. A search for unpublished literature was 
not performed. Literature reviews and systematic reviews also were considered with the 
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objective of identifying cases already reported. All the articles were fully read for final 
selection. 
Third round search 
Each of the publications included in this round was critically appraised for assessment of 
validity and the following data were extracted from the accepted articles onto a standardized 
spreadsheet: Reference & year, Study design, Number of patients in study, Mean age of 
patients, Gender of patients, Location of the lesions, Primary cause of the BRONJ, Type of 
BPs used, Route of administration of BP used, Range of duration of use of BP Triggering 
factors, Co-morbidities, Treatment methods, Outcome variables measured, follow up period, 
outcomes of the different treatments. 
Statistical Analysis 
The duration of BP exposure was defined as time in months from the date of first BP infusion 
administered to the last recorded infusion. 
A qualitative data analysis was performed with the aim of summarizing the results of the 
included studies. The mean age of patients with ONJ and the ratio of male to female patients 
were calculated to determine whether any particular stratum had a greater predisposition to 
develop ONJ than another. The existence of potential risk factors for ONJ was examined; the 
mean dose and range; the treatment duration; and the proportions of patients receiving 
immunosuppressant therapy (eg. corticosteroids) or other comorbidities or a history of dental 
trauma, infection, or surgical procedures. 
The quality of accepted publications was assessed based on a modification of the ASBMR 
[140] by reporting of 12 parameters for all patients diagnosed with BRONJ: age, sex, primary 
cause of the disease, name of bisphosphonate, duration, mode of administration, affected site, 
medical history (concomitant medications, comorbidities), triggering factors, treatment , 
outcome variable measured and treatment outcome. The quality of each publication was 
Publication IV: BRONJ Systematic Review 
Page 66 
classified as good (10-12 variables reported), moderate (5-9 variables), or poor (1-4 
variables). 
RESULTS 
Literature search results 
The results of the literature search are presented by flow chart showing study selection 
according to the PRISMA statement (2009) [264].The initial search strategy yielded 1355 
titles/abstracts from the databases analysed: 1085 from PubMed, 235 from Web of Science, 
35 from Cochrane Library and 5 additional articles were identified through a hand search of 
relevant reference lists, bringing the number of accepted articles to 1360. After title and 
abstract screening, and/or paper analyses, 300 potentially relevant were accepted for article 
retrieval and full-text review. 200 papers were included in the qualitative synthesis and finally 
103 papers were excluded after a preliminary review due to non-compliance with the 
inclusion/exclusion criteria, lack of outcome, not related to our proposed research question or 
irrelevancy (Figure  4.1).  
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Figure  4.1: Flow chart of the study. 
Flow chart of the search strategy and study selection 
used in this systematic review. 
The remaining 97 articles were included in the final review describing 4879 cases of BRONJ. 
The quality of the publications were between poor, moderate and good where 79 publications 
were classified as good (81.5%) and 16 publications were classified as moderate (16.4%) and 
2 publications as poor (2.1%). Of the 97 accepted publications, 35 (36.1%) were case series 
[134, 136, 138, 153, 176, 255, 256, 262, 267-293], 3 (3.1%) were clinical trials [294-296] , 18 
(18.5%) prospective [130, 131, 133, 144, 158, 162, 199, 297-307], 37 (38.2%) retrospective 
studies [132, 137, 164, 165, 198, 202, 224, 241, 249, 308-335] and 4 (4.1%)  clinical reports 
[336-339] (Table  4.2)  
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Table  4.2: Summary of the publications for the systematic review with the study design, 
total number of patients, mean age of patients in years, administration time of BRONJ 
in months and treatment modalities. 
REFERENCE STUDY  DESIGN 
NUMBER  
OF PTS AGE 
ADMIN 
TIME FOR 
BP(MONTHS) 
QUALITY OF 
PUBLICATION TREATMENT 
Thumbigere-Math  2009 
[198] 
Retro 26 64 45.8 G  
 
 
 
 
 
 
Medical and 
Minimal invasive 
Surgery 
 
Thumbigere-Math  
2012[308] 
Retro 18 60 44.3 G 
Anavi-Lev  2013 [293] CS 52 70.7 40 G 
Holzinger  2013 [297] Prosp 88 N/P N/P M 
Saussez  2009 [315] Retro 34 62 34.5 G 
Montebugnoli  2007[136] CS 16 61.2 17.9 G 
Dannemann 2006 [270] CS 14 65 N/P G 
Beninati  2013 [298] Prosp 51 68 41 G 
Alons 2009 [316] Retro 7 66.9 55.2 G 
Lazarovici 2009 [176] CS 101 63.5 48.5 G 
Junquera 2009 [273] CS 21 65.1 25 G 
Stanton 2009 [318] Retro 33 64.5 N/P G 
Estilo 2008 [319] Retro 28 N/P 34.1 G 
Dimitrakopoulos 2006 [320] Retro 11 61 6 G 
Fortuna 2012[299] Prosp 26 68.4 23.3 G 
Abu Id 2008 [322] Retro 78 65.6 12 G 
Pozzi 2007 [323] Retro 35 70 36 G 
Williamson 2010 [300] Prosp 40 64 N/P G 
Longobardi  2007 [276] CS 18 55 42.3 G 
Wutzl  2008 [303] Prosp 58 68.3 35.5 G 
O'Ryan & Lo 2012 [202] Retro 30 77 52.8 G 
Scoletta  2010 [306] Prosp 37 68 25.5 G 
Nomura 2013 [287] CS 13 71.2 29.6 G 
Jabbour 2012 [288] CS 14 69 37.5 G 
Mücke  2011 [144] Prosp 108 68.5 N/P M  
 
Medical, Minimal 
invasive and Major 
Surgery 
Mortensen  2007 [269] CS 7 66 N/P G 
O'Ryan  2009 [137] Retro 59 61.4 N/P G 
Elad  2006 [337] CR 57 62.7 N/P G 
Stockmann  2010 [131] Prosp 50 69.5 31 G 
Ibrahim  2008 [224] Retro 8 66.5 14.6 G 
Kim  2012 [335] Retro 21 64.3 30 G 
Yarom 2007 [317] Retro 11 69.7 49.2 G 
Hong  2010 [327] Retro 24 72.1 43.1 G 
Lerman  2013 [340] Retro 120 63 36 G 
Maurer 2011 [326] Retro 21 69 47.4 G 
Hansen  2013 [339] CR 37 N/P N/P P 
Hoefert  2011 [312] Retro 47 66.1 41.9 G  
 
 
Medical 
Marx  2005 [134] CS 119 N/P N/P G 
Van den Wyngaert 2009 
[338] 
CR 33 58 27 G 
Moretti 2011 [301] Prosp 34 69.0 39 G 
Alsehimy 2014 [302] Prosp 96 66.5 N/P G 
Lazarovici  2010 [285] CS 27 70 N/P G 
Nicolatou-Galitis  2011[341] Prosp 63 63.6 37.1 G 
Epstein  2010 [262] CS 6 75 74.6 G 
Vescovi 2011 [342] Retro 567 67.2 N/P G  
Minimal invasive 
Surgery 
 
Graziani 2012[165] Retro 347 67 23 G 
Mercer 2013 [321] Retro 91 69.8 60 G 
kos 2010 [324] Retro 18 67.0 34.9 G 
Wutzl  2006 [278] CS 17 64.8 32 G 
Ferlito  2012[292] CS 94 66 24 M 
Schubert  2012 [307] Prosp 258 N/P N/P M 
Retro: retrospective CS: Case Series, Prosp: Prospective, RCT: Random Clinical Trial, CR: Clinical Report  N/P: not reported G: Good M: 
Moderate P: Poor 
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Table 4.2: Summary of the publications for the systematic review with the study design, 
total number of patients, mean age of patients in years, administration time of BRONJ 
in months and treatment modalities. 
REFERENCE STUDY  DESIGN 
NUMBER  
OF PTS AGE 
ADMIN 
TIME FOR  
BP(MONTHS) 
QUALITY OF 
PUBLICATION TREATMENT 
Rugani  2010[267] CS 5 75.4 36 G  
 
 
 
 
 
 
 
Laser 
 
 
 
 
  
Romeo  2011 [268] CS 12 62 N/P M 
Angiero  2009 [310] Retro 49 69.7 14.8 G 
Stübinger 2009 [336] CR 8 59.1 53 G 
Vescovi 2014[311] Retro 63 N/P N/P M 
Vescovi 2012 [271] CS 151 66.6 48.2 G 
Vescovi 2007 [274] CS 19 71 N/P M 
Manfredi 2011 [325] Retro 25 70.4 55.9 G 
Atalay 2011 [331] Retro 20 55.4 32.4 G 
Scoletta  2010 [304] Prosp 20 71.3 42.9 G 
Rugani 2013 [343] CS 12 63.9 N/P M 
Vescovi 2010 [333] Retro 91 67 N/P M 
Vescovi 2008 [289] CS 28 70.3 N/P M 
Martins 2012 [309] Retro 22 58.09 24.68 G 
Curi  2011 [272] CS 25 60.7 N/P G  
Growth factor 
(PRP or BMP2) 
Mozzati  2012 [328] Retro 32 69.7 37 G 
Bocanegra-Perez  2012 [305] Prosp 8 66.3 1 G 
Coviello  2012 [291] CS 7 75.57 66 G 
Cicciu  2012 [282] CS 20 N/P N/P P 
Ripamonti  2011[294] RCT 10 65 N/P M  
Ozone Agrillo  2007 [275] CS 58 64 N/P M 
Ripamonti  2012 [296] RCT 24 62.5 N/P G 
Agrillo  2012 [241] Retro 131 60 N/P G 
Boonyapakorn  2008 [199] Prosp 22 61.1 N/P G  
Discontinuation 
  of BP 
Urade  2011 [329] Retro 263 68.1 N/P G 
Park 2010 [279] CS 5 72.6 79.2 G 
Watters  2013 [138] CS 109 64 N/P G 
Wilde  2011 [332] Retro 24 N/P N/P G 
Chiu  2010 [277] CS 12 69.7 67.2 G  
Hyperbaric    
Oxygen 
Freiberger  2012 [295] RCT 22 66.1 N/P M 
Freiberger  2007[256] CS 16 N/P 18 M 
Kwon  2012 [281] CS 6 77.5 55.2 G  
Teriparatide Narvaez  2013 [286] CS 7 72 55.2 G 
KM Kim  2014 [334] Retro 15 77.1 45.6 G 
Pautke  2011 [130] prosp 15 63.2 44.4 G 
Guided 
debridment 
 
Fleisher  2008 [153] CS 10 N/P N/P M 
Seth  2010 [314] retro 11 61.3 N/P G  
 
 
Major Surgery 
 
Carlson & Basile 2009 [133] prosp 82 N/P N/P M 
Badros 2006 [330] retro 22 61 N/P G 
Bedgoni  2011[162] prosp 30 66 N/P G 
Jacobsen  2012 [164] retro 110 67 N/P G 
Voss  2012 [132] retro 21 68.5 40.1 G 
Hanasono  2013 [290] CS 13 66.6 N/P G 
Nocini  2009[255] CS 7 61 N/P G 
Lemound  2012 [284] CS 20 68 34.8 G 
Blus  2013 [283] CS 8 71.3 32 G 
Total  4879 66.5±4.7 38.2±15.7   
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Age and Gender 
A total of 4879 patients were identified and treated in the 97 publications with a mean age of 
66.5 ± 4.7years. In the 4481 cases in which the sex distribution was reported, 1471 were male 
patients (32.8 %) and 3010 were female patients (67.2 %) with a female predilection in the 
ratio of 2:1 among all reported cases.  
BRONJ characteristics 
Eighty nine publications described the site of BRONJ in 4627 patients receiving 
bisphosphonates while only 8 publications [262, 286, 292, 293, 295, 296, 304, 339] , the site 
were not reported. BRONJ lesions were located most commonly in the mandible in 3011 
patient (65.1%), followed by the maxilla in 1320 patients (28.5 %) or both jaws in 296 
patients (6.4 %). 
Primary cause of Disease 
Bisphosphonate therapy was started in 4602 cases for the following indications:  1434 cases 
multiple myeloma (31.2%), 1359 cases breast cancer (29.5%), 903 cases in osteoporosis 
(19.7%) ,442 cases prostate cancer (9.6%), , 116 cases in metastasis (2.5%) and 348 cases in 
other cancers (7.6%) including lung, renal and bladder carcinoma in the review. Most patients 
(60.7 %) had multiple myeloma or metastatic breast cancer. 
Characteristics of Bisphosphonate Treatment 
The bisphosphonate prescribed was specified for all 4118 patients with BRONJ. Overall, 
2427 (58.9%) patients received zoledronate, 571(13.9%) patients received pamidronate, 523 
(12.7%) patients received alendronate, 128 (3.1%) patients received ibandronate, 469 patients 
received a combination of bisphosphonates. 
Bisphosphonate treatment was principally intravenous (IV) in 3245 patients (83.2%) while 
656 patients (16.8%) received oral bisphosphonates. 
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Duration of Treatment 
There was variability in the duration of BP therapy ranging from 1 to 79.2 months with mean 
duration of BP therapy 38.2 ± 15.7. 
Triggering factors and Comorbidities 
The most important triggering factors for the development of BRONJ were described in 3198 
cases in the included articles, whereby tooth extraction was the principal cause in 1974 
patients (61.7%), trauma from manipulation of dental implants in 123 cases ( 3.9 %). A 
history of dental surgery was reported for 230 patients (7.2 %); 159 cases (5.0 %) were 
reported in periodontal diseases and prosthesis-induced trauma in 237 cases (7.4 %). A large 
proportion of BRONJ lesions appeared spontaneously in 475 patients (14.8%). 
With regard to concomitant diseases and medication, 2674 patients had comorbidities: 
diabetes mellitus was observed in 298 patients (11.2%) , 225 (8.4%) patients were 
hypertensive, 1062 (39.7%) patients were under chemotherapy, 215 (8.0%) patients were 
smoking, 108 (4.0%) patients had thrombocoagulopathies, 658 (24.6%) were taking 
corticosteroids and 108 (4.1%) were free from any concomitant diseases. The incidence of 
BRONJ was associated with chemotherapy (39.7%) of the patients compared to corticosteroid 
therapy (24.6%). Characteristics of patients diagnosed with BRONJ in the included articles 
are shown in (Table  4.3). 
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Table  4.3: Characteristics of patients diagnosed with BRONJ. 
 
Characteristics Details Number Percentage (%) 
Gender Male 1471 32.8 
Female 3010 67.2 
Location Maxilla 1320 28.5 
Mandible 3011 65.1 
Both 296 6.4 
Primary cause of the 
disease 
Multiple Myeloma 1434 31.1 
Breast cancer 1359 29.5 
osteoporosis 903 19.7 
Prostate cancer 442 9.6 
Other cancers 348 7.6 
Metastasis 116 2.5 
Type of BP 
adminstrated 
Zoledronate 2427 58.9 
Pamidronate 571 13.9 
Alendronate 523 12.7 
Ibandronate 128 3.1 
Combination 469 11.4 
Route of administration 
of BP 
IV 3245 83.2 
Oral 656 16.8 
Triggering factors Extraction 1974 61.7 
Dental implant 123 3.9 
Dental surgery 230 7.2 
Periodontal disease 159 5.0 
Prosthetic trauma 237 7.4 
Spontaneous 475 14.8 
Comorbidities Diabetes 298 11.2 
Corticosteroids 658 24.6 
Hypertension 225 8.4 
Thrombosis 108 4.0 
Smoking 215 8.0 
Chemotherapy 1062 39.7 
None 108 4.1 
 
Management of Osteonecrosis of the Jaw with the outcome of each treatment 
Regarding the management of the BRONJ lesions, the studies showed discontinuation of BP 
administration (5.1%) in addition to treatment either by medical therapy (50%) or minimal 
invasive surgical therapy (45.9%) whereas (22.4%) of patients underwent major surgical 
procedures, such as segmental resection of the jaw bones. 
Various adjunctive treatments such as hyperbaric oxygen therapy, laser therapy, ozone 
therapy, Teriparatide, Fluorescence guided debridement, treatment with growth factors (PRP 
or BMP 2), Piezotherapy had also being mentioned. 
Medical treatment of BRONJ was reported in 49 publications [131, 134, 136, 137, 144, 158, 
176, 198, 199, 202, 224, 249, 262, 269, 270, 273, 276, 279, 285, 287, 288, 293, 297-303, 306, 
308, 310, 312, 315-323, 325-327, 329, 332, 335, 337, 338] and minimal invasive surgical 
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treatment in 44 publications.[131, 134, 136, 137, 144, 165, 176, 199, 202, 224, 249, 269, 270, 
273, 276, 278, 287, 288, 292, 297-300, 303, 306, 307, 313, 315-324, 327, 329, 335, 337, 339]. 
Major Surgical intervention was delivered to 22 publications [131-133, 137, 144, 162, 164, 
224, 249, 269, 290, 314, 317, 325-327, 329, 330, 332, 335, 337, 339] including use of surgical 
flaps in 2 publications [255, 284] and Piezotherapy [283]. Laser therapy  was reported in 13 
publications [267, 268, 271, 274, 280, 289, 304, 309-311, 325, 331, 333, 336]  , ozone therapy 
in 4 publications [241, 275, 294, 296], Platelet rich plasma in 5 publications [272, 291, 305, 
309, 328] and BMP2 [282], hyperbaric oxygen  in 3 publications [256, 277, 295], teriparatide 
in 3 publications [281, 286, 334]. Fluorescence or tetracycline guided debridement was 
reported in 2 publications [130, 153]. 
715 patients were treated by medical and minimal invasive surgical treatment, 422 patients 
were treated by medical, minimal invasive and major surgical treatment, 286 patients were 
treated by medical treatment only, 767 patients were treated by minimal invasive surgical 
treatment, 252 patients were treated by major surgical treatment, 25 patients were treated by 
guided debridement, 322 patients were treated by laser treatment, 92 patients were treated by 
growth factors treatment, 161 patients were treated by major surgical treatment, 361 patients 
stopped BP treatment in addition to other treatment modalities, 45 patients were treated by 
hyperbaric oxygen, 27 patients were treated by teriparatide (Table  4.4). 
The outcome of the treatment was classified as: complete healing (CH)—complete regrowth 
of oral mucosa over previously exposed bone; partial healing (PH)—either a decrease in 
lesion size (largest linear dimension) or the number of lesions and/or cessation of pain or 
signs of infection; stable disease—no improvement in clinical signs or symptoms; or 
progressive disease—increase in the size or number of lesions or increased pain and severity 
of infection; Regressive disease—decrease in the size or number of lesions or decreased pain 
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and severity of infection and a negligible or no healing (NH) when there was no sign of 
improvement.  
The outcomes of the treatment modalities of the BRONJ were assessed in 3475 patients. 
Outcome of the different treatment modalities were compared as following (Table  4.4). 
Medical and Minimal invasive surgical treatment 
715 patients were treated by medical and conservative surgical treatment; 278 patients 
(38.9%) showed CH, 125 patients (17.5%) showed PH, 94 patients (13.1%) had stable lesions, 
52 patients (7.3%) had progressive lesions, 64 patients (9%) had regressive lesions, only 5 
patients (0.7%) had recurrent lesions,97 patients (13.6%) had NH lesions.  
Medical, Minimal invasive and Major Surgical treatment 
422 patients were treated by medical, conservative and surgical treatment; 169 patients (40%) 
showed CH, 105 patients (24.9%) showed PH, 34 patients (8.1%) had stable lesions, 19 
patients (4.5%) had progressive lesions, 5 patients (1.2%) had regressive lesions, 47 patients 
(11.1%) had recurrent lesions, 43 patients (10.2%) had NH lesions.  
Medical treatment only 
286 patients were treated by medical treatment; 129 patients (45.1%) showed CH, 52 patients 
(18.2%) showed PH, 23 patients (8%) had stable lesions, 8 patients (2.7%) had progressive 
lesions, 52 patients (18.2%) had regressive lesions, 20 patients (6.9%) had recurrent lesions, 2 
patients (0.7%) had NH lesions.   
Minimal invasive surgical treatment 
767 patients were treated by conservative surgical treatment; 301 patients (39.2%) showed 
CH, zero patients (0%) showed PH, 152 patients (19.8%) had stable lesions, 61 patients (8%) 
had progressive lesions, 231 patients (30.1%) had regressive lesions, 0 patients (0%) had 
recurrent lesions, 22 patients (2.9%) had NH lesions.  
Major Surgical treatment 
252 patients were treated by surgical treatment; 207 patients (82.1%) showed CH, 11 patients 
(4.4%) showed PH, 8 patients (3.2%) had stable lesions, 5 patients (2%) had progressive 
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lesions, zero patients (0%) had regressive lesions, 11 patients (4.4%) had recurrent lesions, 10 
patients (4%) had NH lesions.  
Guided Debridement treatment 
25 patients were treated by guided debridement; 12 patients (48%) showed CH, 10 patients 
(40%) showed PH, zero patients (0%) had stable lesions, 1 patient (4%) had progressive 
lesions, zero patients (0%) had regressive lesions, zero patients (0%) had recurrent lesions, 2 
patients (8%) had NH lesions.  
Laser treatment 
322 patients were treated by laser treatment; 146 patients (45.3%) showed CH, 18 patients 
(5.6%) showed PH, 81 patients (25.2%) had stable lesions, 5 patients (1.6%) had progressive 
lesions, 33 patients (10.2%) had regressive lesions, 2 patients (0.6%) had recurrent lesions, 37 
patients (11.5%) had NH lesions.  
Growth factor (PRP & BMP2) treatment 
92 patients were treated by growth factors treatment; 75 patients (81.5%) showed CH, 2 
patients (2.2%) showed PH, 6 patients (6.5%) had stable lesions, zero patients (0%) had 
progressive lesions, 8 patients (8.7%) had regressive lesions, 1 patient (1.1%) had recurrent 
lesions and zero patients (0%) had NH lesions.  
Ozone treatment 
161 patients were treated by surgical treatment; 93 patients (57.8%) showed CH, 27 patients 
(16.8%) showed PH, 5 patients (3.1%) had stable lesions, zero patients (0%) had progressive 
lesions, 28 patients (17.4%) had regressive lesions, zero patients (0%) had recurrent lesions, 8 
patients (5%) had NH lesions.  
Discontinuation of BP treatment in addition to other treatment modalities 
361 patients stopped BP treatment; 127 patients (35.2%) showed CH, 27 patients (7.5%) 
showed PH, 142 patients (39.3%) had stable lesions, 50 patients (13.9%) had progressive 
lesions, 3 patients (0.8%) had regressive lesions, 5 patients (1.4%) had recurrent lesions, 7 
patients (1.9%) had NH lesions.  
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Hyperbaric oxygen treatment 
45 patients were treated by hyperbaric oxygen; 12 patients (26.7%) showed CH, 8 patients 
(17.8%) showed PH, 2 patients (4.4%) had stable lesions, 6 patients (13.3%) had progressive 
lesions, 17 patients (37.8%) had regressive lesions, zero patients (0%) had recurrent lesions 
and zero (0%) patients had NH lesions.  
Teriparatide treatment 
27 patients were treated by teriparatide; 22 patients (81.5%) showed CH, 5 patients (18.5%) 
showed PH, zero patients (0%) had stable lesions, zero patients (0%) had progressive lesions, 
zero patients (0%) had regressive lesions, zero patients (0%) had recurrent lesions and zero 
patients (0%) had NH lesions.  
Table  4.4: Outcome of each treatment modality. 
 
 
Treatment 
Outcome 
Number of patients (%) 
Total 
Number 
of 
patients 
(%) 
CH PH St Pr Rgr Rec NH 
Medical and 
minimal 
invasive surgery 
278(38.9) 125(17.5) 94(13.1) 52(7.3) 64(9) 5(0.7) 97(13.6) 715(21.0) 
Medical, 
minimal 
invasive and 
major  surgery 
169(40) 105(24.9) 34(8.1) 19(4.5) 5(1.2) 47(11.1) 43(10.2) 422(12.1) 
Medical 
treatment 
129(45.1) 52(18.2) 23(8) 8(2.7) 52(18.2) 20(6.9) 2(0.7) 286(8.2) 
Minimal 
invasive surgery 
301(39.2) 0(0) 152(19.8) 61(8) 231(30.1) 0(0) 22(2.9) 767(22.0) 
Major surgery 207(82.1) 11(4.4) 8(3.2) 5(2) 0(0) 11(4.4) 10(4) 252(7.3) 
Guided 
debridement 
12(48) 10(40) 0(0) 1(4) 0(0) 0(0) 2(8) 25(0.7) 
Laser therapy 146(45.3) 18(5.6) 81(25.2) 5(1.6) 33(10.2) 2(0.6) 37(11.5) 322(9.2) 
Growth factors 75(81.5) 2(2.2) 6(6.5) 0(0) 8(8.7) 1(1.1) 0(0) 92(2.6) 
Ozone therapy 93(57.8) 27(16.8) 5(3.1) 0(0) 28(17.4) 0(0) 8(5) 161(4.6) 
Discontinuation 
of 
Bisphosphonates 
127(35.2) 27(7.5) 142(39.3) 50(13.9) 3(0.8) 5(1.4) 7(1.9) 361(10.3) 
Hyperbaric 
oxygen 
12(26.7) 8(17.8) 2(4.4) 6(13.3) 17(37.8) 0(0) 0(0) 45(1.2) 
Teriparatide 22(81.5) 5(18.5) 0(0) 0(0) 0(0) 0(0) 0(0) 27(0.8) 
Total 1571(45.2) 390(11.2) 547(15.8) 207(5.9) 441(12.7) 91(2.6) 228(6.6) 3475 
CH: Complete healing, PH: Partial healing, St: Stable lesion, Pr: Progressive lesion, Rgr: Regressive lesion, Rec: 
recurrent lesion NH: Non healing lesion. 
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Follow-up and Treatment Outcome 
After the initial BRONJ treatment, follow-up periods reported only in 80 publications ranged 
from 4 weeks to 50 months with a mean of 12.9 ± 9.9  
Outcome Measures 
A total of 7outcome variables that were used in the studies were identified.  
The most frequently measured outcome was mucosal healing occurring in 47 publications 
(48%). The bone exposure was the next most frequently used (n=30, 30.6%), followed by 
pain (n=31, 31.6%) then change in signs and symptoms (n=28, 28.6%), improvement of stage   
(n=14, 14.3%), reduction in lesion size and number (n=12, 12.2%) and finally infection 
control (n=7, 7.1%). The treatment of BRONJ and the outcome variables measured with the 
mean follow up of each treatment are summarized in (Table  4.5)  
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Table  4.5: Summary of treatment modalities and the outcome variables measured with 
the mean follow up of each treatment 
 
Treatment Outcome variables measured Follow-up  
(months) 
Medical and Minimal 
invasive 
Improved signs and symptoms, decrease in lesion size and number, elimination 
of pain, reduction in soft and hard tissue inflammation ,no bone exposure or 
bone exposure less than 1-2 mm, no suppuration, improvement of stage, 
persistence of fistula, cessation of pus and extra-oral manifestations, mucosal 
coverage, radiographic success(cessation of bony  destruction),presence or 
recurrence of infection, BRONJ at stage 0 
 
11.1±6.6 
Medical, Minimal 
Invasive and Major 
Surgery  
closure of oroantral, fistula, Stage improvement, healing of the lesion, 
extension of exposed bone areas, bone exposure , decrease of pain, healing of 
mucosa, improved signs and symptoms, asymptomatic lesions, patients free 
from symptoms, recurrence of BRONJ, recurrence of sinusitis 
11.6±5.2 
Medical no fistula, reduction of exposed bone, reduction of the pain, closure of the 
mucosal defect, persistence of exposed bone or progressive necrosis, reduction 
of the size of the lesion, size of necrotic lesions, resolution of BRONJ 
manifestations, cessation of pus or purulent secretion, mucosal inflammation, 
signs and symptoms improvement 
16.4±5.2 
Minimal Invasive Surgery improvement of the stage (transition to a less severe stage ), deterioration of 
wound healing, recurrence rate of wound dehiscence, closure of lesion, pain 
reduction, complete healing of soft tissue, signs of inflammation, exposed 
bone, no symptoms of infection for a minimum of 3 months period. 
6.4±3.6 
Laser efficiency of surgical laser application, pain reduction, infection control, 
mucosal healing, no signs and symptoms, healing evaluated radiographically, 
complete removal of visible necrotic bone, absence of new exposed bone near 
surgical area, no signs of infection, stage improvement, size of the lesion, 
oedema, visual analogue score of pain, presence of pus, fistulas and halitosis, 
bone exposure 
10.7±9.7 
Growth factor (PRP or 
BMP2) 
intact and healed mucosa, no exposed necrotic bone, no sign of infection or 
fistula, absence of pain, no radiographic signs of residual infection or evidence 
of, bone sequestration, Bleeding 
18.2±18.3 
Ozone spontaneous explusion or sequestrum of necrotic bone to be removed 
surgically, healed and re-epithelialized mucosa, presence or absence of oral 
mucosa redness around the lesion area, pethechiae or bleeding, pain intensity, 
diminishing of symptoms 
9.9±5.5 
Discontinuation of BP healing of the mucosa, Pain relief, Bleeding, stage improvement, resolution of 
symptoms, presence  or absence of exposed necrotic bone, radiographic 
evidences of BRONJ, no fistulas, absence of swelling 
27.8±29.2 
Hyperbaric Oxygen 
(HBO) 
clinical evidence of symptom relief, pain reduction, absence of sequestrum, 
oral lesion size and number, regrowth of oral mucosa over exposed bone 
20±5.7 
Teriparatide change of the biochemical markers(osteocalcin and c terminal telopeptide 
cross link type I collagen), clinical and radiographic healing, improvement of 
BRONJ stage 
4.5±2.1 
Major Surgery osseous union judged clinically and radiographically without signs of residual 
infection, or exposed bone at the time of evaluation, post-operative 
complication, infection, recurrence of BRONJ, oral pain, exposed bone, 
mucosal healing, percentage of flap survival, percentage of complications at 
the donor and recipient site, symptoms free 
18±5.2 
Guided Debridment closure of mucosa, exposed bone, symptoms free 1.5±0.7 
 
DISCUSSION 
The aim of this systematic review is to summarize the literature concerning the patients 
receiving bisphosphonates, treatments of BRONJ and outcomes of these treatments.  There 
was high clinical heterogeneity among the studies included, which was unsurprising given the 
differing interventions used and the considerable variations in techniques applied and 
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combinations or delivery of interventions. Differences in the search periods may explain the 
higher prevalence of BRONJ in the present review. 
There are some limitations with respect to the search strategy. It is possible that eligible 
studies were missed despite the extended search. Also excluded was the grey literature for the 
reason that basic information such as authorship, publication date, or publishing body may not 
be discerned with certainty.  This review did not include searches of EMBASE, SCOPUS, or 
abstracts from dental, maxillofacial, and surgical conferences which may also have 
contributed to underestimation of the number of reported BRONJ cases. It’s obvious in this 
systematic review the continuously increasing number of BRONJ cases since its first 
appearance. 
The occurrence of BRONJ appears to be related to cumulative dose, duration of treatment and 
type of bisphosphonate [140, 344-347] where a positive correlation occurs with higher doses, 
longer duration of therapy and nitrogen-containing BPs. 
Earlier studies have reported that the type of BP may play a role in BRONJ development, 
particularly the nitrogen containing BP like pamidronate and zoledronate with higher risk 
with zoledronate followed by pamidronate. [134, 135, 201, 230, 245, 344, 345, 348-350] The 
cumulative hazard of developing BRONJ is significantly greater with zoledronate treatment 
than with pamidronate or pamidronate plus zoledronate.[201] [135] due to the more potent 
inhibitory effect on bone turnover rate and stronger anti-resorptive activity of zoledronate 
compared with pamidronate. Zoledronate is 10 to 100 times more potent than pamidronate. 
[351] Consistent with these studies, we noted that most patients in the publications (58.9%) 
had received zoledronate only or pamidronate (13.9%) or zoledronate plus pamidronate 
(11.4%). 
The mean duration of BP treatment was 38.2±15.7 months. It is a crucial factor for the 
development of BRONJ (192). It has been suggested that development of BRONJ requires a 
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long period of exposure (23). As reported in the literature, the risk of developing BRONJ is 
related to the therapy duration and the risk seems to be higher after 3 years of treatment in 
association with clinical risk factors [253]. Recently, Lo et al [352] reported a higher 
prevalence of BRONJ (0.21%) in patients treated with these drugs for more than 4 years, in 
comparison with those treated less than 2.5 years. 
Current data suggests that IV BPs are much more frequently associated with BRONJ than oral 
BPs [201, 253, 353]. This has led to the development of different management strategies for 
patients on oral or IV BPs. This was in accordance with our search that revealed 83.2% of 
BRONJ lesions were developed from IV BPs. The results confirm data from other studies 
indicating that the prevalence of BRONJ is much lower in patients on oral BPs than in 
patients treated with intravenous BPs.[354]  
A greater incidence of BRONJ has been reported in patients with malignancies particularly in 
those with multiple myeloma and breast cancer. [135, 201, 344, 348] Our results agree with 
these reports stating that BRONJ was more frequently noted in patients with multiple 
myeloma and breast cancer compared with prostate cancer, lung cancer, renal cell carcinoma 
and other neoplasm group. 
With regard to a history of invasive dental treatment, 61.7 % of the patients had undergone a 
dental extraction before development of BRONJ. This finding is consistent with the review by 
Badros et al, which reported a significant association between the occurrence of BRONJ and 
age and a history of dental extraction in patients with multiple myeloma treated with 
intravenous bisphosphonates. [330] In agreement with published reports, tooth extraction in 
this review was associated with the development of BRONJ. [134, 225, 345, 355-
357]According to the systematic review publications, BRONJ was found to be spontaneous in 
14.8%. Our findings correspond with those of the authors reporting a higher percentage of so 
called spontaneous cases varying from 14.1% to 60%. [138, 160, 199, 202, 225, 228, 230, 
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236, 245, 253, 271, 308, 313, 319, 358-362] This may be due to the fact that it is difficult to 
establish the initiating factor in some patients. 
Correlations between the occurrence of BRONJ and specific co-medication such as 
corticosteroids or chemotherapy have been discussed. [363], [354] [246, 364] These 
treatments may also increase the vulnerability of the oral mucosa and reduce its nutritive 
supply. [134, 246, 361] Of the patients, 39.7% were under chemotherapy. Moreover 24.6% 
used corticosteroids. In fact, corticosteroids and some other chemotherapy medications 
possess an anti-angiogenic effect by inhibiting the vascular endothelial growth factor (VEGF) 
and the fibroblast growth factor (FGF).[134, 246, 361, 365] 
There is a considerable discussion in the literature whether aging plays a significant role in 
BRONJ development. Some studies found no statistically significant correlation between 
aging and BRONJ. [200, 366] Some authors include advanced age as a BRONJ co-factor 
[201, 279, 367], which could be related to the physiological effects of aging, including 
inflammatory issues [368], immune dysfunction [369], reduction of the blood flow and the 
remodelling ability [370, 371] , and increased oxidative stress[372]. In fact, these features are 
all implicated with BRONJ pathogenesis and could explain why this disease is not reported in 
young patients, even with other risk factors associated [373].Some authors reported a positive 
correlation between gender and BRONJ [279]. It has been speculated that oestrogen therapy 
may play a role in this correlation, since hormonal reposition has been associated with an 
increased risk of BRONJ[374]. 
Controversial aspects have also been discussed regarding gender as a BRONJ co-factor. Some 
studies found no statistically significant correlation between gender and BRONJ [201, 367] 
.Therefore, we observed that the large proportion of female patients from the studies [208, 
248, 253, 279, 317, 325, 375-380] can represent only a coincidence, since women take oral 
BPs more frequently than males, especially because rheumatoid arthritis and osteoporosis are 
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more common in women [381]. In accordance with other series reported in the literature 
[359], the present review shows a high prevalence of BRONJ among women (67.2%). 
BRONJ affects the mandible more often than the maxilla. There was a mandible/maxilla 
involvement ratio of 2/1, which could be attributed to the decreased vascularity of the 
mandible and to the existing local conditions, distribution that was similar to results reported 
also by other authors [306, 318, 382].  Only the mandible and maxilla appear to be 
susceptible, highlighting their unique nature compared with other parts of the skeleton. The 
jaws are the only bones in the human body that are in frequent contact with the outside world 
and are subject to repeated micro trauma through the presence of teeth and the forces of 
mastication; moreover the turnover of alveolar bone is 10-fold greater than in the long bones 
[250]. BRONJ occurred more often in the mandible (59%) than in the maxilla (27%), as was 
reported by Marx et al [134]. A possible explanation of osteonecrosis, especially in the 
mandible might be the anti-angiogenic effect of bisphosphonate [383-386] and anatomic and 
physiologic feature of mandibular bone that would increase the risk of osteonecrotic 
pathology [387]. This action would result in a direct induction of avascular necrosis of tissue 
repair and may interrupt intraosseous circulation and blood flow of the jaw [236]. 
Furthermore, bisphosphonate can also inhibit endothelial cell function [386] and increase the 
rate of apoptosis [384],  leading to a decrease in capillary-tube formation [388].  
The management of BRONJ is still a controversial topic. Several treatment protocols have 
been proposed, but there is no general consensus for many crucial questions, such as whether 
or not performing surgery is beneficial [268]. Some authors reported that BPs discontinuation 
for a variable period (one to six months) before and after interventions favoured the surgical 
outcome [303, 389] emphasising a possible anti-angiogenetic effect on the soft tissues around 
the necrosis and the removal of this effect may have a role in healing. There may also be 
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psychological aspects; patients may be stressed by the idea of taking drugs that could have an 
adverse effect on the bones. 
Our results suggested that minimal invasive surgical treatment was the most commonly used 
method for the management of the BRONJ in which 767 patients were managed using 
sequestrectomy, curettage, debridement or smoothening of bone. These results were in 
agreement with Alons et al [316]  who treated 7 patients with sequestrectomy and curettage of 
the defect with a minimum of periosteal deflection. Mitsimponas et al [390] reported a 
complete success rate of 53% in a patient group with different surgical procedures, including 
bone smoothing, incision and drainage, ulcer excision and closure after debridement. Eckert et 
al [391] demonstrated a 58% success rate in 24 operated patients. The surgical concept 
included resection of the necrotic bone and a stable soft tissue closure. Millesi et al [392] 
treated 55 patients with sequestrectomy, debridement, or partial resection with or without 
osteosynthesis after 6 months and found an overall complete success in 50%.  
Carlson et al [133] reported high cure rates and improved stages of disease after surgery. 
Carlson states that performing segmental resection of the mandible and partial maxillectomies 
with the intention of achieving vital bone margins are of crucial importance in the 
management of BRONJ. According to Otto et al [393], surgery might be the only curative 
treatment in refractory disease. In these studies the authors favour radical surgery. The 
observation of the efficacy of resection for BRONJ has recently been reported in the dental 
literature (56, 214, 250). 
Medical treatment is favoured by the AAOMS position paper whose authors state that surgery 
should be deferred as long as possible [250]. Van den Wyngaert et al. [338] and Scoletta et 
al.[306] stated that a medical treatment of BRONJ leads to mucosal healing in 50% of cases.  
However, the healing rate of BRONJ lesions in the studied group was also significantly 
associated with the stage of BRONJ at presentation, with lower healing rates observed for 
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high stages [338].Font et al recommended in their BRONJ update a long-term antibiotic 
regime and CHX 3 or 4 times a day. Aggressive surgical therapies were not considered; 
moreover, an inadequate healing with a lack of mucosal closing was confirmed [394]. 
Growth factor application can be considered a challenge because of improving the soft and 
hard tissues healing. Acting like chemotactic agents, they stimulate angiogenesis, migration, 
proliferation, and differentiation of stem cells from the surrounding mesenchymal tissues into 
bone-forming cells in an area of injury [330, 395]. A new therapy of BRONJ based on 
rhBMP-2 application had been discussed and showed how growth factor application involves 
an increase in soft tissue healing [282].Some studies have reported treatment of  refractory 
cases of BRONJ with bone resection followed by topical application of PRP [258, 259, 396] 
in which PRP is an autologous concentration of human platelets and a source of different 
protein growth factors. Protein growth factors such as platelet-derived growth factor, 
transforming growth factor-β, vascular endothelial growth factor, and epidermal growth 
factor-β are polypeptides released from the platelets when they are activated and can induce 
paracrine effects on stimulated cells. [397-399]  
Recurrent BRONJ lesions could be managed successfully by the surgical use of the laser. 
These results are similar to those presented by Stübinger et al [336] and Vescovi et al [333] 
who used an Er:YAG laser for the bony debridement. Also ozone is effective on avascular 
necrosis-related pathologies by stimulating and/or preserving the endogen antioxidant system 
and by blocking the xantine/ xantine oxidase pathway, active in free radical synthesis [400-
402]; by activating blood circulation, increasing red blood cells and hemoglobin concentration 
[403], enhancing diapedesis and phagocytosis, and stimulating the mononucleate phagocytic 
system [403-405]. 
The proposed rationale behind the beneficial effects of hyperbaric oxygen (HBO) therapy in 
BRONJ is increased wound healing, reduction of oedema and inflammation, stem cell 
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mobilization, and moderation of the suppression of bone turnover by BP [406]. Recent studies 
have revealed that HBO therapy also generates reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) that affect the signalling process critical to wound healing [406, 407] . 
HBO therapy also has a possibility to improve inflammation and infection around necrotic 
tissues by increasing blood vessels, oxygen concentration, and antibiotic levels in patients 
with BRONJ [406, 407]. 
Teriparatide (TP), a recombinant human parathyroid hormone (PTH)  , is an osteoanabolic 
agent that has stimulatory effects on osteoblasts and subsequently osteoclasts and increases 
bone turnover by promoting bone formation with a positive balancing in bone metabolism 
[408, 409]. TP regulates bone resorption by increasing osteoclastic activity  [410]. Therefore, 
Teriparatide is known to have quick and strong stimulatory effects on bone remodelling, even 
in the face of previous exposure to bisphosphonates [411-415].  The use of TP on refractory 
BRONJ lesions was first defined by Harper and Fung [416] who observed soft-tissue healing 
in a patient with a 3 month TP administration. Additionally, in a case study, Ohbayashi et al 
[417] demonstrated bone regeneration 6 months after TP therapy in a refractory BRONJ 
patient. Ma et al [415] showed that TP reverses the inhibitory effects of anti-resorptive drugs 
such as BPs in vivo. The BPs suppress osteoclastic activity by inducing apoptosis of these 
cells and cause them to detach from the bone surface [418]. Moreover of the adjunctive 
treatments was the fluorescence- guided bone resection that was introduced in the surgical 
therapy of BRONJ to determine the extent of the surgical debridement [143, 154].  
It is difficult to compare the outcome of different BRONJ therapies for 2 mutually non-
exclusive reasons: First, the definition of therapy success has not been universally defined, 
and in particular studies favouring medical therapy regimens often consider maintaining the 
status as success. Second, only a few studies have, to date, compared the therapy outcome of 
medical and surgical treatment in a controlled clinical manner [136]. 
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The key factors for successful treatment have not been clearly identified yet. There are several 
aspects that are likely to influence the success of surgery and can cause progression of disease 
[267]. Comparing different studies about therapeutic success in BRONJ is made difficult by 
different definitions of success [312]. 
Ruggiero and Drew [419] considered preservation of quality of life by controlling pain, 
managing infection and preventing the development of new areas of necrosis as a treatment 
goal. Taking this into consideration, a relief of symptoms may very well be a “success” for 
the oncologic patient [316]. Vescovi et al [156] defined “clinical success” as a positive result 
(e.g., transition from a higher stage to a lower stage, complete mucosal healing) or a minimum 
time span of 3 months without clinical symptoms. With regard to the definition of BRONJ 
[354] , “clinical success” principally should include absence of pain and other symptoms of 
oral infection, lack of oral or cutaneous fistulas, and an intact mucosal cover over formerly 
exposed bone.[257] 
Comparison between outcomes of different therapies is complicated because of the inclusion 
of patients taking different bisphosphonates and doing so in an uncontrolled clinical manner 
[272]. 
Treatment outcome is considered a success when oral mucosal healing is maintained without 
bone exposure or infection and there is acceptable radiographic healing for a 12-month period 
after surgery. Therefore, following patients for at least 1 year postoperatively may be 
indicated to disclose the possibility of recurrence of disease [272] which was in accordance 
with our results from the publications that showed a mean follow up period of 12.87 ± 9.88 
months. 
Data on treatment outcome of ONJ in the literature are vague and scarce. Marx et al [134] 
reported that 90% of the patients functioned free of pain under continuous antibiotic 
treatment, but they did not specify the type of response (CR, PR, or NR). Mavrokokki et al 
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[345] reported that 70% of the patients were classified as ongoing cases and that 30% had 
been resolved, but there were no details regarding PR and NR. Abu-Id et al [322] recently 
published a multicentre study from Germany, Austria, and Switzerland based on 
questionnaires of 78 ONJ patients. They reported that 60% of their 78 patients were treated 
with minor invasive surgical procedures or medical treatment with local disinfectants and 
antibiotics. The remaining patients were treated radically by means of bone resection up to 
viable bone. Of the patients who were treated medically, 38% were classified as responsive, 
as were 86% of the patients who were treated radically.  
CONCLUSION 
Mucosal coverage is the main goal of BRONJ treatments to prevent secondary infection. 
BRONJ management remains controversial, and there is no definitive standard of care for this 
disease. Nonsurgical, conservative and minimally invasive treatment regimen of BRONJ is 
considered useful for controlling the disease leading to predictable good results in cases of 
low and medium-potency BRONJ. Further research especially for high-potency BRONJ 
(refractory Stage 3 lesions) is indicated. BRONJ might be approached also by new adjunctive 
treatments such as ozone therapy or hyperbaric oxygen or growth factors in order to ensure 
the optimal patient treatment protocol. The application of adjunctive treatments is an opinion-
based approach rather than evidence-based one. Controlled studies or clinical trials should be 
followed to evaluate these adjunctive treatments for the BRONJ patients. 
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5. PUBLICATION V 
GENE THERAPY FOR BONE DEFECTS IN ORAL AND MAXILLOFACIAL 
SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS 
Riham Fliefel, Jan Kühnisch, Michael Ehrenfeld, Sven Otto. Under review in 
Stem cells and Development 2016. 
ABSTRACT 
Craniofacial bone defects are challenging problems for maxillofacial surgeons over the years. 
With the development of cell and molecular biology, gene therapy is a breaking new 
technology with the aim of regenerating tissues by acting as a delivery system for therapeutic 
genes in the craniofacial region rather than treating genetic disorders. A systematic review 
was conducted summarizing the articles reporting gene therapy in maxillofacial surgery to 
answer the question: Was gene therapy successfully applied to regenerate bone in the 
maxillofacial region? Electronic searching of online databases was performed in addition to 
hand-search of the references of the included articles. No language or time restrictions were 
enforced. Meta-analysis was done to assess significant bone formation after delivery of gene 
material in the surgically induced maxillofacial defects. The search identified 2081 articles of 
which 57 were included with 1726 animals. Bone morphogenetic proteins (BMPs) were 
commonly used proteins for gene therapy. Viral vectors were the universally used vectors. 
Sprague-Dawley rats were the frequently used animal model in experimental studies. The 
quality of the articles ranged from excellent to average. Meta-analysis results performed on 21 
articles showed that defects favoured bone formation by gene therapy. Funnel plot showed 
symmetry with the absence of publication bias. Gene therapy is on the top list of innovative 
strategies that developed in the last 10 years with the hope of developing a simple chairside 
protocol in the near future combining improvement of gene delivery as well as knowledge of 
the molecular basis of oral and maxillofacial structures. 
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ABBREVIATIONS 
µCT: Micro computed tomography β-TCP: Beta-tricalcium phosphate 
911 helper: human embryonic retinoblasts 293FT: human embryonic kidney cells with the SV40 
large T antigen 
AAV: Adeno-associated virus,  ADSCs: Adipose derived stem cells 
ALP: Alkaline phosphatase AV: Adenovirus 
b-FGF: Basic fibroblast growth factor BGC: Bioactive glass ceramic 
BMD: Bone mineral density BMMSCs: Bone marrow mesenchymal stem cells 
BMP-2: Bone morphogenetic protein 2 BMP-4: Bone morphogenetic protein 4 
BMP-7: Bone morphogenetic protein 7 BMP-9: Bone morphogenetic protein 9 
CHA: Coral hydroxyapatite CFSE: Carboxyfluorescein diacetate 
succinimidyl ester 
CMPC: Calcium magnesium phosphate cement CRE8: Cre-expressing 293 cells 
EGFP: Enhanced green fluorescence protein DPSCs: Dental pulp stem cells 
FACS: Fluorescence-activated cell sorting ERR: External root resorption 
FEA: Finite element analysis ELISA: Enzyme linked immunosorbent assay 
HA/TCP: Hydroxyapatite/beta-tricalcium 
phosphate 
GAM: Gene activated matrix 
HGF: Hepatocyte growth factor,  HA/COL: Hydroxyapatite/ Collagen 
HVJ: Hemagglutinating virus of Japan HA/PA: Hydroxyapatite/polyamide 
IGF 1: Insulin growth factor HEK293: human embryonic kidney 293 cell line 
LMP-3: LIM mineralization protein 3,  HIF-1α: Hypoxia-inducible factor-1 alpha 
MKP-1: Mitogen-activated protein kinase phosphatase 
1 
iPSCs: Induced pluripotent stem cells 
MBG: Mesoporous bioglass IFU: Infectious units per ml 
N/R: Not reported LacZ: β-galactosidase 
NGF-β: Nerve growth factor beta Luc: Firefly luciferase 
NNB: Natural non-organic bone MOI: multiplicity of infection 
OF: Orthodontic force mSS: Premineralized silk fibroin protein scaffolds 
OSX: Osterix NB: Nano-bubbles 
OSTEOBONE: Calcium silicon phosphorus NIH3T3: mouse embryo fibroblast 
pOBs: Periosteal derived osteoblasts NOD/SCID mice: Non-obese/severe combined 
immunodeficient 
PBS: Phosphate buffered saline OPG: Osteoprotegrin 
PDGF-A: Platelet derived growth factor A PCR: Polymerase chain reaction 
PDLSCs: Periodontal stem cells PDGF-B: Platelet derived growth factor B 
PFU: Plaque forming unit PDLA: Poly D, L-lactide 
Pg-LPS: lipopolysaccharide mediated bone loss PF127: Pluronic F127 
RANKL: Receptor activator of nuclear factor kappa-B 
ligand 
PG13: mouse embryonic fibroblast 
RUNX2: Runt-related transcription factor 2 PLGA: Poly lactic co glycolic acid 
SEM: Scanning electron microscope RSV: respiratory syncytial virus 
TM: Tooth movement SDF: Syngeneic dermal fibroblasts 
TRAP: Tartrate resistance acid phosphatase TGF-b: Transforming growth factor beta 
TU: Transduction units TNFR: Tumour necrosis factor alpha receptor  
VEGF: Vascular endothelial growth factor TSG-6: Tumour necrosis factor alpha-stimulated gene-
6 
WEHI 164: mouse skin fibroblast US: Ultra-sound 
JM 109: Escherichia Coli  WB: Western Blot 
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INTRODUCTION 
Craniofacial anomalies and bone defects resulting from bone loss due to trauma, 
reconstructive surgery, neoplasia, congenital defects, infection or periodontal disease present 
a difficult and challenging problem for maxillofacial surgeons and scientists over the years 
with the goal of restoring facial form, function and occlusion. Conventional therapies are 
directed toward maxillofacial surgery, the use of prostheses or bone grafts. However, the 
effectiveness of these techniques is constrained by donor site morbidity, high cost and 
insufficient tissue resources. Recently, it had been agreed on the urgent need for new 
strategies for craniofacial reconstruction to improve bone regeneration with complete healing 
of the defects regardless of size [420-422]. As an alternative to the traditional techniques, 
“tissue engineering” has developed as a new and promising multi-disciplinary technique in 
the field of maxillofacial reconstruction and surgery [423]. 
With the development of cell and molecular biology, DNA-based technology had appeared as 
a promising method to meet challenges of tissue engineering in different applications. The 
genetic principle is either applied individually or together with tissue engineering to be known 
as gene-enhanced tissue engineering that regenerates lost tissue by local delivery of cells that 
have been genetically-modified to deliver signalling factors at DNA-level [424]. To date, 
gene therapy is the leading technology in medicine providing hope for those individuals that 
are suffering genetic disorders. 
Gene therapy is known to be transferring genetic materials or functioning gene to replace a 
damaged one inducing individual’s own cells to produce a therapeutic agent to improve the 
clinical outcome. It has several advantages over traditional treatments as the expression in 
host cells lasts longer for weeks to years than pharmaceutical compounds or recombinant 
protein which range from several hours to days. It reduces technical challenges associated 
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with ex-vivo protein expression and purification. Finally, the delivery of genetic sequences 
could mimic the natural biologic healing response [425, 426]. 
There have been a couple of advances in gene therapy relevant to dentistry since 1995. When 
applying the gene therapy principles, the maxillofacial region has significant advantages 
compared to other sites in the body, including easy access and observability. Potential 
applications for gene-based tissue engineering therapies in the oral and maxillofacial complex 
include treatment of salivary gland diseases, autoimmune diseases, cancerous and 
precancerous lesions, pain, caries, dermatological disorders, delivery of growth factors for 
periodontal regeneration, pulp capping/dentin regeneration, treatment of malignant neoplasms 
of the head and neck, bone regeneration for bone grafting of large osseous defects in dental 
and craniofacial reconstruction and articular cartilage repair [427, 428]. 
Although gene therapy was originally accepted as a means of treating heritable genetic 
disorders, its application in the craniofacial region is more often directed at regenerating 
tissues by acting as a delivery system for therapeutic genes promoting healing directly to cells 
within the defect or by genetically engineering mesenchymal stem cell progenitors to produce 
factors prior to implantation resulting in higher and more constant levels of protein production 
[2, 44, 429]. 
Thus, we have conducted a systematic review summarizing the articles reporting trials of gene 
therapy worldwide in the field of oral and maxillofacial surgery. 
MATERIAL AND METHODS 
This study was registered in SYRCLE (SYstematic Review Centre for Laboratory animal 
Experimentation) systematic review protocol for animal intervention studies (www.syrcle.nl). 
The guidelines for reporting systematic reviews and meta-analyses of animal studies was 
proposed by Peters et al [430] that are akin to the PRISMA guidelines for the reporting of 
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systematic reviews and meta-analyses of healthcare interventions in human clinical studies 
[431]. 
Review questions 
The following PICO question was mainly addressed: Was gene therapy successfully applied 
to regenerate bone or heal defects in the oral and maxillofacial region?  
Search strategy and selection criteria 
A systematic review of the literature was performed to provide an overview of published 
articles describing gene therapy in the field of Oral and Maxillofacial Surgery. Medical 
databases were searched to 18th December 2015. The data search included a combination of 
the following keywords: ‘‘Gene therapy’’ ‘‘AND’’ ‘‘Maxillofacial surgery’’ ‘‘OR’’ ‘‘Gene 
therapy’’ ‘‘AND’’ ‘‘Bone tissue engineering’’, ‘‘Genetic Engineering’’ ‘‘AND’’ 
‘‘Maxillofacial bone’’, ‘‘Gene therapy’’ ‘‘AND’’ “Distraction Osteogenesis” ‘‘OR’’ ‘‘Gene 
therapy’’ ‘‘AND’’ “Alveolar bone” ‘‘OR’’ ‘‘Gene therapy’’ ‘‘AND’’ “Periodontal tissue” 
‘‘OR’’ ‘‘Gene therapy’’ ‘‘AND’’ “Temporomandibular joint”. All the possible combinations 
of these words were explored. Medical subject headings (MeSH terms) without subheading 
restrictions was used and the heading sequence was ‘‘Gene therapy’’ ‘‘AND’’ ‘‘Dentistry’’. 
In addition, we performed hand-search to the references of the included articles, papers of 
interest and related systematic or non-systematic reviews. The International Journal of Oral 
and Maxillofacial Surgery, Journal of Craniomaxillofacial Surgery, Gene therapy, Molecular 
therapy and Human gene therapy journals were also screened to identify possible references 
not reported elsewhere. No language or time restrictions were enforced. Relevant full 
publications and meeting abstracts were identified by electronic searching of three online 
databases (PubMed, Cochrane library and Web of Knowledge). After the identification of 
articles in the databases, the articles were imported into Endnote X7 software (Thompson 
Reuters, Philadelphia, PA, USA) to store, manage search results and remove duplicates 
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regardless of whether the studies are eventually included or excluded in the systematic 
review. Titles and abstracts identified were screened resulting in a number of seemingly 
relevant studies for the systematic review. The abstracts of the articles were then reviewed 
and the full text was obtained for those articles with apparent relevance. The identified articles 
were selected based on the inclusion criteria and exclusion criteria. 
Inclusion criteria 
(1) Relevant data on Gene therapy, (2) Animal studies, (3) Defects performed in the Oral and 
Maxillofacial region, (4) Any language. 
Exclusion criteria 
(1) In vitro studies, (2) Gene therapy in bones other than maxillofacial, (3) Calvarial bones 
defects, (4) Review articles, (5) letters to the editor, editorials, poster or oral presentations or 
articles with only abstract, (6) Oral cancer or soft tissue lesions, (7) Studies based on the use 
of only growth factors or cell-based therapies. 
To improve the sensitivity of the relevant studies, each publication identified in the electronic 
search were assessed independently by two independent reviewers (RF and SO) to make a 
decision on inclusion/exclusion criteria or data extraction and quality of the articles with 
differences resolved by discussion. 
Data extraction 
All information was extracted using a standardized data form created in Excel. Data extracted 
included: 1) Author, 2) Year, 3) Journal, 4) Country, 5) Language, 6) therapeutic gene, 7) 
Vector, 8) Control gene, 9) Virus Titres (Concentration), 10) Cell lines for generation of 
virus, 11) Experiment design, 12) Disease model, 13) Site, 14) Animal Model, 15) Sample 
size, 16) Defect size, 17) Carrier/Scaffold, 18) Gene delivery route, 19) Stem cells source, 20) 
Experimental groups, 21) Cell concentration to be used in the defect, 22) Analysis methods 
with main endpoint results. 
Publication V: Gene therapy Systematic Review & Meta-analysis 
Page 94 
Data was extracted from either text or tables in the results section of the included studies. 
Data that was presented as graphs was extracted electronically using WebPlotDigitizer 
software, version: 3.9 (WebPlotDigitizer, US, http://arohatgi.info/WebPlotDigitizer, 2015). 
Methodological quality assessment  
The quality assessment of all the included studies in this systematic review was performed 
based on ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines [432] and 
evaluated based on a predefined grading system [433] applied to the following items: (1) 
Title, (2) Abstract/Summary, (3) Introduction/Background, (4) Introduction/ Primary and 
secondary objectives, (5) Methods/Ethical statement, (6) Methods/Study design, (7) 
Methods/Experimental procedure, (8) Methods/Experimental Animals, (9) Methods/Housing 
and husbandry, (10) Methods/Sample size, (11) Methods/Allocation animals to experimental 
groups, (12) Methods/Experimental outcomes, (13) Methods/Statistical methods, (14) 
Results/Baseline data, (15) Results/Numbers analysed, (16) Results/Outcomes and estimation, 
(17) Results/Adverse events, (18) Discussion/Interpretation and scientific implications, (19) 
Discussion/Generalisability and translation, (20) Discussion/ Funding. 
Risk of bias assessment 
Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental 
Studies (CAMARADES) risk of bias tool was applied to assess the internal validity of the 
included studies using RevMan software (version 5.3) [434, 435]. A modified 7-point-item 
check list was used to assess the risk of bias, including: (1) published in a peer-reviewed 
journal; (2) random allocation to treatment or control; (3) treatment allocation concealment; 
(4) blinded assessment of outcome; (5) reporting of a sample size calculation; (6) statement of 
compliance with animal welfare regulations and (7) statement of potential conflict of interest. 
Each trial was assessed by two independent observers (RF and SO) and any differences 
resolved by discussion. 
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Outcome Measure  
The primary outcome measure for this meta-analysis was significant new bone formation by 
histology (% of area and % of volume) or radiograph (bone volume fraction) between the 
experimental and control group. 
Statistical Analysis 
A qualitative data analysis was performed with the aim of summarizing the results of the 
studies included. Meta-analyses as well as forest and funnel plots were conducted using 
RevMan software (Review Manager [RevMan] Version 5.3. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014). Bone formation was assessed as 
continuous outcome variables by inverse variance (IV) method and recorded as the 
standardized mean difference (SMD) with 95% confidence interval (CI). The effect size of the 
SMD was classified as follows: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a 
large effect [436]. The I2 indicating heterogeneity and Cochran's Q statistical test were 
calculated; a value of I2: 0% to 40% might not be important, 30% to 60% may represent 
moderate heterogeneity; 50% to 90% may represent substantial heterogeneity and 75% to 
100% shows considerable heterogeneity [437]. A weighted fixed-effect model was used to 
estimate the overall effect size. Results with a P-value of < 0.0001 were considered indicative 
of statistical significance. Potential publication bias was explored using funnel plot generated 
using RevMan. 
RESULTS 
Search results 
The search identified a total of 2081 references from the different databases and hand search: 
PubMed (n= 2000), Web of science (n= 63), Cochrane library (n= 7), hand-search (n=11). 
After duplicates removal via Endnote duplicate function, 1509 articles were screened for 
titles/abstracts and resulted in only 148 studies for full-text evaluation with the exclusion of 
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1361 articles that were irrelevant to the topic or review articles. Further screening resulted in a 
total of 57 studies which were considered eligible for the systematic review and fulfilled the 
final selection criteria. Figure  5.1 illustrates the search flow and the identification of eligible 
studies.  
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Figure  5.1: Flow-chart of the process of literature 
search and studies included in the review. 
 
Study characteristics 
The articles analysed were published between 1999 and 2015. Most of the studies were 
conducted in USA [438-448] and China [378, 449-477]. However, few studies were 
conducted in Taiwan [478], Japan [479, 480], Spain [481], Germany [482], Italy [483], Korea 
[484] or as a collaboration between two countries [471, 485-492]. Almost all articles (91.3%) 
were published in English [378, 438-457, 459-463, 465-469, 471-475, 477-487, 489-493] 
while only 5 articles (8.7%) [458, 464, 467, 470, 476] were published in Chinese. Bone 
morphogenetic proteins (BMPs) were the most commonly used proteins for gene therapy 
(n=28, 49.1%) [439, 440, 443, 445, 446, 451, 452, 454, 457-459, 463, 464, 466, 467, 470-
474, 478, 482, 484-489] followed by Platelet-derived growth factors (PDGF; n=6, 10.5%) 
[438, 441, 442, 447, 471, 472], while the remaining 23 articles (40.4%) were using various 
proteins as: Enhanced green fluorescent protein (EGFP) [450, 469, 479, 490], Tumour 
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necrosis factor alpha receptor (TNFR) [444], Hepatocyte growth factor (HGF) [449], 
Receptor activator of nuclear factor kappa-B ligand (RANKL) [480, 494], Basic fibroblast 
growth factor (b-FGF) [453, 465], β-galactosidase (LacZ) [493], Osterix (OSX) [455, 456], 
LIM mineralization protein 3 (LMP-3) [483], Vastatin [378], Vascular endothelial growth 
factor (VEGF) [460], Osteoprotegrin (OPG) [461, 475, 476, 492], Runt-related transcription 
factor 2 (RUNX2) [462], Nerve growth factor beta (NGF-β) [468], Tumour necrosis factor 
alpha-stimulated gene-6 (TSG-6) [491], Mitogen-activated protein kinase (MAPK) 
phosphatase 1 (MKP-1) [448] and Hypoxia-inducible factor-1 alpha (HIF-1α) [477]. 
In 30 articles (52.6%) [438-442, 445-449, 452-454, 457, 459, 462, 463, 470-474, 478, 482, 
483, 485, 488, 489, 493, 495], adenovirus was the universally used vector. However, other 
vectors were used as: plasmid (n=12, 21%) [443, 451, 455, 464-467, 475, 476, 479, 486, 496], 
adeno-associated virus (n=4, 7%) [378, 444, 450, 460], hemagglutinating virus of Japan 
(HJV; n=3, 5.3%) [480, 481, 492], liposome (n=2, 3.5%) [482, 487], lentivirus (n= 5, 8.8%) 
[461, 468, 469, 477, 491] and retrovirus (n=1, 1.8%) [490]. For the control genes, Green 
fluorescent protein (GFP) were the most abundant control in 20 articles (35.1%) [378, 446, 
449, 451, 453-455, 457, 460, 462, 465, 468, 470, 472-474, 477, 483, 485, 486, 489, 496] 
followed by β-galactosidase (LacZ) in 9 articles (15.8%) [439, 440, 448, 452, 459, 478, 482, 
485, 488] and Luciferase (Luc) in 6 articles (10.5%) [438, 441, 442, 445, 447, 479] 
respectively. However, in 22 articles (38.6%), the control gene was not reported. Seven 
different packaging cell lines were used for replication of the viruses: HEK293 (human 
embryonic kidney 293 cell line) [378, 440-442, 444, 446, 448-450, 460-463, 470, 472, 473, 
484, 485, 493], 293FT (human embryonic kidney cells with the SV40 large T antigen) [469], 
WEHI 164 (mouse skin fibroblast) [457], NIH3T3 (mouse embryo fibroblast) [480, 481], 
CRE8 (Cre-expressing 293 cells) [483], 911 helper (human embryonic retinoblasts (HER) 
[482] and PG13 (mouse embryonic fibroblast) [490]. The experiments were performed either 
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as in vitro/ in vivo in 38 articles (66.7%) [378, 440, 446-449, 452-454, 457, 459-463, 465-
467, 469, 471-478, 480-486, 488-491] or were completely in vivo studies in 19 articles 
(33.3%) [438, 439, 441-445, 450, 451, 455, 456, 458, 464, 468, 470, 479, 487, 492, 493]. 
Table  5.1 presents the characteristic of the included studies. 
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Table  5.1: Summary of essential features of all studies included in the systematic review 
Author Year Journal Country Language Therapeutic 
Gene 
Vector Control Virus Titres 
(Concentration) 
Cell lines for 
generation of 
virus 
Experiment 
design 
Abramson 
[438] 
2007 Eur Cell Mater USA English PDGF-B AV Luc N/R N/R In vivo 
Alden [439] 2000 J Craniofac Surg USA English BMP-2/BMP-9 AV LacZ 5×107 particle/µl N/R In vivo 
Ashinoff [440] 2004 Ann Plast Surg USA English BMP-2 AV LacZ N/R HEK293 In vitro/In vivo 
Chang [441] 2009 Hum Gene Ther USA English PDGF-B AV Luc N/R HEK293 In vivo 
Chang [442] 2010 Gene Ther USA English PDGF-B AV Luc N/R HEK293 In vivo 
Chang [485] 2003 Gene Ther Taiwan/USA English BMP-2 AV LacZ N/R HEK293 In vitro/In vivo 
Chen [479] 2009 J Dent Res Japan English EGFP Plasmid Luc N/R JM 109 In vivo 
Chen[443] 2007 Plast Reconstr Surg USA English BMP-4 Plasmid N/R N/R N/R In vivo 
Chen[478] 2008 Gene Ther Taiwan English BMP-2 AV LacZ 50 MOI N/R In vitro/In vivo 
Cirelli [444] 2009 Gene Ther USA English TNFR AAV N/R 5-20×1012 DRP/ml HEK293 In vivo 
Cao[449] 2015 Stem Cell Res Ther China English HGF AV GFP 50-400 MOI HEK293 In vitro/In vivo 
Dai [450] 2007 Front Biosci China English EGFP AAV N/R N/R HEK293 In vivo 
Dunn [445] 2005 Mol Ther USA English BMP-7 AV Luc N/R N/R In vivo 
Hu [451] 2007 J Orthop Res China English BMP-7 Plasmid GFP N/R N/R In vivo 
Iglesias-
Linares [481] 
2011 Orthod Craniofac Res Spain English RANKL HVJ N/R N/R NIH3T3 In vitro/In vivo 
Jiang [486] 2006 Int J Oral Maxillofac Surg China/Canada English BMP-4 Plasmid GFP N/R JM 109 In vitro/In vivo 
Jiang [454] 2009 Clin Oral Implants Res China English BMP-2 AV GFP 50 PFU/cell (MOI) N/R In vitro/In vivo 
Jiang [452] 2009 Biomaterials China English BMP-2 AV LacZ 80 PFU/cell (MOI) N/R In vitro/In vivo 
Jiang [453] 2010 Bone China English b-FGF AV GFP N/R N/R In vitro/In vivo 
Jin [446] 2003 J Periodontol USA English BMP-7/Noggin AV GFP 200 PFU/cell (MOI) HEK293 In vitro/In vivo 
Jin [447] 2004 Mol Ther USA English PDGF-B /PDGF-A AV Luc 200 PFU/cell (MOI) N/R In vitro/In vivo 
Kanzaki [480] 2006 Gene Ther Japan English RANKL HVJ N/R N/R NIH3T3 In vitro/In vivo 
Kroczek [487] 2010 J Craniomaxillofac Surg Germany 
Netherlands 
English BMP-2 Liposome N/R N/R N/R In vivo 
Kuboki [493] 1999 Arch Oral Biol Japan English LacZ AV N/R N/R HEK293 In vivo 
Lai [455] 2014 J Zhejiang Univ Sci B China English OSX Plasmid GFP N/R N/R In vivo 
Lai [456] 2011 Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 
China English OSX Plasmid N/R N/R N/R In vivo 
Lattanzi [483] 2008 Gene Ther Italy English LMP-3 AV GFP N/R CRE8 In vitro/In vivo 
Li [457] 2010 J Biomed Mater Res A China English BMP-7 AV GFP N/R WEHI 164 In vitro/In vivo 
Li [458] 2010 Zhonghua Yi Xue Za Zhi China Chinese BMP-7 N/R N/R N/R N/R In vivo 
Li [378] 2009 Arch Oral Biol China English Vastatin AAV GFP 5×103, 1×104-5×104 
PFU/cell (MOI) 
HEK293 In vitro/In vivo 
Long [459] 2011 Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 
China English BMP-2 AV LacZ 100 PFU/cell (MOI) N/R In vitro/In vivo 
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Table  5.1(cont.): Summary of essential features of all studies included in the systematic review 
Author Year Journal Country Language Therapeutic 
Gene 
Vector Control Virus Titres 
(Concentration) 
Cell lines for 
generation of 
virus 
Experiment 
design 
Park J [482] 2003 Gene Ther Germany English BMP-2 AV 
Liposome 
LacZ 1-3×1010 PFU/ml 911 helper In vitro/In vivo 
Park S [484] 2015 J Biomed Mater Res A Korea English BMP-2 AV N/R 100 PFU/cell (MOI) HEK293 In vitro/In vivo 
Rabie [460] 2007 Gene Ther China English VEGF AAV GFP N/R HEK293 In vitro/In vivo 
Steinhardt 
[488] 
2008 Tissue Eng Part A Israel/USA English BMP-2 AV LacZ 3000 PFU/cell N/R In vitro/In vivo 
Su [461] 2015 Stem Cell Res Ther China English OPG Lentivirus N/R 1.5×106 TU/ml HEK293 In vitro/In vivo 
Sun [489] 2010 Arch Oral Biol China/USA English BMP-2 AV GFP 50 PFU/cell N/R In vitro/In vivo 
Sun [463] 2013 J Oral Maxillofac Surg China English BMP-2 AV N/R N/R HEK293 In vitro/In vivo 
Sun [462] 2014 J Orthop Res China English Runx2 AV GFP 5×109 PFU/ml Runx2 
2×1010 PFU/ml GFP 
HEK293 In vitro/In vivo 
Sun [464] 2007 Shanghai Kou Qiang Yi 
Xue 
China Chinese BMP-2 Plasmid N/R N/R N/R In vivo 
Tan [465] 2009 Cytotherapy China English b-FGF Plasmid GFP N/R N/R In vitro/In vivo 
Tang [466] 2008 Cell Biol Int China English BMP-2 Plasmid N/R N/R N/R In vitro/In vivo 
Tang [467] 2006 Zhonghua Kou Qiang Yi 
Xue Za Zhi 
China Chinese BMP-2 Plasmid N/R N/R N/R In vitro/In vivo 
Wang [468] 2015 Br J Oral Maxillofac Surg China English NGF-β Lentivirus GFP N/R N/R In vivo 
Wei [490] 2013 Stem Cells Dev USA/China English EGFP Retrovirus N/R N/R PG13 In vitro/In vivo 
Wen [469] 2012 Arch Oral Biol China English EGFP Lentivirus N/R N/R 293FT In vitro/In vivo 
Yang [491] 2014 PLoS One USA/China English TSG-6 Lentivirus N/R N/R N/R In vitro/In vivo 
Ye [470] 2006 Shanghai Kou Qiang Yi 
Xue 
China Chinese BMP-2 AV GFP 100 MOI HEK293 In vivo 
Yu [448] 2011 Gene Ther USA English MKP-1 AV LacZ N/R HEK293 In vitro/In vivo 
Zhang [473] 2007 Biomaterials China English BMP-7 AV GFP 2×1010 particles/ml HEK293 In vitro/In vivo 
Zhang [472] 2009 J Control Release China English BMP-7/PDGF-B AV GFP 2×1010 particles/ml HEK293 In vitro/In vivo 
Zhang [471] 2015 J Clin Periodontol Switzerland 
China 
English BMP-7/PDGF-B AV N/R 1.4×1010 PFU/ml N/R In vitro/In vivo 
Zhao [474] 2010 Oral Dis China English BMP-2 AV GFP 80 PFU/cell (MOI) N/R In vitro/In vivo 
Zhao [492] 2012 Orthod Craniofac Res China/Japan English OPG HVJ N/R N/R N/R In vivo 
Zhou [476] 2010 Hua Xi Kou Qiang Yi Xue 
Za Zhi 
China Chinese OPG Plasmid N/R N/R N/R In vitro/In vivo 
Zhou [475] 2012 Int J Periodontics 
Restorative Dent 
China English OPG Plasmid N/R N/R N/R In vitro/In vivo 
Zou [477] 2012 PLoS One China English HIF-1α Lentivirus GFP 7 MOI N/R In vitro/In vivo 
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Alveolar bone defects with or without dental implant were the prevalent model used for gene 
therapy in 20 articles (35.1%) [438, 439, 442, 443, 445, 452, 457, 461, 463, 466, 467, 472-
474, 477, 482, 483, 485, 486, 488], periodontal disease with or without alveolar bone 
involvement (n=17, 29.8%) [441, 444, 446-449, 458, 464, 465, 469, 471, 475, 476, 478, 479, 
484, 491] followed by distraction osteogenesis (n=9, 15.8%) [440, 451, 453, 455, 456, 459, 
462, 468, 487], temporomandibular joint (n=4, 7%) [378, 450, 460, 493], orthodontic tooth 
movement (n= 3, 5.2%) [480, 481, 492], sinus floor elevation (n=2, 3.5%) [454, 489], tooth 
restoration with bio-root regeneration (n=1, 1.8%) [490] and central fissures (cleft) (n=1, 
1.8%) [470]. Most of the defects were in the mandible (n=39, 68.4%) [378, 439-441, 446, 
447, 450-453, 455-470, 472-477, 482-484, 486-489, 493] while 16 articles (28%) [438, 442-
445, 448, 454, 471, 478-481, 485, 489, 491, 492] showed that the defects were created in the 
maxilla. One article was reported in both jaws (1.8%) [449] and the location was missing in 
one article (1.8%) [490]. The posterior mandible (premolar-molar area) was the most frequent 
region. However, some studies did the experiments in the anterior region. 
Sprague-Dawley rats were the frequently used animal model in experimental studies of gene 
therapy (n=17, 29.8%) [378, 438-442, 444, 445, 447, 448, 450, 451, 460, 466, 467, 469, 491] 
followed by Wistar rats in 6 studies (10.5%) [479-483, 492], Lewis Fisher in 3 studies (5.3%) 
[446, 452, 474] and ginue-pigs or mice in one article each (n=2, 3.5%) each [488, 493]. White 
New Zealand rabbits were also used as a small animal model for the studies (n=14, 24.6%) 
[453-457, 459, 461-463, 468, 470, 478, 486, 489]. For large animals models, dogs and pigs 
were commonly used in 11 (19.3%) [443, 458, 464, 465, 471-473, 475-477, 482] and 4 (7%) 
studies respectively [449, 485, 487, 490]. Sample size ranged between 4 and 24 for large 
animal models. However, for small animal models, the sample size ranged between 11 and 
144 animals. 
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Two different defect shapes were identified: circular (n=9, 15.8%) [439, 452, 464-467, 474, 
482, 488], rectangular (n=22, 38.6%) [441, 443, 445-447, 449, 454, 457, 461, 463, 469, 471-
473, 475-478, 483, 485, 486, 489] and 26 studies (45.6%) [378, 438, 440, 442, 444, 448, 450, 
451, 453, 455, 456, 458-460, 462, 468, 470, 479, 480, 484, 487, 490-494] did not mention the 
shape of the defect. Variable diameters were recognised for the circular defects ranging from 
1 to 6 mm. The rectangular defects were characterised by heterogeneity of dimensions. 
Gene delivery route was ex-vivo in 35 articles (61.4%) [446, 449-459, 461-463, 465-470, 
474-478, 482-490], in-vivo in 21 articles (36.8%) [378, 438-445, 447, 448, 460, 464, 471-
473, 479-481, 492, 493] and both in only one article (1.8%) [491]. For in-vivo gene delivery 
route (direct injection or GAM), physiological saline, collagen gels or lipid bubbles were used 
to deliver the genetically modified cells or material to the defect. The scaffolds used for 
seeding of the cells differed in each study. The used scaffolds were: beta-tricalcium phosphate 
(β-TCP) [454, 461, 474], Bioactive glass ceramic (BGC) [463], Coral hydroxyapatite (CHA) 
[466, 467], Hydroxyapatite/ Collagen (HA/COL) [483, 484], Hydroxyapatite/ beta-tricalcium 
phosphate (HA/TCP) [490], Premineralized silk fibroin protein scaffolds (mSS) [452], 
Natural non-organic bone (NNB) [486], Mesoporous bioglass/silk fibrin (MBG) [471], 
hydroxyapatite/polyamide (HA/PA) [457], Pluronic F127 (PF127) [478], Poly D, L-lactide 
(PDLA) [443], Poly lactic co glycolic acid (PLGA) [475, 476], Calcium magnesium 
phosphate cement (CMPC) [477] and Calcium silicon phosphorus (OsteoBone) [489]. 
Regarding the source of transfected/transduced stem cells, mesenchymal stem cells (MSCs) 
were used in 25 experiments (43.8%) either from bone marrow or adipose tissue or induced 
pluripotent [451-459, 465-468, 474-478, 482, 486-489, 491], while different type of cells such 
as syngeneic dermal fibroblasts (SDFs) [446, 483], dental pulp stem cells (DPSCs) [449, 
490], periodontal derived stem cells (PDLSCs) [461, 463, 469, 472, 473, 484, 490] and 
periosteal derived osteoblast cells (pOBs) [470] were used in other studies with different 
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concentration of the cells. All the experiments had been divided into different study groups 
for comparing the efficiency of gene therapy in the disease model. Table  5.2 shows the 
extracted data from the included studies with reference to the disease model and animals used. 
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Table  5.2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Abramson 
[438] 
Alveolar bone defect 
with dental implant 
Maxilla 
(bilateral: first 
molars) 
Male 
Sprague 
Dawley rats 
16 N/R 2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Collagen alone 
Untreated control 
8×1011 
particles/ml 
8×1010 
particles/ml 
Alden [439] Alveolar bone defect Mandible 
(bilateral: angle) 
Sprague 
Dawley rats 
13 4 mm 
circular 
Physiological 
saline 
In-vivo 
(local 
injection) 
---------- BMP 2 
BMP 9 
LacZ 
3.75×108 
particles/7.5 µl 
Ashinoff [440] Distraction 
Osteogenesis 
Mandible 
(Right side: body) 
Male 
Sprague 
Dawley rats 
54 N/R N/R In-vivo 
(local 
injection) 
---------- Untreated control 
BMP2 
LacZ 
1×1010 IFU 
Chang [441] Periodontal alveolar 
bone defect 
Mandible 
(Buccal plate:1st 
and 2nd molars 
roots) 
Sprague 
Dawley rats 
144 3×2×1 
mm3 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Collagen alone 
5.5×108 PFU/ml 
5.5×109 PFU/ml 
in 20µl collagen 
Chang [442] Alveolar bone defect 
with dental implant 
Maxilla 
(Bilateral: first 
molars) 
Male 
Sprague 
Dawley rats 
100 N/R 2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Luc 
rhPDGF-BB 
Collagen alone 
5.5×108 PFU/ml 
5.5×109 PFU/ml 
Chang [485] Alveolar bone defect Maxilla 
(Bilateral: 
infraorbital rim) 
Female 
miniature 
swine 
20 3×1.2 
cm2 
Collagen 
Type I 
Ex-vivo ---------- BMP2 
LacZ 
N/R 
Chen [479] Periodontal Disease Maxilla 
(labial PDL: 
incisors) 
Male Wistar 
rats 
29 N/R Lipid 
bubbles 
In-vivo 
(GAM) 
---------- DNA 
DNA/US 
DNA/NB 
DNA/US/NB 
N/R 
Chen [443] Alveolar bone defect Maxilla 
(Bilateral: anterior) 
Foxhound 
dogs 
N/R 2 cm PDLA In-vivo 
(GAM) 
---------- BMP-4 scaffold  
Autograft 
Scaffold only  
Blank control 
N/R 
Chen [478] Periodontal alveolar 
bone defect 
Maxilla 
(Bilateral: incisors) 
Male New 
Zealand 
White rabbits 
12 15×7×5 
mm3 
PF127 Ex-vivo BMMSCs BMP-2 transfected MSCs/PF127 
Βgal transfected MSCs/PF127 
Untransfected MSCs/PF127 
PF127 only 
50×106cell/ml 
Cirelli [444] Periodontal Disease Maxilla 
(Bilateral: 
palatal gingival 
tissue between 
molars) 
Male 
Sprague 
Dawley rats 
45 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
---------- Vehicle 
Pg-LPS 
TNFR:Fc 
TNFR:Fc + Pg-LPS 
1×1011DRP/100ml 
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Table 5.2 (cont.): Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Cao [449] Periodontal Disease Maxilla&Mandible 
(First molars) 
Male 
Wuzhishan 
mini-pigs 
20 5×7×3mm3 Physiological 
saline 
Ex-vivo DPSCs DPSCs 
HGF-DPSCs 
DPSCs sheet 
HGF-DPSCs sheet  
Blank control 
1×107cells/0.6 ml 
Dai [450] Tempromandibular joint 
(Mandibular Condylar 
growth) 
Mandibular 
condyles 
Female 
Sprague 
Dawley rats 
60 N/R N/R Ex-vivo ---------- EGFP 
PBS only 
2×1011 genome 
copies/50 µl 
Dunn [445] Alveolar bone defect 
with dental implant 
Maxilla 
(First molars) 
Sprague–
Dawley rats 
44 2×1 
mm2 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- Luc 
BMP 7 
2.5×1011 particles 
Hu [451] Distraction 
Osteogenesis 
Mandible 
(Right side) 
Male 
Sprague-
Dawley rats 
44 N/R Physiological 
saline 
Ex-vivo BMMSCs BMP 7 
EGFP-N1 
physiological saline 
1×106 cell/0.15 ml 
Iglesias-
Linares [481] 
Orthodontic tooth 
movement 
Maxilla 
(Bilateral:Second 
molars) 
Wistar rats 72 N/R Solution In-vivo 
(local 
injection) 
---------- TM force + PBS (R&L) 
TM force + Corticotomy (R)/TM 
force + Flap surgery(L) 
TM force + RANKL (R)/TM force 
+ Plasmid without RANKL insert 
(L) 
Cortictomy (R)/Flap Surgery (L) 
RANKL (R)/Plasmid without 
RANKL insert (L) 
N/R 
Jiang [486] Alveolar bone defect Mandible 
(Bilateral) 
Female New 
Zealand 
White rabbits 
14 15×6 
mm2 
NNB Ex-vivo BMMSCs NNB/EGFP-BMP 4 
NNB/EGFP 
NNB/untransfected bMSCs 
NNB alone 
Blank control 
50×106 cell/scaffold 
Jiang [454] Sinus floor elevation Maxilla 
(Bilateral) 
Male New 
Zealand 
rabbits 
20 13×3×5 
mm3 
β-TCP Ex-vivo BMMSCs β-TCP alone 
Untransduced bMSCs/ β-TCP 
EGFP–bMSCs/ β-TCP 
BMP-2–bMSCs/ β-TCP 
2×107 cell/scaffold 
Jiang [452] Alveolar bone defect Mandible 
(Ascending ramus) 
Male Fisher 
344 rats 
24 5mm 
circular 
mSS Ex-vivo BMMSCs mSS/bMSCs transduced BMP 2 
mSS/bMSCs transduced LacZ 
mSS/bMSCs 
mSS alone 
2×107 cell/scaffold 
Jiang [453] Distraction 
Osteogenesis 
Mandible 
(Right side: 
between 1st 
premolar and 
mental foramen) 
Male New 
Zealand 
rabbits 
42 N/R Physiological 
saline 
Ex-vivo BMMSCs b-FGF transfected MSCs in 
physiological saline, 
EGFP transfected MSCs in 
physiological saline. 
Physiological saline 
1×107cell/0.15 
ml 
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Table 5.2 (cont.): Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem 
cell 
source 
Experimental groups Cell 
concentration 
Jin [446] Periodontal alveolar 
bone defect 
Mandible  
(Bilateral: 
mandibular 1st and 
2nd molar:buccal 
root PDL) 
Lewis rats 25 0.3×0.2 
cm2 
Gelatin 
sponge 
Ex-vivo SDFs GFP control-treated 
Noggin-treated 
BMP 7  
1×106 cell/scaffold 
Jin [447] Periodontal alveolar 
bone defect 
Mandible 
(Bilateral buccal 
plate of 1st and 2nd 
molars) 
Sprague–Dawley 
rats 
30 0.3×0.2 
cm2 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- Luc 
PDGF-B 
PDGF-A 
Collagen matrix alone 
2.5×1011 viral 
particles(PN)/ml 
Kanzaki [480] Orthodontic tooth 
movement 
Maxilla  
(Right 1st molar of 
OF group) 
Male Wistar rats 25 N/R Vector 
solution 
In-vivo 
(local 
injection) 
---------- Control group 
OF group with or without 
RANKL 
Mock group 
N/R 
Kroczek [487] Distraction 
Osteogenesis 
Mandible 
(Right side) 
Female 
Goettingen mini-
pigs 
24 N/R Aqueous 
solution 
Ex-vivo BMMSCs BMP 2 group  
BMP 7 group  
TGF-b group 
IGF 1 group 
Liposome vector group 
No induction group 
4×105cell/dish 
Kuboki [493] Tempromandibular joint Mandibular 
condyles 
(Bilateral) 
Hartley guinea-
pigs 
16 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
---------- Gene 
Placebo 
Control 
4.8×107 PFU/cell 
Lai [455] Distraction 
Osteogenesis 
Mandible  
(Right side) 
Male New 
Zealand rabbits 
44 N/R Physiological 
saline 
Ex-vivo ADSCs transfected ADSCs 
EGFP-N1transfected ADSCs 
physiological saline only 
1×107cell/0.2 
ml 
Lai [456] Distraction 
Osteogenesis 
Mandible  
(Left side: anterior 
to 1st molar) 
Male New 
Zealand rabbits 
44 N/R Physiological 
saline 
Ex-vivo BMMSCs transfected BMMSCs,  
autologous BMMSCs 
physiological saline only 
1×107cell/0.2 
ml 
Lattanzi 
[483] 
Alveolar bone defect Mandible  
(behind the root of 
the incisor) 
Wistar rats 36 5×5 mm2 HA/COL  Ex-vivo SDFs LMP-3 transduced SDF on 
HA/COL 
Untransduced SDF on HA/COL 
HA/COL scaffold without cells 
Control group EGFP 
N/R 
Li [457] Alveolar bone defect Mandible 
(Bilateral) 
New Zealand 
rabbits 
44 12×8 
mm2 
HA/PA  
 
Ex-vivo BMMSCs Scaffold  seeded with BMP 7 
transduced MSCs 
Scaffolds seeded with 
osteogenically cultured MSCs. 
Pure HA/PA scaffolds  
2×106cell/scaffold 
Li [458] Periodontal Disease Mandible 
(Bilateral:premolar 
teeth) 
Adult Beagle 
dogs 
5 N/R collagen 
membrane 
Ex-vivo BMMSCs Pure collagen membrane  
Collagen membrane / transfected 
cells Collagen membrane / 
untransfected cells 
1×107 cell/scaffold 
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Table 5.2 (cont.): Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Li [378] Tempromandibular joint Mandibular 
condyles 
(Bilateral) 
Female Sprague–
Dawley rats 
30 N/R N/R In-vivo 
(local 
injection) 
------------ Vastatin 
EGFP 
2×1011 genome 
copies/50µl 
Long [459] Distraction Osteogenesis Mandible  
(Right side: between 
anterior teeth and 
1st premolar) 
Male Japanese 
rabbits 
36 N/R Physiological 
saline 
Ex-vivo BMMSCs Distraction  0.8 mm/d  
Distraction of 2.4mm/d with 
MSCs transfected with lacZ  
Distraction of 2.4 mm/d with 
MSCs transfected with BMP-2. 
1×107cell/ ml 
Park J [482] Alveolar bone defect Mandible 
(Left ramus) 
Wistar rats 56 6mm 
circular 
Collagen 
sponge 
Ex-vivo BMMSCs BMP-2-infected BMSC 
LacZ-infected BMSC 
Untreated BMSC 
Empty collagen sponges 
1×106 cell/scaffol  
Park S [484] Periodontal alveolar 
bone defect with dental 
implant 
(Peri-implantitis wound) 
Mandible 
(Bilateral: premolars 
and 1st molar) 
Adult Beagle dogs 6 N/R HA/COL 
hydrogel  
Ex-vivo PDLSCs HA with collagen gel (control 
group,) 
HA with collagen gel/ PDLSCs  
HA with collagen 
gel/BMP2/PDLSC  
N/R 
Rabie [460] Tempromandibular joint  Mandibular 
condyles 
(Bilateral) 
Female Sprague–
Dawley rats 
90 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
------------ VEGF 
EGFP 
PBS  
2×1011 genome 
copies/50µl 
Steinhardt 
[488] 
Alveolar bone defect Mandible  
(Right side) 
NOD/SCID mice N/R 1mm 
circular 
Collagen 
sponge 
Ex-vivo BMMSCs MSC-BMP2 
MSC-lacZ  
Control group (no implant) 
5×106 cell/scaffold 
Su [461] Alveolar bone defect Mandible 
(Left side: alveolar 
bone of incisors) 
Male New 
Zealand rabbits 
20 5×10×4 
mm3 
β-TCP Ex-vivo PDLSCs Control  
β-TCP  
PDLSCs/β-TCP  
OPG-PDLSCs/β-TCP  
5×106 cell/scaffold 
Sun [489] Sinus floor elevation Maxilla 
(Bilateral) 
Male New 
Zealand rabbits 
8 13×3×5 
mm3 
OsteoBone Ex-vivo BMMSCs BMP-2-infected BMSC/Scaffold 
EGFP-infected BMSC/Scaffold 
2×107 cell/scaffol  
Sun [463] Alveolar bone defect Mandible 
(Bilateral) 
Adult New 
Zealand rabbits 
18 10×6 
mm2 
BGC Ex-vivo PDLSCs BMP-2–modified tissue-
engineered bone 
Unmodified tissue-engineered 
bone 
Single BGC graft  
Defects without any implantation  
2×107 cell/scaffold 
Sun [462] Distraction Osteogenesis Mandible  
(Right side: anterior 
to 1st premolar) 
Female New 
Zealand rabbits 
90 N/R Physiological 
saline 
Ex-vivo ADSCs Runx2 transfected ADSCs  
GFP-transfected ADSCs 
 
1×107 cell/ml 
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Table 5.2 (cont.): Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem 
cell 
source 
Experimental groups Cell 
concentration 
Sun [464] Periodontal alveolar 
bone defect 
Mandible  
(Bilateral: 
premolars) 
Adult beagle dogs 6 5mm Collagen 
sponge 
In-vivo 
(GAM) 
------------ BMP-2 plasmid group 
BMP-2 group 
PBS 
N/R 
Tan [465] Periodontal Disease Mandible 
(Bilateral: 1st, 2nd 
and 3rd premolars) 
Male beagle dogs 4 5mm 
vertical 
Sodium 
alginate 
Ex-vivo BMMSCs bFGF transfected BMSCs 
Untransfected BMSCs 
2×107 cell 
Tang [466] Alveolar bone defect Mandible 
(Left ramus) 
Female Sprague 
Dawley rats 
40 4mm 
circular 
CHA Ex-vivo BMMSCs Control groups: empty defect 
CHA/autologous transfected BMP-2 
CHA/untreated autologous BMSCs 
5×106 cell/scaffold 
Tang [467] Alveolar bone defect Mandible 
(Ramus) 
Female Sprague-
Dawley rats 
24 4mm 
circular 
CHA Ex-vivo BMMSCs Control groups: left untreated 
BMSCs that transfected with BMP-2 
5×109 cell/scaffold 
Wang [468] Distraction 
Osteogenesis 
Mandible 
(Bilateral) 
Male New 
Zealand rabbits 
20 N/R Physiological 
saline 
Ex-vivo BMMSCs MSC transduced with NGF-b 
Control: EGFP 
5×106 cell/0.1ml 
Wei [490] Tooth restoration/Bio-
Root regeneration 
N/R Inbred miniature 
pigs 
18 N/R HA/TCP Ex-vivo DPSCs 
PDLSCs 
HA/TCP 
Autologous Vc-induced PDLSCs in 
HA/TCP/DPSC 
Allogeneic Vc-induced PDLSCs in 
HA/TCP/DPSC 
1×106 cell/scaffold 
Wen [469] Periodontal alveolar 
bone defect 
Mandible 
(Right 1st molars) 
Sprague-Dawley 
rats 
6 1×3 
mm2 
Collagen 
gel 
Ex-vivo PDLSCs eGFP transfected PDLSCs 
untransfected PDLSCs 
Empty defect 
5×105 cell 
Yang [491] Periodontal Disease Maxilla  
(Bilateral: 1st 
molar) 
Female Sprague–
Dawley rats 
30 N/R systemic: 
culture 
media 
Local: 
Matrigel 
Ex-vivo/ 
In vivo 
(systemic) 
iPSC-
derived 
MSCs 
Healthy control  
Untreated periodontitis  
iPSC-MSCs-treated periodontitis  
iPSC- MSCs/TSG-6-treated 
periodontitis  
5×106 cell/200µl 
media 
L: 1×106 cell/20µl 
gel 
Ye [470] Central fissures Mandible New Zealand 
rabbits 
45 N/R Bioglass Ex-vivo pOBs BMP-2 transfected POBs/bioglass  
EGFP transfected POBs/bioglass  
Untransfected POBs/bioglass  
Bioglass only  
Blankcontrol  
2×107 cell/scaffold 
Yu [448] Periodontal Disease Maxilla  
(1st and 2nd 
molars) 
Male Sprague–
Dawley rats 
51 N/R HEPES In-vivo 
(local 
injection) 
------------ MKP-1 
LacZ 
HEPES- buffered saline 
1×109 PFU 
Zhang [473] Alveolar bone defect 
with dental implant 
Mandible 
(Bilateral: Premolar 
region) 
Adult hybrid dogs 9 6×5×4 
mm3 
Chitosan/ 
Collagen 
In-vivo 
(GAM) 
PDLSCs Pure scaffold 
Scaffolds with BMP7  
Scaffolds with Easy1 
1×107 cell/scaffold 
Zhang [472] Alveolar bone defect 
with dental implant 
Mandible  
(Bilateral: Premolar 
region) 
Adult hybrid dogs 6 6×5×4 
mm3 
Chitosan/ 
Collagen 
In-vivo 
(GAM) 
PDLSCs Scaffolds with Easy1: control  
Scaffolds with BMP 7 
Scaffolds with PDGF-B  
Scaffolds with BMP-7/PDGF-B  
1×107 cell/scaffold 
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Table 5.2 (cont.): Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem 
cell 
source 
Experimental groups Cell 
concentration 
Zhang [471] Periodontal Disease Maxilla  
(2nd & 3rd 
premolars) 
Male beagle dogs 5 5×5 
mm2 
MBG/silk 
fibrin  
In-vivo 
(GAM) 
------------ Control non-filled defects 
scaffold alone 
PDGF-B scaffold 
BMP7 scaffold 
PDGF-B + BMP7 scaffold 
5×105 cell/scaffold 
Zhao [474] Alveolar bone defect Mandible 
(Bilateral: ramus) 
Male Fisher 344 
rats 
11 5mm 
circular 
β-TCP Ex-vivo BMMSCs b-TCP alone 
b-TCP with untreated bMSCs 
b-TCP with bMSCs transduced 
with EGFP 
b-TCP with bMSCs transduced 
with BMP-2 
2×107 
cell/scaffold 
Zhao [492] Orthodontic tooth 
movement 
Maxilla  
(Right 1st molars) 
Male Wister rats 18 N/R Vector 
solution 
In-vivo 
(local 
injection) 
------------ OPG transfection group 
Mock vector transfection group 
Control group 
N/R 
Zhou [476] Periodontal alveolar 
bone defect 
Mandible 
(Bilateral: 
premolars) 
Male purebred 
beagle dogs 
4 4×4×3 
mm3 
PLGA  Ex-vivo BMMSCs BMSCs/OPG-PLGA 
BMSCS-PLGA 
1×106 
cell/scaffold 
Zhou [475] Periodontal alveolar 
bone defect 
Mandible 
(Bilateral: 
premolars) 
Male purebred 
beagle dogs 
4 4x4x3 
mm3 
PLGA Ex-vivo BMMSCs BMSCs/OPG-PLGA 
BMSCS-PLGA 
PLGA 
Negative control: root planing only  
1×106 
cell/scaffold 
Zou [477] Alveolar bone defect 
with dental implant 
Mandible 
(Bilateral: 
premolars region) 
Adult male 
labrador retriever 
dogs 
5 6×5×4 
mm3 
CMPC  Ex-vivo BMMSCs Blank  
CMPC  
CMPC/BMSCs/GFP 
CMPC/BMSCs/HIF 
CMPC/BMSCs/cHIF 
2×105 
cell/scaffold 
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Different analysis methods were used for either the in-vitro or in-vivo experiments as: 
Western blot (n=12, 21%) [440, 446, 448, 461, 462, 465, 475-478, 485, 486], In-situ 
hybridization (n=6, 10.5%) [450, 460, 463, 466, 467, 482], PCR (n=27, 47.3%) [378, 438, 
441, 442, 444, 446, 447, 450, 453, 454, 457, 460-462, 464, 465, 469, 471-474, 477, 482, 483, 
488, 491, 493], Bioluminescence (n=5, 8.7%) [438, 441, 445, 447, 479], µCT (n= 20, 35%) 
[439, 442, 444, 448, 449, 452, 453, 459, 462, 465, 471, 474, 477, 478, 483, 485, 487, 488, 
492], [490], Histology (n=48, 84.2%) [439-443, 445-449, 451-458, 461-466, 468-471, 473-
490, 492, 493], Staining (n=16, 28%) [440, 448, 449, 452, 454, 461, 466, 469, 474, 478, 482, 
483, 485, 487, 488, 493], Radiograph (n=18, 31.5%) [440, 443, 444, 451-453, 455-457, 459, 
462, 466, 470, 474, 475, 477, 482, 490], Histomorphometry (n=22, 38.5%) [440, 443, 445-
447, 451, 452, 454, 457, 458, 461, 463, 466, 468, 470, 471, 473, 474, 477, 486, 489, 490], 
SEM (n=14, 24.5%) [442, 445, 451, 457, 461, 466, 471, 473, 474, 476, 477, 486, 490, 491], 
Biomechanical analysis (n=8, 14%) [442, 453, 457, 459, 462, 470, 485, 490], 
Immunohistochemistry (n=25, 43.8%) [378, 446-448, 451-453, 456, 457, 460, 461, 466, 467, 
469, 475-477, 480, 482, 484, 485, 487, 489, 490, 492], Confocal microscopy (n=7, 12.2%) 
[452, 461, 472, 473, 479, 482, 489], Bone resorption assay (n=2, 3.5%) [480, 481], ALP 
activity (n=7, 12.2%) [446, 461, 463, 469, 471, 473, 486], Immunofluorescence (n=15, 
26.3%) [378, 453, 455-457, 460, 461, 465, 469, 474, 481, 483, 486, 488-490], FACS (n=12, 
21%) [378, 446, 449, 460, 465, 469, 477, 478, 482, 488, 490, 491], TRAP (n=3, 5.2%) [444, 
460, 491], Cell proliferation (n=8, 14%) [446, 457, 461, 463, 465, 469, 471, 484] or ELISA 
(n=16, 28%) [444, 448, 449, 452, 459, 460, 463, 471-473, 478, 482, 484, 488, 489, 491]. 
Table  5.3 summarizes the endpoint results of the main analytical methods used for the 
experiments either in vitro or in vivo.
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Table  5.3: Endpoint results of the main analytical methods used for the experiments 
 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Abramson 
[438] 
 PDGFB demonstrated more mineralized 
tissue at 4 weeks than 2 weeks. Viral copies 
in blood and organs not significantly different 
between treated and untreated rats at all time 
points 
   
Alden [439]    3D CT showed marked 
osteogenesis and bony healing in 
BMP-2 and BMP-9 treatment 
groups while control did not show 
notable healing.  
Slight healing of the defect in control. However, 
BMP-2 and BMP-9 showed marked bony 
regeneration across the defect site. BMP-2-
treated defect demonstrated almost complete 
regeneration of the mandible indistinguishable 
from the normal mandible. 
Ashinoff 
[440] 
   Increased radio-density in BMP-2-
treated animals with increased new 
bone formation compared to 
control  
 
Chang [441]  Viral vector of PDGFB was detected within 
the first week in DNA and gradually 
decreased to undetectable levels after 2 
weeks. 
Luc/collagen showed high level 
in animals receiving high-dose 
Luc compared with low-dose.  
 Two weeks after surgery, nearly complete bone 
bridging of the alveolar bone in both PDGF-B 
groups whereas limited bridging in collagen-
only animals. At 35 days, bone had completely 
bridged all of the defect area.  
Chang [442]  Absence of PDGF-B in bloodstream.  µCT showed higher bone volume 
fraction in PDGF-B and rhPDGF-
BB groups than low dose PDGF-B 
and Luc groups. 
Bone was noted at coronal margin in Luc group 
and thicker bone trabeculae were evident in all 
PDGF-treated specimens. At day 14, near-
complete defect fill was noted for all PDGF 
groups 
Chang [485]    3D CT revealed complete repair of 
defects implanted with BMP-2. 
However, small islands of bone 
formation were observed in the 
βgal. Immunohistochemistry 
results revealed positive staining in 
BMP-2 cell constructs. 
cancellous bone formation at defects implanted 
with BMP-2. Visible bone formation was noted 
at defect site implanted with BMP-2 cell 
constructs while βgal control had islands of bone 
formation with variable thickness and marked 
notching in the infraorbital rim.  
Chen [479]   At day 1 after treatments: DNA+NB 
and DNA+US treatments were as 
low as with DNA alone treatment. 
Ultrasonication after DNA + NB 
injection significantly increased 
luciferase activity. Rats with 
removed gingivae exhibited weak 
luciferase activity in labial tissues of 
maxillary incisors  
 Histology showed no haemorrhage or 
inflammation, while fluorescence images 
showed EGFP expression mostly confined to 
labial gingival tissues of maxillary incisors 
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Table 5.3 (cont.): Endpoint results of the main analytical methods used for the experiments 
 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Chen [443]    At week 4, rhBMP-4 and autograft-treated 
groups showed a significant increase in bone 
regeneration when compared with the defect-
only group and the scaffold only groups. No 
tooth eruption was seen at the 4-week time 
point in any of the four groups. New bone 
could be differentiated from grafted bone. By 
week 12, the entire defect had been filled. 
The difference between new and grafted 
bone could not be seen. All four groups 
exhibited tooth eruption at 12 weeks. 
Chen [478] Showed that the 
adenovirus mediated 
BMP-2 gene was 
positively expressed and 
processed in MSCs of 
the defect. 
  3D CT showed that BMP-2 group had the 
highest mean regenerated bone volume and 
there were no significant differences between 
the other three groups. 
6 weeks, BMP-2 group exhibited greater 
amounts of new bone formation. The newly 
regenerated trabecular bone was covered by 
a thick layer of osteoid and osteoblasts with 
continual bone-forming activity. The β-gal 
group exhibited woven bone formation, 
from the apical aspect of the defect to the 
middle of the root. The PF127 group 
displayed minimal amounts of bone 
formation at the apical third 
Cirelli [444] TNFR:Fc protein 4 
weeks before Pg-LPS 
delivery showed high 
level which were 
sustained during 8-week 
experimental period 
compared to Pg-LPS, 
vehicle or no treatment. 
High expression of IL-6, IL-10, RANKL 
and OPG observed at 4 weeks in Pg-LPS-
exposed animals, but not in TNRF:Fc. 
 2Dand 3D µCT of maxillae showed linear 
bone loss. Significant alveolar bone 
destruction was observed in Pg-LPS group 
continuously over 8 weeks. Administration of 
TNFR:Fc prevented linear bone resorption 
during entire study compared with Pg-LPS 
only treated group.  
An intense inflammatory cell infiltrate 
observed in subepithelial connective tissue 
and surrounding alveolar bone of  
periodontia of Pg-LPS- animals but a 
significantly less intense inflammatory 
reaction was observed in TNFR:Fc+Pg- 
LPS animals. Control animals did not show 
evidence of inflammatory cell infiltrates. 
Cao [449] Increased expression of 
HGF in transfected 
MSCs.  
  3D CT indicated limited bone formation in 
the control group. In contrast, marked bone 
regeneration occurred in the hDPSC, HGF-
hDPSC, hDPSC sheet and HGF-hDPSC sheet 
groups. The heights of newly regenerated 
bone were significantly higher in all 
treatment groups compared with control 
group. The bone volumes in all treatment 
groups were significantly larger than the 
volume in the control group. 
At week 12, new periodontal tissue 
regeneration within the periodontal defects 
was significantly less pronounced in the 
control group compared with the 
regeneration in the treatment groups. 
Alveolar bone regeneration was also more 
pronounced in the HGF-hDPSC, hDPSC 
sheet group and HGF-hDPSC sheet group 
than in the control group. The percentages 
of periodontal bone in the hDPSC injection, 
HGF-hDPSC injection, hDPSC sheet, and 
HGFhDPSC sheet groups were 
significantly higher than that of the control 
group. 
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Dai [450]  PCR of eGFP in heart, kidney, spleen and 
liver, mRNA was not detected reducing 
the prospects of systemic adverse effects. 
RT-PCR of transgene expression in the 
mandibular condyle revealed constant 
expression throughout the experiment. At 
day 21, there was a substantial increase in 
transgene expression. 
   
Dunn [445]   Showed sustained release of the gene 
product. All implants displayed the 
localized nature of expression in the 
near vicinity of the oral implants. The 
gene was expressed strongly for the 
first few days with peak expression at 
day 4 then declined by 2–5 weeks. 
 BMP-7-treated defects displayed tissue 
consistent with early osteoid formation 
throughout the defect area. Ad/Luc group 
exhibited normal bone healing, with most 
specimens showing minimal bone formation at 
the defect borders. At 28 days, bone formation 
was heightened both at the defect margins and 
along the dental implant surface in Ad/BMP-7-
treated sites. 
Hu [451]  Confirmed transcription of BMP-7 in 
transfected MSCs in contrast with 
negative signal in MSCs transfected with 
N1. 
 Radiodensity of callus in group 
A at 2 weeks was greater than in 
group B which was higher than 
group C. After 6 weeks of 
healing, more mineralization of 
distraction zone was seen in all 
three groups, but group A had 
greater radiodensity.  
Immunocytochemistry showed BMP-7 
expression in transfected MSCs while MSCs 
transfected with N1 exhibited negative signals. 
Bone regeneration in the distraction gaps was 
intramembranous ossification. At 2 weeks, 
positive signals for BMP-7 were found in the 
distraction zones in all three groups. Strong 
BMP-7 expression of was observed in group A, 
moderate in group B, and weak in group C. At 6 
weeks, very weak BMP-7 positive staining was 
seen and a similar pattern and intensity was 
noted among the three groups. 
Iglesias-
Linares [481] 
    TM force groups with corticotomy or RANKL 
transfection showed a larger bone resorption area 
than control groups. Transfection group under 
orthodontic force maintained a higher bone 
resorption rate than corticotomy group under 
force throughout the experiment. 
Jiang [486]     No inflammation or giant cell-type reaction was 
observed in any of the groups in 
immunohistochemistry.  
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Jiang [454]     At week 2, newly formed trabeculae were 
found in the four groups. Just a slight newly 
formed bone was observed in group A; 
however, more bone area was found in group 
B and group C. In group D, a larger area of 
newly formed bone was found not only in the 
periphery but also in the centre of the space. 
At week 8, newly formed bone area increased 
in all four groups. 
Jiang [452] BMSCs transduced with 
BMP-2 produced higher 
levels of BMP-2 during the 
entire culture period as 
compared with LacZ and 
untransduced MSCs using 
ELISA 
Upregulation of collagen type I 
in MSCs transduced with BMP-
2. Runx2 showed moderate 
upregulation. Osteopontin 
showed sustained marked 
upregulation. Osteocalcin 
showed a steep increase. 
Osteogenic markers in LacZ 
transduced bMSCs remained at 
basal levels. 
 A larger defined radio-opaque new bone 
formation and mineralization was observed in 
BMP-2- transduced bMSCs group when 
compared to the LacZ and untransduced groups.  
 
Increased bone formation in BMP-2-
transduced bMSCs implants, less bone 
formation in LacZ or untransduced bMSCs-
seeded scaffolds and no obvious bone 
formation was found in scaffold alone defects 
using histological sections. 
Immunohistochemistry displayed intensive 
BMP-2 staining in both bone matrix and 
surrounding fibroblastic-like tissue for BMP-
2-transduced bMSCs whereas in LacZ bMSCs 
and untransduced bMSCs groups, BMP-2 
staining was present but much weaker. No 
obvious positive staining was detected in the 
scaffold alone group. 
Jiang [453]  bFGF was at a highest level at 
day 7 in bFGF transfected MSCs 
and sustained at high level in the 
next 3 weeks. Negative signal of 
bFGF was detected in MSCs or 
MSCs transfected with EGFP. 
 At 8 weeks, radiodensity of distracted callus in 
group was higher than those in groups A and B 
while radiodensity in group B was higher than in 
group A. µCT showed that the lingual cortical 
bone was formed well than the buccal cortical 
bone in all groups. 
Immunohistochemistry showed bFGF 
expressed in bFGF transfected MSCs while 
negative signals in MSCs transfected with 
EGFP. Histology revealed newly formed 
trabeculae in all groups. 
Jin [446]     Expression of BMP-7 and noggin was 
undetectable by 10 and 35 days after surgery by 
immunohistochemistry. Minimal to no 
osteogenesis was seen in GFP and noggin 
groups at early time point. Defects treated with 
BMP-7 demonstrated cartilage and limited 
areas of bone in the majority of the defects. At 
35 days extensive bone formation was seen in 
most of the defects treated by BMP-7 while 
minimal osteogenesis and cementogenesis and 
lack of fibre insertion was noted in GFP and 
noggin groups. 
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Jin [447]  PCR showed expression of PDGF-
B in PDGF-B transduced SDFs but 
not in cells transduced by luc or 
PDGF-A or cells without any 
adenovirus transduction.  
The highest was at day 1 post-gene 
delivery and decreased at days 4-7. At 
14-28 days postgene transfer, luciferase 
decreased compared to day 1. 
 Immunostaining was performed at days 3, 
7and 14. In PDGF-B-treated group, greater 
numbers of positively stained cells on the 
surfaces of the alveolar bone and denuded 
tooth roots as well as the tissues 
surrounding the collagen matrix containing 
PDGF-B compared to other treatments at 
both days 3 and 7. At 3 days after treatment, 
no significant evidence of bone or 
cementum formation in any of the treatment 
groups and very few cells invaded into the 
adenovirus collagen implant. 
Kanzaki [480]     No severe inflammations in periodontal 
tissue on repeated local RANKL gene 
transfer. Strong RANKL protein expression 
in the periodontium after 2 or 4 days from 
RANKL gene transfer. Very few RANKL 
protein expressions in the periodontium 
after 6 days from RANKL gene transfer. 
The number of osteoclasts was high at day 2 
after RANKL gene transfer. The number of 
osteoclasts was reduced time dependently. 
Kroczek [487]    Some differences between early and late period 
of consolidation in relation to the 
osteoinductive substance applied. The central 
distraction zone had no ossification. Induction 
with TGF-b revealed crystallization spots 
dispersed homogenously over the central 
distraction zone. Osteoinduction with BMP-7 
showed consolidation of the central distraction 
zone after 1 week with a small gap in the 
central distraction zone. In the late 
consolidation period, the gap was bridged by 
fine bone trabeculae. Induction with BMP-2 
resulted in an accelerated, dense new bone 
formation. 
Lamination of the distracted bone areas 
adjacent to the osteotomy sites with 
longitudinally orientated columns of 
lamellar bone. The bone trabeculae showed 
osteoid deposition and early mineralization 
along their sides. The process of bone 
formation resembled more an 
intramembranous than chondroid 
ossification mode. Induction with TGF-b 
resulted in bone formation similar to one 
without induction. Positive immunostaining 
of BMP-2 was observed in distracted callus 
in all groups. Cellular elements with 
increased BMP-2 expression were found 
both in the distraction zone and in the 
consolidated osseous area close to the 
osteotomy region. A reduced BMP-2 
expression was found in the central 
distraction zones.  
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Kuboki 
[493] 
 The absence of LacZ in liver, kidney, 
heart, and brain in LacZ- or control 
group. In TMJ of LacZ-injected animals, 
expression of LacZ was detected and not 
detected in the joints of control group. 
  There was no observable difference between the 
virus-injected and the PBS-injected joints. The 
frontal section of the mandibular joint 1 week after 
LacZ injection clearly showed that articular 
surface-lining cells were stained blue.  
Lai [455]    Radiodensity of distraction areas in group A 
was higher than that in groups B and C at 
Weeks 2 and 6 after the distraction procedure. 
Bone cells in the distracted areas were stretched 
along in the direction of the distraction. At 2 week, 
the two fragments of mandibles in all groups were 
filled with newly formed bone trabeculae. Similar 
results were seen in groups B and C, but much 
denser and thicker bone trabecules were observed 
in the distracted areas in group A than in group B 
and group C. At 6 weeks, the distraction gaps of 
the mandible were full of newly generated bone in 
all three groups.  
Lai [456]    Radiograph of a distracted mandible at 2 
weeks showed that callus appeared to be 
greater in group A when compared with group 
B which was higher than group C. 
Bone regeneration in distraction gaps was 
intramembranous ossification. At 2 weeks, the new 
bone trabeculae formation began bridging in the 3 
groups. More thick and dense trabecules were seen 
in the distraction gaps in group A than group B and 
C. At 6 weeks, the gaps were filled with newly 
formed bone in all groups. At 2 weeks, 
immunohistochemistry of BSP showed areas of 
fibrous connective tissue within the gaps and were 
mainly detected in the cellular components of 
fibroblast like cells, preosteoblasts, and osteoblasts 
in all 3 groups. Cells in group A showed greater 
amount and more intense staining for BSP within 
the gaps than group B which is more than group C. 
Lattanzi 
[483] 
 Efficient LMP-3 expression 24 and 48 h. 
qPCR demonstrated that LMP-3 in 
transduced cells slightly increased in a 
time-dependent manner. 
 All rats treated with LMP-3 transduced SDFs 
showed positive X-rays at 8 and 12 weeks 
after surgery. No radiological evidences of 
bone formation could be demonstrated in 
three out of four animals at the earliest time 
point and in animals treated with scaffold 
alone or with non-transduced cells. 3DµCT 
revealed the successful repair of the defects 
implanted with LMP-3 cell constructs, which 
occurred in a time-related manner until 12 
weeks after implantation. No bone formation 
was observed in the control group. 
All rats treated with LMP-3 transduced SDFs 
showed positive histology at 8 and 12 weeks. No 
histological evidences of bone formation could be 
demonstrated in three out of four animals at the 
earliest time point and in animals treated with 
scaffold alone or with non-transduced cells.  
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Li [457]  BMP-7 was expressed in 
BMP-7 transfected MSCs 
while MSCs transfected with 
N1 exhibited negative 
signals. 
 Radiodensity in group A was higher than in 
group B and C. At 8 weeks, increasing 
mineralization in the implants was seen in 
group A than the other two groups. 
Immunocytochemistry showed BMP-7 was expressed in BMP-7 
transfected MSCs while N1 transfected MSCs exhibited negative 
signals. Immunocytochemistry of ALP and collagen I in group A 
was stronger than in group B. New bone formation was found in 
the implanted area in all three groups. At 4 weeks, the interface 
zone was surrounded by primitive mesenchymal cells 
differentiated into osteoblasts and new bone matrix was 
progressively deposited and became ossified. At week 4 and 8, 
all the parameters were significantly higher in group A than in 
group B than in group C. However, no significant difference in 
these parameters was found among three groups at week 16. 
Li [458]     The percentage of new alveolar area in transfected and non-
transfected BMSC were significantly higher than the control and 
there was also significant difference between two experimental 
groups. The percentage of new cementum length in two 
experimental groups was significantly higher than the control 
but there was no significant difference between two BMSCs 
groups. 
Li [378]  Vastatin was only found  
in  the  experimental 
group. There were no 
transcripts detectable in 
the control group.   
  Positive signals in immunostaining at day 7 while absence of 
signals in control group. Expression of Vastatin was the 
highest on day 7, decreased from day 14 to day 60. The 
expression was in the proliferative and chondroblast layers 
on day 7. On day 14, Vastatin expressed in chondrocyte and 
pre-hypertrophic chondrocyte layers. The expression 
moved to the pre-hypertrophic chondrocyte and 
hypertrophic chondrocyte layers on day 21. On day 30, the 
expression moved deeper  to hypertrophic chondrocyte 
layer. Only minor e xpression could be found in the deep 
hypertrophic chondrocyte layer on day 60. 
Long [459] BMP-2 levels 
were 
significantly 
higher in BMP-
2 transfected 
MSCs 
compared with 
lacZ–transfected 
MSCs 
  The distraction gaps in group B rabbits did not 
show ideal new bone formation at week 2 
while group A and C showed partial. The 
distraction gap in group A and C animals 
showed more mature new bone formation and 
higher radiopacity at week 4 compared with 
week 2. At week 8, radiograph of group A and 
C were almost identical to each other. µCT 
showed little new bone formation in the 
distraction gaps of group B animals at week 2. 
However, in groups A and C, new bone tissue 
was gradually mineralized from the centre to 
the margin in the distraction gap. More 
trabecular bone was mineralized at week 4 in 
group C than in group A. Groups A and C 
looked similar at week 8. 
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Park J [482]     Immunocytochemistry of osteocalcin showed mineralization in 
genetically modified BMSC but rarely in control group. In both 
gene transfer groups, the amount of osteocalcin increased similarly. 
At 4 weeks endochondral bone formation occurred in the gene 
transfer groups and in the control; however, the amount of newly 
formed bone in the control was much less than in genetically 
modified BMSC. Treatment of defects with BMP-2-infected 
BMSC resulted in nearly complete bony healing within 4 weeks 
after the transplantation.  
Park S [484] BMP-2 expression level in 
the BMP2/ PDLSCs was 
significantly higher than 
in non-transduced 
PDLSCs. BMP-2 
expression increased for 7 
days and decreased until 
day 21. 
  The bone was lost at 4 months after the 
induction of experimental peri-implantitis in 
radiographs. 
The bone labelling experiments demonstrated that new bone 
formation and re-osseointegration in the BMP2/PDLSC group 
occurred along the implant surface until week 8. PDLSC group 
showed less newly formed bone than BMP2/PDLSC group. The 
control group showed a limited amount of new bone formation 
around the peri-implantitis defects. 
Rabie [460] VEGF delivered group 
was higher than those two 
control groups from day 
21 to day 60. VEGF 
expressed from 
mandibular condyle was 
significantly increased 
from day 14 and lasted 
during the whole time 
periods. On day 30, VEGF 
expression was more than 
in control group. 
the expression of VEGF 
in condylar cartilage at 
day 7 and the maximum 
level at 21 days 
consistent with the 
result of in situ 
hybridization. 
  Immunohistochemistry confirmed increased VEGF expression in 
VEGF delivered condyle and positive signal in nearly all layers of 
condyle at day 30. VEGF expression was limited to the 
hypertrophic layer in control groups.  
The length and width of the condylar head increased significantly. 
The length of the condylar process significantly increased. 
Collagen type II was positive in chondroblast and hypertrophic 
layer. In control groups, collagen type II and type X positive layer 
decreased with age. However, after VEGF delivery, the collagen 
type II positive layer was significantly increased at day 21, 
compared to eGFP and PBS injection.  
Steinhardt 
[488] 
 High levels of BMP2 in 
the cells but the protein 
expression levels were 
very similar. 
 Almost fully regenerated defect after 8 
weeks. Minimal regeneration was observed 
after 8 weeks in control group infected with 
lacZ. 
Masson trichrome staining revealed formation of new bone tissue 
and almost complete healing of the defect implanted with MSC-
hBMP2. Minimal amount of new bone tissue was evident but no 
complete regeneration in lacZ or no implant.  
Su [461]  Increased OPG level in 
hOPG transfected cells 
compared with non-
transfected cells. 
  Toluidine blue staining showed no bone regeneration detected at 
the alveolar bone control group. A small amount of new bone 
could be seen in the β-TCP group with some osteoid formation in 
the periphery and centre of β-TCP scaffold. PDLSCs/β-TCP group 
showed more new alveolar bone formation, with numerous small 
bone trabeculae interconnected with each other. 
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Sun [489] High BMP-2 in MSCs 
transduced with BMP-2 as 
compared with EGFP. 
   BMP-2 immunocytochemistry showed high staining in BMP-2 
infected MSCs than that in control and EGFP infected cells. In 
BMP-2-MSCs/scaffold and EGFP-MSCs/scaffold, more newly 
formed trabeculae were found dose to the parent bony wall and 
lifted membrane. At 4 weeks after implantation, newly formed 
bone area in the entire augmented area was larger than that at 2 
weeks. 
Sun [463] High concentration of BMP-2 in 
the supernatant of cultured cells. 
There was no BMP-2 detected in 
uninfected cells during the entire 
time course. 
   More new bone tissue was found in the peripheral part of the 
grafted defects than in the central part. The central part of the 
grafts showed that the amount of bone in groups A and B was 
significantly larger than in group C. In the unfilled controls, there 
was more fibrous connective tissue formed in the defects after 12 
weeks and no full bone healing was found. 
Sun [462]  q-PCR showed the higher 
expression of Runx2 in 
Runx- transfected ADSCs 
than GFP transfected 
ADSCs and controls. 
 At week 9, radiograph of Groups A2 
and D2 showed mature bone 
formation. µCT indicated the 
formation of new bone in Groups A2 
and D2 than in the other two groups. 
Little new bone formation was 
observed in the distraction gaps of 
Groups B2 and C2. 
The distraction gaps in specimens from Groups A2 and D2 were 
filled primarily with fibrous tissue and tiny trabeculae at week 3. 
By 6 weeks, more new bone tissue was formed with thicker and 
wider trabeculae.  
Sun [464]     At 8 weeks, a complete osseous healing occurred and dense new periodontal ligament fibers rich in blood vessels were 
observed in  BMP-2 group and rhBMP-2 group whereas 
fewer new bone occurred and sparse collagen fibers aligned 
irregularly were observed in the blank control group. The 
height of new bone and cementum were significantly greater 
in the two experimental group than in the blank control 
group. 
Tan [465]    New bone formation in the two groups 
but the density of the newly formed 
bone in the bFGF-modified BMSC 
group was higher than that in BMSC-
alone. µCT showed extensive new 
bone apposition in continuity with the 
trabecular host bone structure in the 
bFGF-modified BMSC transplantation 
group and BMSC-alone 
transplantation group. 
Both groups exhibited periodontal regeneration, including newly 
formed cementum, periodontal ligament and bone. The newly 
formed bone and periodontal ligament in sites receiving bFGF-
modified BMSC were greater than those receiving BMSC alone.  
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Tang [466]    Radiographs confirmed that implanted 
BMSCs expressing BMP-2 promoted bone 
formation.. 
BMP-2 expression was detected by immunohistochemistry in transfected cells but 
not in the untreated BMSCs. Bone formation was observed on the composites 
seeded with transfected BMSCs expressing BMP-2 and the group implanted with 
CHA seeded with untreated BMSCs but the negative control implants did not induce 
bone formation. At 4 weeks the bone defects that were treated with transfected 
BMSCs showed formation of mature bone matrix with a trabecular pattern at the 
defect margin. At week 8, the defect was nearly completely closed and the newly 
formed mature bone had a typical trabecular pattern. 
Tang [467]     New bone formation was found at the margin of the defect treated with the BMSC 
modified by hBMP-2 gene transfer at 4 weeks and appeared mature 8. However, the 
amount of newly formed bone was much less with some adipose tissue at defect 
margins 8 weeks in control group.  
Wang 
[468] 
Secretion of NGF 
from the 
transduced MSC 
which increased 
to day 7. 
   Control group had signs of nerve degeneration with few regenerating nerve fibres 
whereas in experimental group there were abundant regenerating nerve fibres.  
Wei [490]    Six months after transplantation, bone-like 
tissue formation was observed in HA/TCP 
group with no obvious boundary between 
the newly regenerated tissue and bone as 
well as HA/TCP/ DPSC/PDLSC sheet 
implant formed a hard root structure and a 
clear PDL space was found between the 
implant and surrounding bony tissue. µCT 
demonstrated that there was no obvious hard 
root structure and PDL space in HA/TCP 
group whereas a visible root structure and 
PDL space-like areas in 
HA/TCP/DPSC/PDLSC sheet group. 
PDLSCs sheet had two or three layers and uniformly spread as a two dimensional 
tissue structure. Immunostaining for vimentin was positive. Fibronectin and type I 
collagen were present in the harvested PDLSC sheet.  
Wen [469]  At 7 days, the 
expression levels 
of COL-1 and 
RUNX2 in 
PDLSCS were 
higher than those 
in eGFP-PDLSCs; 
the expression 
levels of ALP and 
OPN eGFP-
PDLSCs were 
similar to those in 
PDLSCs.  
  6 weeks after surgery new regenerated bone, newly formed cementum and 
periodontal ligament were observed in group A and B. Strong expression of GFP 
and OPN was observed in the newly formed bone and cementum in the 
experimental group. 
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Yang [491] The production of 
proinflammatory cytokines 
was also significantly 
decreased in serum samples. 
Increased TSG-6 expression in 
transfected iPSC-MSCs whereas low 
TSG-6 expression in untransfected 
iPSC-MSCs. Systemic administration 
of iPSC-MSCs and iPSC-MSCs/ TSG-
6 reduced periodontal inflammation. 
  The infiltration of inflammatory cells in the 
periodontal tissues was markedly decreased 
in iPSC-MSCs/TSG-6 group.  
Ye [470]    Higher bone density was found in the rabbit 
mandibular central fissures of group I 4 to 8 
weeks after implantation. 
Much more new bony callus in group I than 
in other groups. 
Yu [448]    Cells transduced with MKP-1 exhibited 
reduced bone resorption after LPS 
stimulation compared with LacZ or HEPES 
control. 
There were no significant inflammatory 
cells and few multinucleated osteoclasts on 
the alveolar bone surface in the periodontal 
tissues injected with PBS. In contrast, there 
were significantly more inflammatory cells 
more fibroblasts and more multinucleated 
osteoclasts in the periodontal tissues 
injected with LPS. Immunohistological 
staining revealed that MKP-1 was present 
in the periodontal tissues of rats injected 
with MKP-1 but undetectable in control 
groups of rats.  
Zhang [473] The maximum concentration 
of BMP7 in the culture media 
was detected after 6–9 days 
incubation and then followed 
by a moderate decline. 
Significant differences in expression 
levels of OPN and BSP when HPLCs 
were cultured in BMP7 scaffolds. 
  The new bone formation of Group 2 was 
significantly greater than other groups at 4 
and 8weeks. BMP7 group significantly 
increased the percentage bone defect fill in 
the defects compared to other groups. 
Zhang [472] HPLCs incubated in Group 3 
produced higher level PDGF-B 
and produced higher level 
BMP7 in Group 2 during the 
entire culture period. There 
was no significant difference in 
the production of PDGF 
between groups 3 and 4. 
Similar results were noted in 
BMP7 secreted by Group 2 
and Group 4. 
Osteopontin and Type I collagen 
values of the PDGF-B expressing 
scaffolds were significantly greater 
than that of the control. The significant 
differences were observed in the 
mRNA expression levels of 
osteopontin, bone sialoprotein and 
Type I collagen when the HPLCs were 
cultured in combination scaffolds 
compared with BMP-7 or PDGF-B 
expressing scaffolds. 
  The new bone formation of the BMP-7 
expressing scaffolds and the combination 
were significantly greater than that of the 
control at 4 and 8 weeks. 
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Zhang [471] By 7 days, over fourfold significant 
increases in PDGF-B and BMP7 was 
observed. The addition of adPDGF-B 
significantly increased cell 
recruitment approximately eight times 
more than control scaffolds and over 
six times higher than BMP7 scaffolds. 
In all scaffolds containing BMP7 
or PDGF-B+BMP7, mRNA levels 
of each gene was significantly 
increased. The scaffolds 
containing adPDGF-B alone was 
only able to significantly 
upregulate mRNA levels of 
COL1.  
 Control defects demonstrated little 
tissue formation with regeneration of 
periodontal tissues. Defects filled with 
scaffolds alone regenerated little new 
periodontal tissues. Compared to 
scaffolds/PDGF-B. In contrast, scaffolds 
containing BMP7 demonstrated greater 
new bone formation. Scaffolds with 
PDGF-B and BMP7 demonstrated 
qualitative features similar to those of 
native periodontal structures.  
Control defects demonstrated little tissue 
formation with regeneration of periodontal 
tissues below 20% for cementum, alveolar 
bone and PDL. Defects filled with scaffolds 
alone regenerated less new periodontal 
tissues. Scaffolds containing PDGF-B 
demonstrated new formation of PDL. In 
contrast, scaffolds containing BMP7 
demonstrated greater new bone formation. 
Scaffolds with PDGF-B and BMP7 
demonstrated qualitative features similar to 
those of native periodontal structures.  
Zhao [474]  OPN and OCN from BMP-2-
transduced MSCs showed only a 
slight increase relative to GFP-
transduced MSCs. At 9 days of 
culture, OPN dramatically 
increased in BMP-2-transduced 
MSCs compared with GFP-
transduced MSCs. 
 Radiopacities at the defect sites inβ-TCP 
alone group, untreated MSCs ⁄β-TCP 
group and GFP-transduced MSCs ⁄β-
TCP group. µCT showed that bone 
formation was less for defects filled 
with untreated MSCs ⁄β-TCP and GFP-
transduced MSCs ⁄β-TCP but still 
advanced when compared with the 
implantation of β-TCP alone. 
Substantial new bone formation was 
observed after 8 weeks in the critical 
size defects which received BMP-2-
transduced MSCs ⁄β-TCP construct. 
mall amount of irregularly arranged woven 
bone tissue at the centre pores of β-TCP 
scaffold and fibrous connective tissue was still 
frequently observed. In the defects filled with 
implantation of BMP-2-transduced MSCs ⁄β-
TCP construct, mature newly formed bone 
tissue with few fibrous connective tissues 
infiltration was observed in the β-TCP pores 
at both centre and marginal area. Bone 
marrow also largely formed accompanied with 
the bony ingrowth. 
Zhao [492]    BMD and BVF were significantly 
increased in the OPG transfection group 
compared to the control and mock 
groups. 
The amount of ERR in the three groups was 
minimal and no significant differences among 
the three groups at the first two time points. 
By the last day of orthodontic tooth 
movement, the volume of ERR in all three 
groups was significantly increased. After 2 
weeks of retention, the volume of ERR in all 
three groups was significantly decreased 
especially in OPG transfection group. In the 
control and mock groups, there was 
significantly more ERR by the last day of 
retention. Immunohistochemistry showed that 
OPG protein expression was facilitated in the 
periodontium when was injected in the OPG 
transfection group. 
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Table 5.3 (cont.): Endpoint results of the main analytical methods used for the experiments 
 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Zhou [476]     After 6 weeks, the height of new alveolar bone 
and cementum and the formation of new 
connective tissue were significantly greater in 
the experimental group than in the control 
groups. 
Zhou [475]    New bone formation was observed in the defect. The 
height of the newly formed bone was more than that of 
the original bone crest and there was close fusion between 
the old and new bone. In the cell control group and 
scaffold control group, the height of the newly formed 
bone was not as good as that in the experimental group. In 
the negative control, there was virtually no new bone 
formation. 
Immunohistochemistry showed that the 
expression of OPG protein in the BMSCs OPG 
group was higher than that in the control group. 
Significantly more tissue regeneration for the 
scaffolds with BMSCs OPG was noted 
compared with the other groups. 
Zou [477]  HIF-1a mRNA and protein 
expression was upregulated in 
the target gene groups 
compared with the control 
group. 
 Scaffolds implanted in the correct position and tightly 
contacted the implant. In the HIF-1a expressing groups, 
new bone formation and osseointegration were superior to 
the GFP, CMPC and blank groups as measured by bone 
density and the bone contact ratio of dental implants. µCT 
showed that the new bone formation in the HIF and cHIF 
groups was greater than that in the other groups at 12 
weeks. 
Higher in HIF group than CMPC group, the 
blank group or the GFP group but less than the 
percentage in the cHIF group. BIC in each target 
gene groups was significantly higher than the 
control groups and no significant difference was 
observed between the CMPC group and the 
blank group. There were significant differences 
in bone density between the cHIF or HIF group 
and each control group but no significant 
difference was seen among the three control 
groups. 
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Methodological quality assessment of included articles 
The items included in the assessment of the quality of the articles are summarized in 
Table  5.4. 
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Table  5.4: Categories and grading used to assess the quality of the selected studies 
Item Description  Grade 
1 Title 0 = inaccurate/not concise 
1 = accurate and concise 
2 Abstract 
Summary of the background, research objectives, including details of the species or strain of 
animal used, key methods, principal findings  and conclusions of the study 
0 = clearly inaccurate 
1 = possibly accurate 
2 = clearly accurate 
3 Introduction 
Background-objectives, experimental approach and rationale, relevance to human biology 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
4 Introduction 
Objectives-primary and secondary 
0 = not clear 
1 = clear 
5 Methods 
Ethical statement-nature of the review permission, relevant licenses, national and 
institutional guidelines for the care and use of animals 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
6 Methods 
Study design-number  of experimental and control  groups, any steps taken to minimize  bias 
(i.e., allocation concealment, randomization, blinding) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
7 Methods 
Experimental  procedure-precise details (i.e., how, when, where, why) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
8 Methods 
Experimental animals-species, strain, sex, developmental stage, weight, source of animals 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
9 Methods 
Housing and husbandry-conditions and welfare-related assessment interventions (i.e., type of 
cage, bedding  material,  number of cage companions, light/dark cycle, temperature, access 
to food  and water) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
10 Methods 
Sample size-total number of animals used in each experimental group, details of calculation  
methods 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
11 Methods 
Allocation of animals to experimental groups-randomization or matching, order in which 
animals were treated or assessed 
0 = no 
1 = yes 
12 Methods 
Experimental outcomes-definition of primary and secondary outcomes 
0 = no 
1 = unclear/not complete 
2 = yes 
13 Methods 
Statistical methods-details and unit of analysis 
0 = no 
1 = unclear/not complete 
2 = yes 
14 Results 
Baseline data characteristics and health status of animals 
0 = no 
1 = yes 
15 Results 
Number analysed-absolute  numbers in each group included in each analysis, explanation for 
exclusion 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
16 Results 
Outcomes and estimation-results for each analysis with a measure of precision, as standard 
error or confidence  interval 
0 = no 
1 = unclear/not complete 
2 = yes 
17 Results 
Adverse events-details and notifications for reduction 
0 = no 
1 = unclear/not complete 
2 = yes 
18 Discussion 
Interpretation/scientific implications-study limitations including animal model, implications 
for the 3Rs 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
19 Discussion 
Generalizability/translation-relevance to human biology 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
20 Discussion 
Funding-sources, role of the funders 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
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The quality of finally selected studies was assessed by different categories [432, 433]. A 
relationship was driven between the Quality Score/Maximum Score by dividing the maximum 
score by category to the total score (T=36). Three possible quality coefficients: was 
conducted: 0.8–1 Excellent, 0.5–0.8 Average, <0.5 Poor as reported elsewhere [432, 433, 
497]. In the included articles, 21 articles were excellent articles fulfilling nearly all the criteria 
of the ARRIVE guidelines with coefficients 0.8-1. Thirty-five articles were qualified as 
average articles with coefficients 0.5-0.8 and only one article was categorized as being of 
poor quality with coefficients <0.5. All the titles of the manuscripts were accurate. The 
abstracts were clearly accurate in 24 articles (42.1%) and possibly accurate in 30 articles 
(52.6%) and clearly inaccurate in 3 articles (5.3%). Introduction (background, objectives, 
experimental approach and rationale, relevance to human biology) was clear and sufficient in 
all the articles. Introduction (Objectives-primary and secondary) was clear in nearly all the 
articles (n=56, 98.2%) while only one article was not clear (n=1, 1.8%). The methods (Ethical 
statement-nature of the review permission, relevant licenses, national and institutional 
guidelines for the care and use of animals) were clearly sufficient in 50 articles (87.7%), 
possibly sufficient in one article (1.8%) and clearly insufficient in 6 articles (10.5%). The 
methods (study design-number of experimental and control groups, any steps taken to 
minimize bias, that is, allocation concealment, randomization and blinding) were possibly 
sufficient in 12 articles (21%) and clearly sufficient in 45 articles (78.9%). The methods 
(experimental procedure-precise details, that is, how, when, where, why) were clearly 
sufficient in 34 article (59.6%), possibly sufficient in 22 articles (38.6%) and clearly 
insufficient in one article (1.8%) of the manuscripts. The methods (experimental animals-
species, strain, sex, maturity, weight, source of animals) were possibly sufficient in 25 articles 
(43.8%) and clearly sufficient in 32 articles (56.1%). The methods (housing and animal-
husbandry and welfare-related assessment interventions, that is, type of cage, bedding 
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material, number of cage companions, light/dark cycle, temperature, access to food and water) 
were clearly insufficient in 41 articles (72%) and possibly sufficient in 16 articles (28%). The 
methods (sample size-total number of animals used in each experimental group, details of 
calculation methods) were clearly adequate in 53 articles (93%), possibly adequate in 3 article 
(5.2%) and clearly inadequate in one article (1.8%). The methods (allocation of animals to 
experimental groups-randomization or matching, order in which animals were treated or 
assessed) were expressed in 52 articles (91.2%) and were not expressed in five article (8.8%). 
The methods (experimental outcomes-definition of primary and secondary outcomes) were 
unclear/incomplete in 6 articles (10.5%) and absent in one article (1.8%) while 50 articles 
(87.7%) showed complete outcomes. The methods (statistical methods-details and unit of 
analysis) were missing in 7 articles (12.3%) and were provided in 50 articles (87.7%).  
The results (baseline data characteristics and health status of animals) were not provided in 33 
articles (57.9%) and were provided in 24 articles (42.1%). Results (number analysed-absolute 
numbers in each group included in each analysis, explanation for exclusion) were clearly 
inadequate in 4 articles (7%), possibly adequate in 44 articles (79%) and clearly adequate in 
only 8 articles (14%). Results (outcomes and estimation results for each analysis with a 
measure of precision, as standard error or confidence interval) were not complete in 17 
articles (30%) and complete in 40 articles (70%). Results (adverse events details and 
notifications for reduction) were missing in 6 articles (10.5%), not complete in 33 articles 
(58%) and clearly accurate in 18 article (31.5%). The discussions (interpretation/scientific 
implications-study limitations including animal model, implications for the 3Rs) were clearly 
inadequate in one article (1.8%), possibly adequate in 51 article (89.4%) and clearly adequate 
in 5 article (8.8%). Discussions (generalizability/translation-relevance to human biology) 
were inadequate in 2 articles (3.5%), possibly adequate in 46 article (80.7%) and clearly 
adequate in 9 article (15.8%). Discussions (funding-sources, role of the funders) were clearly 
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inadequate in 3 articles (5.3%) and clearly adequate in 54 articles (94.7%). Table  5.5 
represents the assessment of the quality of the published articles included in the review. 
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Table  5.5: Quality assessment of articles included using ARRIVE guidelines 
Reference Items  Score 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 T(36) 
Abramson[438] 1 0 2 1 0 2 0 1 0 2 1 0 0 0 0 1 0 0 0 2 14 0.38 
Alden[439] 1 1 2 1 0 1 1 1 0 2 1 1 0 0 0 2 0 2 2 2 21 0.58 
Ashinoff[440] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 2 2 2 1 1 2 33 0.91 
Chang[441] 1 2 2 1 2 2 2 2 0 2 1 2 2 1 2 1 2 2 2 2 34 0.94 
Chang[442] 1 2 2 1 2 2 2 1 0 2 1 2 2 1 1 1 0 1 1 2 28 0.77 
Chang[485]  1 1 2 1 0 1 1 2 0 2 1 2 2 1 1 2 2 1 1 2 27 0.75 
Chen[479] 1 1 2 1 2 1 1 1 0 2 1 2 2 1 2 1 2 1 1 2 28 0.77 
Chen[443] 1 2 2 1 2 1 1 1 0 1 1 1 2 1 2 2 1 1 1 2 26 0.72 
Chen[478] 1 2 1 1 2 2 2 2 1 1 1 1 0 1 1 2 1 1 1 2 26 0.72 
Cirelli[444] 1 2 2 1 2 2 2 2 1 2 1 2 2 0 1 2 0 1 2 2 31 0.86 
Cao[449] 1 2 1 1 2 2 2 2 0 2 1 1 2 0 2 2 1 1 1 2 28 0.77 
Dai[450] 1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 1 0 1 1 2 26 0.72 
Dunn[445] 1 2 2 1 2 2 2 2 0 2 0 2 2 0 1 1 0 1 1 2 27 0.75 
Hu[451] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 1 2 2 1 1 2 31 0.86 
Iglesias-
Linares[481] 
1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 2 2 2 2 2 31 0.86 
Jiang[486] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Jiang[454] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Jiang[452] 1 2 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Jiang[453] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 2 2 1 1 1 2 31 0.86 
Jin[446] 1 2 2 1 2 2 2 1 0 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Jin[447]  1 2 2 1 0 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Kanzaki[480] 1 2 2 1 2 2 1 1 0 2 1 2 2 1 1 2 2 2 2 2 32 0.88 
Kroczek[487] 1 2 2 1 2 1 2 2 0 2 0 2 2 1 1 2 1 1 1 2 29 0.80 
kuboki[493] 1 1 2 1 2 2 2 1 0 2 1 2 0 0 1 1 2 1 1 2 26 0.72 
Lai[455] 1 1 2 1 2 2 2 1 0 2 1 2 2 1 1 2 2 1 1 2 30 0.83 
Lai[456] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 1 2 2 1 1 2 31 0.86 
Lattanzi[483] 1 1 2 1 2 2 2 1 0 2 1 2 0 1 2 2 1 1 1 2 28 0.77 
Li[457] 1 1 2 1 2 2 1 1 0 2 1 2 2 0 1 2 1 1 1 2 27 0.75 
Li[458] 1 1 2 1 2 2 1 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Li[378] 1 2 2 1 1 2 1 1 0 1 1 1 2 0 0 1 1 1 1 2 22 0.61 
Long[459] 1 1 2 1 2 2 2 2 0 2 1 2 2 0 1 2 2 1 1 2 30 0.83 
Park J[482] 1 2 2 1 0 2 2 1 1 2 1 2 0 0 1 1 1 1 1 2 25 0.69 
Park S[484] 1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 2 1 2 1 2 29 0.80 
Rabie[460] 1 2 2 1 2 1 1 1 0 2 1 2 2 0 1 2 1 1 1 2 27 0.75 
Steinhardt[488] 1 2 2 1 2 1 2 1 0 0 0 2 2 0 1 2 1 1 2 2 25 0.69 
Su[461] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 1 1 1 0 27 0.75 
Sun[489] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Sun[463] 1 1 2 1 2 2 2 1 1 2 1 2 2 1 1 1 1 1 2 0 28 0.77 
Sun[462] 1 2 2 1 2 2 1 2 0 2 1 2 2 0 1 2 2 1 1 2 30 0.83 
Sun[464] 1 2 0 0 0 1 1 2 0 2 0 1 2 0 0 2 1 1 0 2 18 0.5 
Tan[465] 1 2 2 1 2 1 1 2 1 2 1 2 2 1 1 2 2 1 2 2 32 0.88 
Tang[466] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 2 1 1 2 30 0.83 
Tang[467] 1 1 2 1 2 1 1 2 0 2 1 2 0 0 1 2 1 1 1 2 25 0.69 
Wang[468] 1 2 2 1 2 2 2 2 0 2 1 2 2 1 1 1 1 1 1 2 30 0.83 
Wei[490] 1 1 2 1 2 2 1 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Wen[469] 1 1 2 1 2 2 2 1 1 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Yang[491] 1 1 2 1 2 2 2 1 0 2 1 2 2 0 1 1 1 1 1 2 27 0.75 
Ye[470] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Yu[448] 1 1 2 1 2 2 1 1 1 2 1 2 2 0 1 1 1 1 1 2 27 0.75 
Zhang[473] 1 0 2 1 2 1 1 1 0 2 1 2 2 1 1 2 1 1 1 2 26 0.72 
Zhang[472] 1 0 2 1 2 1 1 1 0 2 1 2 2 1 1 1 1 1 1 2 25 0.69 
Zhang[471] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 1 1 1 2 28 0.77 
Zhao[474] 1 1 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Zhao[492] 1 1 2 1 2 2 1 2 1 2 0 2 2 1 1 2 2 1 2 2 31 0.86 
Zhou[476] 1 1 2 1 2 2 2 1 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Zhou[475] 1 1 2 1 2 2 1 2 0 2 1 2 2 1 2 2 1 1 1 0 27 0.75 
Zou[477] 1 2 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Category score 
(quality obtained) 
57 76 108 56 100 100 89 88 16 110 52 105 100 25 61 96 68 60 63 110   
Max category 
score (quality 
expected) 
57 114 114 57 114 114 114 114 114 114 57 114 114 57 114 114 114 114 114 114   
T: Total score for all the 20 items (36 points), Score: score of the items/the total score. 
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Risk of bias assessment of the included articles 
Overall, all the studies were having low risk of bias in publishing in peer-reviewed journals. 
Random allocation of the treatment or control were reported in 29 articles [378, 439, 446, 
447, 449-456, 459-461, 465, 468, 469, 474, 475, 477, 479, 483, 486, 489-492] and three 
studies [454, 457, 462] had a low risk of bias in random allocation concealment. Blinding of 
outcome assessment was performed in 13 studies [440, 444-447, 449-451, 453, 455, 456, 468, 
481] and only two studies [442, 450] were reporting sample size calculation The statement of 
compliance with animal welfare regulations were reported in 51 studies [378, 440-445, 447-
463, 465-481, 483, 484, 486-493] while conflict of interest were in 11 studies [441-443, 448, 
449, 461, 468, 469, 489, 490]. More details about possible risk of bias were presented in 
Figure  5.2. 
Publication V: Gene therapy Systematic Review & Meta-analysis 
Page 132 
 
Figure  5.2: Risk of bias graph for the studies included 
in this systematic review.  
Assessment of risk of bias using modified 
CAMARADES tool. Panel (A) Risk of bias of all 
included studies with the percentage of risk of bias for 
each item of assessment; Panel (B) Author name of 
each study and with their respective result in each item 
of assessment. Item (1) published in a peer-reviewed 
journal; (2) random allocation to treatment or control; 
(3) treatment allocation concealment; (4) blinded 
assessment of outcome; (5) reporting of a sample size 
calculation; (6) statement of compliance with animal 
welfare regulations and (7) statement of potential 
conflict of interest respectively. 
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Meta-analysis 
Fourteen studies were included in the histological meta-analysis of percentage of area of 
newly formed bone by gene therapy whereas three studies were included in percentage of 
volume of newly formed bone. However, four studies were included in the radiographic meta-
analysis of the bone formation by calculating the bone volume fraction. Figure  5.3 
summarizes the results of forest plot of gene therapy treatment versus control treatment. 
Percentage of area of bone formation by histology: 
Pooled data from gene vs reporter comprising of 9 inter-group comparisons generated from 7 
original studies involving 204 animals (102 treated and 102 control groups) was (SMD=1.74, 
95% CI, I2=64%, P<0.00001) while data from gene vs scaffold comprising of 5 inter-group 
comparisons generated from 4 original studies involving 68 animals (34 treated and 34 
control groups) was (SMD=1.17, 95% CI, I2=87%, P=0.0004). 
Pooled data from gene/scaffold vs reporter/scaffold comprising of 6 inter-group comparisons 
generated from 4 original studies involving 48 animals (24 treated and 24 control groups) was 
(SMD=1.31, 95% CI, I2=45%, P=0.0006). However, data from gene/scaffold vs scaffold 
comprising of 4 inter-group comparisons generated from 4 original studies involving 48 
animals (24 treated and 24 control groups) was (SMD=2.12, 95% CI, I2=82%, P<0.00001). 
Finally, pooled data from gene/scaffold vs untransfected cells/scaffold comprising of 3 inter-
group comparisons generated from 3 original studies involving 46 animals (23 treated and 23 
control groups) was (SMD=1.62, 95% CI, I2=67%, P<0.00001).  
Percentage of area of bone formation by histology is presented in (Figure  5.3A). 
Percentage of volume of bone formation by histology: 
Pooled data from gene vs reporter comprising of 2 inter-group comparisons generated from 2 
original studies involving 52 animals (36 treated and 36 control groups) was (SMD=1.71, 
95% CI, I2=48%, P<0.00001) while data from gene vs saline comprising of 3 inter-group 
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comparisons generated from 3 original studies involving 108 animals (54 treated and 54 
control groups) was (SMD=2.34, 95% CI, I2=0%, P<0.00001). 
Percentage of volume of bone formation by histology is presented in (Figure  5.3B). 
Bone volume fraction for bone formation by radiograph: 
Pooled data from gene vs reporter comprising of 4 inter-group comparisons generated from 4 
original studies was performed involving 84 animals (42 treated and 42 control groups), 
(SMD=1.36, 95% CI, I2=86%, P<0.00001). Bone volume fraction for bone formation by 
radiograph is presented in (Figure  5.3C)  
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Figure  5.3: Forest plot of standard mean difference (SMD), 
with 95% Confidence Interval (CI) in bone formation by 
histology and radiograph comparing different subgroups.  
Panel (A) represents forest plot of percentage area of bone 
formation by histology. Several subgroups were analysed as: 
Gene vs Reporter gene, Gene vs Scaffold, Gene/Scaffold vs 
Reporter/Scaffold, Gene/Scaffold vs Scaffold, Gene/Scaffold 
vs Untransfected cells/Scaffold. Panel (B) represents forest 
plot of percentage volume of bone formation by histology. 
Panel (C) represents forest plot of bone volume fraction 
detected by 3D µCT. the diamond represents the overall effect 
within each subgroup. 
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Publication bias  
Funnel plots of the study results are shown in Figure  5.4. Symmetrical funnel plots were 
obtained in all the models. The funnel plot of the study standard error by effect size (SMD) 
was symmetric. The funnel plot of standard error versus effect size (standard mean difference) 
was symmetrical indicating the absence of potential publication bias among the meta-analysis 
of bone formation by histology (Figure  5.4A&B) or radiograph (Figure  5.4C). 
 
Figure  5.4: Funnel plot showing publication bias among the studies.  
The symmetry of the funnel plot shows there was no evidence of publication bias 
among the studies. Each symbol on the funnel plot represents an individual study 
estimate included in the meta-analysis. The y-axis displays the standard error and 
the x-axis displays the standardized mean difference. SE: Standard Error; SMD: 
Standardized mean difference. 
DISCUSSION 
Several literature reviews have focused on gene therapy in bone tissue engineering, dentistry 
or oral and maxillofacial surgery [44, 428, 498, 499]. However, there has been no systematic 
review or meta-analysis with a specific focus on research covering gene therapy in the field of 
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Oral and Maxillofacial Surgery. Thus, we have conducted a comprehensive systematic review 
of the studies addressing efforts made in the field of gene therapy for healing of maxillofacial 
defects revealing the raised success rate during the recent years. Our meta-analysis results 
provided evidence that gene therapy was beneficial in treating maxillofacial defects in terms 
of improving bone formation based on histological and radiographic measures. However, it is 
important to keep in mind that several factors such as variability in research methods, 
characteristics of laboratory animals, interventions and outcome measures play role in meta-
analysis of animal studies. 
Although gene therapy was initially considered as a means of correcting hereditary disorders 
by changing the genes that cause the disease [500], more recent research is applying gene 
therapy to produce continuous amounts of biologically active molecules in the defects such as 
its potent ability for alveolar bone regeneration, periodontal healing and dental implants 
osseo-integration [471]. Clinical trials using gene therapy are now underway in salivary gland 
regeneration for dental application (https://clinicaltrials.gov/ct2/show/NCT00004178) and 
bone regeneration (https://clinicaltrials.gov/ct2/show/NCT02293031). However, future 
clinical trials for the use of gene therapy in periodontal regeneration remain hopeful for the 
near future. 
From our results, multiple genes were used as osteogenic factors for gene therapy in the 
maxillofacial region because of their potent induction of de novo bone formation in vivo with 
varying results as soluble growth factors (PDGF, FGFs), morphogens (BMPs), angiogenetic 
factors (VEGF), intracellular regulators (LIM mineralization protein-1: LMP-1), transcription 
factors associated with bone/cartilage-related gene expression (Runx2) [501, 502]. All of 
these biological factors have been investigated for their potential use in bone tissue 
engineering and repair. However, BMPs were preferred candidates for local gene therapy for 
bone regeneration as they are the only group that can initiate and sustain the entire bone 
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formation cascade [503]. Some studies proved the feasibility of transferring BMP genes [504, 
505]. On the other hand, previous investigations had reported the effect of PDGF on osseous 
wound healing showing that PDGF signalling plays role in chemotaxis and proliferation of 
osteoblasts and fibroblasts [506]. However, PDGF’s ability to induce osteogenic 
differentiation is less clear. Recently, LMP-1 proved the initiation of membranous bone 
formation in vitro and in vivo [507]. Unlike BMPs acting extracellularly through cell surface 
receptors, LMP-1 is an intracellular signalling molecule involved in osteoblast differentiation 
[499]. 
Another critical element of gene therapy is the vector which is the vehicle that facilitates the 
transfer of genetic material into the target cell nucleus without degradation or causing 
toxicity. Two kinds of vectors have been employed as vehicles: viral and non-viral vectors. 
Gene transfer via viral vectors is called transduction while transfer via the non-viral vectors is 
transfection. Different viral vectors have been introduced as DNA-based like adenoviruses, 
adeno-associated viruses or RNA-based viral vectors as retroviruses and lentiviruses. Non-
viral vectors can be plasmids, liposomes or polyplexes. Each vector has its own advantages 
and disadvantages. Viral vectors have the advantage of its ability to carry the gene efficiently 
and ensure long-term expression but they can only trigger short-term gene expression and are 
highly immunogenic. Another advantage of viral vectors is that they are non-virulent due to 
their modified genome in which the essential viral genes are replaced by the therapeutic gene 
being unable to replicate in the absence of these critical gene products. Non-viral vectors 
could be also used due to their safety profile and minimal immunogenicity. However, the 
main disadvantage in their use is the insufficient transfection efficiencies. [41, 501, 508-511].  
For viral-based gene therapy, it is necessary to allow continuous high-titre virus production. 
The viruses are replicated in either human or non-human cell lines. A whole panel of different 
cell lines has been used all-over the years to generate viral vector to be used as therapeutic 
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product. HEK293 cells and their derivatives have been extensively used for production of 
different vectors because of their easy handling and the possibility to grow them as adherent 
as well as suspension cells [512, 513]. In line with our findings, several studies had proved 
the efficiency of viral vector in the transfer of the DNA [514-516] while other studies have 
used non-viral vectors [517, 518]. 
Reporter gene assays have emerged as a rapid and sensitive strategy for indirectly monitoring 
transgene expression by cloning the promoter region of the gene of interest correlated to the 
reporter gene and measure reporter gene expression as a reflection of the expression of the 
gene of interest [519]. It is important to use a reporter gene that is not naturally expressed in 
the cell or organism under study. Different strategies of making the fusion construct and their 
applications have been reported [520]. Commonly used reporter genes that induce visually 
identifiable characteristics usually involve fluorescent proteins as green fluorescent protein 
(GFP), which causes cells that express it to glow green under UV light and the enzyme 
luciferase [521], which catalyses a reaction with a luciferin to produce light. Another common 
reporter gene is the lacZ expressed in bacteria, which encodes the protein β-galactosidase. 
This enzyme causes bacteria expressing the gene to appear blue when grown on a medium 
that contains the substrate analogue X-gal. In our results, several reporter genes have been 
used which gives an add-on to the experiments being an internal control for the expression of 
the gene of interest. 
Various biological delivery systems have been applied for directing therapeutic gene to target 
cells. In the in-vivo approach, cells can be genetically modified in situ or the vector is 
administered to the defect via systemic or local direct injection associated with a biomaterial. 
The latter combination of vector and biomaterial is called gene activated matrix (GAM). 
GAMs are three-dimensional biomaterials acting as a scaffold for vectors introduced to a 
localised area and useful for avoiding unintended spread of transfection to local tissues. 
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Regarding the ex vivo approach, cells are removed, genetically modified and re-implanted in 
the defect by direct injection or using a biomaterial as carrier [522-524].  
Genetic modification of stem or progenitor cells serves as an important advancement in 
regenerative medicine to improve their in-vivo performance. By combining gene with cell 
therapy, stem cell function may be enhanced by improving proliferative capacity or 
differentiation of the stem cells. Another important function of stem cells is for drug delivery 
exerting paracrine or endocrine actions. The most common cell source is mesenchymal stem 
cells (MSC) which can be isolated from bone marrow, muscle tissue, peripheral blood, 
umbilical cord, adipose tissue, liver, multiple dental tissues or induced pluripotent stem cells 
(iPSC) [525, 526]. MSC are adult stem cells capable of self-renewal and differentiation into 
multiple lineages including cartilage, adipose, and bone which have been used for treating 
bone-related diseases [527]. The induced pluripotent stem cells (iPSCs) is a new source of 
stem cell generated from human somatic cells into a pluripotent stage [528]. Various cells 
such as gingival or dermal fibroblasts, periosteal cells, primary articulated joint chondroblasts, 
bone marrow stromal cells/ MSCs, muscle-derived stem cells, fat-derived stem cells, 
osteoblasts and myoblasts have been successfully transduced using in vivo or ex vivo 
techniques and the different vector systems [501]. From our results, the most commonly used 
stem cells in the maxillofacial region were genetically modified bone marrow, adipose, 
periodontal and dental pulp stem cells. Other studies used the same cells for regeneration of 
bone and other organs: BMMSCs [529, 530], ADSCs [531-533], PDLSCs [534], DPSCs 
[535]. 
Animal models are valuable tools in biomedical research in particular gene therapy to test the 
safety, efficacy, dosage and localization of transgene expression in models that closely 
resemble human diseases. Animal craniofacial models for gene therapy exist not only for 
bone [536] but also for periodontal ligaments [447], TMJ [460], cartilage [537] as well as 
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salivary glands [538]. Such models have critical-size defects with the absence of spontaneous 
complete osseous regeneration of the created defects during the lifetime of the animals [5, 
39]. 
Considering limitation of our systematic review, meta-analysis was conducted for only few 
included studies due to the high level of heterogeneity in reporting the treatment outcomes. 
Moreover, the studies which were included in our meta-analysis generally used animal 
models for gene therapy. Therefore, randomized clinical studies in humans are needed to 
confirm our conclusions. However, meta-analysis was performed only to articles that had 
clearly reported bone formation (primary outcome) either by percentage of area or volume 
histologically as well as radiographically.  
CONCLUSION 
Challenging approaches had emerged for oral and maxillofacial reconstruction in the last 
decade due to the complex nature of craniofacial defects. Tissue engineering is attracting the 
spotlights as a new paradigm for bone regeneration which requires the collaboration of 
multidisciplinary teams of surgeons, biologists and biomedical engineers. Gene therapy is on 
the top list of innovative strategies in tissue engineering that developed in the last 10 years. 
While significant progress has been made towards preclinical studies of gene therapy in the 
maxillofacial region building the scientific basis of this technique, gene therapy is still in the 
clinical trials phase in salivary glands and craniofacial defects.  
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6. PUBLICATION VI 
PATHOGENESIS OF ANTIRESORPTIVE DRUG-RELATED OSTEONECROSIS 
OF THE JAW 
Riham Fliefel and Sven Otto. Pathogenesis of antiresorptive drug-related 
osteonecrosis of the jaw. In: Kenneth E Fleisher, Risto Kontio, Sven Otto. 
Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—a Guide to 
Research. Switzerland: AOCMF; 2016. p64. ISBN: 978-3-905363-10-4. 
ABSTRACT 
In this chapter, three questions are raised and discussed: 
 Which theories exist for the pathogenesis of antiresorptive drug-related osteonecrosis 
of the jaw (ARONJ)? 
 Why jaw bones are predominantly affected? 
 Why can nitrogen-containing bisphosphonates and denosumab cause ARONJ? 
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Bones are constantly remodelled through osteoblastic (bone formation) and osteoclastic (bone 
resorption) activity to maintain skeletal strength and integrity. However, imbalance between 
these phenomena affects bone mineral density leading to bone disorders as osteoporosis, 
Paget’s disease, myeloma, bone metastases secondary to cancer as well as osteogenesis 
imperfecta and inflammatory bone loss. One of the recent treatment of bone disorders is the 
use of antiresorptive drugs including hormone replacement therapy, selective estrogen 
receptor modulators, bisphosphonates and denosumab which reduce the occurrence of bone 
pain, pathological fracture and spinal cord compression [539-542]. 
Among the antiresorptive drugs, bisphosphonates (BPs) are stable analogues of natural 
inorganic pyrophosphates [217, 543, 544]. They can be classified into non-nitrogen- BPs that 
metabolically interfere with adenosine triphosphate-dependent (ATP) intracellular pathways 
and nitrogen BPs which inhibit farnesyl pyrophosphate synthase [545, 546]. Denosumab is a 
new antiresorptive drug with a novel mechanism of action [547]. Both denosumab and 
bisphosphonates target osteoclasts. However, their effects on osteoblasts are largely indirect 
[548]. 
The mechanisms of action of BPs in bone metabolism are complex and multifactorial altering 
the osteoclast cytoskeleton stimulating apoptosis and reducing proton-pump expression [549-
551]. They interfere with chemotaxis and attachment of osteoclast to bone together with 
suppressing mature osteoclast function by defective intracellular vesicle transport which in 
turn prevents osteoclast from forming a tight scaling zone or ruffled border, required for bone 
resorption [55, 552, 553]. In addition, they inhibit recruitment, activation and differentiation 
of osteoclast precursors [554]. The clinical efficacy of bisphosphonates rises from their ability 
to bind strongly to bone mineral [544]. The initial clearance of BPs occurs through renal 
excretion or adsorption to bone mineral extending over a period of weeks to years [555]. 
During bone resorption, the acidic pH in the resorption lacuna increase the dissociation of BP 
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from bone [556]. This is followed by the uptake of the BP most likely by fluid-phase 
endocytosis [557]. 
Bone resorption is regulated through RANK/RANKL/OPG pathway [548, 558]. Receptor 
activator of nuclear factor kappa-B ligand (RANKL) is a transmembrane and soluble protein 
highly expressed by osteoblasts [559, 560]; its receptor, Receptor activator of nuclear factor 
kappa-B (RANK), is located on the cell membrane of osteoclasts and preosteoclasts [560, 
561]. RANK/RANKL binding stimulates the formation, activity, and survival of osteoclasts, 
resulting in increased bone resorption [562]. Osteoprotegerin (OPG) is a naturally occurring 
soluble, non-signalling “decoy receptor” for RANKL. OPG inhibits osteoclast activity by 
binding to RANKL preventing its interaction with RANK [562-564]. Both RANKL and OPG 
are produced by osteoblasts [565]. 
Denosumab is a fully human monoclonal antibody that was developed specifically to interact 
with RANK/RANKL/OPG pathway [544]. By binding to RANKL, it prevents the maturation 
and differentiation of preosteoclasts in the extracellular environment and promotes apoptosis 
of osteoclasts [566]. It has several advantages over bisphosphonates, including better 
tolerability, ease of subcutaneous injection, shorter half-life and reduced incidence of 
nephrotoxicity rendering it the drug of choice for patients with renal diseases or prostate 
cancer [567]. In contrast to the bisphosphonates, denosumab does not become embedded 
within bone tissue [547, 548]. Denosumab is cleared from the bloodstream through the 
reticuloendothelial system, with a half-life of approximately 26 days without inducing the 
formation of neutralising antibodies [568]. 
Antiresorptive drugs have numerous side effects including the upper gastrointestinal where 
nausea, vomiting, epigastric pain and dyspepsia occurs after oral administration of the drugs 
for the treatment of osteoporosis. Subsequently, several cases of renal failure were reported 
with the use of intravenous bisphosphonates. A possible mechanism of the renal toxicity was 
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the strong affinity of the bisphosphonates for metal ions and their tendency to form complexes 
and aggregates with metal ions. Non-specific conjunctivitis is the most common ocular side 
effect of bisphosphonates which usually improves without therapy and despite continuing 
treatment with bisphosphonates. Transient hypocalcaemia with secondary 
hyperparathyroidism is also a side effect of bisphosphonate administration. There is a 
possibility of severe and sometimes incapacitating bone, joint, and/or muscle 
(musculoskeletal) pain in patients taking bisphosphonates [569, 570]. 
No potential adverse effect of antiresorptive drugs has been more widely reported than 
medication-related osteonecrosis of the jaw (MRONJ) that ranges in severity from painless, 
small areas of exposed bone to significant bone exposure associated with severe pain, 
sequestration, infection, fistula or jaw fracture [29, 140, 354, 571]. The pathogenesis of the 
disease is certain with many questions regarding the potential mechanisms underlying the 
pathophysiology [186, 558, 572]. Five main mechanisms had also been proposed: i) impaired 
healing; ii) angiogenesis; iii) local toxicity; iv) immunomodulation; and v) infections. Most 
likely a combination of these facilitate development of MRONJ [573]. However, the leading 
theory to explain the mechanism suggests that it is caused by cessation of bone remodelling 
and bone turnover by the inhibition of osteoclasts [134]. 
MRONJ most commonly occurs in the oral cavity as the jaws are covered by a thin layer of 
periosteum and epithelium. The alveolar bone of the jaws is daily remodelled with a high rate 
of bone turnover. and the presence of teeth and gum providing an easy entrance for bacterial 
infection [572, 574].The oral structures are subjected to a wide variety of stresses, which may 
be physiologic, iatrogenic or inflammatory. The constant stress leads to trauma to the mucosa 
with exposure of bone [572]. Prolonged use of bisphosphonates may suppress bone turnover 
with accumulation of microcracks resulting in decreased biomechanical competence [140, 
344]. BPs cause excessive reduction of bone turnover resulting in an increased risk of bone 
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necrosis in osseous repair [575, 576]. However, this theory failed to explain why exposed 
necrotic lesions are rarely seen in bones other than the jaws. MRONJ does not appear to occur 
in other conditions associated with reduced bone turnover, such as hypoparathyroidism and in 
patients with reported MRONJ, the bone turnover markers were not suppressed [577, 578]. In 
patients with breast cancer and bone metastases treated with zoledronate or denosumab, bone 
scintigraphy images suggest that the bone turnover of the mandible and the maxilla is not 
overtly changed when compared to other bones [579].  
Blood supply may play role in MRONJ as its reduction might lead to delayed wound healing 
due to the antiangiogenic effect [230 ]. Antiresorptive medications may inhibit angiogenesis 
by inhibiting the formation of blood vessels, endothelial cells, fibroblast growth factor, and 
endothelial growth factor impairing endothelial cell (EC) functions leading to altered adhesion 
and migration. Furthermore, there is reduced proliferation, increased apoptosis, and decreased 
capillary-like tube formation in ECs that might cause bone necrosis [386, 580, 581]. In a 
study by Wehrhan et al [582], mucoperiosteal tissue samples from BRONJ patients and 
controls were assessed for vascularization with CD31 staining and neo-angiogenesis by 
CD105. Although there was no difference in vascularization between sample groups, there 
were significantly fewer CD105-positive vessels in BRONJ samples suggesting that neo-
angiogenesis was suppressed in BRONJ patients. Histological evaluation of BRONJ tissue 
revealed decreased p63 gene expression, indicating a reduction in basal cell progenitors and 
might lead to impaired healing of the oral mucosa [583]. Although bisphosphonates, 
bevacizumab and sunitinib all have antiangiogenic effects, the effects of denosumab on 
angiogenesis is largely unknown. [584-586]. As such, impaired vascularization may play only 
a minor role in development of MRONJ [587]. 
Soft tissue cytotoxicity might also play a role explaining why bone is directly exposed to the 
oral environment through teeth and periodontal ligaments [588]. Local infection, tooth 
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extraction in particular, could result in the release of bisphosphonates into the local tissues. 
Provided that the local concentration of drug is high enough, the proliferation of adjacent 
epithelial cells could be inhibited and thus slow down the healing of the breached mucosal 
barrier [589]. However, soft tissue toxicity has not been reported with denosumab. BPs was 
explored on a variety of cells, including gastrointestinal cells, cervical epithelial cells, renal 
cells, prostate epithelial cells, and oral mucosal cells [572]. Antiresorptive drugs also acts on 
immunity including the impairment of myeloid cells function [590, 591], dendritic cell [592] 
and T-cell upregulation [593]. They increase the antigenicity of cancer cells as targets and 
increase adaptive immunity. This impairment of local immunity with an infectious tendency 
may be a key element in MRONJ [573]. 
Infection and periodontal disease are critical factors associated with MRONJ. However, 
controversy exists as to whether (1) BP inhibition of bone remodelling results in necrosis with 
subsequent infection or (2) the direct toxic effects of BPs on the oral mucosa allow for 
invasion of oral pathogens causing infection with subsequent necrosis [293, 594]. Among all 
the bones, jaw seems to be the most liable to bacterial infection since mucosa covering the 
alveolar bone is very thin and vulnerable and teeth easily become a pathway for bacteria from 
the outside into the bone. After administration, BPs accumulate in the bone and during 
physiological remodelling, osteocytes are exposed to BPs in bone [595]. BPs bind to bone at 
neutral pH and released from bone in an acidic milieu; thus, pH and infections might play an 
important role in the pathogenesis of MRONJ. This physiologic mechanism takes place in the 
resorption lacunas during bone resorption, where acid pH increases the dissociation between 
BP and hydroxyapatite. To date, this well-known feature has not been linked to the 
pathogenesis of BRONJ, but may prove to be the missing part in the multifactorial puzzle [18, 
173]. 
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Aghaloo et al. [596] found that necrosis of the alveolar bones developed after placement of a 
wire ligature around the crown of maxillary molar in a rat periodontal disease model. The 
results showed that periodontitis, which is presumably infection-related can trigger 
osteonecrosis. When periodontitis occurs, inflammatory cells are recruited to the sites to 
eliminate the causative pathogens. However, the blockade of bone resorption with BP may 
render it difficult for these cells to access to the pathogens, allowing the infection to persist. 
The resulting accumulation of bacterial toxins and inflammation generated superoxides will 
promote bone necrosis. [595]. Mechanism of MRONJ is so much related to immunity and 
infections rather than being aseptic or avascular in origin [584]. It is mostly following 
invasive dental procedures suggesting that MRONJ likely involves a drug-induced 
compromise in the bone response to invasive trauma. Even though the underlying indication 
for dental extraction in these patients may have been infection, MRONJ did not manifest until 
after extraction in most cases. For a direct in-vivo mechanism to be identified, it is yet unclear 
whether invasive trauma by itself is sufficient to precipitate MRONJ in bisphosphonate-
treated individuals [29, 578]. Polymicrobial infection and periodontal disease may contribute 
to development of MRONJ as a biofilm-associated infection. Filleul et al. [359] found out that 
actinomyces were present in 70% of all cases. Thumbigere-Math et al. [198] found 
Actinomyces-like microorganisms in all bone specimens of patients during microbiological 
examination. In an animal models treated with BPs, bacterial infection was sufficient enough 
to cause MRONJ [597]. Sterile inflammation alone in the soft tissues surrounding the jaw is 
not enough to induce MRONJ [598]. Treatment with antibiotics in animal models [599] and 
mucoperiosteal coverage on the day of tooth extraction in a rat model prevented the 
development of MRONJ [600]. 
The presence of the infectious component in MRONJ is the most dangerous aspect. Oral 
pathogens should be prevented from reaching the bone surface, and optimum oral hygiene is 
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essential. The current regimens which consist of oral antiseptics and antibiotics are not always 
successful. Ideally, treatment aims to eradicate the underlying infection, prevent secondary 
infection, stop the disease process and control symptoms [601]. Traumatic intervention should 
be avoided, but where it must be undertaken, strict adherence is necessary. The proposed 
sequence of events in the development of MRONJ with infection could justify temporary 
discontinuation of the drug to allow recovery of macrophage production and function [31]. 
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7. PUBLICATION VII 
NEW AND INNOVATIVE TREATMENT STRATEGIES FOR MEDICATION-
RELATED OSTEONECROSIS OF THE JAW 
Riham Fliefel and Pit Voss. New and Innovative Treatment Strategies for 
Medication-Related Osteonecrosis of the Jaw. In: Sven Otto. Medication-Related 
Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. 
Heidelberg: Springer; 2015. p220. ISBN: 978-3-662-43732-2. 
ABSTRACT 
A large variety of treatment options have been proposed for the management of medication-
related osteonecrosis of the jaw in particular for osteonecrosis of the jaw due to 
bisphosphonate intake. More recently, regenerative concepts using stem cells from different 
sources and growth factors have been introduced for the treatment of medication-related 
osteonecrosis of the jaws. These new and innovative concepts seem to be promising future 
options in the management of osteonecrosis of the jaws. 
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In the current literature, treatment options for patients with established medication-related 
osteonecrosis of the jaw differ. While the first guidelines focused on preserving the patient's 
quality of life by controlling pain and secondary infection, nowadays there is a trend to a more 
surgical approach with the aim of complete mucosal healing of the lesions [419, 602]. As 
described in the previous chapters, a large variety of treatment modalities have been reported 
including conservative medical management, various types of surgery, hyperbaric oxygen, 
and ozone and laser therapy[256, 603, 604]. In large lesions with pathological fractures, 
reconstruction with vascularized or non-vascularized bone has been described, but remains 
problematic due to poor bone healing and an obligatory graft resorption phase, donor site 
morbidity, and infection of foreign material. Because bisphosphonates are often administered 
in patients with generalized bone pathologies and the molecules not only bind to the jaws, it is 
not unlikely that the transferred bone will either be affected by bony metastases or also 
develop osteonecrosis of the jaws [605, 606]. In osteonecrotic lesions, among others, the lack 
of osteogenic precursors and a shortage of endothelial progenitor cells (EPCs) cause an 
insufficient vascular support, so that safe alternative therapies are needed to enhance the 
osteogenesis and vasculogenesis [581, 607]. While tissue engineering is the branch that brings 
biology, bioengineering, clinical sciences, and biotechnology together for the purpose of 
generating new tissues and organs and the development of biologic substitutes that can restore 
and maintain normal function, a variety of approaches are utilized that combine the use of 
morphogens, growth factors, and cytokines, with scaffolds and carriers and cells [608-610]. 
During the last years, the increased interest on stem cells allowed the evolution of new 
horizons in treatment perspectives. Stem cells are immature, undifferentiated cells that can 
divide and multiply for an extended period of time, differentiating into specific types of cells 
and tissues. They are defined as cells that self-replicate and are able to differentiate into at 
least two different cell types, and both criteria must be present for a cell to be called a "stem 
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cell" [611, 612]. Embryonic stem cells (ESCs), adult stem cells (ASCs), and induced 
pluripotent stem cells (iPSCs) represent the three different major types of stem cells [613]. 
During embryonic development, embryonic stem cells are derived from cells of the inner cell 
mass of the blastocysts. They are pluripotent and give rise to all derivatives of the three 
primary germ layers. The most important and potential use of ESCs is clinically in 
transplantation medicine, where they can be used to develop cell replacement therapies [611, 
612, 614, 615]. In contrast, iPSCs refer to adult or somatic stem cells that have been 
genetically reprogrammed to behave like ESC [616]. 
ASCs are multipotent because their potential is normally limited to one or more lineages of 
specialized cells [614]. In addition to bone marrow, various tissues have been found to 
harbour mesenchymal stem cell (MSC)-like populations including adipose tissues, muscles, 
tendons, dental pulps, periodontal ligaments, umbilical cord blood, placenta, periosteum, 
liver, cartilage, synovium, synovial fluid, spleen, and thymus [617-623]. In vitro expanded 
bone marrow stem cells (BMMSCs) may be a rich source of osteogenic progenitor cells that 
are capable of promoting the repair or regeneration of skeletal defects when cultured in the 
presence of dexamethasone, inorganic phosphate, and vitamin C. BMMS can be induced to 
become osteoblast-like eel in vitro and form calcified nodules [624, 625]. 
Cell-Based Therapy in Craniofacial Tissue Engineering 
The bone is the second most frequently transplanted tissue with increasing frequency. 
Reconstruction of craniofacial components is of the most important and intricate objectives 
stem cell-mediated regenerative medicine [626-628]. The craniofacial bone has an essential to 
in supporting the adjacent soft tissue, providing anchoring for dental structures and providing 
stable although flexible framework for craniofacial cartilage structures. Embryologically, 
most craniofacial bones are derived from mesenchymal tissue through membranous 
ossification [629]. 
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Facial development, including that of the teeth and oral cavity, is a classic act of interactions 
by stem cells of the epithelium, craniofacial mesoderm and neural crest-derived mesenchyme 
[630, 631]. Cranial neural crest cells (CNC) play an important role in development of the 
teeth, alveolar crest, and jaw bone [632]. Thus, the biologically unique features of cranial 
neural crest cell-derived bone should be considered in the etiopathology of antiresorptive 
drug-induced osteonecrosis of the jaw. 
Stem cell-based strategies are currently a promising approach in craniofacial bone tissue 
engineering as they supply sufficient numbers of cells that can not only form bone and 
associated tissue but also maintain bone as it undergoes turnover throughout life [610, 633]. 
Regenerative medicine for bone healing has reached the patient in the form of cell therapy 
approaches to treat localized bone defects or systemic diseases of the skeleton [634]. 
Mesenchymal stem cells (MSCs) have been isolated from a variety of mesenchymal tissues 
and they can differentiate into a wide array of cell types, including osteoblasts, chondrocytes 
and adipocytes. They participate in regeneration injured tissues in different ways. On one 
hand, they directly differentiate into tissue-specific cells a1 thus substitute damaged or lost 
cells. On the other hand, they indirectly influence tissue regeneration by secretion of soluble 
factors. Thirdly, they are able to modulate the inflammatory response. Thus, they can promote 
vascularization, cell proliferation, and differentiation and modulate inflammatory processes 
[635]. 
As a result of their slower growth rate and the absence of telomerase activity in vitro, 
mesenchymal stem cells (MSCs) are presumed to have a lower risk for tumour formation 
compared with embryonic stem cells (ESCs) [636]. This suggests that mesenchymal stem 
cells may have broader therapeutic applications compared to other adult stem cells. Bone 
marrow-derived mesenchymal stem cells (BMMSCs) can be concentrated from bone marrow 
aspirate with different techniques. The FICOLL method (synthetic polysaccharide) and the 
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BMAC method (bone marrow aspirate concentrate) are established methods for mononuclear 
cell concentration from iliac crest aspirate [626]. Percutaneous or intraoperative local 
administration of cell suspensions delivers progenitor or lineage-committed cells directly to 
the wound site. Mesenchymal stem cells functional properties have been proved by several 
experimental and clinical studies using autologous BMMSC implants for healing, cell 
architecture repair, and recovery of local blood flow on injured and ischemic tissues for 
alveolar ridge augmentation and long bone defects [637-639]. Autologous bone marrow or 
autologous mesenchymal stem cells were successfully implanted in a number of patients to 
enhance fracture and osteotomy healing; fill bone defects; treat pseudoarthrosis, bone cysts, 
and osteonecrosis or enhance spinal fusion [635]. In a randomized controlled trial, it has been 
shown that the new bone formation in sinus lift procedures using autologous mesenchymal 
stem cells in combination with bovine bone mineral is equivalent to autologous bone and 
bovine bone mineral [640]. 
Experimental and Clinical Cell-Based Therapy in Medication-Related Osteonecrosis of 
the Jaw 
Several authors have focused on the treatment of osteonecrosis of the jaw with mesenchymal 
stem cells. With the ability to induce ectopic bone formation and angiogenesis, MSCs might 
become a promising treatment option for antiresorptive drug-induced osteonecrosis of the 
jaws [641]. In a mouse model, a mesenchymal stem cell-based approach to treat osteonecrosis 
of the jaw was tested. At 2 weeks after tooth extraction, ONJ-like wild-type mice receiving 
intravenous infusions with mesenchymal stem cells healed with complete soft tissue and bone 
regeneration at the extracted alveolar socket suggesting that cell-based immunotherapy using 
T regulatory cells (Tregs) or mesenchymal stem cells are promising therapeutic strategies to 
prevent and treat ONJ-like lesions in wild-type mice. It is discussed that cell-based therapy 
using systemic mesenchymal stem cell infusions can prevent or cure antiresorptive drug-
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induced osteonecrosis of the jaws via re-establishment of the immune balance between 
inhibition of T-helper-producing interleukin 17 cells (th17) and increase in Tregs [642]. 
In a swine model, Li et al. reported the treatment of ONJ lesions with allogenic mesenchymal 
stem cells and concluded to have discovered that allogenic mesenchymal stem cell-based 
infusions provide a safe and effective therapeutic modality for treating ONJ lesions, which 
sheds light on potential clinical applications for treating patients suffering from medication-
related osteonecrosis of the jaws [643]. 
In a case report, Cella et al. published to have cured a patient with refractory osteonecrosis of 
the jaw, with autologous mesenchymal stem cells that were aspirated from the iliac crest and 
transplanted intra-lesionally on a gelatine sponge carrier after concentration with the FICOLL 
method. This procedure allowed a clinical improvement of symptoms and induced novel 
ossification with complete remission from a stage 3 bisphosphonate-induced osteonecrosis of 
the jaw [260]. In another case report, Elad et al. presented a patient with bisphosphonate-
induced osteonecrosis of the jaw, where bone marrow cells were re-suspended in saline and 
injected along the mucosal margins of two areas of exposed bone. No complications were 
observed with considerable reduction in the size of the alveolar bone exposures following the 
local infiltration of the hematopoietic stem cells. Complete healing of the lesion was achieved 
within a few months of the procedure showing great potential of hematopoietic stem cells to 
treat osteonecrosis of the jaws [607, 644]. 
In our own experience, a case series of 8 patients with refractory bisphosphonate-induced 
osteonecrosis of the jaws, the lesions was managed with surgical resection of necrotic bone 
followed by mesenchymal stem cell grafting. Marrow derived cells were aspirated from the 
iliac crest and concentrated using a chair-side bone marrow mesenchymal stem cells. These 
MSCs were then grafted into the defect with autologous thrombin and a BioGide membrane. 
In all cases bony edges were rounded and the wound closed using a three-layer technique. At 
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12-15 months follow-up, all patients showed satisfactory healing with no signs of wound 
infection, dehiscence, or recurrence of osteonecrosis of the jaw. Only one patient developed 
significant complications, that of sepsis of unknown origin, 2 months postoperatively 
(unpublished own data). 
Growth Factors in Treatment of Medication-Related Osteonecrosis of the Jaw 
Growth factors are soluble-secreted signalling polypeptides capable of instructing specific 
cellular responses in a biological environment [645]. The specific cellular response triggered 
by growth factor signalling can result in a very wide range of cell actions, including cell 
survival, control over migration, differentiation, or proliferation of a specific subset of cells 
[646]. A variety of growth factors produced by osteogenic cells, platelets, and inflammatory 
cells-including bone morphogenetic proteins (BMPs), insulin-like growth factors 1 and 2, 
transforming growth factor-β1 (TGF-β1), platelet-derived growth factor, and fibroblast 
growth factor 2-are functionally involved in bone healing. The bone matrix serves as a 
reservoir for these growth factors [647-649]. Growth factor application to patients suffering 
osteonecrosis of the jaws can be considered a challenge because of improving the soft and 
hard tissues healing. Acting like chemotactic agents, they stimulate angiogenesis, migration, 
proliferation, and differentiation of stem cells from the surrounding mesenchymal tissues into 
bone forming cells in an area of injury [330, 395]. The discovery of bone morphogenetic 
proteins (BMPs) as osteoinductive factors and the subsequent development of commercially 
available recombinant forms of BMPs have offered the potential to replace traditional grafting 
techniques with de novo bone formation [650, 651]. Bone morphogenetic protein type 2 
(BMP-2) application substituting the necrotic bone removal could be considered a therapeutic 
option for reconstruction of localized bone defects of medication-related osteonecrosis of the 
jaws. rhBMP-2 was applied using an absorbable collagen sponge carrier to 20 patients who 
underwent surgical removal of necrotic bone related to bisphosphonate therapy. The collagen 
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was fixed to the soft tissue by an absorbable suture. The postoperative controls showed an 
increase in the soft tissue healing and new bone formation of the treated sites [282]. 
Some researchers have proposed also the use of platelet-rich plasma (PRP) in ONJ surgery 
based on surgical debridement and reconstruction combined with the use of platelet-rich 
plasma produced from the patient's autologous blood [258, 259, 291, 305, 328, 396, 652-656]. 
The rationale for the employment of PRP in patients affected by osteonecrosis of the jaws is 
based on the thesis that the presence of growth factors constitutes stimulations for bone 
healing, which is similar to physiological healing. The growth factors in platelet-rich plasma 
might accelerate epithelial wound healing, decrease tissue inflammation after surgery, 
improve the regeneration of bone and soft tissues, and promote tissue vascularization. The 
additional advantages related to the use of this product are its biocompatibility and safety as 
an autologous product [657, 658]. 
In a prospective study, Scoletta et al. reported of only one wound dehiscence after extraction 
of 202 teeth in 63 patients under intravenous bisphosphonate treatment. After extraction, the 
sockets were filled with scaffold-like autologous PRP [659]. In a case series of 25 patients 
with osteonecrotic lesions due to bisphosphonate intake, treatment of ONJ with a combination 
of bone resection and platelet-rich plasma was found to be an effective therapy that should be 
considered an alternative treatment modality for the management of advanced ONJ cases 
[660]. 
Lee et al. also described the successful management of complications of dental implant 
surgery of 2 patients taking the oral form of bisphosphonates, including platelet-rich plasma 
and hyperbaric oxygen [396]. Several other studies reported of enhanced mucosal healing of 
patients with ONJ due to bisphosphonate intake treated with surgical removal of the exposed 
bone, platelet-rich plasma, and primary closure under antibiotic coverage [259, 305, 328, 
653]. 
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Nitrogen-containing bisphosphonates are able to inhibit pyrophosphate synthase in the 
mevalonate pathway. The consequently decreased synthesis of the metabolite geranylgeraniol 
is believed to largely account for the development of bisphosphonate-induced osteonecrosis of 
the jaws. In an in vitro study, Ziebart et al. demonstrated that geranylgeraniol can rescue the 
negative effect of bisphosphonates in human umbilical cord vein endothelial cells, fibroblasts, 
and osteogenic cells [661]. Geranylgeraniol could lead to new treatment strategies for 
bisphosphonate-induced osteonecrosis of the jaws that have to be proven in animal studies. 
Conclusion 
The implementation of stem cell-based concepts and the use of growth factors are promising 
future treatment modalities for patients suffering from medication-related osteonecrosis of the 
jaw. 
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OTHER PROJECTS DURING PHD 
 Regeneration of Critical-sized defects in oral and maxillofacial surgery in minipigs. 
Dr. Florian Probst. AO Grant Jan 2013. 
 Large animal model for antiresorptive drug induced osteonecrosis of the jaw. PD Dr. 
Dr. Sven Otto. AO Grant May 2014. 
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Osteomyelitis is a serious complication in oral and maxillofacial surgery affecting bone healing. Bone
remodeling is not only controlled by cellular components but also by ionic and molecular composition of
the extracellular fluids in which calcium phosphate salts are precipitated in a pH dependent manner.
Objective: To determine the effect of pH on self-renewal, osteogenic differentiation and matrix miner-
alization of mesenchymal stem cells (MSCs).
Methods: We selected three different pH values; acidic (6.3, 6.7), physiological (7.0e8.0) and severe
alkaline (8.5). MSCs were cultured at different pH ranges, cell viability measured by WST-1, apoptosis
detected by JC-1, senescence was analyzed by b-galactosidase whereas mineralization was detected by
Alizarin Red and osteogenic differentiation analyzed by Real-time PCR.
Results: Self-renewal was affected by pH as well as matrix mineralization in which pH other than
physiologic inhibited the deposition of extracellular matrix but did not affect MSCs differentiation as
osteoblast markers were upregulated. The expression of osteocalcin and alkaline phosphatase activity
was upregulated whereas osteopontin was downregulated under acidic pH.
Conclusion: pH affected MSCs self-renewal and mineralization without influencing osteogenic differ-
entiation. Thus, future therapies, based on shifting acid-base balance toward the alkaline direction might
be beneficial for prevention or treatment of osteomyelitis.
Crown Copyright © 2016 Published by Elsevier Ltd on behalf of European Association for Cranio-Maxillo-
Facial Surgery. All rights reserved.1. Introduction
Osteomyelitis (OM) of the jaw is a debilitating disease (Sanchez
et al., 2013) in which severe bone infection leads to dysfunction,
progressive inflammatory destruction, marked bone resorption at
sites of infection, and abnormal bone formation (Teitelbaum et al.,
1997; Sax and Lew 1999). It occurs more frequently in themandible
than in the maxilla (Singh et al., 2010) with Staphylococcus aureus
creating an acidic environment, decreasing the pH to 5.5e7.0 (Ma
et al., 2010) as a result of massive infiltration of neutrophils and
macrophages (Issekutz and Bhimji, 1982; Spector et al., 2001; Ottoand Regenerative Medicine
aumstr. 20, 80336, Munich,
55814.
.de (R. Fliefel).
vier Ltd on behalf of European Aset al., 2010; Pavlukhina et al., 2010; Hatzenbuehler and Pulling,
2011; Humber et al., 2011). It is well known that infection and
inflammation interfere with the process of bone healing and
regeneration by excessive bone resorption as well as impaired bone
formation by activation of several cell populations producing in-
flammatory cytokines with an impact on bone remodeling
(Marriott et al., 2004; Romas and Gillespie, 2006; Thomas and
Puleo, 2011, Redlich and Smolen, 2012).
Bone remodeling is controlled not only by osteoblasts and os-
teoclasts (Eriksen, 2010) but also by the ionic and molecular
composition of the extracellular fluids in which calcium phosphate
salts are precipitated in a pH-dependent manner (Chakkalakal
et al., 1994; Kohn et al., 2002; Iyemere et al., 2006). Osteoblasts
are the most affected cells by pH and acidity of the extracellular
microenvironment (Arnett and Dempster, 1990; Chakkalakal et al.,
1994; Green, 1994; Wu et al., 1997). On a cellular level, evenmodestsociation for Cranio-Maxillo-Facial Surgery. All rights reserved.
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zation and energy metabolism, as it was suggested that changes in
acidebase balance in the extracellular microenvironment can
direct bone formation and resorption (Chakkalakal et al., 1994;
Green 1994; Ramp et al., 1994; Kaysinger and Ramp, 1998). It was
shown that alkaline pH enhances mineralization of osteoblasts and
decreases the activity of osteoclasts, whereas acidic surroundings
can activate osteoclasts as well as impair osteoblast differentiation
and in severe cases can cause osteoblast death (Muzylak et al.,
2007; Han et al., 2009; Shen et al., 2012).
MSCs are adult stem cells originating from the mesoderm,
possessing self-renewal ability and multi-lineage differentiation
into mesoderm lineages such as chondrocytes, osteocytes, and
adipocytes, and also ectodermic and endodermic cells (Wei et al.,
2013). MSCs exist in almost all tissues including bone marrow,
adipose tissue, synovium, periosteum, and perichondrium, as well
as cartilage (Larsen and Jensen, 1989). They have the ability to
migrate into sites of injury, releasing trophic and growth factors
and differentiated toward terminally committed cells, making them
prime candidates for use in regenerative medicine (Pereira et al.,
1995; Pittenger et al., 1999; Bianco et al., 2001; Kim et al., 2005;
Nuschke et al., 2014). Recently, MSCs have shown great potential
in clinical practice upon activation by biological or pharmacological
means, leading to improvement in bone healing by modulating
their differentiation into osteoblasts (Knight and Hankenson, 2013;
Qin et al., 2014). The chemical and physical environment of MSCs
has a strong influence on their behavior, inwhichmatrix acidity is a
crucial factor (Moore and Lemischka, 2006; Wuertz et al., 2008).
The effect of the pH of the tissue microenvironment on bone
mineralization and repair has been previously reported (Swenson
and Claff, 1946; Arnett and Dempster, 1986; Newman et al., 1987).
However, the mechanisms underlying pH-related destruction of
bone in osteomyelitis and osteogenic differentiation of human
mesenchymal stem cells under various pH conditions have not
been discussed. As tissue engineering becomes more of a clinical
reality through the ongoing bench-to-bedside transition, research
in this field must focus on addressing relevant clinical situations.
Although most in vivo work in the area of bone tissue engineering
focuses on bone regeneration within sterile, surgically created de-
fects, there is a growing need for investigation of bone tissue en-
gineering approaches within contaminated or scarred wound beds,
such as those that may be encountered following traumatic injury
or during delayed reconstruction/regeneration (Nair et al., 2011).
Our study is novel and of importance when considering bone in-
fections, as it might be used in future clinical applications for pre-
vention and treatment of some bone infections or diseases. It
explains what happens in the bone microenvironment during pH
changes, which could be a key study not only for bone infection/
disease but also adds an important facet to the linkage between pH
and other hard tissue mineralization. Thus, in the present study, we
aimed to determine the effect of pH on viability and proliferation of
human MSCs, and to investigate the role of the pH on human
MSCemediated osteogenesis, expression of osteoblast markers,
and matrix mineralization. This may contribute to understanding
how changing pH modulates biological and biochemical processes
during bone healing in osteomyelitis.
2. Material and methods
2.1. Cell culture
All experiments were performed with commercially available
human MSCs (hMSCs; Lonza, Basel, Switzerland). Cells were
cultured in high-glucose Dulbecco's modified Eagle's medium
(DMEM; Life Technologies, California, USA), supplemented with10% fetal bovine serum (FBS; Life Technologies, California, USA), 1%
penicillin/streptomycin (GE Healthcare, Little Chalfont, UK) at 37 C
in a humidified atmosphere of 5% CO2. Cells between passages 5
and 10 were used from three donors for the experiments.
2.2. Preparation of pH culture media
The pH of the culture mediumwas adjusted to one of six values
(6.3, 6.7, 7.0, 7.4, 8.0, or 8.5) by adding an appropriate amount of 6M
HCl or 10MNaOH to the supplementedDMEM. Before resuspending
the cells, the culture media were kept in the incubator for 24 hours
under culture conditions to allow the desired pH value to equilibrate
(CO2-dependent). After incubation, a small adjustment in pH was
occasionally required to create the desired final pH. The pH was
monitored with a pH meter (Mettler Toledo GmbH, Giessen, Ger-
many). The pHmediawere filtered using a syringe driven through a
0.22-mm sterile filter and stored at 4 C to be used later. For pH ex-
periments, normal mediumwas replaced with various pHmedia 24
hours upon cell plating and was kept throughout the experiment.
2.3. Self-renewal analysis and WST-1 assay
Long-term cell growth was evaluated by calculation of increased
cell number as described previously (Alberton et al., 2012). The
effect of pH on hMSCs proliferation in monolayer culture was
evaluated over a 5-day time course. Cells were plated into 35-mm
dishes at a density of 3.0  104 and incubated in different pH me-
dia. At each time point, cell yield was divided by the number of cells
plated at the start of the experiment to obtain a fold-change in cell
number. The experiment was repeated twice.
Cell viability was assessed withWST-1 assay (Roche Diagnostics,
Risch-Rotkreuz, Switzerland) as previously described (Kohler et al.,
2013). Cells were seeded at a density of 1.7  103 cells per well in
96-well plates and incubated with different pH media for 3 days.
The WST-1 was mixed with the fresh complete medium, added to
the wells, and incubated for 4 hours at 37 C in 5% CO2. WST-1 was
quantified bymeasuring the absorbance at 450 nm usingMultiskan
FCmicroplate plate reader (Thermo Scientific, Massachusetts, USA).
Each experiment was repeated at least twice with two different
donors to obtain the mean values.
2.4. JC-1 staining for apoptosis detection
One of the hallmarks of apoptosis is mitochondrial disruption,
which is characterized by changes in the mitochondrial membrane
potential. These changes were detected by using the fluorescent
dye 5,50,6,6'-tetrachloro-1,10,3,3'-tetraethylimidacarbocyanine iodide
(JC-1; Life Technologies, California, USA), a membrane-permeable
dye that accumulates in mitochondria in a membrane poten-
tialedependentmanner. To ascertainwhether pH induced apoptosis,
slides were coated with collagen, hMSCs (7.0  103 cells) were
cultured in different pH media for 24 hours. They were stained with
JC-1 at 37 C for 60 minutes, and Hoechst 33342 (Thermo Scientific,
Massachusetts, USA) was used as the counterstain (Popov et al.,
2011). Cells were mounted on slides and pictured with Axio
Observer.Z1 fluorescence microscope (Zeiss, Oberkochen, Germany).
The positive control was cells treated with hydrogen peroxide for 5
minutes, and thenegative controlwas cells cultured innormalmedia.
2.5. Detection and quantification of senescent cells
Senescence-associated b-galactosidase (SA b-Gal; Sigma Aldrich,
Missouri, USA) staining was used to detect senescent cells as pre-
viously described (Kohler et al., 2013). Cells were seeded at a density
of 3.0 104 in 35-mmdishes and cultured at different pHmedia for
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overnight. The cells were observed under an Axiovert 40 CFL mi-
croscope (Zeiss, Oberkochen, Germany). The percentage of blue cells
expressing b-galactosidase (senescent cells) was calculated. The
proportion of cells positive for SA-bgal activity was determined by
counting the number of blue cells in the total population.
2.6. Osteogenic differentiation of hMSCs
Osteogenic differentiationwas performed (Alberton et al., 2012).
Shortly, cells were counted and plated at density of 3.2  104 on
35 mm dishes. After 24 hours, normal media were replaced with
pH-adjusted osteogenic media, and cells were cultured for 21 days.
The osteogenic media consisted of DMEM supplemented with
100 nM dexamethasone, 10 mM b-glycerophosphate, and 150 mM
ascorbic-2-phosphates (Sigma Aldrich, Missouri, USA). Media were
changed twice per week. As a control, hMSCs were cultured at
different pH media without osteogenic reagents.
Alizarin Red staining was performed on day 21. Mineralized
nodules were visualized and photographed with Axiovert 40 CFL
microscope (Zeiss, Oberkochen, Germany). An osteogenic quanti-
fication kit was used for quantification of the staining (Merck
Millipore, Darmstadt, Germany). The osteogenic differentiationwas
calculated versus standard curve, and the absorbance was
measured at 405 nm using Multiskan FC microplate reader plate
reader (Thermo Scientific, Massachusetts, USA).
2.7. Alkaline phosphatase activity and mineralization
The differentiation of cells to osteoblasts was evaluated as a
function of alkaline phosphatase (ALP) activity. The ALP assay was
performed on days 0, 2, 5, 7, 10 and 14 of culture. For this, cells were
seeded in 35-mm dishes and cultured at different pH media. The
media were changed twice per week. ALP released from the cells
was measured with a commercially available ALP assay kit (Stem-
TAG; Cell Biolabs, California, USA). The amount of enzyme released
by the cells was quantified by comparison with a standard curve.
The experiment was repeated twice with two different donors. The
enzyme activities expressed as nanamoles (nmol) of protein.
2.8. Reverse transcriptionepolymerase chain reaction analysis of
osteogenic genes
Reverse transcriptionepolymerase chain reaction (RT-PCR) was
used to evaluate the osteogenic differentiation at different pH after
21 days. RNA was isolated as previously described (Alberton et al.,
2012) by QIAzol reagent (Qiagen, Hilden, Germany). RNA concen-
tration and quality was analyzed by NanoDrop (Thermo Scientific,
Massachusetts, USA). Reverse transcription of RNA into comple-
mentaryDNA (cDNA)was doneusing Transcriptor First Strand cDNA
Synthesis Kit (Roche, Basel, Switzerland). RT-PCR was used toTable 1
Sequences of the polymerase chain reaction primers with the annealing temperatures an
Gene Name Primer sequen
GAPDH Glyceraldehyde 3-phosphate dehydrogenase F: CAA CTA CA
R: GCC AGT GG
RunX2 Runt-related transcription factor 2 F: TCT TCA CAA
R: TGG ATT AA
OCN Osteocalcin F: GGC ACA AA
R: CAC TGG GC
OPN Osteopontin F: CTG ATG AA
R: CCG CTT AT
Col1a1 Collagen 1alpha 1 F: AGG GCT CC
R: TAC AGG AAanalyze the expression of the osteogenic genes. The primers for the
target genes used and PCR conditions are shown in Table 1. The gel
electrophoresis was visualized and photographed using gel imager
(Vilber Lourmat, Eberhardzell, Germany). Bandswere quantitatively
analyzed by ImageJ (http://imagej.nih.gov/ij/). Gene expressionwas
calculated as the ration to the housekeeping gene (GAPDH).
2.9. Statistical analysis
All of the experiments were repeated at least two times with
three different donors each, and the results were expressed as
means ± standard deviations. Statistical analysis was performed by
using GraphPad Prism (GraphPad, California, USA) using one-way
analysis of variance, followed by the Tukey test to determine the
statistical significance among the different groups. Levels of sig-
nificance were indicated at P < 0.05, P < 0.01, and P < 0.0001.
3. Results
3.1. hMSC self-renewal under different pH conditions
First, we analyzed hMSC self-renewal by examining the effect of
pHon the cell proliferation andviability. For this,weculturedhMSCs
in the six different pH conditions for 5 days. We found that the
exposure of hMSCs to pH (6.3, 6.7, and 8.5) had a negative effect on
proliferation capability in comparison tophysiologic pH (7.0, 7.4, and
8.0), indicating that the latter pHs are optimal for cell growth
(Fig.1A). Thenwe analyzed cell activity bymeasuring the enzymatic
catabolism of formazan toWST-1. Our results showed that, similarly
to proliferation, the viability of hMSCs was influenced by pH, and
more viable cells were observed at physiologic pH (7.0, 7.4, and 8.0)
while cell viability at pH (6.3, 6.7, and 8.5) decreased (Fig. 1B).
These findings suggested that the physiological pH (7.0, 7.4, and
8.0) was suitable for hMSC growth. Since the cell viability at pH 8.5
was severely decreased, this result indicated that alkaline envi-
ronment up to a certain limit was advantageous for cell growth.
3.2. pH effect on hMSCs apoptosis and senescence
Observing the fact that pH (6.3, 6.7, and 8.5) resulted in less self-
renewal of hMSCs, we next investigated the reasons for this. We
checked whether the cells had undergone apoptosis or senescence.
Apoptosis was inspected using JC-1 staining that shows the loss of
the mitochondrial membrane potential. In healthy cells, the dye
stains the mitochondria bright red, whereas in apoptotic cells, the
mitochondrial membrane potential collapses and JC-1 stains the
cells green. The results showed that cells cultured in different pH
media appeared orange-red and the green cells were the positive
control, suggesting that pHdidnot induce apoptosis in cells (Fig. 2A).
In addition, we tested whether different pH would trigger
senescence. We found that treatment of hMSCs with different pHd the expected sizes of the amplified products.
ce (F, R, 50-30) Tannealing (C) Product size (bp)
T GGT TTA CAT GTT C
A CTC CAC GAC
50 C 181
ATC CTC CCC
A AGG ACT TGG TG
55 C 230
G AAG CCG TAC TC
A GAC AGT CAG AA
56 C 242
C TGG TCA CTG ATT TTC
A TAA TCT GGA CTG CTT
60 C 347
A ACG AGA TCG AGA TCC G
G CAG ACA GGG CCA ACG TCG
54 C 223
Fig. 1. Effect of pH on proliferation and viability of human bone marrow stem cells (hMSCs). (A) Proliferation of human bone marrow stem cells (hMSCs) in different pH media from
day 0 to day 5. hMSCs grown in pH 97.0, 7.4, and 8.0 showed the highest proliferation rate compared with those grown in pH 6.3, 6.7, and 8.5. (B) Effect of pH on viability of hMSCs
cultured at different pH for 3 days was measured at the indicated time points using WST-1 assay and expressed as optical density at 450 nm (A450) as described in Material and
Methods. Error bars represent standard deviations (n ¼ 2).
Fig. 2. Apoptosis and senescence of human bone marrow stem cells (hMSCs) at different pH. (A) Morphological observation of JC-1 and Hoechst 33342 staining of cells treated at
different pH examined with fluorescence microscope at 10 magnification; scale bar represents 100 mm. The experiments were performed in two different donors. Cells at different
pH appeared orange-red, whereas the positive control (hydrogen peroxideetreated cells) showed strong green fluorescence and indicated typical apoptotic morphology. (B) hMSCS
senescence at different pH conditions measured by SA b-Gal activity assay. The nuclei of senescent cells are surrounded by cyan dye; a significant increase in cell size was detected at
pH 6.3, 6.7, and 8.5. Staining was quantified by positive cell count. Error bars represent the means ± SD; n ¼ 2. P < 0.0001.
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bated at pH (6.3, 6.7, and 8.5) appeared flattened and were more
positive for b-gal staining, whereas at physiologic pH (7.0, 7.4, and
8.0), cellsmaintained their spindle shape andonlya fewstainedblue
(Fig. 2B). Quantification of b-gal staining demonstrated that the
staining frequencyofhMSCswasapproximately58%blue-positiveat
pH 6.3, 56% at pH 6.7, and 25% for pH 8.5. In contrast, the frequency
for pH 7.0was 30%, whereas at pH 7.4, it was 18% and at pH 8.0 it was
about 15%, which nearly lacked detectable b-gal activity (Fig. 2B).3.3. Osteogenic differentiation of hMSCs and mineralization assay
We performed osteogenic differentiation of hMSCs in different
pH osteogenic media (OD) or control media. At day 21, Alizarin RedFig. 3. Osteogenic differentiation of human bone marrow stem cells (hMSCs) and quantifi
Alizarin Red; scale bars represent 1 cm. (B) Morphology of hMSCs grown in control or osteog
incubated for 21 days in DMEM containing 10% fetal bovine serum and observed under a
ferentiation showed significant difference of the amount of soluble Alizarin Red. The ave
P < 0.0001.staining confirmed osteogenic differentiation and matrix mineral-
ization of hMSCs. Cells grown in OD exhibited red staining at pH
(7.0, 7.4, and 8.0); among them, pH 8.0 showed the strongest
staining. At pH other than physiologic, the cells showed weaker or
no mineralization (Fig. 3A and B).3.4. Quantitative estimation of ALP activity and RT-PCR of
osteogenic genes
To validate the defected mineralization under various pH con-
ditions, we first investigated the changes in ALP activity. Our results
showed no significant differences at different pH conditions at days
0, 2, 5, and 7. However, from day 10 to day 14, ALP activity showed a
significant difference, as its activity increased proportionally atcation of Alizarin Red staining. (A) Osteogenic differentiation of hMSCs stained with
enic medium (OD) at different pH (magnification 10, scale bars ¼ 100 mm). Cells were
phase contrast microscope with Alizarin Red staining quantification. Osteogenic dif-
rage absorbance value at 405 nm. Error bars represent standard deviations; n ¼ 2.
Fig. 4. Alkaline phosphatase (ALP) activity of the osteogenic differentiated mesenchymal stem cells at different pH, with the expression level of bone-related markers (OPN, OCN,
Runx2, and Col1a1) of hMSCs cultured in control and osteogenic media (OD) at different pH values for 21 days. (A) ALP activity was measured during the course of osteogenic
differentiation from day 0 to day 14 and showed that it was inversely proportional to the pH: when the pH increased, the ALP activity increased, and vice versa. (B) Reverse
transcriptionepolymerase chain reaction data of OPN, OCN, Runx2, and Col1a1 representative of three independent experiments from three different donors were combined
together and analyzed. Runx2 codes for major osteogenic transcription factors; Col1a1 is an early marker of osteogenic differentiation; OCN and OPN are markers of late stages of
osteogenesis. GAPDH was used as the control housekeeping gene for this study. Graphs representing mean values of relative optical densities of polymerase chain reaction results
are shown in the mRNA expression patterns of osteogenic marker genes in cells at day 21; the results are expressed as the fold change relative to the respective control.
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showed that all of the important osteogenic markers were
expressed by the cells in comparison to control media. From the
assessed genes, pH media had an effect on OPN and OCN, whereas
Col1a1 and Runx2 was pH independent. OPN increased gradually
with increasing the pH of the media until pH 8.0 and then down-
regulated at pH 8.5. The expression of OPN in osteogenic differen-
tiated cells was always higher compared to control media. In
contrast to OPN, OCN had an opposite correlation whereby pH (6.3and 6.7) showed higher expression, followed by pH 8.5 and then
the physiologic pHs (Fig. 4B).
4. Discussion
In this study, we confirmed that hMSCs are sensitive to pH as
their self-renewal and mineralization were significantly affected.
Our study provides new insight into the mechanism underlying
pH-related bone destruction and adds an important facet to the
R. Fliefel et al. / Journal of Cranio-Maxillo-Facial Surgery 44 (2016) 715e724 721linkage between pH and bone infections that might be used clini-
cally in the future to treat osteomyelitis of the jaw. We have
selected pH values in accordance to their relevance in vivo as fol-
lows: pH 6.3 to 6.7 is common in infection (Otto et al., 2010) and in
cultures with high cell numbers but limited nutrients (Naciri et al.,
2008); pH 7.0 to 7.4 is commonly used in cell culture (Mackenzie
et al., 1961) and a typical value in the bloodstream (Arnett, 2008);
and pH 8.0 to 8.5 is recommended for greater production of oste-
ocytes (Moghadam et al., 2014). An in vitro approach was used to
answer two clinically important questions: First, what is the effect
of pH on self-renewal and differentiation? Second, how can we
make use of this knowledge for preventing or treating osteomyelitis
of the jaw?
Osteomyelitis is prevalent in the facial skeleton associated with
abnormal bone remodeling and massive bone resorption. It also
presents a major complication ensuing orthopedic and maxillofa-
cial surgeries as well as routine dental extractions (Uskokovic et al.,
2013). There is increased formation and activity of osteoclasts in
osteomyelitis, together with the elimination of the osteoblasts
responsible for new bone matrix deposition following infection
(Mori et al., 2007). Infection causes some essential changes in the
extracellular milieu. On these occasions, the pH of the bone tissue
environment often falls below pH 7.0, whereas in healthy tissues
this pH value varies in the range 7.35e7.45 (Kinnari et al., 2009).
During early embryonic development, pH regulation is critical
for cell metabolism, intracellular ionic signaling, differentiation,
quiescence, and proliferation (Taylor and Hodson, 1984; Musgrove
et al., 1987). pH controlled self-renewal (proliferation and
viability) as well as expression of extracellular matrix proteins, not
only in fibroblasts but also in several cell types by affecting the
cytoskeleton and cell adhesion molecules in addition to arresting
the cell cycle at the G1 phase (Laffey et al., 2000; Wuertz et al.,
2009; Teo et al., 2014). Our results demonstrate that changes in
pH other than the physiologic can negatively influence cell prolif-
eration and viability of MSCs, which might be caused by several
factors such as apoptosis or senescence.
It is not clear what determines whether cells undergo senes-
cence or apoptosis. One determinant is cell type; for example,
damaged fibroblasts and epithelial cells tend to senesce, whereas
damaged lymphocytes tend to undergo apoptosis (Campisi and
d'Adda di Fagagna, 2007). Although it is well known that pH reg-
ulates many vital cell functions (Busa and Nuccitelli, 1984), the ef-
fect of pH on apoptotic signaling is poorly defined. Loss of the
mitochondrial membrane potential is a hallmark of intrinsic
apoptosis, because it is associated with the release of pro-apoptotic
proteins into the cytosol (Brunelle and Letai 2009). Some studies
have demonstrated that severe extracellular acidification or alka-
lization induced a pro-apoptotic effect (D'Arcangelo et al., 2000;
Cutaia et al., 2005); in addition, other studies revealed a link be-
tween acidosis and apoptosis (Webster et al., 1999; Aoyama et al.,
2005), and another study showed that pH had no effect on
mitochondria-mediated apoptosis in hMSCs (Brandao-Burch et al.,
2005). Even though viability testing revealed a pH dependency, it
was difficult to draw conclusions about apoptotic processes.
Comparing the apoptotic events in our experiment, we did not find
increased apoptosis throughout the different pH conditions. It is
possible that this may represent a time-dependent phenomenon,
and that 7 days or more may be required to observe an enhance-
ment in hMSC apoptosis. Cellular senescence occurs in response to
various cellular stresses with the loss of proliferative capacity,
despite continued viability and metabolic activity (Kuilman et al.,
2010). From our results, we saw that the strongest senescence
occurred under the acidic pH (6.3 and 6.7). Taken together, we
found that the effect of pH on proliferation or viability is modulated
through increased senescence.MSCs are characterized not only by the capacity for self-
renewal but also by the ability to differentiate into osteoblasts
and deposition of matrix minerals in which pH plays a regulatory
role in the process of mineralization and bone repair (Chakkalakal
et al., 1994; Di Benedetto et al., 2015). Poor mineralization at
alkaline conditions beyond pH 8.0 affected the solubility of cal-
cium and magnesium pyrophosphate with no beneficial effect on
bone mineralization (Simao et al., 2013). It was also suggested that
acidic pH reduces bone mineralization via increased hydroxyapa-
tite solubility, and that systemic alkali therapy can be used to treat
osteomalacia and the bone pain associated with it (Richards et al.,
1972; Disthabanchong et al., 2004; Brandao-Burch et al., 2005).
The physicochemical mechanism also plays a role in matrix
mineralization, based on the fact that low pH decreases calcium
and phosphate tissue deposition because it increases their solu-
bility (Larsen and Jensen, 1989, Iyemere et al., 2006). The most
effective ways to destroy the ability of the nucleation core to
induce mineral formation is exposure to acidic citrate buffer (Wu
et al., 1993). Also, the nucleation activity and core is operative
only within a very narrow pH range, between 7.4 and 7.8 (Valhmu
et al., 1990). Either below or above this range, its ability to nucleate
mineral formation was very much reduced. However, in studies by
Wu et al (Wu et al., 2008), the pH range in which rapid mineral
formation occurred was broader (pH 7.4e8.0), indicating that at
pH 8.0, the nucleation core is highly stable and insoluble. In
accordance with these data, our results showed that a slight
elevation in pH from 7.4 to 8.0 significantly increases the miner-
alization, and the rise of pH to 8.5 does not further drive differ-
entiation. This implies that small pH fluctuations will facilitate
bone formation by elevating the phosphate ratio at least in the
very narrow pH zone where the nucleation core is operative, up to
a maximum of pH 8.0.
Since we have found defective mineralization at certain pH
conditions, a question regarding the reason for the defective
mineralization remained. It occurred due to impairment of osteo-
genic differentiation or due to the change in the extracellular
environment. Therefore we performed PCR to analyze the key
osteogenic markers for differentiation and mineralization. From
our results, the PCR results were different from the Alizarin red
staining, and late markers of osteogenesis were expressed on PCR
with a lack of mineralization in the staining.
Osteoblasts arise from mesenchymal stem cells and determine
the formation and structural organization of bone extracellular
matrix and its mineralization (Marie, 2008). ALP is synthesized by
the osteoblasts and is presumed to be involved in the calcification
of bone matrix (Masrour Roudsari and Mahjoub, 2012). Some re-
searchers have shown that pH 8.5 was optimum for ALP activity
toward inorganic pyrophosphate during bone formation, whereas
the activity was retained at pH 7.3 to 7.4 (Harada et al., 1986;
Kaunitz and Yamaguchi, 2008). It was reported that decreasing
the extracellular pH reduced the amount of collagen and ALP ac-
tivity in mesenchymal stem cells, whereas others reported that
alkaline pH decreased the ALP activity and could delay the differ-
entiation of MSCs (Kohn et al., 2002; Leem et al., 2012). It was
shown in the literature that a higher calcium concentration inhibits
the ALP activity but stimulates the expression of OPN associated
with the osteogenic differentiation (Cheng et al., 2013). ALP activity
appeared to decrease duringmineralization (McLean et al., 1987). In
another study, it was also reported that a consistent marked loss of
ALP activity occurs duringmineralization. The time of onset and the
extent of decline in ALP activity were found to mirror almost
exactly the time of onset and the extent of calcium accumulation by
the matrix vesicles (MV) (Genge et al., 1988). Our results showed
that ALP was decreased at higher pH, indicating that mineralization
downregulated the ALP activity.
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levels of several key osteogenic genes such as Runx2, collagen I
(Col1a1), OPN, and OCN. We reported that among the analyzed
genes only OPN and OCN were slightly influenced by the different
pH values. In the body, OPN is normally linked to mineralization of
the tissues (Kohri et al., 1993) and, similar to our data, was found to
be sensitive to pH (Frick and Bushinsky, 1998; Brandao-Burch et al.,
2005). The highest expression that we observed was less than pH
8.0, whereas the least was detected at acidic pH (6.3 and 6.7). The
other osteogenic marker, OCN is linked to terminally differentiated
osteoblasts; however, its role in bone mineralization remains un-
clear, because in OCN-deficient mice, it was discovered that
osteocalcin does not necessarily ensure normal osteoblast function
(Ducy et al., 1996). The trend in OCN expression in our hMSCs
showed increased levels under lower and higher pH values
(different from physiologic). Analysis of the other two osteogenic
markers, collagen I and Runx2, showed no significant changes upon
pH treatment. In all pH conditions during differentiation, we found
strong upregulation of both genes. Collagen I is the main building
protein of bone, whereas Runx2 is the master regulator of osteo-
blast lineage (Komori et al., 1997; Otto et al., 1997; Jonason et al.,
2009) that controls expression of several osteogenic genes,
among which is collagen I (Ducy et al., 1997). Expression of Runx2
and collagen I can be affected by the pH was dependent on the MSC
donor (Sprague et al., 1994; Frick and Bushinsky, 1998; Brandao-
Burch et al., 2005; Disthabanchong et al., 2006).
The difference between the osteogenic markers expression and
the matrix mineralization can be explained by initiation of matrix
vesicleemediated mineralization followed by collagen-mediated
mineralization. The matrix vesicle mineralization is characterized
by an initial formation of apatite or primary nucleation intracellu-
larly within matrix vesicles (MV) that transport hydroxyapatite
(HA) crystals outside of the cells (Ali et al., 1970; Anderson, 1995;
Anderson et al., 2005; Golub, 2009). During collagen-mediated
mineralization (secondary nucleation), MV membranes break
down and expose preformed HA to the extracellular fluid, allowing
propagation of HA deposition onto the collagenous ECM (Anderson,
1995; Anderson et al., 2005), leading to mineralization by physi-
cochemical and biochemical processes (Millan, 2013). At low pH,
calcium and phosphate tissue deposition decreases by increasing
HA solubility with 10-fold for each unit decrease in pH (Thylstrup
and Fejerskov, 1986; Larsen and Jensen, 1989; Iyemere et al.,
2006). According to our data, pH had an effect on hMSCs miner-
alization potential whereby induction of mineralization was more
efficient at physiologic pH 7.0, 7.4, and 8.0 and much less at pH 6.3,
6.7, and 8.5.
Taken together, our study demonstrates that different pH con-
ditions can strongly affect both cell self-renewal and mineraliza-
tion. However, the same pH did not affect cell osteogenic potential,
since the main lineageespecific markers were expressed.
A number of limitations of this study needed to be considered.
For instance, one question still not answered is whether compari-
son to diseased tissue would have been advantageous to determine
cell responses to alterations in the physicochemical environment.
Direct comparison can often be complicated due to inherent het-
erogeneity of both normal and diseased tissue and the difficulty in
obtaining bone samples. Another limitation is that cells from
different lots or donors were used, causing variability of the results
represented by large means and standard deviations. Despite these
limitations, the effect of pH on the gene expression remains.
5. Conclusion
In this study, it was demonstrated that MSCs were highly sen-
sitive to small shifts in external pH, as their viability, proliferation,and mineralization were affected. However, the osteogenic differ-
entiation was not affected by pH. Thus, we think that at the injured
sites, MSC behavior could be altered by the extracellular pH. The
results of our study indicate that changing the pH of culture me-
dium from normal to alkaline medium could improve the differ-
entiation of MSCs to osteoblasts. There are currently various
treatments clinically available for treating osteomyelitis of the jaw
due to the complex nature of the infection, including the presence
of microorganisms and change in pH. Future therapies for treating
osteomyelitis could be based on shifting the pH of the local envi-
ronment in the alkaline direction to overcome the acidic inflam-
matory exudates released during infection.Conflict of interest
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Introduction: The delineation of the necrotic bone is a crucial step in the surgical treatment of
medication-related osteonecrosis of the jaw (MRONJ). Several different approaches have been described
including the innovative technique of fluorescence-guided surgery. However, until now there is a lack of
data regarding the outcome. Therefore, the aim of the present study is to investigate the long-term
success rates of fluorescence-guided surgery in the treatment of MRONJ.
Patients and methods: 54 Patients were prospectively assigned for surgical treatment of medication-
related osteonecrosis of the jaw using fluorescence-guided surgery. Patients received doxycycline
100 mg twice a day for at least seven days preoperatively. Surgical treatment of MRONJ included com-
plete removal of necrotic bone, which was monitored using the visual enhanced lesion scope (Velscope),
followed by smoothening sharp bony edges and meticulous wound closure. Procedure success was
assessed as postoperative maintenance of full mucosal coverage without pain, infection or bone exposure
during regular follow-up.
Results: The study included a total of 54 patients (32 female and 22 male, mean age 71.4 ± 9.2 years). In
the last follow-up an intact mucosa and absence of exposed bone, pain or signs of infectionwas identified
in 47 of 54 patients (87%) and 56 of 65 lesions (86.2%) after first surgery using fluorescence-guidance. In 4
patients with 6 lesions a second fluorescence-guided surgery was necessary to achieve complete mucosal
closure. Respectively, including the case with second surgical attempt 51 of 54 patients (94.4%) and 62 of
65 lesions (95.4%) showed complete mucosal healing.
Conclusion: The study shows that fluorescence-guided surgery is a safe and successful treatment option
which can be considered for all stages of MRONJ. The technique seems also promising for MRONJ cases
under denosumab.
© 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.1. Introduction
There is an ongoing debate on treatment strategies for
medication-related osteonecrosis of the jaw (MRONJ): namely non-
surgical (conservative) versus surgical treatment. The success ratesaxillofacial Surgery, Ludwig-
, 80337, Germany. Tel.: þ49
hen.de, Otto_Sven@web.de
axillo-Facial Surgery. Published byfor surgical strategies in MRONJ cases under bisphosphonates are
significantly higher (Pautke et al., 2011; Stockmann et al., 2010;
Voss et al., 2012; Carlson and Basile, 2009) than conservative
treatment regimens (Marx et al., 2005; Hoff et al., 2008;
Montebugnoli et al., 2007; O'Ryan et al., 2009; Watters et al.,
2013; Fliefel et al., 2015) even though a direct prospective com-
parison between surgical and non-surgical treatment is missing till
date.
MRONJ is currently diagnosed by the presence of exposed
jawbone for a period that exceeds 8 weeks (Khosla et al., 2007,
2007; Ruggiero et al., 2009). Consequently, a successful therapyElsevier Ltd. All rights reserved.
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mucosal integrity (Carlson and Basile, 2009; Ristow et al., 2015).
Due to the fact that the infected necrotic and exposed bone will not
be revitalized and resurrected, MRONJ should be removed even if
only small bone areas are affected. Thus, the aim of the surgical
therapy should be a complete removal of the necrotic bone. But
even among those who favor surgical therapy there is an uncer-
tainty as to which surgical technique is more effective. Indeed, the
challenge as well as the limitations of theMRONJ therapy is that the
margins of the osteonecrosis cannot be exactly determined, and
therefore a clear demarcation of the necrotic bone is difficult if not
impossible (Khosla et al., 2007, 2007; Pautke et al., 2009). The
complete removal of necrotic bone is of crucial importance because
otherwise there is the risk of disease recurrence or progression
(Mucke et al., 2011; Carlson and Basile, 2009). Furthermore, it must
be avoided to unintentionally and unnecessarily remove healthy
bone without signs of osteonecrosis. Still, surgical experiences
supported by various imaging modalities are used to remove only
as much as necessary and the least amount possible of necrotic
bone (Hutchinson et al., 2010; Fabbricini et al., 2009; Dore et al.,
2009; Guggenberger et al., 2013). Therefore, surgical therapy is
dependent on the surgeon and can neither be comparable nor
reproducibly objectified.
Fluorescence-guided bone surgery has shown promising results
in the surgical MRONJ management (Assaf et al., 2014; Pautke et al.,
2006; Otto et al., 2013). Providing a controllable therapeutic
approach, this technique may help to define the transitions be-
tween necrotic and non-necrotic bone during the surgical proce-
dure. Due to the fact that this surgical approach is easy to apply and
reproducible it may help to objectify surgical MRONJ therapy
auguring an improvement of the treatment.
Therefore, the aim of this study is to examine the success rate of
fluorescence-guided surgery in MRONJ patients in terms of post-
operative mucosal integrity and absence of bone exposure.
Furthermore, pain, infection rates as well as disturbances of
sensitivity are monitored.
2. Materials and methods
2.1. Patients
Over a period of 5 years (2010e2014), 54 patients were recruited
and prospectively included in our monocentric cohort study
(Department of Oral and Maxillofacial Surgery, Ludwig-
Maximilians-University, Munich, Germany). 32 female and 22
male patients were enrolled with a mean age of 71.4 (standard
deviation ±9.2 years; age range, 45e91 years). Inclusion criteria
were: Exposed necrotic jawbone over a period of more than 8
weeks (according Ruggiero et al., 2009, 2014); with a history of
antiresorptive drug treatment (bisphosphonates and/or denosu-
mab) in the absence of radiotherapy to the head and neck region
(Ruggiero et al., 2009, 2014). Exclusion criteria were a history of
head and neck irradiation, metastatic bone disease of the maxil-
lofacial region and contradictions for surgery under general anes-
thesia. After obtaining the approval of the institutional ethics
committee (LMU 189/10), patients were informed about all treat-
ment options and provided written informed consent.
2.2. Surgical procedure
All surgical procedures were performed by the same board-
certified and specialized Oral and Maxillofacial Surgeons (SO) un-
der general anesthesia using a nasal intubation. The surgeries were
performed under sterile conditions following a standardized
operation protocol (Pautke et al., 2011).All patients received 100 mg doxycycline twice a day for at least
7 days preoperatively. Surgical procedures were performed as the
fluorescence guided surgery technique described previously by our
group using the VELscope® system (LED Dental, White Rock, British
Columbia, Canada) to induce and visualize fluorescence of the jaw
bone (Pautke et al., 2011, 2009, 2012; Otto et al., 2013). After sur-
gical bone exposure was performed the bone fluorescence showed
viable bone in a bright greenish fluorescence and necrotic bone
areas showed none or only pale fluorescence. Reddish fluorescence
was considered as a bacterial colonization or infection of necrotic
bone parts and the respective areas were removed. Necrotic bone
was removed using a burr a homogenous greenish bone fluores-
cence was observed as described in previous studies (Assaf et al.,
2014; Pautke et al., 2009, 2010, 2011; Fleisher et al., 2008). It
should be stressed that only necrotic and infected bone parts were
removed and the surrounding vital bone was preserved which
means that no resections including safety margins have been per-
formed. Thereafter, sharp bony edges were smoothened using burrs
and diamante burrs. A tension free wound closure was achieved
using mucoperiostal flaps and simple as well as back stitches
(Serafit 3-0, SERAG-Wiesner GmbH Germany). In extensive cases of
the maxillary molar and premolar region (stage 2 and 3) a second
layer of wound closurewas achieved using the buccal fat pad before
mucoperiostal closure.
All patients stayed in hospital for at least 48 h after surgery.
Patients received the routine postoperative instructions and
routine postoperative analgesic drug therapy; antibiotic treatment
was continued using Augmentin 2.2 g or Unacid 3g intravenously
three times per day for 3e5 days. In case of a penicillin allergy
clindamycine 600 mg was used. In cases of severe infection (mainly
stage 2 and 3) metronidazole 500 mg (1-0-1) was administered
additionally. In cases of renal function disturbances the doses were
adjusted accordingly. The antibiotic treatment was continued orally
after discharge from hospital for 2e4 weeks orally.
2.3. Measurements
Regular clinical examinations were performed daily during in-
patient treatment, weekly during the first month and monthly
during first year of out-patient treatment. The surgical treatment
was only considered a success if full mucosal coverage without
signs of residual infection or exposed bonewas achieved at the time
of last follow-up. Furthermore, all patients were asked for pain and
were examined for signs of sinusitis and checked for oro-antral
fistula in cases of upper jaw lesions and checked for sensitivity in
the lower lip area in cases of MRONJ of the lower jaw.
2.4. Statistical analysis
Descriptive statistics were computed using SPSS version 16.
Results are expressed as percentages or as mean values including
standard deviation and range. Means were compared by statistical
testing (students t-test), where p < 0.05 was considered to be
significant.
3. Results
3.1. Baseline characteristics
54 patients (32 female and 22 male) patients with a mean age of
71.4 years (standard deviation 9.2 years) were included in the
study. The mean age of the female patients was 70.4 years (stan-
dard deviation 7.6 years), themean age of all male patients was 72.9
years (standard deviation 7.0 years). Respectively, there was no
significant difference (see Fig. 1).
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nant disease, specifically breast cancer (n ¼ 20; 37%), prostate
cancer (n ¼ 16; 29.6%), and multiple myeloma (n ¼ 4; 7.4%). There
were also cases of metastatic thyroid cancer (n ¼ 2), squamous cell
carcinoma (n¼ 1), bronchial cancer (n¼ 1), and endometrial cancer
(n ¼ 1) in the study cohort. In the remaining 9 (16.7%) patients
osteoporosis was the cause of the antiresorptive treatment. An
overview is given in Fig. 2.
Of the 54 patients included, 47 were treated with nitrogen-
containing bisphosphonates (87%), 3 had a history of denosumab
intake (5.5%) and the remaining 4 patients (7.4%) reported a
sequential intake of bisphosphonates and denosumab. The most
common antiresorptive drugs within the cohort were zoledronate
(n¼ 40; 74.1%), alendronate (n¼ 5; 9.3%), ibandronate (n¼ 2; 3.7%)
and denosumab (n ¼ 3; 5.5%) or the combination of bisphospho-
nate and denosumab (n ¼ 4; 7.4%). The mean duration of intake of
the antiresorptive drugs was 46.3 months (SD 31.8 months).
The 54 patients revealed 65 MRONJ lesions. 40 of the lesions
(61.5%) were located in themandible and 25 (38.5%) were located in
the maxilla. The majority of the lesions referred to stage 2 (n ¼ 42;
64.6%) and stage 3 (n¼ 8; 12.3%) according to Ruggiero et al. (2014).
It is worth mentioning that also stage 1 lesions were included
(n ¼ 14; 21.5) and even a singular case of stage 0 (n ¼ 1; 1.5%). The
mean follow-up of the patients was 12.9 months (median 11
months; range 1e39 months).3.2. Results of fluorescence-guided bone surgery
The first surgical intervention using fluorescence-guided bone
surgery resulted in complete mucosal healing in 47/54 of the
evaluated patients (87%) and 56/65 lesions (86.2%) without any
kind of bone exposure and without complaints at the time of last
follow-up. Typical cases are illustrated in Figs. 3 and 4.
2/54 (3.7%) patients were also free of complaints and had no
bone exposure and a complete mucosal coverage of the bone.
However, in these patients the lesions in the maxilla were thatFig. 1. Comparison of age and age range between male and female patients suffering
from MRONJ.extensive (AAOMS stage 3) that oro-antral fistula persisted. Both
patients preferred an obturator prosthesis instead of another sur-
gical approach to close the oro-antral fistula. One of these two cases
is illustrated in Fig. 5.
5/54 patients (9.3%) with 7/65 lesions (10.8%) showed stage
improvement and were free of pain after first surgery but still had
bone exposure present. 4 of these patients (with 6 of the 7 lesions)
underwent a second surgery using fluorescence-guided bone sur-
gery, which in all 4 patients and all 6 lesions resulted in complete
mucosal healing. An overview of the treatment outcome after first
surgery and including the 4 cases with second surgery is provided
in Table 1.
Only in one single patient (1 lesion) the bone exposure persisted
and was subsequently treated conservatively as the patients sys-
temic condition had worsened over time caused by the underlying
malignant disease. The initial stage improvement (stage 2 prior to
surgery and stage 1 after surgery) gradually worsened over time
back to the initial stage 2.
Taken together the results of the first and second surgery 51/54
patients (94.4%) and 62/65 lesions (95.4%) showed complete
mucosal healing and no bone exposure. Two further patients were
free of complaints and had no bone exposure but developed oro-
antral communication. Only one patient with a single lesion
showed persistent bone exposure which could not be addressed by
a second surgery due to the worsened general condition of the
patient.
It is worth mentioning that no continuity resection had to be
performed in the mandible, whereas the removal of MRONJ in the
maxilla resulted in resection-like defects in 4 cases. Two of those
cases developed a persistent oro-antral fistula. None of the pa-
tients showed a recurrence of MRONJ in the respective area after
complete mucosal healing in the further postoperative course.
None of the patients developed a pathological fracture of the
mandible.
4. Discussion
There is an ongoing debate and certainly no consensus yet
regarding the management of patients with MRONJ. Moreover,
there is not even consensus regarding the main treatment aim and
the optimal outcome measures.
While some authors recommend conservative treatment pro-
tocols mainly aiming in relief of pain and control of infection, a
number of papers have suggested that in patients with a good
performance status the primary aim of treatment should be
mucosal healing as this is the physiological status, rather than bone
exposure without symptoms (Assaf et al., 2014; Carlson and Basile,
2009; Pautke et al., 2011; Vescovi et al., 2008; Otto, 2015). Con-
servative treatment cannot achieve this aim, neither considering
the frequency nor the predictability especially in oncological pa-
tients who have received long term intravenous courses of
nitrogen-containing bisphosphonates. In this respect Hoff et al.
(2008) reported 23% healing (3/13 patients) and similarly
Nicolatou-Galitis et al. reported mucosal healing in only 14.9% of
BRONJ cases (7/47) managed conservatively, notably after a median
time of 8 months (range 2e36 months, mean 14.7 months), while
pain subsided in 80.9% (38/47) (Nicolatou-Galitis et al., 2011). It is
also worth mentioning that 4 of the 7 patients who showed com-
plete healing referred to stage 0 according to the AAOMS definition
(Ruggiero et al., 2009, 2014). This in turn means that the outcome
results for cases with bone exposure are even less convincing.
Regardless of the type of definition or staging system applied, the
vast majority of patients with BRONJ (especially oncological pa-
tients) cannot be cured using conservative measurements and have
long lasting jaw bone exposure which can not only affect their
Fig. 2. Overview of the underlying diseases leading to antiresorptive treatment with bisphosphonates and denosumab in patients suffering from MRONJ.
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logical treatment options including immuno- or chemotherapy and
possibly further antiresorptive treatment with bisphosphonates or
denosumab (Then et al., 2012; Otto et al., 2012). Conservative
treatment might be adequate if the aim of treatment is to slow
down or stop disease progression and to alleviate pain andFig. 3. Illustration of a 74-year old male patient suffering from prostate cancer who has rec
and putrid exudation of the right mandible (regio 47/48) according to a medication-related o
surgery (b). During surgery there was necrotic bone with diminished fluorescence in the ling
and smoothening of sharp bony edges the fluorescence was homogenously green (e and f)superinfection of the exposed bone, while there is increasing evi-
dence supporting surgical protocols if the aim of treatment is
mucosal healing.
In this respect our study showed that fluorescence-guided bone
surgery is a reliable and promising treatment option for patients
suffering from MRONJ.eived intravenous treatment with zoledronate over 2 years and exposed necrotic bone
steonecrosis of the jaw (regio 47/48) prior to (a) and one year after fluorescence-guided
ual aspect of the mandible (c and d). After complete removal of the necrotic bone parts
.
Fig. 4. Illustration of a 58-year old female patient suffering from breast cancer who received 56 months zoledronate and developed a medication-related osteonecrosis of the jaw in
her left mandible (region 37/38 mainly lingual aspect). The illustration depicts the clinical intraoral situation prior to (a) and 3 months after surgery (b). The intraoperative clinical
and fluorescence view prior to removal of the necrotic bone (c and d) and after the removal of necrotic bone and smoothening of sharp bony edges (e and f) are also illustrated. Note
the weak green fluorescence in the lingual aspect regio 37/38 corresponding to the necrotic bone area (d) as well as the reddish fluorescence in this area corresponding to the
bacterial infection of this region prior to removal of the necrotic and infected bone parts as well as the homogenous greenish fluorescence after the removal and the absence of red
fluorescence after the removal of necrotic bone parts.
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reported mucosal integrity of 92% after surgical resection in a case
series of 95 patients (Carlson and Basile, 2009). Likewise, other
authors stated a healing rate up to 89% (12 month follow up;
n ¼ 50) (Stockmann et al., 2010) as well as 88 % (60 weeks follow
up; n ¼ 24) after surgical treatment. Prospective case series further
support the benefit of a surgical treatment of BRONJ: Bedogni et al.
(2011) (n ¼ 30) surgical treatment: 90 % healing 6 months follow
up, Schubert et al. (2012) (n ¼ 54) surgical treatment: 89 % healing
(min. 3 months follow up), Jacobsen et al. (2012) (n ¼ 64 surgical
treatment: 78 % healing (7 years follow up)). It is however hard to
compare the different studies because the underlying study cohortswere composed of different populations regarding the proportion
of oncological and osteoporotic patients, regarding the surgical
protocol applied (e.g. only removal of necrotic bone versus resec-
tion) and regarding the outcome evaluation and postoperative
follow-up but the bottom line of all of the above mentioned studies
was that patients suffering fromMRONJ can successfully be treated
using surgical treatment protocols.
Comparative studies also seem to substantiate these findings.
The multivariate analysis of Mücke and co-workers showed a lower
recurrence rate for surgically-treated ONJ patients when compared
to conservative treatment (n ¼ 108) (Mucke et al., 2011), as well as
the multivariate analysis of (Graziani et al., 2012, 2013) (n ¼ 347)
Fig. 5. Illustration of a 62-year old female patient suffering from metastatic breast cancer who received zoledronate intravenously (4 mg every 4 weeks) for more than 3 years and
developed an extremely extended stage III MRONJ in her right maxilla with bone exposure suppuration which was also extremely painful on palpation (a). After antibiotic pre-
treatment the patient was treated surgically. After exposure (b) the whole extent of the MRONJ lesion became visible which included parts of the hard palate and parts of the facial
wall of the maxillary sinus. After removal of parts of the necrotic bone (c and d) it became obvious that the whole alveolar process of the right maxilla was necrotic and infected. The
necrotic bone was completely removed using fluorescence-guided surgery (e) and a double-layered plastic wound closure was performed using the buccal fat pad and muco-
periosteum. In the postoperative course the patient was free of pain but developed a wound healing disturbance and a oro-antral fistula. After complete healing there was no bone
exposure but the oro-antral fistula persisted (f). As the patient was free of complaints she did want to go for another surgery to close the oro-antral fistula. So she was treated using
an obturator prosthesis as described in detail elsewhere (Troeltzsch et al., 2015).
Table 1
Comparison of pre- and post-operative signs and symptoms of MRONJ in the patient cohort which was treated using fluorescence-guided surgery; n ¼ number of patients
(n ¼ number of lesions).
Pre-operatively
Total n ¼ 54 (65)
After first surgery
Total n ¼ 54 (65)
After second surgery in n ¼ 4 (6); total 54 (65)
Bone exposure 53 (63) 5 (7) 1 (1)*
Pain/complaints 43 (51) 1 (1) 1 (1)**a
Impaired sensitivity N. V3 7 (7) 1 (1) 1 (1)**b
Sinusitis/oro-antral fistula 7 (8) 2 (2) 2 (2)**b
Pathological fracture 0 0 0
*change due to complete mucosal healing in 4 patients with 6 lesions who underwent second surgery.
**no change as none of the affected patients was treated surgically again.
a Due to worsening of underlying malignant disease.
b Due to patients wish and no need for second surgery.
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ment versus conservative protocols. Finally, a 2014 systematic re-
view by Rupel et al. (2014), and another very recent systematic
review meeting PRISMA guidelines (Liberati et al., 2009) which
analysed data from 97 studies and 4,867 patients suggest that
surgical treatment protocols are superior to conservative manage-
ment (Fliefel et al., 2015).The most important parts for a successful surgical treatment of
MRONJ include pre- and postoperative antibiotic treatment, com-
plete removal of the necrotic and often infected bone parts,
smoothening of sharp bony edges and a complete and reliable
plastic wound closure. The aim of the preoperative antibiotic
treatment is to stop disease progression and to reduce infection in
order to provide optimal conditions for the surgical treatment. The
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conditions for bone and soft tissue healing and in order to avoid
reinfection of necrotic bone parts. Fluorescence-guidance might be
a tool to optimize the completeness of removal of necrotic bone
parts. Smoothening of sharp bony edges is of special importance
because of the remodeling suppression caused by antiresorptive
drugs and seems therefore even more important when the anti-
resorptive activity is high (e.g. after multiple years of intravenous
bisphosphonate intake or shortly after the last application of anti-
resorptive drugs with short half-life e.g. denosumab). The aim of
the plastic wound closure is to ensure that the delayed and en-
dangered healing of the jaw bone treated with antiresorptive drugs
can take place in an undisturbed manner. In the experience of the
authors of this article safe and reliable mucoperiostal flaps closed
with multiple back stitches seems sufficient. However, it is rec-
ommended to perform double layered wound closure whenever
possible. In this respect for example the use of the buccal fat pad in
cases of MRONJ of themolar and premolar region of themaxilla and
the use of the mylohyoid flap in themandibular molar regionmight
have advantages. The postoperative antibiotic treatment should
protect thewound healing period and avoid reinfection of the bone.
A prolonged antibiotic treatment seems to have advantages.
According to several guidelines including the AAOMS position
paper and the ASBMR expert panel recommendation early stages of
MRONJ should be treated conservatively and surgical treatment
should only be applied to stages 2 and 3 (Khan et al., 2015; Ruggiero
et al., 2014; Williams and O'Ryan, 2015). The authors of this paper
disagree with these opinions especially in patients receiving
intravenous administrations of bisphosphonates in the oncological
setting (Otto et al., 2015). In fact treatment of all stage 0 and 1 le-
sions resulted in complete mucosal healing with minimal
morbidity and a predictable and reasonable time frame. Further-
more, after complete mucosal healing the respective patients had
no restrictions regarding their further oncological or osteological
treatment including further antiresorptive treatment. Actually,
surgical treatment of early MRONJ lesions offers a lot of advantages
including the usually smaller extent of the lesions leading to less
extended surgical removal of bone and minor functional impair-
ments. Besides that lack of infection usually offers better conditions
for surgical treatment. Therefore, the authors of this paper call for a
re-evaluation of concepts and aim for a change of paradigms.
Instead of long lasting, unpredictable conservative treatment ap-
proaches usually resulting in improvements of symptoms but
rarely leading to complete mucosal healing should be replaced by
early surgical interventions aiming in complete mucosal healing in
a predictable timeframe and resulting in optimized functional
outcomes as respective surgeries which frequently occur after un-
successful conservative treatment approaches can be avoided.
Indeed, it is worth mentioning that after changing our treatment
concept to early surgical interventionwe did not experienceMRONJ
cases, in which we had to perform continuity resections of the
mandible and no microvascular reconstructions were necessary
any more, which we experienced during the timeframe where we
applied a more conservative treatment approach in early stages. So
in fact so called conservative treatment protocols might lead to the
necessity of more aggressive and large resections including all
functional impairments over the long run (Williams and O'Ryan,
2015) The authors of this paper do not doubt that ablative sur-
gery including continuity resections of the mandible and micro-
vascular reconstructions are necessary in selected cases of MRONJ
whereas a lot more cases of osteoradionecrosis require this radical
treatment. We think that the progression of MRONJ cases pre-
senting in early stages can be avoided when treated adequately.
However, conservative treatment approaches and the role of drug
holidays might well be different in MRONJ cases under denosumabespecially in cases without prior bisphosphonate treatment
because of the much shorter half-life of denosumab (26 days) when
compared to bisphosphonates in bone (Otto, 2015).
Regarding the specific technique of fluorescence-guided bone
resection it needs to be mentioned that it is not yet certain what
exactly causes the intraoperative fluorescence. Recent reports
suggest that there is an auto-fluorescence without tetracycline
bone labeling, leading to similar bone fluorescence of tetracycline-
exposed tissue (Vescovi et al., 2015; Ristow and Pautke, 2014).
Indeed, it is well known that not only tetracycline but also com-
ponents of the extracellular matrix e.g. calcified tissues (bone or
teeth) have fluorescence properties (Pautke et al., 2010, 2011). A
combination of these components might contribute to the fluo-
rescence effects that can be used in the treatment of MRONJ.
Therefore, further basic and clinical research is needed in order to
investigate the fluorescence properties and their differences. Once
the causes for fluorescence-guided surgical approaches might be
suitable not only for MRONJ but also for osteoradionecrosis and
osteomyelitis (Pautke et al., 2010).
Limitations of the present study include the inhomogeneous
recall intervals of some of the patients which were mainly due to
their underlying diseases and respective oncological treatment
protocols. Furthermore there were only very few cases of MRONJ
due to Denosumab intake. Given the much shorter half-life of
Denosumab when compared to nitrogen-containing bisphospho-
nates there might be a different and more important role of con-
servative treatment protocols especially when there is no pre-
treatment with bisphosphonates and no further necessity of anti-
resorptive treatment. However, up to now there is no study which
directly compares the outcome of conservative and surgical treat-
ment and there is also no study comparing conventional surgical
treatment versus fluorescence-guided surgery.
The available data might not yet be robust enough to inform
guidelines on the treatment of MRONJ, especially as there is hardly
any data on how to manage patients exposed to denosumab where
conservative treatment might theoretically play a different role due
to its much shorter half-life. There is an urgent need of prospective
randomized trials comparing surgical and non-surgical treatment
of MRONJ and including patient-centered outcome measures like
quality of life before, during and after treatment. Ultimately, the
clinical decision making will always be based on individual risk
assessment, especially as most patients with MRONJ have multiple
comorbidities, which require knowledge about the predictable ef-
ficacy and limitations of the all treatment options.
5. Conclusion
We conclude that fluorescence-guided bone resection is a reli-
able surgical treatment option for patients suffering from
medication-related osteonecrosis of the jaw.
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INTRODUCTION 1 
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially devastating 2 
complication of antiresorptive drugs used globally to treat bone disorders as osteoporosis, 3 
skeletal complications associated with osseous metastasis and multiple myeloma (Licata AA 4 
2005, Peer A and Khamaisi M 2015). Nowadays, the pathophysiology of MRONJ is not 5 
clearly understood. Numerous theories have been proposed, neither of which can provide an 6 
adequate explanation of the disease. MRONJ was perceived as a type of avascular necrosis 7 
due altered bone turnover or direct toxicity to the soft tissue, infection, inflammation, 8 
inhibition of angiogenesis or suppression of innate or acquired immunity have been identified 9 
as possible explanations of the disease process (Mitsimponas KT et al. 2014).  10 
Bacterial infection to the maxillofacial region has been suggested as key factor for the 11 
pathogenesis and progression of MRONJ (Otto S et al. 2010, Otto S et al. 2010). The oral 12 
cavity comprises of more than 750 bacterial species existing as mixed biofilm communities 13 
(Pushalkar S et al. 2014). The mandible and maxilla are covered by thin layer of mucosa in 14 
close proximity to the external environment. After invasive dental procedures, oral trauma or 15 
soft tissue infection, microbial biofilms in the mouth and saliva gain access to the exposed 16 
jaw bone and play a significant role in the necrosis of the bone, inhibition of oral wound 17 
healing and facilitating bacterial colonization on bone surface (Sedghizadeh PP et al. 2012, Li 18 
CL et al. 2015). Actinomyces were regularly found in MRONJ suggesting a latent role of 19 
infection in the pathogenesis (Hansen T et al. 2006, Hansen T et al. 2007, Lazarovici TS et al. 20 
2009). Actinomyces are filamentous gram-positive anaerobic bacteria that usually can be 21 
found in calculus, periodontal pockets, carious lesions and oral mucosal surfaces, in addition 22 
to the upper respiratory, gastrointestinal tracts and vagina. They are common saprophyte 23 
bacteria of low virulence in nature causing no disease as long as they stay on the surface of 24 
the mucosa but in certain conditions where the integrity of the mucosal barrier is 25 
compromised, the bacteria may be pathogenic and gain access to the oral tissues or jawbones 26 
initiating a prolonged chronic inflammatory process, creating a tumor-like mass, tissue 27 
destruction, osteolysis and multiple sinus tracts (Hall V 2008, Kaplan I et al. 2009, Norouzi F 28 
et al. 2013). 29 
MRONJ lesions are usually colonized by oral bacteria and the use of systemic antibiotics 30 
failed to restrict the bacterial colonization and effective healing of the lesion. It is important to 31 
identify the bacterial species colonizing jaw bone associated with the disease to delineate the 32 
pathogenesis. Moreover, it is not well understood whether the bacteria involved in MRONJ is 33 
similar or different to other biofilm associated bone infections in the oral cavity (Ji X et al. 34 
2012). Recently, bone abnormalities were studied by various modalities but none proved to be 35 
reliable in describing the infectious nature of the disease. Recent advances using biomolecular 36 
profiling to describe MRONJ flora have decreased this gap (Hinson AM et al. 2014). 37 
Here, we identify the bacterial profiles that colonize MRONJ bone samples determined by 38 
culture approaches and polymerase chain reactions (PCR) with clinical features of patients. 39 
This line of investigation could provide rationale in the future for MRONJ therapeutics and 40 
targeted antimicrobial therapy. 41 
PATIENTS AND METHODS 42 
This is a retrospective study of MRONJ patients treated at the Department of Oral and 43 
Maxillofacial Surgery, Ludwig-Maximillians-University Clinic, Munich from January 2008 to 44 
December 2014. Inclusion criteria were based on the American association of oral and 45 
maxillofacial surgery (AAOMS) Position paper (Ruggiero SL et al. 2014). Patients missing 46 
clinical, radiographic or follow-up data were excluded or if they had a history of head and 47 
neck radiation. Appropriate Institutional Review Board approval was obtained. 48 
Clinical data relevant to the study were extracted and entered into an excel datasheet with a 49 
detailed history concerning: age, gender, location and teeth involved in the lesion, primary 50 
cause of the disease, comorbidities, clinical presentation, MRONJ clinical staging, type of 51 
antiresorptive drug, route of administration and pathological/microbiological findings of bone 52 
samples. Bone samples were obtained from bone resection surgeries and were sent for 53 
microbiological investigations and PCR. Due to high likelihood of false positive culture from 54 
environmental exposure, we considered only at least strongly positive culture result (+2) as 55 
positive culture. One bone sample from each MRONJ patient was cut into fragments and 56 
prepared for microbiological analysis as described below. 57 
Bone samples have been introduced in classical bacterial diagnostics. For this, aerobic 58 
cultures were prepared on Columbia blood-agar, MacConckey-agar and Columbia-CAN-agar, 59 
anaerobic cultures on Schaedler-agar and Schaedler-KV-agar (all agar plates from BD, 60 
Heidelberg, Germany). Besides, the swabs were cultivated in thioglycolate broth. All aerobe 61 
cultures have been read after 24h, 48h and 72h, the anaerobic cultures after 2d, 5d and 7d. The 62 
bacterial counts have been enumerated semi-quantitative and bacterial colonies were objected 63 
to MALDI-TOF MS for further species identification. 64 
Samples were evaluated by the use of Microflex LT mass spectrometer (Bruker Daltonik 65 
GmbH, Bremen, Germany) in linear positive-ion mode across the m/z range of 2,000 to 66 
20,000 Da. Each spot was measured by using 240 laser shots at 60 Hz in groups of 40 shots 67 
per sampling area of the spot. Spectra were analyzed by using MALDI Biotyper software (v 68 
3.1 – Build 65). Sample preparation included either the “direct transfer method”, the 69 
“Extended Direct Transfer method (EDT)” or the “ethanol/formic acid extract method” as 70 
previously described (Schulthess B et al. 2014). Resulting spectra were compared against 71 
reference spectra using Bruker MALDI-TOF Biotyper software to obtain identification with a 72 
confidence score. For most isolates, the MSP (Main Spectral Projection) reference spectra 73 
were those contained in the Bruker database of 2013 (database version V 3.3.1.2) containing 74 
364 genera, 2185 species and 4613 individual MSP. Results with score values >2 were 75 
considered as correct species identification, results displaying values of 1.5≤ and ≤2 were 76 
accepted as correct genus identification. 77 
Identification of bacteria by sequencing of 16S rDNA has been performed as described 78 
previously with some modifications (Wragg P et al. 2014). In brief, crude bacterial lysates 79 
were prepared directly from culture plates by suspending bacteria from a clonal culture in 100 80 
μl of RT-PCR grade water (approximately McFarland Standard 2.0) and placed in a hot block 81 
at 100 °C for 10 min. A ~800 bp-fragment of 16S rDNA was amplified using the universal 82 
primer pair FD1 5′-AGAGTTTGATCCTGGCTCAG-3′ and 800r 5′-83 
GAGTACCAGGGTATCTAATCC-3′. Resulting PCR amplicons were sequenced using the 84 
same primers and standard sequencing methods. Data from both strands was aligned in 85 
SeqMan (DNASTAR Lasergene 8 Suite) to generate a contig of around 800 bp. The 86 
consensus sequences were then used to compare with online databases (NCBI BLAST—87 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the Ribosomal Database Project 88 
(http://rdp.cme.msu.edu/). Identification criteria of 99% sequence identity for identification to 89 
species level were applied (Drancourt M et al. 2000) where matches had to be to the species 90 
type strain. The identities of type strains, as well as accession numbers in NCBI for equivalent 91 
16S rDNA sequences, are available at http://www.bacterio.cict.fr/ for all validly published 92 
bacterial species. 93 
Statistical analysis 94 
Descriptive statistics were computed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). 95 
Results are expressed as mean values including standard error of the mean and range. Means 96 
were compared by statistical testing (Student's t-test), where P< 0.05 was considered to be 97 
significant. 98 
RESULTS 99 
A total of 150 patients were diagnosed with MRONJ from 2008 to 2014. However, 95 100 
patients satisfied the inclusion criteria and form the basis of this study. Flow chart of the 101 
number of patients included in the study are illustrated in (Fig.1). The mean age of the 102 
patients was 69.9 ± 8.7 years; with a male to female ratio of 1:1.4 (39 males and 56 females). 103 
Breast cancer was the primary cause for the administration of antiresorptive drugs (n=35; 104 
36.8%), followed by prostate cancer (n=24; 25.3%) and osteoporosis (n=13; 13.7%) in 105 
addition to multiple myeloma (n=10; 10.5%), lung cancer (n=4; 4.2%) and finally other 106 
cancers (n=9; 9.5%). The relevant comorbidities identified included: diabetes mellitus (n=17; 107 
17.9%), cardiovascular diseases (n=29; 30.5%), chemotherapy (n=57; 60%), irradiation other 108 
than head and neck (n=51; 53.7%), steroid intake (n=28; 29.5%), anti-angiogenic drugs (n=2; 109 
2.1%) and smoking (n=28; 29.5%). The most commonly administrated antiresorptive drugs 110 
(ARD) were bisphosphonates (BPs) in 85 patients (89.5%) of which, zoledronate in 58 111 
(61.1%), pamidronate in 3 (3.2%), ibandronate in 2 (2.1%), combination of BPs in 22 112 
(23.1%). Only ten patients received denosumab (10.5%). Among the ARD groups, 79 patients 113 
(83.2%) had intravenous ARD, 6 patients (6.3%) with oral and 10 patients (10.5%) had 114 
subcutaneous injection. The baseline characteristics of the patients included in the study are 115 
listed in (Table 1). 116 
Initial presentation of the lesion was only one case referred to stage 0 (1.1%) with no bone 117 
exposure but non-specific signs and symptoms of MRONJ. Fifteen patients (15.8%) were 118 
categorized as stage 1 where bone was exposed in the absence of pain and clinical signs of 119 
infection. The majority of cases (n=59; 62.1%),) were classified as stage 2 based on exposed 120 
necrotic bone in the maxillofacial region accompanied by pain or signs of infection. Twenty 121 
patients (21.1%). were presented with stage 3 lesions with complications such as pathological 122 
fracture, extraoral fistula formation, extension of the lesion to the inferior border of the 123 
mandible or to the floor of the maxillary sinus. Most of MRONJ lesions were located in the 124 
mandible (n=55; 57.9%), 25 patients (26.3%) had maxillary lesions and 15 patients (15.8%) 125 
had involvement of the maxilla and mandible. Characteristics of MRONJ lesions are 126 
presented in (Table 2). The posterior teeth specially the first and second molars were the most 127 
affected teeth by MRONJ than the anterior teeth. The frequency of MRONJ in teeth of each 128 
quadrant is represented in (Fig.2). 129 
Regarding the onset of MRONJ, the most frequent signs and symptoms were: pain in 81 130 
patients (85.3%), exposed bone in 70 patients (73.7%), disturbance in wound healing in 55 131 
patients (57.9%), inflammation in 54 patients (56.8%), pus in 39 patients (41.1%), 132 
pathological fracture in 9 patients (9.5%), swelling in 55 patients (57.9%), fistula in 35 133 
patients (36.8%) and sinus involvement in 13 patients (13.7%). The lesions were stratified 134 
into lesions with a known triggering event or spontaneous development of MRONJ. The most 135 
common events prior to the development of MRONJ lesions were extraction in 56 patients 136 
(58.9%), dentoalveolar surgery in 15 patients (15.8%), denture sores in 4 patients (4.2%), 137 
periodontal treatment in 7 patients (7.4%) and lesions developed spontaneously in 13 patients 138 
(13.7%). Histopathological examination of the bone specimens revealed typical picture of 139 
MRONJ lesions where nearly all the patients showed an active inflammatory process with 140 
necrotic bone (n=94, 98.9%), inflammatory cell infiltrate (n=87, 91.6%) and bacterial 141 
colonization (n=67, 70.5%). The characteristics of MRONJ lesions are illustrated in Table 2. 142 
Ninety five patients had undergone microbiological culture tests. However, only 55 patients 143 
had undergone PCR for actinomyces. Based on bone culture results, the most common 144 
microorganism were both actinomyces and mixed oral flora (n=23, 24.2%) each then 145 
enterobacter group (n=19, 20%), streptococci (n=18, 18.9%), miscellaneous microorganisms 146 
(n=13, 13.6%), candida (n=9, 9.4%) and finally enterococcus (n=5, 5.2%) (Fig.3). As 147 
actinomyces were the most commonly found microorganisms, we therefore performed PCR to 148 
confirm the presence of actinomyces. Of the 55 patients, 53 (96.4%) were PCR and culture 149 
positive and 35 (63.6%) were positive only for PCR but negative for actinomyces culture. The 150 
results are shown in Table.3.  151 
DISCUSSION 152 
The main objective of this study was to identify microorganisms manifested in MRONJ with 153 
special attention to actinomyces using microbiological cultures and PCR which might be 154 
useful in assisting surgeons in making proper decisions on the treatment modality of the 155 
disease based on the hypothesis that infection maybe the most important factor negatively 156 
influencing the onset and progression of MRONJ.  157 
MRONJ can reduce the patient's quality of life and may produce significant morbidity due to 158 
impairment of chewing, swallowing and speaking as well as deterioration of facial aesthetics. 159 
Thus, it is of tremendous importance to treat those patients to adequately eliminate pain, 160 
control infection of soft and hard tissue and eradicate bone exposure (Maurer P et al. 2011). 161 
From the results of our study, it was proved that actinomyces were highly prevalent in 162 
MRONJ patients by microbiological culture which was consistent with an earlier study on 163 
MRONJ bone samples (Hansen T et al. 2007). A previous study on a pathological specimen 164 
of MRONJ lesion showed that the lesions were composed of areas with active inflammatory 165 
cells with acellular necrotic debris and bone resorption (Favia G et al. 2009). The 166 
histopathological findings of the bone samples in our study were similar.  167 
The terminology MRONJ had been well recognised worldwide nowadays due to the increase 168 
in the prevalence of the disease. The pathogenesis of the disease raised many questions 169 
regarding the potential mechanisms underlying the pathophysiology (Allen MR and Burr DB 170 
2009). Several mechanisms had also been proposed as: i) oversuppression of bone turnover, 171 
ii) a response to infection, iii) immunomodulation, iv) ischemia due to the antiangiogenetic 172 
effects of BPs, v) soft tissue toxicity. Arguably, all theories could play a role in the 173 
pathogenesis of BRONJ. However, none of them was able to explain why the jawbone is the 174 
exclusive target (Otto S et al. 2010, Otto S et al. 2010). However, microbial infection in the 175 
pathogenesis of MRONJ is debatable and is not fully elucidated with few publications 176 
referring to the importance of infection as a prime component in the multifactorial disease 177 
(Otto S et al. 2010, Hinson AM et al. 2014, Katsarelis H et al. 2015). In our study, we have 178 
confirmed the presence of actinomyces in the bone samples but it is not clearly known 179 
whether osteonecrosis occurs first and then infection of the necrotic lesion or infected lesion 180 
undergoes osteonecrosis (Hoefert S 2015, Kim KM et al. 2015). There are some evidences 181 
showing that infection is necessary for osteonecrosis with formation of a bacterial biofilm in 182 
the lesion (Sedghizadeh PP et al. 2009, Aspenberg P et al. 2010, Otto S et al. 2010) as the 183 
oral cavity is occupied by hundreds of bacterial species existing as mixed biofilm. When the 184 
patient immunity is decreased, those microorganisms show opportunistic infection as 185 
actinomyces which are dominant pathogenic microorganisms detected at MRONJ by 186 
histopathological studies (Boff RC et al. 2014).  187 
From our results, we confirmed that PCR using 16S rRNA was useful in identifying 188 
actinomyces directly from bone samples. PCR targeting the 16S rRNA gene of the 189 
actinomyces is highly conserved within species of the same genus and is thus considered the 190 
new standard for classification and identification of bacteria as well as a reliable method for 191 
the distinction of species that are difficult to cultivate (Lau SK et al. 2004, Elsayed S et al. 192 
2006). PCR is superior to microbiological cultures in diagnosis of oral actinomyces as being 193 
highly sensitive and rapidly detecting actinomyces either dead or alive. Another advantage is 194 
that it quantifies DNA rather than viable organisms. However, culturing methods cannot 195 
detect non-viable bacteria (Kaya D et al. 2013). Previous studies have used different 196 
molecular methodologies to identify and differentiate actinomyces from oral samples after 197 
anaerobic cultivation, including PCR-RFLP, chromosomal DNA fingerprinting, 16S rRNA 198 
gene sequencing and oligonucleotide–DNA hybridization using universal primers or 199 
oligonucleotide probes (Sato T et al. 1998, Ruby JD et al. 2002, Tang G et al. 2004).  200 
Fifty-three (96.4%) of the 55 bone samples reacted positively with the universal primer pair 201 
designed for actinomyces suggesting their presence. These results show that PCR targeting 202 
the 16S rRNA region can be used to detect actinomyces in MRONJ bone samples.  203 
Microbiological cultures were used as a traditional technique to identify actinomyces from 204 
bone samples. Anaerobic culturing was done in all 95 samples. However, these results were 205 
confirmed by PCR for 55 bone samples. The positive PCR results of the bone samples that 206 
were negative to culture were attributed to the high sensitivity of the PCR compared to culture 207 
methods, the way of transporting the specimens to the laboratory, death of some actinomyces 208 
during culturing and the inhibition of growth of actinomyces by the presence of other 209 
organisms affecting their ability to grow in culture. However, DNA from dead organisms can 210 
still be detected by PCR as explained by another study (Kaya D et al. 2013). 211 
From our results, MRONJ occurred in the mandible twice as likely to be affected as in the 212 
maxilla which was in agreement with previous studies (Boonyapakorn T et al. 2008, 213 
Thumbigere-Math V et al. 2009). Age older than 65 years was found to be a risk factor for 214 
MRONJ. Some studies recognized no statistically significant correlation between ageing and 215 
MRONJ (Vahtsevanos K et al. 2009) whereas others have included advanced age as a 216 
potential co-factor (Bamias A et al. 2005). Correlations between MRONJ and comorbidities 217 
as diabetes mellitus, cardiovascular disease, chemotherapy or steroid intake have been 218 
discussed. These comorbidities affect bone remodelling by microvascular ischemia and 219 
compromised wound healing as well as impaired osteoblastic differentiation and function  and 220 
the additional immunosuppressive and antiangiogenic effects (O'Ryan FS and Lo JC 2012, 221 
Fliefel R et al. 2015). The great majority of MRONJ occur in females. The reason for the 222 
female dominance seems to be due to the higher number of breast cancer patients compared 223 
with prostate cancer patients and the greater prevalence of osteoporosis in females than in 224 
men (Bamias A et al. 2005). MRONJ has been reported in patients with malignancies, 225 
particularly in those with breast and prostate cancer. (Lopes RN et al. 2015) The profile of 226 
patients affected by this complication seems to show a similar pattern in our study. The 227 
majority of patients presented with MRONJ were at stages II which is comparable to findings 228 
in other studies (O'Ryan FS et al. 2009, Otto S et al. 2013). The classic clinical presentation of 229 
MRONJ is bone exposure with signs of infection, swelling and a purulent discharge (Lopes 230 
RN et al. 2015). Our study has corroborated that MRONJ is more frequent in subjects on 231 
intravenous bisphosphonates as reported elsewhere (Khosla S et al. 2007, Otto S et al. 2012). 232 
The cumulative risk of developing MRONJ was significantly greater in patients receiving 233 
zoledronic acid.  234 
Although no consensus has been reached regarding the mechanism of MRONJ, in the present 235 
study, MRONJ developed either spontaneously or due to dentoalveolar reasons as tooth 236 
extraction, periodontal disease and denture trauma. Previous studies had shown that dental 237 
treatment is a risk factor for developing MRONJ (Hoff AO et al. 2008). In contrast, some 238 
studies had proved that tooth extraction and dentoalveolar surgical procedures aimed at 239 
treating and curing local infections leading to decreased risk for the development of MRONJ 240 
(Saia G et al. 2010, Mozzati M et al. 2013, Otto S et al. 2015). local infections were treated 241 
and overcome by the removal of infected teeth and suspicious bony lesions, and by antibiotic 242 
treatment and mucosal coverage of the extraction wounds, protecting the extraction sockets 243 
from bacterial ingrowth after extraction (Otto S et al. 2015). 244 
One limitation of this study was that there was no control group of untreated MRONJ 245 
patients. In addition, no non-MRONJ patients were characterized for bacterial species. The 246 
number of patients was reduced from 150 to 95 due to the incomplete records or absence of 247 
histopathological, microbiological or PCR diagnosis.  248 
CONCLUSION 249 
The pathogenesis of MRONJ had raised many questions regarding the potential mechanisms 250 
underlying the pathophysiology with special attention to the role of microbial infection. 251 
Actinomyces were the most frequent microorganisms in the disease. However, this does not 252 
necessarily lead to the pathogenic role. PCR was found to be the most reliable method for the 253 
detection of these microorganisms. 254 
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Highlights 
1. We hypothesized that local bacterial infections plays a critical role in the pathogenesis 
of medication-related osteonecrosis of the jaw (MRONJ) 
2. Bacterial profile of MRONJ bone samples was determined using microbiological 
culture and PCR. 
3. Actinomyces were the most frequent microorganisms in the disease. However, this 
does not necessarily lead to the pathogenic role. PCR was found to be the most 
reliable method for the detection of these microorganisms. 
Highlights (for review)
Table 1: Characteristics of patients diagnosed with MRONJ. 
Variable Category Number of patients (%) 
(n=95) 
Age (years) Mean 69.9 ± 8.7 years 
Gender    
 Male 39 (41.1) 
 Female 56 (58.9) 
Primary cause    
 Breast cancer 35 (36.8) 
 Prostate cancer 24 (25.3) 
 Multiple myeloma 10 (10.5) 
 Osteoporosis 13 (13.7) 
 Lung cancer 4 (4.2) 
 Other (Colon, Systemic Mastocytosis, Renal, 
Bladder, Thyroid, Endometrium) 
9 (9.5) 
Comorbidities   
 Diabetes Mellitus 17 (17.9) 
 Cardiovascular disease 29 (30.5) 
 Chemotherapy 57 (60) 
 Irradiation (body) 51 (53.7) 
 Steroid intake 28 (29.5) 
 Antiangiogenic drugs 2 (2.1) 
 Smoking 28 (29.5) 
Antiresorptive drug (ARD)   
Bisphosphonate:  85 (89.5) 
 Zoledronate 58 (61.1) 
 Pamidronate 3 (3.2) 
 Ibandronate 2 (2.1) 
 Combination 22 (23.1) 
Denosumab  10 (10.5) 
Route of administration    
 Intravenous 79 (83.2) 
 Oral 6 (6.3) 
 Subcutaneous 10 (10.5) 
 
Table
Table 2: Characteristics of MRONJ lesions 
Characteristics Number of patients (%) 
Staging of MRONJ  
Stage 0 1 (1.1) 
Stage 1 15 (15.8) 
Stage 2 59 (62.1) 
Stage 3 20 (21.1) 
Clinical presentation  
Pain 81 (85.3) 
Exposed bone 70 (73.7) 
Disturbance in wound healing 55 (57.9) 
Inflammation 54 (56.8) 
Pus 39 (41.1) 
Pathological fracture 9 (9.5) 
Swelling 55 (57.9) 
Fistula 35 (36.8) 
Sinus involvement 13 (13.7) 
Histopathological Features  
Necrotic bone 94(98.9) 
Inflammatory infiltrate 87(91.6) 
Bacterial colonization 67(70.5) 
Location  
Mandible 55 (57.9) 
Maxilla 25 (26.3) 
Both 15 (15.8) 
Triggering events  
Extractions 56 (58.9) 
Dentoalveolar surgery 15 (15.8) 
Denture sore 4 (4.2) 
Periodontal treatment 7 (7.4) 
Spontaneous 13 (13.7) 
 
Table
Table 3: PCR results of MRONJ bone samples 
Culture  
(n=55) 
PCR (n, %) 
Positive Negative 
Positive 18(32.7) 0(0) 
Negative 35(63.6) 2(3.6) 
Total  53(96.4) 2(3.6) 
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Wereadwith great interest the recent article “Diagnosis andManagement of Osteonecrosis of the Jaw: A Systematic
Review and International Consensus” by Khan and colleagues.(1)
Medication-related osteonecrosis of the jaw (MRONJ) is a
potentially severe adverse side effect of antiresorptive agents, and
although a significant body of literature has been produced, there
remains little evidence-based guidance for clinicians with respect to
most aspects of this disease. Therefore, we applaud the attempt of
Khan and colleagues to provide a much-needed systematic review.
However,it isimportantthatanyreviewonthistopicisaddressed
on thebasis of thebest available evidence and abalancedanalysis
of the literature. More importantly, systematic reviews require
rigorous research methods and a clear and transparent presenta-
tion of results in order to limit bias and maximize readability.(2–4)
In the work of Khan and colleagues,(1) we have identified several
issues that we suggest carry a risk of affecting the validity of their
results.
Assessing the risk of bias is a crucial part of systematic
reviews.(5,6) Khan and colleagues presented the criteria they
used to assign level of evidence and grade recommendations,
but unfortunately provided little information regarding
qualitative assessment of reviewed studies, related risk of
bias, as well as the process of article selection. Overall, it is hard
to understand how and why articles were selected or excluded.
The presentation of data on incidence and prevalence makes
the interpretation of the results difficult. It is well established
that incidence data without definition of a time period can be
meaningless;(7) nevertheless, results upon incidence of MRONJ
are in several instances presented without mentioning the
relevant time frame. There are also inconsistencies between
different sections of the article: For example, in the abstract, it is
stated that “in the osteoporosis patient population MRONJ
incidence is estimated at 0.001 to 0.01%,” whereas different
figures are reported in the results (0.15% to <0.001% person-
years of exposure). Furthermore, the authors state that the
prevalence of MRONJ in the oncological setting ranges from “0
to 0.186%” whereas the work of Walter and colleagues, which
they cite, reports a prevalence of 18.6%.(8)
Khan and colleagues report that the incidence of MRONJ in
the osteoporosis population would only be “marginally higher
than the incidence in the general population,” which in the
abstract is reported to be <0.001%.(1) This statement is quite
Received in original form March 1, 2015; accepted April 2, 2015. Accepted manuscript online Month 00, 2015.
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confusing because it remains unclear what they mean by
“incidence of jaw necrosis in the general population.” Possibly
the authors refer to other disorders that may cause jaw necrosis
in the absence of antiresorptive therapy. We wonder whether it
is appropriate to associate different populations with different
disorders when incidence/prevalence is discussed in a system-
atic review. Also, we could not find any clear reference in the text
supporting the reported <0.001% incidence; it remains uncer-
tain where this figure comes from.
We also found it singular and rather unusual for a systematic
review to provide a detailed description of an unrelated, poorly
characterized, and not widely accepted disease entity, namely
oral ulceration and bone sequestration (OUBS).(1) Its relevance to
the intended systematic review on MRONJ remains unclear. The
articles cited in the main part of the paper (Introduction)(9–11) do
not provide convincing evidence regarding the impact this
questionable disease may have upon patients, and certainly
they cannot suggest that a significant portion of cases of MRONJ
could, in fact, represent misdiagnosed OUBS.
The definition of MRONJ continues to cause significant
controversy. Khan and colleagues seem to disregard the
suggestions of different independent research groups who
have called for a change in the traditional definition(12) so as to
include the nonexposed variant of MRONJ,(13–23) which can
represent up to 25% of all cases.(13) We wonder whether the
authors concluded that these articles were in some way flawed
and, therefore, had to be excluded from the systematic review. It
is also rather surprising that they decided not to embrace the
revised 2014 AAOMS consensus, which agrees that individuals
presenting with bone that can be probed via sinus tracts do fit
MRONJ definition.(24)
With respect to MRONJ treatment, readers would expect a
systematic review toprovide a balanced and fair comparisonof the
outcomes of different interventions, both surgical andnonsurgical.
However, Khan and colleagues suggest that “conservative therapy
is the mainstay of care” with no robust convincing evidence in
support of this statement. Althoughwe agree that there is a lack of
consensus, as well as very little information on the outcomes of
denosumab-related ONJ, we think that this review does not
provide a fair and comprehensive summary of current knowledge
and available evidence.
For example, whenmucosal healing is considered the primary
outcome,(25–28) a number of articles have reported that less than
one-third of patients managed with long-term conservative
treatment, especially in the oncological setting, would show
evidence of mucosal healing (23% and 14.9% of Hoff and
colleagues(29) and Nicolatou-Galitis and colleagues(30) case
series, respectively). This means that the majority of MRONJ
patients managed conservatively would present persistent
jawbone exposure, which not only can affect their quality of
life(31) but may also limit the oncological treatment options,
including further antiresorptive treatment.(32,33) Although
conservative treatment might be adequate to slow down
disease progression and control pain and infections, there is
increasing evidence supporting surgical treatment protocols.
Case series from different research groups report percentages of
mucosal healing that are consistently around and above 80%,
with outcome endpoints ranging from 3months to 7 years post-
treatment. Examples include Carlson and colleagues (92%), (26)
Stockmann and colleagues (89%), (34) Bedogni and colleagues
(90%), (35) Schubert and colleagues (89%), (36) and Jacobsen and
colleagues (78%). (37) Comparative studies also seem to confirm
these results.(38,39) Finally, both the systematic review by Rupel
and colleagues(40) and another recent systematic review
meeting PRISMA guidelines(6) suggest that surgical therapy
can be superior to conservative management.(41)
We feel that these are important aspects completing the
review of Khan and colleagues.(1)
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Background: This article represents the first systematic review entirely dedicated toward a disease called
oral ulceration with bone sequestration (OUBS). We performed this review in order to further define and
outline this disease. A secondary interest was to recognize the prevalence and importance of OUBS in
relation to other oral disorders accompanied by ulceration and bone exposure.
Material and methods: The systematic review was registered with PROSPERO (registration number
CRD42015024294) and performed in cooperation with Harvard's Countway Library. Searches were built
using MeSH terms and proximity operators previously mentioned in OUBS descriptions. Database
searches were performed through EMBASE, Medline, and PubMed, followed by a handsearch of bibli-
ographies for relevant articles. Articles were assessed against eligibility and inclusion criteria centering
on bone exposure without known etiologic cause. We sought to gather information on patient age, sex,
anatomical location, clinical presentation, and comorbidities. PRISMA guidelines were followed.
Results: The searches identified 766 records total. Despite considerable inspection, we found only 8
articles qualifying for our review. In the 8 articles, there were a total of 24 patients fulfilling the criteria of
OUBS. Although some abstracts mentioned idiopathic nature, most authors presented clinical cases with
probable causes to ulceration and sequestration. The mean age of these patients was 43.21 ± 11.94 years.
The male to female ratio was 3:1. The predominant area of occurrence was the mandible (n ¼ 23, 95.8%).
Conclusion: The representation of OUBS in the literature remains scarce. More data must be generated
and gathered on the concept of OUBS so as to determine the true incidence and importance of this
disease. Despite rare occurrences of conditions characterizing OUBS, the recent discussion of this topic in
the scientific community calls for more knowledge to be brought forth, with great benefit to patients
suffering from ulcerative diseases and osteonecrosis.
© 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Oral ulceration with bone sequestration (OUBS) has been used
variably by authors and practitioners to characterize oral ulceration
and bone sequestration without an etiologic cause (Khan et al.,
2015). The most common locations reported for ulceration and
subsequent bone exposure occur at the mylohyoid ridge, mandib-
ular tori, palatal tori, and mandibular exostosis (Farah and Savage,
2003). No precise definition for OUBS has been provided oraxillofacial Surgery, Ludwig-
a, 80337 Munich, Germany.
(S. Otto).
axillo-Facial Surgery. Published byaccepted, and there has been recent debate in the literature per-
taining to the disorder's conceptualization (Khan et al., 2015; Otto
et al., 2015a). It is a rare condition which contains cases previ-
ously recognized by the term ‘lingual mandibular sequestration and
ulceration’ (Peters et al., 1993). Almazrooa and Woo (2009) define
OUBS as, “spontaneous sequestration of the lingual mandibular
bone, usually in the area of the mylohyoid ridge, in patients with no
significant underlying systemic condition.” Previously, to the best
of our knowledge, only one review has been attempted on OUBS
(Khan et al., 2015).
The objective of this current systematic review was to distin-
guish between various ulcerative disorders of the oral cavity and
that of OUBS. Although oral ulceration is common, it is normally
self-limiting and the progression to bone exposure andElsevier Ltd. All rights reserved.
B. Palla et al. / Journal of Cranio-Maxillo-Facial Surgery 44 (2016) 257e264258sequestration is extremely rare (Farah and Savage, 2003). Medical
practitioners still must be aware of the local, systemic, and
anatomical predispositions which lead to increasingly destructive
ulcerative disorders. Our secondary interest concerned assessing
the prevalence and importance of OUBS in relation to other oral
maladies associated with bone exposure. The determination of a
general prevalence value will be significant since OUBS has
recently been stressed as a potential differential diagnosis per-
taining to ONJ (Khan et al., 2015). We sought to collect articles and
case reports mentioning idiopathic bone exposure or sequestra-
tion in order to begin constructing a framework for characterizing
this concept.
2. Materials and methods
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Moher et al., 2009). Searches were
conducted on 13th July 2015 after being registered with PROSPERO
(registration #CRD42015024294). No date limits were applied for
the beginning of the search in order to obtain all relevant articles.
Research experts at Harvard's Countway Library were consulted for
expertise in article identification. Databases were screened based
on the MeSH and Emtree terms developed in conjunction with
Harvard's Countway Library. The search was ended on 13th July
2015.
We searched Embase, MEDLINE, and PubMed for articles that
mentioned key words for oral ulceration with exposed, necrotic,763 records 
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Fig. 1. Flow chart foridiopathic, unexplained, spontaneous, or sequestered bone.
Controlled vocabulary terms (both MeSH and Emtree) were used
when available and appropriate. Searches were linked by OR op-
erators and intersections of concepts linked consecutively with
AND statements. Proximity operators (NEAR/n) allowed for detec-
tion of words possibly combined in unpredictable ways. Appendix 1
contains search algorithms used. Each search contains field tags
which tell interfaces which indexes to search. A final handsearch
through bibliographies of relevant articles was conducted in order
to accumulate as much information on OUBS as possible.
Inclusion criteria were met if: 1) the abstract made any discus-
sion on oral ulceration and bone sequestration without providing
an etiologic cause; 2) an ‘idiopathic’ or an ‘unknown’ etiology was
stated in the abstract regardless of pathologic mechanisms dis-
cussed; 3) full article in English language was available. Records
were excluded if one of the following criteria pertained: 1) lan-
guage other than English; 2) pertaining diagnostic methods unre-
lated to OUBS; 3) pertaining to animals and unrelated to OUBS; 4)
pertaining to therapy unrelated to OUBS; 5) pertaining to topics
irrelevant to OUBS; 6) etiologic cause of oral ulceration or bone
sequestration was given in abstract (i.e. antiresorptive drugs,
osteomyelitis, osteoradionecrosis, trauma, neoplasia, etc). This
systematic review followed the PRISMA guidelines (6).
3. Results
The searches returned a total of 766 records. After duplicates
were removed, 726 records remained (Fig. 1). All 726 articles wereitional records 
tified through 
ndsearch
40 duplicate 
records
712 Records Excluded:
● 4 non-English
● 29 Diagnostic
● 45 Animal
● 47 Therapeutic
● 111 Irrelevant
● 476 Etiology Given
6 Records Excluded:
● 1 Book chapter (6)
● 1 Meeting Presentation (7)
● 1 Supplement (8)
● 1 Unrelated (9)
● 2 Review Articles (1, 2)
record selection.
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based on the exclusion criteria. Of the records excluded, 4 were not
in English, 29 discussed diagnostic material unrelated to OUBS, 45
pertained to animals, 47 discussed therapy unrelated to OUBS, 111
were irrelevant to the topic, and 476 discussed or specified an
etiology. These etiologic causes occurred individually and in com-
bination within categories associated with infection: bacteria and
osteomyelitis (118 records), fungal (9 records), viral (7 records),
myiasis (2 records); treatment: systemic medications such as
bisphosphonates (155 records), denosumab (4 records), and other
drugs including antiangiogenic agents (11 records), drugs such as
cocaine and Krokadil (5 records), osteoradionecrosis (18 records);
trauma (8 records); and alternative causes such as neoplasia (63
records), congenital or genetic defects (39 records), autoimmune or
autoinflammatory (23 records), avascular necrosis (5 records), and
other various bone disorders (9 records). A post-analysis term
search for ‘idiopathic’was performed and identified 20 abstracts in
which it was used as a descriptor, however none of these articles
made it to the final inclusion stage. This selection process left 14
records eligible for full-text review.
Of these 14 articles, 8 were synthesized in the qualitative
analysis (Table 1 and Supplement 1& 2). Six papers were excluded:
Huebsch (1965) was not available electronically, was published in
1965, and did not specify idiopathic causes. Two records by Khan
(2014); Khan et al. (2013) were excluded because one was a con-
ference presentation and the other a supplemental document.
Boffano et al. (2012) was excluded because although mentioning
idiopathic causes of mandibular fractures in the abstract, the paper
itself made no mention of idiopathic pathologies. Two papers
pertained to OUBS andwere valuable in its conceptualization (Khan
et al., 2015; Farah and Savage, 2003), however, neither article
presented new clinical cases on OUBS so they were not included in
the analysis. The 8 remaining articles presented 24 different patient
cases in total.
Papers were read in full to extract information for the comple-
tion of Table 1. If an article failed to present information or char-
acteristics of the clinical presentation we identified and calculated
it as absent in the table. Nometa analysis was performed due to low
number of cases and the possibility of ascertainment bias in these
patient's access to care. Racial categories were excluded due to
outdated terms (i.e. Mongoloid, East Indian) used in older articles.
Readers can also consider implications of notoriety bias with ONJ,
discussed by De Boissieu et al. (2014). However, as this bias regar-
ded bisphosphonates in relation to chemotherapeutic agents and
not idiopathic causes, its relevance to OUBS was minimal.
In the 8 articles, there were a total of 24 patients fulfilling the
criteria of OUBS. Quantitative data was reported but is supported
only through qualitative descriptions as the literature contained
insufficient power (n < 30). The mean age of these patients was
43.21 ± 11.94 years. Therewas amale predilection in the ratio of 3:1
as there were 18 male patients (75%) and 6 female patients (25%).
The most common location was the mandible (n ¼ 23, 95.8%), with
one case occurring in both the maxilla and mandible (n ¼ 1, 4.2%),
and no cases occurring solely in the maxilla (n ¼ 0, 0.0%). Comor-
bidities that were detected in the patients included: 4 patients
presenting with systemic disease (rheumatoid arthritis, glomer-
ulosclerosis, type II diabetes, allergic disorder), 3 patients presented
with infections (periodontitis, actinomyces infection), and 2 pa-
tients receiving relevant medications (prednisolone and
bisphosphonates, and methotrexate). The most common predis-
posing factors were loss of lingual inclination in 9 patients (ex-
tractions, restoration, missing teeth), exostoses and tori in 8
patients, or 6 patients with other causes (1 with bruxism, 1 with
foreign particulate, 1 with periodontal scaling, 2 with minor aph-
thous stomatitis, and 2 with a stress-induced tongue thrust habit),as well as no causes indicated in 6 cases. Clinically, all 24 patients
presented with bone sequestration. Some clinically relevant infor-
mation was missing and marked as absent, as such, 17 cases con-
tained descriptions of ulceration (n ¼ 17, 70.8%), 3 cases described
no ulceration (n¼ 3,12.5%), and 4 cases did not present information
on ulceration (n¼ 4, 16.7%). Bone exposurewas explicitly described
in 11 cases (n ¼ 11, 45.8%), and sinus tract involvement was spec-
ified in 2 patients (n ¼ 2, 8.3%).
None of the articles included in the study contained reliable
information on the prevalence or incidence of OUBS in the general
population. Due to limited number of patients identified and
without data regarding the underlying general population, no
calculation of prevalence or incidence could be performed.
4. Discussion
This systematic review attempted to distinguish between OUBS
and other oral ulcerative disorders, as well as to assess the preva-
lence and importance of OUBS. OUBS has recently been stressed
with more attention as a differential diagnosis for osteonecrosis of
the jaw (ONJ). There is a high prevalence of oral soft tissue lesions in
the general population, although progression to bone sequestration
is extremely rare (Shulman et al., 2004). Multiple risk factors can
cause the accumulation and perpetuation of ulcers however, in
which local and systemic factors can lead to sequestration via in-
dependent pathomechanisms. These cases present frequently to
health clinics and it is essential that medical practitioners are aware
of the underlying disorders in their provision of treatment. OUBS is
a recent concept to the osteologic field and this report aims to
clarify its conceptualization and understanding.
The rare occurrence of OUBS, its poor representation in the
literature, differing definitions and descriptions by authors, lack of
understanding or awareness by practitioners, and perhaps inade-
quate retrieval methods from the literary searches above limit the
power of this review. Further limitations to the retrieval of relevant
articles pertain to a publication bias in which disorders with un-
determined causes would be less likely to be written up by prac-
titioners, and less likely to be published by journals. We chose
broad terms in our search which would underlie descriptions of
OUBS. However, we found this terminology used in a wide array of
abstracts. For instance, the term idiopathic was alone used as a
descriptive term by authors in 20 abstracts, none of which made it
to our qualitative analysis. Frequently records came up for medi-
cation related osteonecrosis of the jaw (MRONJ) cases in which
authors used the terms idiopathic in a non-specific manner.
Although we were searching for OUBS we found many more re-
cords concerning disorders such as bisphosphonate related osteo-
necrosis of the jaw (BRONJ), osteomyelitis, osteoradionecrosis,
neoplasia, and other bone disorders (Lee et al., 2015; Mücke et al.,
2015; Otto et al., 2015b).
We identified 8 articles pertaining to disorders which could be
classified as OUBS. Although most authors describe an idiopathic
disorder in the abstract, all but two articles contained detailed
clinical presentations which described and discussed some distinct
ulcerative etiology. Furthermore, many articles even discussed the
role of these local and systemic factors pertaining to the patient
case, as well as the pathological process which linked such an ul-
cerative event to bone sequestration.
We determined a predilection for middle age (mean
43.21 ± 11.94 years), with only 1 case occurring in a patient under
32 years old. This finding is supported with the knowledge that
ulcerations are more likely to occur with age, occurring due to
weakening mucosa and impaired immunity and increased proba-
bility of losing teeth (Dhanuthai et al., 2015). It was also muchmore
likely that males suffered from ulceration and bone sequestration
Table 1
Qualitative analysis.
Article Case # Age Sex Anatomical location Clinical presentation Comorbidities
Carrard et al.,
2009 (24)
1 38 Male Bilateral exostoses in mandibular
lingual molar area
Bilateral ulcerations (15  7 mm)
with exposed necrotic bone
sequestrum; symptomatic 1 month
Bilateral exostoses in lingual mandibular
cortical bone; Bruxism
Flaitz, 2000 (29) 1 56 Female Left lingual mucosa covering
mylohyoid ridge near left molars
Ulcer (3  8 mm) with exposed
necrotic bone sequestrum;
symptomatic 2 months, worsening
last 2 weeks
Rheumatoid arthritis managed with prednisone
and methotrexate
Jackson and
Malden
(2007) (20)
1 41 Male Right lingual mucosa covering
mylohyoid ridge near molars
12 mm ulceration and exposed
necrotic bone sequestrum;
symptomatic 1 week
1 week post-extraction #48; #47 also missing
2 57 Male Right lingual mucosa covering
mylohyoid ridge and molar region
15 mm ulceration and exposed
necrotic bone sequestrum;
symptomatic 1 week
1 month post-extraction #47; food debris
present
3 48 Male Left lingual mucosa covering
mylohyoid ridge near molar region
12 mm ulceration and exposed
necrotic bone sequestrum;
symptomatic 2 months
Glomerulosclerosis managed with prednisolone
and alendronic acid, actinomyces-like infection
Kessler (2005)
(30)
1 40 Male Right lingual mucosa covering
mylohyoid ridge near molar region
Ulceration and exposed necrotic
bone sequestrum; symptomatic 3
weeks
None described by practitioner
Koshal et al.
(2010) (16)
1 5 Male Left mandibular buccal alveolus
with deciduous canine and first
molar (#73 & #74)
Demarcated, necrotic, non-healing
alveolar bone division;
symptomatic 2 months
None described by practitioner
Peters et al.
(1993) (4)
1 53 Female Lingual mucosa covering
mylohyoid ridge
3mm ulcer with 2mm sequestrum;
symptomatic 12 weeks
None described by practitioner
2 55 Male Lingual mucosa covering
mylohyoid ridge
3mm ulcer with 3mm sequestrum;
symptomatic 8 weeks
Type II Diabetes
3 42 Female Lingual mucosa covering
mylohyoid ridge
3 mm sequestrum; symptomatic 3
weeks
Bilateral mandibular tori; missing first molar
4 32 Male Lingual mucosa covering
mylohyoid ridge
3e4 mm ulcer with 4 mm
sequestrum; symptomatic “few
months”
Missing first and third molar
5 50 Female Lingual mucosa covering
mylohyoid ridge
4 mm sequestrum None described by practitioner
6 34 Male Lingual mucosa covering
mylohyoid ridge
3 mm sequestrum; symptomatic 2
weeks
None described by practitioner
7 33 Male Lingual mucosa covering
mylohyoid ridge
8mm ulcer with 6mm sequestrum;
symptomatic 1 week
Restorations 1 week prior to onset
8 47 Male Lingual mucosa covering
mylohyoid ridge
6 mm sequestrum None described by practitioner
9 57 Male Lingual mucosa covering
mylohyoid ridge
3mm ulcer with 2mm sequestrum;
symptomatic 3 weeks
Missing second and third molar
10 55 Female Lingual mucosa covering
mylohyoid ridge
4 mm ulcer with 10 mm
sequestrum
Bilateral mandibular tori; Missing all posterior
molars
11 40 Male Lingual mucosa covering
mylohyoid ridge
8mm ulcer with 3mm sequestrum;
symptomatic 2 weeks
Bilateral mandibular tori; Missing third molar;
Hypertension controlled with medication;
recent flu
Scully
(2002a,b) (14)
1 45 Male Inferior to left mandibular lingual
oblique ridge
5mm ulcer with 3mm sequestrum;
symptomatic 5 days
Scaling session few days prior to onset; minor
aphthous stomatitis
2 53 Male Inferior to left mandibular lingual
oblique ridge
5mm ulcer with 4mm sequestrum;
symptomatic 10 days
History of minor aphthous stomatitis
Sonnier and
Horning
(1997) (15)
1 32 Male Left lingual mucosa near tooth #34 Ulceration with 3 bony lesions on
central tori; symptomatic 4 months
Bilateral mandibular tori; Stressful habit
(tongue thrush) during periodontal residency
2 53 Male Bilateral mandibular lingual
mucosa
10 mm ulcers bilaterally with
necrotic bone sequestrum;
symptomatic 2 weeks
Exostoses present along entire lingual
mandible; Periodontitis (4e7 mm probing
depth)
3 38 Female Right lingual mucosa on
mandibular near teeth #45 and #46
No ulceration, 3 sinus tracts leading
to multiple bony lesions
(5  15  1 mm) on exostoses;
symptomatic 2 weeks
Exostoses present near tooth #45 and #46;
multiple restorations
4 33 Male Biopsy on facial gingiva near teeth
#15 and #16; sequestrum near
tooth #28; sequestrum near sinus
tract of tooth #26
No ulceration, 1 sinus tract,
3  2  1 mm sequestrum;
symptomatic 1 month
Allergic gingivitis\mucositis; Periodontitis (5
e7 mm probing depths); Early multifocal
osseous dysplasia; Vasculitis; Hyperplasia with
intermittent exostosis
*Tooth numbering according to the FDI World Dental Federation notation.
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reasons from increased alcohol consumption, tobacco use,
increased masticatory loads, prominent mylohyoid ridge, but none
of these can be discussed with adequate power.
After review it was noted that this area of research has three
foundational papers, Peters et al. (1993), Scully (2002a,b), and
Sonnier and Horning (1997). We identified only one article, Koshaland the presenting 5 year-old patient, which was not reliant on
these authors for substantiation (Koshal et al., 2010). The significant
role these papers continue to sustain should call for critical review.
These articles were published in 1992, 1997, and 2002, respectively.
The advancement in molecular pathology, cytopathology, and his-
topathology over the past decade is not part of the case reports and
disease identification process. Furthermore, some descriptions
B. Palla et al. / Journal of Cranio-Maxillo-Facial Surgery 44 (2016) 257e264 261were performed retrospectively, lacking information on clinical
presentation, anatomical location, and possible risk factors. Inter-
estingly, these foundational articles stress ulcerative risk factors
such as trauma, infection, systemic disorders, neoplasia, anatomical
predispositions, and others. This retrieval process has indicated
that many authors are using the term idiopathic (as well as spon-
taneous, unexplained, etc.), when actually discussing cases with
these identifiable predisposing factors. Finally, these papers pre-
sent only 17 patients total and with little published literature
recently, authors have been overly reliant on these papers. Some
authors have even cited letters to the editor such as Scully
(2002a,b), Friel and Macintyre (2002), and Dhanrajani (2008) for
validation of the OUBS concept.
Oral ulcerations are quite common in the general population.
Although most ulcers resolve within a few days to weeks, the high
prevalence causes frequent presentation to medical practitioners
for evaluation and proper treatment. Ulcerative events occur due to
a combination of predisposing factors. Anatomically, the mylohyoid
ridge of the lingual mandible is the most common area associated
with OUBS, secondary being mandibular tori followed by
mandibular exostoses (Farah and Savage, 2003). These areas are
prone to ulceration as the mucosa which covers these prominences
is stretched thin and harbors minimal amounts of connective tissue
(Chanavaz, 1995). The lack of connective tissue predisposes these
areas to ulceration from sudden or chronic trauma, while the
decreased blood supply allows for progressive ulceration via
impaired abilities to heal and fight infections (Chanavaz, 1995).
As authors have previously mentioned, there is a pathological
link between ulceration and the subsequent bacterial colonization
which results an avascular insult (Farah and Savage, 2003; Carrad
et al., 2009; Otto et al., 2015a). Similar to the predisposition of
the mucosa, the cortical bone of the maxilla and mandible is far
removed from the alveolar blood supply (Chanavaz, 1995). Tori andTable 2
Risk factors of ulceration and bone sequestration.
Category Condition
Infection
Bacterial Actinomyces (Kaplan et al., 2009); Syphilis (Scott and Flint, 2
Viral EBV (Dojcinov et al., 2010); HCV (Carrozzo and Scally, 2014);
Fungal Aspergillus (Sugata et al., 1994); Candidiasis (Garcia-Cuesta e
Parasitic Leishmaniasis (Nadler et al., 2014); Myiasis (Moshref et al., 2
Treatment
Systemic Medications Antiangiogenic Agents, Bisphosphonates, Denosumab, TKIs, m
Corticosteroids (Mouries et al., 2013); Immunosuppressants
Direct Toxicities Dental Agents (arsenic paste (Chen and Sung, 2014) and formo
2002)
Radiation Osteoradionecrosis (Reuther et al., 2003)
Trauma
Dental Trauma Dentures (Martori et al., 2014); Toothbrushing (Endo et al., 2
Mastication Trauma Predisposing Factors: Exostoses of Mandible (Kermer et al., 19
Missing Teeth; Loss of Lingual Inclination; Clenching/Grindin
Other Procedural Trauma/Intubation (Almazrooa et al., 2010); Vom
Gingival Injury (Alonso Chevitarese et al., 2004)
Other
Neoplasia Adenocarcinoma (Orlandi et al., 2007); Sarcomas (Hagstr€om e
2012); Burkitt's Lymphoma (Ferry, 2006)
Immunogenic Diabetes (Silva et al., 2015); Crohn Disease (Rowland et al., 20
et al., 2012); Wegener's Granulomatosis (Genuis and Pewarc
Behçet's Disease (Unizony et al., 2015); Lichen Planus (Gupta
Bone Disorders Systemic Sclerosis (Nagy et al., 1994); Osteopetrosis (Albuqu
Dysplasia (Rekabi et al., 2013); CNO (Winters and Tatum., 20
Congenital\
Genetic Defects
Gorham's Disease (Reddy and Jatti, 2012); Paget's Disease (P
Arteriovenous Malformations (Churojana et al., 2012); Conge
Granulomatous Disease (Dar-Odeh et al., 2010); Cherubism (
Other Avascular Necrosis (Nguyen and Heggie, 2014); Recurrent Ap
Neutropenia (Shete et al., 2012); Pyoderma Gangrenosum (P
Hyperparathyroidism (Praveen and Thriveni, 2012); Hypothy
(Dhanuthai et al., 2015); Excessive Tobacco or Alcohol (Chanexostoses only further exaggerate this lack of perfusion, length-
ening the ischemic insult and slowing healing process which will
result in necrosis. Finally, the posterior mandible harbors a large
number of bacteria and debris due to decreased flexibility of the
tongue and increased masticatory loads which lead to trauma and
chronic irritation (Farah and Savage, 2003). Indeed, many of the
histologic reports in this review specified high bacterial infiltrates
in the sequestered bone.
For the identification of ulcerative risk factors, Almazrooa and
Woo (2009) have provide a basic outline for which we have
expanded upon in Table 2. The staging and treatment of OUBS
would be unproductive. As OUBS includes multiple disorders of
various etiology, patients care would be more effective when
specified at the underlying causes. Healthcare professionals must
identify the comorbidities and varying combination of risk factors
which each case presents. This treatment, specified toward the
management of a specific risk factors, is more beneficial. For
instance, lesions caused by recurrent aphthous stomatitis (RAS)
will require an antibacterial mouthrinse (Tarakji et al., 2015),
mandibular and palatal tori may require surgical removal (García-
García et al., 2010), loss of lingual inclination will require pros-
thetic rehabilitation and dental realignment, osteomyelitis can be
treated from antibiotic treatment to decortication (Agarwal et al.,
2014), and the treatment of cases related to bisphosphonates or
denosumab will vary from conservative measures to invasive sur-
gery depending on the stage and severity.
As cytologic, histologic, and pathologic innovations continue
and electronic records maintain full patient reports, previously
classified ‘idiopathic lesions’will continue to move towards various
established etiologies. The idiopathic label is retreating and giving
way to more scientific classifications. OUBS is such a label, and
patients stand to benefit muchmorewhen their treatment is aimed
at their explicit disorder and known disease pathogenesis. When005); Tuberculosis (Andrade and Mhatre, 2012)
HIV (Reznik, 2005); HSV (Arduino and Porter, 2008); VZV (Mendieta et al., 2005)
t al., 2014); Mucormycosis (Rahman et al., 2013)
008)
TOR inhibitors (Hamadeh et al., 2015); Calcium Antagonists (Cohen et al., 1999);
(Lopez-Pintor et al., 2010)
cresol (Ege et al., 2014)) HeavyMetals (Dunsche et al., 2003); Cocaine (Seyer et al.,
006); Impaction (Prodromidis et al., 2011)
96); Mandibular or Palatal Tori (Cortes et al., 2014); Prominent Mylohyoid Ridge;
g/Bruxism (Sirirungrojying and Kerdpond, 1999)
iting (Russo et al., 2008); Foreign Body Entrapment (Ho et al., 2010); Self Inflicted
t al., 2011); Leukemia (Vourexakis, 2015); Lymphoma (NK\T\B Cell) (Darling et al.,
10); Ulcerative Colitis (Elahi et al., 2012); Arthritis (Kato et al., 2014); SLE (Khatibi
huk, 2014); SAPHO (Scully et al., 2008); GVHD (Margaix-Mu~noz et al., 2015);
and Jawanda, 2015)
erque et al., 2006); Cemento-Osseous Dysplasia (Rao et al., 2014); Florid Osseous
14); CRMO (Monsour and Dalton, 2010)
olisetti et al., 2014); Acatalasia (Delgado and Calderon, 1979); Maxillomandibular
nital Insensitivity to Pain with Anhidrosis (Fruchtman et al., 2013); Chronic
Mehrotra et al., 2011)
hthous Stomatitis (Akintoye and Greenberg, 2014); Anemia (K et al., 2014);
aramkusam et al., 2010); Perry-Romberg Syndrome (Al-Aizari et al., 2015);
roidism or Hyperthyroidism (Chandna and Bathla, 2011); Age Extremities
dra and Govindraju, 2012); Malnutrition (Thomas and Mirowski, 2010)
B. Palla et al. / Journal of Cranio-Maxillo-Facial Surgery 44 (2016) 257e264262no etiology is apparent, we should no longer default to an unex-
plained cause. Therefore moving forward, we propose that the ul-
cerative disorders currently identified by the label OUBS should be
separately classified as distinct processes. OUBS can maintain its
idiopathic conception but more material, knowledge, and cases
must be generated, presented, and discussed.
5. Conclusion
Similar to the call by other authors, there needs to be further
discussion on the topic of OUBS. Furthermore, more clinical data is
necessary. Both institutions and practitioners should identify and
publish cases of ulceration and bone sequestration taking care to
note the formatted information of Table 1 and the etiologies pro-
vided in Table 2. The current findings of this systematic review
demonstrate that the OUBS concept cannot be regarded as one
distinct entity, but rather it incorporates multiple, ulcerative dis-
orders occurring in various locations, and due to a variety of both
local and systemic effects. Practitioners must acknowledge many
etiologic causes of ulceration, the predisposition for certain
anatomical areas and abnormalities, and the link between ulcera-
tion and the subsequent insult leading to bone sequestration.
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Appendix 1. Search Algorithms
Search A
Embase, MEDLINE in Embase.com (Elsevier)
13 July 2015, 584 records
(((oral OR mouth OR lingual OR palatal OR palate OR mandibl*
OR maxilla* OR buccal OR jaw) NEAR/9 (lesion* OR ulcer*)):ab,ti OR
'mouth ulcer'/exp)
AND
(((necro*ORsequest*ORexposedORexposure)NEAR/4 (bone*OR
mandib*ORmaxill*OR jaw)):ab,tiORosteonec*:ab,tiOR (osteoNEXT/
1 necrot*):ab,ti OR osteomyelitis:ab,ti OR 'jaw osteonecrosis'/exp OR
'osteomyelitis'/exp OR 'osteonecrosis':de OR 'osteomyelitis':de)
Search B
PubMed
13 July 2015, 10 records
((oral[tiab] OR mouth[tiab] OR lingual[tiab] OR palatal[tiab] OR
palate[tiab] ORmandibl*[tiab] ORmaxilla*[tiab] OR buccal[tiab] OR
jaw[tiab]) AND (lesion*[tiab] OR ulcer*[tiab]))
AND((necro*[tiab] OR sequest*[tiab] OR exposed[tiab] OR exposure
OR osteonec*[tiab] OR osteo necrot*[tiab] osteomyelitis[tiab]) AND
(bone*[tiab] OR mandib*[tiab] OR maxill*[tiab] OR jaw[tiab]))
NOT
medline[sb]Search C
EMBASE
13th July 2015, 169 records
idiopathic:ab,ti OR unexplained:ab,ti OR spontaneous:ab,ti OR
((unknown OR unexplained) NEAR/3 (cause* OR etiolog*)):ab,ti
AND (((necro* OR sequest* OR exposed OR exposure) NEAR/4
(bone* OR mandib* OR maxill* OR jaw)):ab,ti OR osteonec*:ab,ti OR
osteo AND necrot*:ab,ti OR osteomyelitis:ab,ti OR 'jaw osteonec-
rosis'/exp OR 'jaw osteonecrosis' OR 'osteomyelitis'/exp OR 'osteo-
myelitis' OR 'osteonecrosis':de OR 'osteomyelitis':de) AND
(oral:ab,ti OR mouth:ab,ti OR lingual:ab,ti OR palatal:ab,ti OR pal-
ate:ab,ti OR mandibl*:ab,ti OR maxilla*:ab,ti OR buccal:ab,ti OR
jaw:ab,ti)Search D
Handsearch
13the20th July 2015, 3 recordsAppendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jcms.2015.11.014.References
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Abstract: 
Craniofacial bone defects are challenging problems for maxillofacial 
surgeons over the years. With the development of cell and molecular 
biology, gene therapy is a breaking new technology with the aim of 
regenerating tissues by acting as a delivery system for therapeutic genes 
in the craniofacial region rather than treating genetic disorders. A 
systematic review was conducted summarizing the articles reporting gene 
therapy in maxillofacial surgery to answer the question: Was gene therapy 
successfully applied to regenerate bone in the maxillofacial region? 
Electronic searching of online databases was performed in addition to 
hand-search of the references of the included articles. No language or time 
restrictions were enforced. Meta-analysis was done to assess significant 
bone formation after delivery of gene material in the surgically induced 
maxillofacial defects. The search identified 2081 articles of which 57 were 
included with 1726 animals. Bone morphogenetic proteins (BMPs) were 
commonly used proteins for gene therapy. Viral vectors were the 
universally used vectors. Sprague-Dawley rats were the frequently used 
animal model in experimental studies. The quality of the articles ranged 
from excellent to average. Meta-analysis results performed on 21 articles 
showed that defects favoured bone formation by gene therapy. Funnel plot 
showed symmetry with the absence of publication bias. Gene therapy is on 
the top list of innovative strategies that developed in the last 10 years with 
the hope of developing a simple chair-side protocol in the near future 
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combining improvement of gene delivery as well as knowledge of the 
molecular basis of oral and maxillofacial structures. 
  
 
 
Page 1 of 62
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly/Not for Distribution1 
 
ABBREVIATIONS 
µCT: Micro computed tomography β-TCP: beta tricalcium phosphate 
911 helper: human embryonic retinoblasts 293FT: human embryonic kidney cells with the SV40 
large T antigen 
AAV: Adeno-associated virus,  ADSCs: Adipose derived stem cells 
ALP: Alkaline phosphatase AV: Adenovirus 
b-FGF: Basic fibroblast growth factor BGC: Bioactive glass ceramic 
BMD: Bone mineral density BMMSCs: Bone marrow mesenchymal stem cells 
BMP-2: Bone morphogenetic protein 2 BMP-4: Bone morphogenetic protein 4 
BMP-7: Bone morphogenetic protein 7 BMP-9: Bone morphogenetic protein 9 
CHA: Coral hydroxyapatite CFSE: Carboxyfluorescein diacetate 
succinimidyl ester 
CMPC: Calcium magnesium phosphate cement CRE8: Cre-expressing 293 cells 
EGFP: Enhanced green fluorescence protein DPSCs: Dental pulp stem cells 
FACS: Fluorescence-activated cell sorting ERR: External root resorption 
FEA: Finite element analysis ELISA: Enzyme linked immunosorbent assay 
HA/TCP: Hydroxyapatite/beta-tricalcium 
phosphate 
GAM: Gene activated matrix 
HGF: Hepatocyte growth factor,  HA/COL: Hydroxyapatite/ Collagen 
HVJ: hemagglutinating virus of Japan HA/PA: hydroxyapatite/polyamide 
IGF 1: Insulin growth factor HEK293: human embryonic kidney 293 cell line 
LMP-3: LIM mineralization protein 3,  HIF-1α: hypoxia-inducible factor-1 alpha 
MKP-1: Mitogen-activated protein kinase phosphatase 
1 
iPSCs: Induced pluripotent stem cells 
MBG: Mesoporous bioglass IFU: infectious units per ml 
N/R: Not reported LacZ: β-galactosidase 
NGF-β: Nerve growth factor beta Luc: firefly luciferase 
NNB: Natural non-organic bone MOI: multiplicity of infection 
OF: Orthodontic force mSS: Premineralized silk fibroin protein scaffolds 
OSX: Osterix NB: Nano-bubbles 
OSTEOBONE: Calcium silicon phosphorus NIH3T3: mouse embryo fibroblast 
pOBs: Periosteal derived osteoblasts NOD/SCID mice: non-obese/severe combined 
immunodeficient 
PBS: Phosphate buffered saline OPG: Osteoprotegrin 
PDGF-A: Platelet derived growth factor A PCR: Polymerase chain reaction 
PDLSCs: Periodontal stem cells PDGF-B: Platelet derived growth factor B 
PFU: plaque forming unit PDLA: Poly D, L-lactide 
Pg-LPS: lipopolysaccharide mediated bone loss PF127: Pluronic F127 
RANKL: Receptor activator of nuclear factor kappa-B 
ligand 
PG13: mouse embryonic fibroblast 
Runx2: Runt-related transcription factor 2 PLGA: Poly lactic co glycolic acid 
SEM: Scanning electron microscope RSV: respiratory syncytial virus 
TM: Tooth movement SDF: syngeneic dermal fibroblasts 
TRAP: Tartrate resistance acid phosphatase TGF-b: Transforming growth factor beta 
TU: Transduction units TNFR: Tumour necrosis factor alpha receptor  
VEGF: Vascular endothelial growth factor TSG-6: Tumour necrosis factor alpha-stimulated gene-
6 
WEHI 164: mouse skin fibroblast US: Ultra-sound 
JM 109: Escherichia Coli  WB: Western Blot 
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INTRODUCTION 1 
Craniofacial anomalies and bone defects resulting from bone loss due to trauma, 2 
reconstructive surgery, neoplasia, congenital defects, infection or periodontal disease present 3 
a difficult and challenging problem for maxillofacial surgeons and scientists over the years 4 
with the goal of restoring facial form, function and occlusion. Conventional therapies are 5 
directed towards maxillofacial surgery, the use of prostheses or bone grafts. However, the 6 
effectiveness of these techniques is constrained by donor site morbidity, high cost and 7 
insufficient tissue resources. Recently, it had been agreed on the urgent need for new 8 
strategies for craniofacial reconstruction to improve bone regeneration with complete healing 9 
of the defects regardless of size [1-3]. As an alternative to the traditional techniques, “tissue 10 
engineering” has developed as a new and promising multi-disciplinary technique in the field 11 
of maxillofacial reconstruction and surgery [4]. 12 
With the development of cell and molecular biology, DNA-based technology had appeared as 13 
a promising method to meet challenges of tissue engineering in different applications. The 14 
genetic principle is either applied individually or together with tissue engineering to be known 15 
as gene-enhanced tissue engineering that regenerates lost tissue by local delivery of cells that 16 
have been genetically-modified to deliver signalling factors at DNA-level [5]. To date, gene 17 
therapy is the leading technology in medicine providing hope for those individuals that are 18 
suffering genetic disorders. 19 
Gene therapy is known to be transferring genetic material or functioning gene to replace a 20 
damaged one inducing individual’s own cells to produce a therapeutic agent to improve the 21 
clinical outcome. It has several advantages over traditional treatments as the expression in 22 
host cells lasts longer for weeks to years than pharmaceutical compounds or recombinant 23 
protein which range from several hours to days. It reduces technical challenges associated 24 
with ex-vivo protein expression and purification. Finally, the delivery of genetic sequences 25 
could mimic the natural biologic healing response [6,7]. 26 
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There have been a couple of advances in gene therapy relevant to dentistry since 1995. When 27 
applying the gene therapy principles, the maxillofacial region has significant advantages 28 
compared to other locations in the body including easy access and inspection. Gene-based 29 
tissue engineering in the oral and maxillofacial complex include treatment of salivary gland 30 
diseases, autoimmune diseases, cancerous and precancerous lesions, pain, caries, 31 
dermatological disorders, delivery of growth factors for periodontal and pulp regeneration, 32 
treatment of malignant neoplasms of the head and neck, bone regeneration of large osseous 33 
defects in the craniofacial region and articular cartilage repair [8,9]. 34 
Although gene therapy was originally accepted as a means of treating heritable genetic 35 
disorders, its application in the craniofacial region is more often directed at regenerating 36 
tissues by acting as a delivery system for therapeutic genes promoting healing directly to cells 37 
within the defect or by genetically engineering mesenchymal stem cell progenitors to produce 38 
factors prior to implantation resulting in higher and more constant levels of protein production 39 
[10-12]. 40 
Thus, we have conducted a systematic review summarizing the articles reporting trials of gene 41 
therapy worldwide in the field of oral and maxillofacial surgery. 42 
MATERIAL AND METHODS 43 
This study was registered in SYRCLE (SYstematic Review Centre for Laboratory animal 44 
Experimentation) systematic review protocol for animal intervention studies (www.syrcle.nl). 45 
The guidelines for reporting systematic reviews and meta-analyses of animal studies was 46 
proposed by Peters et al [13] that are akin to the PRISMA guidelines for the reporting of 47 
systematic reviews and meta-analyses of healthcare interventions in human clinical 48 
studies.[14] 49 
Review questions 50 
The following PICO question was mainly addressed: Was gene therapy successfully applied 51 
to regenerate bone or heal defects in the oral and maxillofacial region?  52 
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Search strategy and selection criteria 53 
A systematic review of the literature was performed to provide an overview of published 54 
articles describing gene therapy in the field of Oral and Maxillofacial Surgery. Medical 55 
databases were searched to 18
th
 December 2015. The data search included a combination of 56 
the following keywords: ‘‘Gene therapy’’ ‘‘AND’’ ‘‘Maxillofacial surgery’’ ‘‘OR’’ ‘‘Gene 57 
therapy’’ ‘‘AND’’ ‘‘Bone tissue engineering’’, ‘‘Genetic Engineering’’ ‘‘AND’’ 58 
‘‘Maxillofacial bone’’, ‘‘Gene therapy’’ ‘‘AND’’ “Distraction Osteogenesis” ‘‘OR’’ ‘‘Gene 59 
therapy’’ ‘‘AND’’ “Alveolar bone” ‘‘OR’’ ‘‘Gene therapy’’ ‘‘AND’’ “Periodontal tissue” 60 
‘‘OR’’ ‘‘Gene therapy’’ ‘‘AND’’ “Temporomandibular joint”. All the possible combinations 61 
of these words were explored. Medical subject headings (MeSH terms) without subheading 62 
restrictions was used and the heading sequence was ‘‘Gene therapy’’ ‘‘AND’’ ‘‘Dentistry’’. 63 
In addition, we performed hand-search to the references of the included articles, papers of 64 
interest and related systematic or non-systematic reviews. The International Journal of Oral 65 
and Maxillofacial Surgery, Journal of Craniomaxillofacial Surgery, Gene therapy, Molecular 66 
therapy and Human gene therapy journals were also screened to identify possible references 67 
not reported elsewhere. No language or time restriction was enforced. Relevant full 68 
publications and meeting abstracts were identified by electronic searching of three online 69 
databases (PubMed, Cochrane library and Web of Knowledge). After the identification of 70 
articles in the databases, the articles were imported into Endnote X7 software (Thompson 71 
Reuters, Philadelphia, PA, USA) to store, manage search results and remove duplicates 72 
regardless of whether the studies are eventually included or excluded in the systematic 73 
review. Titles and abstracts identified were screened resulting in a number of seemingly 74 
relevant studies for the systematic review. The abstracts of the articles were then reviewed 75 
and the full text was obtained for those articles with apparent relevance. The identified articles 76 
were selected based on the inclusion criteria and exclusion criteria. 77 
Inclusion criteria 78 
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(1) Relevant data on Gene therapy, (2) Animal studies, (3) Defects performed in the Oral and 79 
Maxillofacial region, (4) Any language. 80 
Exclusion criteria 81 
(1) In vitro studies, (2) Gene therapy in bones other than maxillofacial, (3) Calvarial bones 82 
defects, (4) Review articles, (5) letters to the editor, editorials, poster or oral presentations or 83 
articles with only abstract, (6) Oral cancer or soft tissue lesions, (7) Studies based on the use 84 
of only growth factors or cell-based therapies. 85 
To improve the sensitivity of the relevant studies, each publication identified in the electronic 86 
search were assessed independently by two independent reviewers (RF and SO) to make a 87 
decision on inclusion/exclusion criteria or data extraction and quality of the articles with 88 
differences resolved by discussion. 89 
Data extraction 90 
All information was extracted using a standardized data form created in Excel. Data extracted 91 
included: 1) Author, 2) Year, 3) Journal, 4) Country, 5) Language, 6) therapeutic gene, 7) 92 
Vector, 8) Control gene, 9) Virus Titres (Concentration), 10) Cell lines for generation of 93 
virus, 11) Experiment design, 12) Defect model, 13) Site, 14) Animal Model, 15) Sample 94 
size, 16) Defect size, 17) Carrier/Scaffold, 18) Gene delivery route, 19) Stem cells source, 20) 95 
Experimental groups, 21) Cell concentration to be used in the defect, 22) Analysis methods 96 
with main endpoint results. 97 
Data was extracted from either text or tables in the results section of the included studies. 98 
Data that was presented as graphs was extracted electronically using WebPlotDigitizer 99 
software, version: 3.9 (WebPlotDigitizer, US, http://arohatgi.info/WebPlotDigitizer, 2015). 100 
Methodological quality assessment  101 
The quality assessment of all the included studies in this systematic review was performed 102 
based on ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines [15] and 103 
evaluated based on a predefined grading system [16] applied to the following items: (1) Title, 104 
(2) Abstract/Summary, (3) Introduction/Background, (4) Introduction/ Primary and secondary 105 
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objectives, (5) Methods/Ethical statement, (6) Methods/Study design, (7) 106 
Methods/Experimental procedure, (8) Methods/Experimental Animals, (9) Methods/Housing 107 
and husbandry, (10) Methods/Sample size, (11) Methods/Allocation animals to experimental 108 
groups, (12) Methods/Experimental outcomes, (13) Methods/Statistical methods, (14) 109 
Results/Baseline data, (15) Results/Numbers analysed, (16) Results/Outcomes and estimation, 110 
(17) Results/Adverse events, (18) Discussion/Interpretation and scientific implications, (19) 111 
Discussion/Generalisability and translation, (20) Discussion/ Funding. 112 
Risk of bias assessment 113 
Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental 114 
Studies (CAMARADES) risk of bias tool was applied to assess the internal validity of the 115 
included studies using RevMan software (version 5.3) [17,18]. A modified 7-point-item check 116 
list was used to assess the risk of bias, including: (1) published in a peer-reviewed journal; (2) 117 
random allocation to treatment or control; (3) treatment allocation concealment; (4) blinded 118 
assessment of outcome; (5) reporting of a sample size calculation; (6) statement of 119 
compliance with animal welfare regulations and (7) statement of potential conflict of interest. 120 
Each trial was assessed by two independent observers (RF and SO) and any differences 121 
resolved by discussion. 122 
Outcome measure  123 
The primary outcome measure for this meta-analysis was significant new bone formation by 124 
histology (% of area and % of volume) or radiograph (bone volume fraction) between the 125 
experimental and control group. 126 
Statistical Analysis 127 
A qualitative data analysis was performed with the aim of summarizing the results of the 128 
studies included. Meta-analyses as well as forest and funnel plots were conducted using 129 
RevMan software (Review Manager [RevMan] Version 5.3. Copenhagen: The Nordic 130 
Cochrane Centre, The Cochrane Collaboration, 2014). Bone formation was assessed as 131 
continuous outcome variables by inverse variance (IV) method and recorded as the 132 
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standardized mean difference (SMD) with 95% confidence interval (CI). The effect size of the 133 
SMD was classified as follows: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a 134 
large effect [19]. The I
2
 indicating heterogeneity and Cochran's Q statistical test were 135 
calculated; a value of I
2
: 0% to 40% might not be important, 30% to 60% may represent 136 
moderate heterogeneity; 50% to 90% may represent substantial heterogeneity and 75% to 137 
100% shows considerable heterogeneity [20]. A weighted fixed-effect model was used to 138 
estimate the overall effect size. Results with a p<0.0001 were considered indicative of 139 
statistical significance. Potential publication bias was explored using funnel plot generated 140 
using RevMan. 141 
RESULTS 142 
Search results 143 
The search identified a total of 2081 references from the different databases and hand search: 144 
PubMed (n= 2000), Web of science (n= 63), Cochrane library (n= 7), hand-search (n=11). 145 
After duplicates removal via Endnote duplicate function, 1509 articles were screened for 146 
titles/abstracts and resulted in only 148 studies for full-text evaluation with the exclusion of 147 
1361 articles that were irrelevant to the topic or review articles. Further screening resulted in a 148 
total of 57 studies which were considered eligible for the systematic review and fulfilled the 149 
final selection criteria. Figure 1 illustrates the search flow and the identification of eligible 150 
studies. Supplementary Table 1 summarizes excluded articles with reasons for exclusion. 151 
Study characteristics 152 
The articles analysed were published between 1999 and 2015. Most of the studies were 153 
conducted in USA [21-31] and China [32-61]. However, few studies were conducted in 154 
Taiwan [62], Japan [63,64], Spain [65], Germany [66], Italy [67], Korea [68] or as a 155 
collaboration between two countries [55,69-76]. Almost all articles (91.3%) were published in 156 
English [21-41,43-47,49-53,55-59,61-71,73-77] while only 5 articles (8.7%) [42,48,51,54,60] 157 
were published in Chinese. Bone morphogenetic proteins (BMPs) were the most commonly 158 
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used proteins for gene therapy (n=28, 49.1%) 159 
[22,23,26,28,29,34,35,37,40,42,43,47,48,50,51,54-58,62,66,68-73] followed by Platelet-160 
derived growth factors (PDGF; n=6, 10.5%) [21,24,25,30,55,56], while the remaining 23 161 
articles (40.4%) were using various proteins as: Enhanced green fluorescent protein (EGFP) 162 
[33,53,63,74], Tumour necrosis factor alpha receptor (TNFR) [27], Hepatocyte growth factor 163 
(HGF) [32], Receptor activator of nuclear factor kappa-B ligand (RANKL) [64,78], Basic 164 
fibroblast growth factor (b-FGF) [36,49], β-galactosidase (LacZ) [77], Osterix (OSX) [38,39], 165 
LIM mineralization protein 3 (LMP-3) [67], Vastatin [41], Vascular endothelial growth factor 166 
(VEGF) [44], Osteoprotegrin (OPG) [45,59,60,76], Runt-related transcription factor 2 167 
(Runx2) [46], Nerve growth factor beta (NGF-β) [52], Tumour necrosis factor alpha-168 
stimulated gene-6 (TSG-6) [75], Mitogen-activated protein kinase (MAPK) phosphatase 1 169 
(MKP-1) [31] and Hypoxia-inducible factor-1 alpha (HIF-1α) [61]. 170 
In 30 articles (52.6%) [21-25,28-32,35-37,40,43,46,47,54-58,62,66,67,69,72,73,77,79], 171 
adenovirus was the universally used vector. However, other vectors were used as: plasmid 172 
(n=12, 21%) [26,34,38,48-51,59,60,63,70,80], adeno-associated virus (n=4, 7%) 173 
[27,33,41,44], hemagglutinating virus of Japan (HJV; n=3, 5.3%) [64,65,76], liposome (n=2, 174 
3.5%) [66,71], lentivirus (n= 5, 8.8%) [45,52,53,61,75] and retrovirus (n=1, 1.8%) [74]. For 175 
the control genes, Green fluorescent protein (GFP) were the most abundant control in 20 176 
articles (35.1%) [29,32,34,36-38,40,41,44,46,49,52,54,56-58,61,67,69,70,73,80] followed by 177 
β-galactosidase (LacZ) in 9 articles (15.8%) [22,23,31,35,43,62,66,69,72] and Luciferase 178 
(Luc) in 6 articles (10.5%) [21,24,25,28,30,63] respectively. However, in 22 articles (38.6%), 179 
the control gene was not reported. Seven different packaging cell lines were used for 180 
replication of the viruses: HEK293 (human embryonic kidney 293 cell line) [23-25,27,29,31-181 
33,41,44-47,54,56,57,68,69,77], 293FT (human embryonic kidney cells with the SV40 large 182 
T antigen) [53], WEHI 164 (mouse skin fibroblast) [40], NIH3T3 (mouse embryo fibroblast) 183 
[64,65], CRE8 (Cre-expressing 293 cells) [67], 911 helper (human embryonic retinoblasts 184 
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(HER) [66] and PG13 (mouse embryonic fibroblast) [74]. The experiments were performed 185 
either as in vitro/ in vivo in 38 articles (66.7%) [23,29-32,35-37,40,41,43-47,49-51,53,55-186 
62,64-70,72-75] or were completely in vivo studies in 19 articles (33.3%) [21,22,24-187 
28,33,34,38,39,42,48,52,54,63,71,76,77]. Table 1 presents the characteristic of the included 188 
studies.  189 
Alveolar bone defects with or without dental implant were the prevalent model used for gene 190 
therapy in 20 articles (35.1%) [21,22,25,26,28,35,40,45,47,50,51,56-58,61,66,67,69,70,72], 191 
periodontal disease with or without alveolar bone involvement (n=17, 29.8%) [24,27,29-192 
32,42,48,49,53,55,59,60,62,63,68,75] followed by distraction osteogenesis (n=9, 15.8%) 193 
[23,34,36,38,39,43,46,52,71], temporomandibular joint (n=4, 7%) [33,41,44,77], orthodontic 194 
tooth movement (n= 3, 5.2%) [64,65,76], sinus floor elevation (n=2, 3.5%) [37,73], tooth 195 
restoration with bio-root regeneration (n=1, 1.8%) [74] and central fissures (cleft) (n=1, 1.8%) 196 
[54]. Most of the defects were in the mandible (n=39, 68.4%) [22-24,29,30,33-36,38-54,56-197 
61,66-68,70-73,77] while in 16 articles (28%) [21,25-28,31,37,55,62-65,69,73,75,76] the 198 
defects were created in the maxilla. One article reported defects in both jaws (1.8%) [32] and 199 
the location was missing in one article (1.8%) [74]. The posterior mandible (premolar-molar 200 
area) was the most frequent region. However, some studies did the experiments in the anterior 201 
region. 202 
Sprague-Dawley rats were the frequently used animal model in experimental studies of gene 203 
therapy (n=17, 29.8%) [21-25,27,28,30,31,33,34,41,44,50,51,53,75] followed by Wistar rats 204 
in 6 studies (10.5%) [63-67,76], Lewis Fisher in 3 studies (5.3%) [29,35,58] and ginue-pigs or 205 
mice in one article each (n=2, 3.5%) each [72,77]. White New Zealand rabbits were also used 206 
as a small animal model for the studies (n=14, 24.6%) [36-40,43,45-47,52,54,62,70,73]. For 207 
large animals models, dogs and pigs were commonly used in 11 (19.3%) [26,42,48,49,55-208 
57,59-61,66] and 4 (7%) studies respectively [32,69,71,74]. Sample size ranged between 4 209 
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and 24 for large animal models. However, for small animal models, the sample size ranged 210 
between 11 and 144 animals. 211 
Two different defect shapes were identified: circular (n=9, 15.8%) [22,35,48-51,58,66,72], 212 
rectangular (n=22, 38.6%) [24,26,28-30,32,37,40,45,47,53,55-57,59-62,67,69,70,73] and 26 213 
studies (45.6%) [21,23,25,27,31,33,34,36,38,39,41-44,46,52,54,63,64,68,71,74-78] did not 214 
mention the shape of the defect. Variable diameters were recognised for the circular defects 215 
ranging from 1 to 6 mm. The rectangular defects were characterised by heterogeneity of 216 
dimensions. 217 
Gene delivery route was ex-vivo in 35 articles (61.4%) [29,32-40,42,43,45-47,49-54,58-218 
62,66-74], in-vivo in 21 articles (36.8%) [21-28,30,31,41,44,48,55-57,63-65,76,77] and both 219 
in only one article (1.8%) [75]. For in-vivo gene delivery route (direct injection or GAM), 220 
physiological saline, collagen gels or lipid bubbles were used to deliver the genetically 221 
modified cells or material to the defect. The scaffolds used for seeding the cells differed in 222 
each study. The used scaffolds were: beta-tricalcium phosphate (β-TCP) [37,45,58], Bioactive 223 
glass ceramic (BGC) [47], Coral hydroxyapatite (CHA) [50,51], Hydroxyapatite/ Collagen 224 
(HA/COL) [67,68], Hydroxyapatite/ beta-tricalcium phosphate (HA/TCP) [74], 225 
Premineralized silk fibroin protein scaffolds (mSS) [35], Natural non-organic bone (NNB) 226 
[70], Mesoporous bioglass/silk fibrin (MBG) [55], hydroxyapatite/polyamide (HA/PA) [40], 227 
Pluronic F127 (PF127) [62], Poly D, L-lactide (PDLA) [26], Poly lactic co glycolic acid 228 
(PLGA) [59,60], Calcium magnesium phosphate cement (CMPC) [61] and Calcium silicon 229 
phosphorus (OsteoBone) [73]. Regarding the source of transfected/transduced stem cells, 230 
mesenchymal stem cells (MSCs) were used in 25 experiments (43.8%) either from bone 231 
marrow or adipose tissue or induced pluripotent [34-40,42,43,49-52,58-62,66,70-73,75], 232 
while different type of cells such as syngeneic dermal fibroblasts (SDFs) [29,67], dental pulp 233 
stem cells (DPSCs) [32,74], periodontal derived stem cells (PDLSCs) [45,47,53,56,57,68,74] 234 
and periosteal derived osteoblast cells (pOBs) [54] were used in other studies with different 235 
Page 11 of 62
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly/Not for Distribution11 
 
concentration of the cells. All the experiments had been divided into different study groups 236 
for comparing the efficiency of gene therapy in the disease model. Table 2 shows the 237 
extracted data from the included studies with reference to the disease model and animals used. 238 
Different analysis methods were used for either the in-vitro or in-vivo experiments as: 239 
Western blot (n=12, 21%) [23,29,31,45,46,49,59-62,69,70], In-situ hybridization (n=6, 240 
10.5%) [33,44,47,50,51,66], PCR (n=27, 47.3%) [21,24,25,27,29,30,33,36,37,40,41,44-241 
46,48,49,53,55-58,61,66,67,72,75,77], Bioluminescence (n=5, 8.7%) [21,24,28,30,63], µCT 242 
(n= 20, 35%) [22,25,27,31,32,35,36,43,46,49,55,58,61,62,67,69,71,72,76], [74], Histology 243 
(n=48, 84.2%) [22-26,28-32,34-40,42,45-50,52-55,57-74,76,77], Staining (n=16, 28%) 244 
[23,31,32,35,37,45,50,53,58,62,66,67,69,71,72,77], Radiograph (n=18, 31.5%) [23,26,27,34-245 
36,38-40,43,46,50,54,58,59,61,66,74], Histomorphometry (n=22, 38.5%) [23,26,28-246 
30,34,35,37,40,42,45,47,50,52,54,55,57,58,61,70,73,74], SEM (n=14, 24.5%) 247 
[25,28,34,40,45,50,55,57,58,60,61,70,74,75], Biomechanical analysis (n=8, 14%) 248 
[25,36,40,43,46,54,69,74], Immunohistochemistry (n=25, 43.8%) [29-31,34-36,39-249 
41,44,45,50,51,53,59-61,64,66,68,69,71,73,74,76], Confocal microscopy (n=7, 12.2%) 250 
[35,45,56,57,63,66,73], Bone resorption assay (n=2, 3.5%) [64,65], ALP activity (n=7, 251 
12.2%) [29,45,47,53,55,57,70], Immunofluorescence (n=15, 26.3%) [36,38-252 
41,44,45,49,53,58,65,67,70,72-74], FACS (n=12, 21%) 253 
[29,32,41,44,49,53,61,62,66,72,74,75], TRAP (n=3, 5.2%) [27,44,75], Cell proliferation (n=8, 254 
14%) [29,40,45,47,49,53,55,68] or ELISA (n=16, 28%) [27,31,32,35,43,44,47,55-255 
57,62,66,68,72,73,75]. Table 3 summarizes the endpoint results of the main analytical 256 
methods used for the experiments either in vitro or in vivo. 257 
Methodological quality assessment of included articles 258 
The items included in the assessment of the quality of the articles are summarized in Table 4. 259 
The quality of finally selected studies was assessed by different categories [15,16]. A 260 
relationship was driven between the Quality Score/Maximum Score by dividing the maximum 261 
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score by category to the total score (T=36). Three possible quality coefficients were 262 
conducted: 0.8–1 Excellent, 0.5–0.8 Average, <0.5 Poor as reported elsewhere [15,16,81]. In 263 
the included articles, 21 articles were excellent articles fulfilling nearly all the criteria of the 264 
ARRIVE guidelines with coefficients 0.8-1. Thirty-five articles were qualified as average 265 
articles with coefficients 0.5-0.8 and only one article was categorized as being of poor quality 266 
with coefficients <0.5. All the titles of the manuscripts were accurate. The abstracts were 267 
clearly accurate in 24 articles (42.1%) and possibly accurate in 30 articles (52.6%) and clearly 268 
inaccurate in 3 articles (5.3%). Introduction (background, objectives, experimental approach 269 
and rationale, relevance to human biology) was clear and sufficient in all the articles. 270 
Introduction (Objectives-primary and secondary) was clear in nearly all the articles (n=56, 271 
98.2%) while only one article was not clear (n=1, 1.8%). The methods (Ethical statement-272 
nature of the review permission, relevant licenses, national and institutional guidelines for the 273 
care and use of animals) were clearly sufficient in 50 articles (87.7%), possibly sufficient in 274 
one article (1.8%) and clearly insufficient in 6 articles (10.5%). The methods (study design-275 
number of experimental and control groups, any steps taken to minimize bias, that is, 276 
allocation concealment, randomization and blinding) were possibly sufficient in 12 articles 277 
(21%) and clearly sufficient in 45 articles (78.9%). The methods (experimental procedure-278 
precise details, that is, how, when, where, why) were clearly sufficient in 34 article (59.6%), 279 
possibly sufficient in 22 articles (38.6%) and clearly insufficient in one article (1.8%) of the 280 
manuscripts. The methods (experimental animals-species, strain, sex, maturity, weight, source 281 
of animals) were possibly sufficient in 25 articles (43.8%) and clearly sufficient in 32 articles 282 
(56.1%). The methods (housing and animal-husbandry and welfare-related assessment 283 
interventions, that is, type of cage, bedding material, number of cage companions, light/dark 284 
cycle, temperature, access to food and water) were clearly insufficient in 41 articles (72%) 285 
and possibly sufficient in 16 articles (28%). The methods (sample size-total number of 286 
animals used in each experimental group, details of calculation methods) were clearly 287 
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adequate in 53 articles (93%), possibly adequate in 3 article (5.2%) and clearly inadequate in 288 
one article (1.8%). The methods (allocation of animals to experimental groups-randomization 289 
or matching, order in which animals were treated or assessed) were expressed in 52 articles 290 
(91.2%) and were not expressed in five article (8.8%). The methods (experimental outcomes-291 
definition of primary and secondary outcomes) were unclear/incomplete in 6 articles (10.5%) 292 
and absent in one article (1.8%) while 50 articles (87.7%) showed complete outcomes. The 293 
methods (statistical methods-details and unit of analysis) were missing in 7 articles (12.3%) 294 
and were provided in 50 articles (87.7%).  295 
The results (baseline data characteristics and health status of animals) were not provided in 33 296 
articles (57.9%) and were provided in 24 articles (42.1%). Results (number analysed-absolute 297 
numbers in each group included in each analysis, explanation for exclusion) were clearly 298 
inadequate in 4 articles (7%), possibly adequate in 44 articles (79%) and clearly adequate in 299 
only 8 articles (14%). Results (outcomes and estimation results for each analysis with a 300 
measure of precision, as standard error or confidence interval) were not complete in 17 301 
articles (30%) and complete in 40 articles (70%). Results (adverse events details and 302 
notifications for reduction) were missing in 6 articles (10.5%), not complete in 33 articles 303 
(58%) and clearly accurate in 18 article (31.5%). The discussions (interpretation/scientific 304 
implications-study limitations including animal model, implications for the 3Rs) were clearly 305 
inadequate in one article (1.8%), possibly adequate in 51 article (89.4%) and clearly adequate 306 
in 5 articles (8.8%). Discussions (generalizability/translation-relevance to human biology) 307 
were inadequate in 2 articles (3.5%), possibly adequate in 46 article (80.7%) and clearly 308 
adequate in 9 articles (15.8%). Discussions (funding-sources, role of the funders) were clearly 309 
inadequate in 3 articles (5.3%) and clearly adequate in 54 articles (94.7%). Table 5 represents 310 
the assessment of the quality of the published articles included in the review. 311 
Risk of bias assessment of the included articles 312 
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Overall, all the studies were having low risk of bias in publishing in peer-reviewed journals. 313 
Random allocation of the treatment or control were reported in 29 articles [22,29,30,32-314 
39,41,43-45,49,52,53,58,59,61,63,67,70,73-76] and three studies [37,40,46] had a low risk of 315 
bias in random allocation concealment. Blinding of outcome assessment was performed in 13 316 
studies [23,27-30,32-34,36,38,39,52,65] and only two studies [25,33] were reporting sample 317 
size calculation The statement of compliance with animal welfare regulations was reported in 318 
51 studies [23-28,30-47,49-65,67,68,70-77] while conflict of interest were in 11 studies [24-319 
26,31,32,45,52,53,73,74]. More details about possible risk of bias were presented in Fig 2. 320 
Meta-analysis 321 
Fourteen studies were included in the histological meta-analysis of percentage of area of 322 
newly formed bone by gene therapy whereas three studies were included in percentage of 323 
volume of newly formed bone. However, four studies were included in the radiographic meta-324 
analysis of the bone formation by calculating the bone volume fraction. Fig.3 summarizes the 325 
results of forest plot of gene therapy treatment versus control treatment. 326 
Percentage of area of bone formation by histology (Fig.3A): 327 
Pooled data from gene vs reporter comprising of 9 inter-group comparisons generated from 7 328 
original studies involving 204 animals (102 treated and 102 control groups) was (SMD=1.74, 329 
95% CI, I
2
=64%, p<0.00001) while data from gene vs scaffold comprising of 5 inter-group 330 
comparisons generated from 4 original studies involving 68 animals (34 treated and 34 331 
control groups) was (SMD=1.17, 95% CI, I
2
=87%, P=0.0004). 332 
Pooled data from gene/scaffold vs reporter/scaffold comprising of 6 inter-group comparisons 333 
generated from 4 original studies involving 48 animals (24 treated and 24 control groups) was 334 
(SMD=1.31, 95% CI, I
2
=45%, P=0.0006). However, data from gene/scaffold vs scaffold 335 
comprising of 4 inter-group comparisons generated from 4 original studies involving 48 336 
animals (24 treated and 24 control groups) was (SMD=2.12, 95% CI, I
2
=82%, p<0.00001). 337 
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Finally, pooled data from gene/scaffold vs untransfected cells/scaffold comprising of 3 inter-338 
group comparisons generated from 3 original studies involving 46 animals (23 treated and 23 339 
control groups) was (SMD=1.62, 95% CI, I
2
=67%, p<0.00001). 340 
Percentage of volume of bone formation by histology (Fig.3B): 341 
Pooled data from gene vs reporter comprising of 2 inter-group comparisons generated from 2 342 
original studies involving 52 animals (36 treated and 36 control groups) was (SMD=1.71, 343 
95% CI, I
2
=48%, P<0.00001) while data from gene vs saline comprising of 3 inter-group 344 
comparisons generated from 3 original studies involving 108 animals (54 treated and 54 345 
control groups) was (SMD=2.34, 95% CI, I
2
=0%, p<0.00001). 346 
Bone volume fraction for bone formation by radiograph (Fig.3C): 347 
Pooled data from gene vs reporter comprising of 4 inter-group comparisons generated from 4 348 
original studies was performed involving 84 animals (42 treated and 42 control groups), 349 
(SMD=1.36, 95% CI, I
2
=86%, p<0.00001). 350 
Publication bias  351 
Funnel plots of the study results are shown in Fig.4. Symmetrical funnel plots were obtained 352 
in all the models. The funnel plot of the study standard error by effect size (SMD) was 353 
symmetric. The funnel plot of standard error versus effect size (standard mean difference) was 354 
symmetrical indicating the absence of potential publication bias among the meta-analysis of 355 
bone formation by histology (Fig.4 A&B) or radiograph (Fig.4C). 356 
DISCUSSION 357 
Several literature reviews have focused on gene therapy in bone tissue engineering, dentistry 358 
or oral and maxillofacial surgery [9,12,82,83]. However, there has been no systematic review 359 
or meta-analysis with a specific focus on research covering gene therapy in the field of Oral 360 
and Maxillofacial Surgery. Thus, we have conducted a comprehensive systematic review of 361 
the studies addressing efforts made in the field of gene therapy for healing of maxillofacial 362 
defects revealing the raised success rate during the recent years. Our meta-analysis results 363 
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provided evidence that gene therapy was beneficial in treating maxillofacial defects in terms 364 
of improving bone formation based on histological and radiographic measures. 365 
Although gene therapy was initially considered as a means of correcting hereditary disorders 366 
by changing the genes that cause the disease [84], more recent research is applying gene 367 
therapy to produce continuous amounts of biologically active molecules in the defects such as 368 
its potent ability for alveolar bone regeneration, periodontal healing and dental implants 369 
osseo-integration [55]. Clinical trials using gene therapy are now underway in salivary gland 370 
regeneration for dental application (https://clinicaltrials.gov/ct2/show/NCT00004178) and 371 
bone regeneration (https://clinicaltrials.gov/ct2/show/NCT02293031). However, future 372 
clinical trials for the use of gene therapy in periodontal regeneration remain hopeful for the 373 
near future. 374 
From our results, multiple genes were used as osteogenic factors for gene therapy in the 375 
maxillofacial region because of their potent induction of de novo bone formation in vivo with 376 
varying results as soluble growth factors (PDGF, FGFs), morphogens (BMPs), angiogenetic 377 
factors (VEGF), intracellular regulators (LIM mineralization protein-1: LMP-1), transcription 378 
factors (Runx2) associated with bone and cartilage-related gene expression [85,86]. All of 379 
these biological factors have been investigated for their potential use in bone tissue 380 
engineering and repair. However, BMPs were preferred candidates for local gene therapy for 381 
bone regeneration as they can initiate and sustain the entire bone formation cascade [87]. 382 
Some studies proved the feasibility of transferring BMP genes [88,89]. On the other hand, 383 
previous investigations had reported the effect of PDGF on osseous defect healing showing 384 
that PDGF signalling plays role in chemotaxis and proliferation of osteoblasts and fibroblasts 385 
[90]. However, PDGF’s ability to induce osteogenic differentiation is less clear. Recently, 386 
LMP-1 proved the initiation of membranous bone formation in vitro and in vivo [91]. Unlike 387 
BMPs acting extracellularly through cell surface receptors, LMP-1 is an intracellular 388 
signalling molecule involved in osteoblast differentiation [83]. 389 
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Another critical element of gene therapy is the vector which is the vehicle that facilitates the 390 
transfer of genetic material into the target cell nucleus without degradation or causing 391 
toxicity. Two kinds of vectors have been employed as vehicles: viral and non-viral vectors. 392 
Gene transfer via viral vectors is called transduction while transfer via the non-viral vectors is 393 
transfection. Different viral vectors have been introduced as DNA-based like adenoviruses, 394 
adeno-associated viruses or RNA-based viral vectors as retroviruses and lentiviruses. Non-395 
viral vectors can be plasmids, liposomes or polyplexes. Each vector has its own advantages 396 
and disadvantages. Viral vectors have the advantage of its ability to carry the gene efficiently 397 
and ensure long-term expression but they can only trigger short-term gene expression and are 398 
highly immunogenic. Another advantage of viral vectors is that they are non-virulent due to 399 
their modified genome in which the essential viral genes are replaced by the therapeutic gene 400 
being unable to replicate in the absence of these critical gene products. Non-viral vectors 401 
could be also used due to their safety profile and minimal immunogenicity. However, the 402 
main disadvantage in their use is the insufficient transfection efficiencies. [85,92-96].  403 
For viral-based gene therapy, it is necessary to allow continuous high-titre virus production. 404 
The viruses are replicated in either human or non-human cell lines. A whole panel of different 405 
cell lines has been used all-over the years to generate viral vector to be used as therapeutic 406 
product. HEK293 cells and their derivatives have been extensively used for production of 407 
different vectors due to the ease of handling and possibility to grow as adherent as well as 408 
suspension cells [97,98]. In line with our findings, several studies had proved the efficiency of 409 
viral vector in the transfer of the DNA [99-101] while other studies have used non-viral 410 
vectors [102,103]. 411 
Reporter gene assays have emerged as a rapid and sensitive strategy for indirectly monitoring 412 
transgene expression by cloning the promoter region of the gene of interest correlated to the 413 
reporter gene and measure reporter gene expression as a reflection of the expression of the 414 
gene of interest [104]. It is important to use a reporter gene that is not naturally expressed in 415 
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the cell or organism under study. Different strategies of making the fusion construct and their 416 
applications have been reported [105]. Commonly used reporter genes are green fluorescent 417 
protein (GFP) which is a fluorescent protein causes cells that express it to glow green under 418 
UV light, luciferase (Luc) [106] produces light by a catalytic reaction with luciferin. Another 419 
common reporter gene expressed in bacteria is the protein β-galactosidase (LacZ) causing 420 
bacteria expressing the gene to appear blue when grown on a medium that contains the 421 
substrate analogue X-gal. In our results, several reporter genes have been used which gives an 422 
add-on to the experiments being an internal control for the expression of the gene of interest. 423 
Various biological delivery systems have been applied for transferring therapeutic gene to 424 
target cells. In the in-vivo approach, cells can be genetically modified in situ or the vector is 425 
administered to the defect via systemic or local direct injection associated with a biomaterial. 426 
The combination of vector and biomaterial is called gene activated matrix (GAM). GAMs are 427 
three-dimensional biomaterials acting as a scaffold for vectors introduced to a localised area 428 
and useful for avoiding unintended spread of transfection to local tissues. Regarding the ex 429 
vivo approach, cells are removed, genetically modified and re-implanted in the defect by 430 
direct injection or using a biomaterial as carrier [107-109].  431 
Genetic modification of stem or progenitor cells serves as an important advancement in 432 
regenerative medicine to improve their in-vivo performance. By combining gene with cell 433 
therapy, stem cell function may be enhanced by improving proliferation or differentiation of 434 
the stem cells. Another important function of stem cells is for drug delivery exerting paracrine 435 
or endocrine actions. The most common cell source is mesenchymal stem cells (MSC) which 436 
can be isolated from bone marrow, muscle tissue, peripheral blood, umbilical cord, adipose 437 
tissue, liver, multiple dental tissues or induced pluripotent stem cells (iPSC) [110,111]. MSC 438 
are adult stem cells capable of self-renewal and differentiation into multiple lineages as 439 
cartilage, adipose and bone which have been used for treating bone-related diseases [112]. 440 
The induced pluripotent stem cells (iPSCs) is a new source of stem cell generated from 441 
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human somatic cells into a pluripotent stage [113]. Various cells such as gingival or dermal 442 
fibroblasts, periosteal cells, primary articulated joint chondroblasts, bone marrow stromal 443 
cells/ MSCs, muscle-derived stem cells, fat-derived stem cells, osteoblasts and myoblasts 444 
have been successfully transfected or transduced by different vector systems using in vivo or 445 
ex vivo techniques [114]. From our results, the most commonly used stem cells in the 446 
maxillofacial region were genetically modified bone marrow, adipose, periodontal and dental 447 
pulp stem cells. Other studies used the same cells for regeneration of bone and other organs: 448 
BMMSCs [115,116], ADSCs [117-119], PDLSCs [120], DPSCs [121]. 449 
Animal models are valuable tools in biomedical research in particular gene therapy to test the 450 
safety, efficacy, dosage and localization of transgene expression in models that closely 451 
resemble human diseases. Animal craniofacial models for gene therapy exist not only for 452 
bone [122] but also for periodontal ligaments [30], TMJ [44], cartilage [123] as well as 453 
salivary glands [124]. Such models have critical-size defects with the absence of spontaneous 454 
complete osseous regeneration of the created defects during the lifetime of the animals 455 
[125,126]. 456 
Considering limitation of our systematic review, meta-analysis was conducted for only few 457 
included studies due to the high level of heterogeneity in reporting the treatment outcomes. It 458 
is also important to consider variability in research methodologies, characteristics of 459 
laboratory animals, different interventions and measurement of outcome variables play role in 460 
meta-analysis of animal studies. Moreover, the studies which were included in our meta-461 
analysis generally used animal models for gene therapy. Therefore, randomized clinical 462 
studies in humans are needed to confirm our conclusions. However, meta-analysis was 463 
performed only to articles that had clearly reported bone formation (primary outcome) either 464 
by percentage of area or volume histologically as well as radiographically.  465 
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CONCLUSION 466 
Challenging approaches had emerged for oral and maxillofacial reconstruction in the last 467 
decade due to the complex nature of craniofacial defects. Tissue engineering is attracting the 468 
spotlights as a new paradigm for bone regeneration which requires the collaboration of 469 
multidisciplinary teams of surgeons, biologists and biomedical engineers. Gene therapy is on 470 
the top list of innovative strategies in tissue engineering that developed in the last 10 years. 471 
While significant progress has been made towards preclinical studies of gene therapy in the 472 
maxillofacial region building the scientific basis of this technique, gene therapy is still in the 473 
clinical trials phase in salivary glands and craniofacial defects. 474 
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FIGURE LEGENDS 1 
Fig.1: Flow-chart of the process of literature search and studies included in the review. 2 
Fig.2: Risk of bias graph for the studies included in this systematic review. Assessment of 3 
risk of bias using modified CAMARADES tool. Panel (A) Risk of bias of all included studies 4 
with the percentage of risk of bias for each item of assessment; Panel (B) Author name of 5 
each study and with their respective result in each item of assessment. Item (1) published in a 6 
peer-reviewed journal; (2) random allocation to treatment or control; (3) treatment allocation 7 
concealment; (4) blinded assessment of outcome; (5) reporting of a sample size calculation; 8 
(6) statement of compliance with animal welfare regulations and (7) statement of potential 9 
conflict of interest respectively. 10 
Fig.3: Forest plot of standard mean difference (SMD), with 95% Confidence Interval 11 
(CI) in bone formation by histology and radiograph comparing different subgroups. 12 
Panel (A) represents forest plot of percentage area of bone formation by histology. Several 13 
subgroups were analysed as: Gene vs Reporter gene, Gene vs Scaffold, Gene/Scaffold vs 14 
Reporter/Scaffold, Gene/Scaffold vs Scaffold, Gene/Scaffold vs Untransfected cells/Scaffold. 15 
Panel (B) represents forest plot of percentage volume of bone formation by histology. Panel 16 
(C) represents forest plot of bone volume fraction detected by 3D µCT. the diamond 17 
represents the overall effect within each subgroup. 18 
Fig.4: Funnel plot showing publication bias among the studies. The symmetry of the 19 
funnel plot shows there was no evidence of publication bias among the studies. Each symbol 20 
on the funnel plot represents an individual study estimate included in the meta-analysis. The 21 
y-axis displays the standard error and the x-axis displays the standardized mean difference. 22 
SE: Standard Error; SMD: Standardized mean difference. 23 
 24 
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TABLE LEGENDS 25 
Table 1: Summary of essential features of all studies included in the systematic review. 26 
Table 2: Extracted data from included studies with description of disease model and animal 27 
model used. 28 
Table 3: Endpoint results of the main analytical methods used for the experiments. 29 
Table 4: Cat gories and grading used to assess the quality of the selected studies. 30 
Table 5: Quality assessment of articles included using ARRIVE guidelines. 31 
Supplementary Table 1: Excluded articles with the reasons of exclusion. 32 
Supplementary Table 2: SYRCLE protocol for registering systematic review for animal 33 
intervention studies. 34 
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Fig.1: Flow-chart of the process of literature search and studies included in the review.  
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Fig.2: Risk of bias graph for the studies included in this systematic review. Assessment of risk of bias using 
modified CAMARADES tool. Panel (A) Risk of bias of all included studies with the percentage of risk of bias 
for each item of assessment; Panel (B) Author name of each study and with their respective result in each 
item of assessment. Item (1) published in a peer-reviewed journal; (2) random allocation to treatment or 
control; (3) treatment allocation concealment; (4) blinded assessment of outcome; (5) reporting of a 
sample size calculation; (6) statement of compliance with animal welfare regulations and (7) statement of 
potential conflict of interest respectively.  
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Fig.3: Forest plot of standard mean difference (SMD), with 95% Confidence Interval (CI) in bone formation 
by histology and radiograph comparing different subgroups. Panel (A) represents forest plot of percentage 
area of bone formation by histology. Several subgroups were analysed as: Gene vs Reporter gene, Gene vs 
Scaffold, Gene/Scaffold vs Reporter/Scaffold, Gene/Scaffold vs Scaffold, Gene/Scaffold vs Untransfected 
cells/Scaffold. Panel (B) represents forest plot of percentage volume of bone formation by histology. Panel 
(C) represents forest plot of bone volume fraction detected by 3D µCT. the diamond represents the overall 
effect within each subgroup.  
397x693mm (300 x 300 DPI)  
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Fig.4: Funnel plot showing publication bias among the studies. The symmetry of the funnel plot shows there 
was no evidence of publication bias among the studies. Each symbol on the funnel plot represents an 
individual study estimate included in the meta-analysis. The y-axis displays the standard error and the x-
axis displays the standardized mean difference. SE: Standard Error; SMD: Standardized mean difference.  
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Table 1: Summary of essential features of all studies included in the systematic review  
Author Year Journal Country Language Therapeutic 
Gene 
Vector Control Virus Titres 
(Concentration) 
Cell lines for 
generation of 
virus 
Experiment 
design 
Abramson [1] 2007 Eur Cell Mater USA English PDGF-B AV Luc N/R N/R In vivo 
Alden [2] 2000 J Craniofac Surg USA English BMP-2/BMP-9 AV LacZ 5×10
7 particle/µl N/R In vivo 
Ashinoff [3] 2004 Ann Plast Surg USA English BMP-2 AV LacZ N/R HEK293 In vitro/In vivo 
Chang [4] 2009 Hum Gene Ther USA English PDGF-B AV Luc N/R HEK293 In vivo 
Chang [5] 2010 Gene Ther USA English PDGF-B AV Luc N/R HEK293 In vivo 
Chang [6] 2003 Gene Ther Taiwan/USA English BMP-2 AV LacZ N/R HEK293 In vitro/In vivo 
Chen [7] 2009 J Dent Res Japan English EGFP Plasmid Luc N/R JM 109 In vivo 
Chen[8] 2007 Plast Reconstr Surg USA English BMP-4 Plasmid N/R N/R N/R In vivo 
Chen[9] 2008 Gene Ther Taiwan English BMP-2 AV LacZ 50 MOI N/R In vitro/In vivo 
Cirelli [10] 2009 Gene Ther USA English TNFR AAV N/R 5-20×10
12 DRP/ml HEK293 In vivo 
Cao[11] 2015 Stem Cell Res Ther China English HGF AV GFP 50-400 MOI HEK293 In vitro/In vivo 
Dai [12] 2007 Front Biosci China English EGFP AAV N/R N/R HEK293 In vivo 
Dunn [13] 2005 Mol Ther USA English BMP-7 AV Luc N/R N/R In vivo 
Hu [14] 2007 J Orthop Res China English BMP-7 Plasmid GFP N/R N/R In vivo 
Iglesias-
Linares [15] 
2011 Orthod Craniofac Res Spain English RANKL HVJ N/R N/R NIH3T3 In vitro/In vivo 
Jiang [16] 2006 Int J Oral Maxillofac Surg China/Canada English BMP-4 Plasmid GFP N/R JM 109 In vitro/In vivo 
Jiang [17] 2009 Clin Oral Implants Res China English BMP-2 AV GFP 50 PFU/cell (MOI) N/R In vitro/In vivo 
Jiang [18] 2009 Biomaterials China English BMP-2 AV LacZ 80 PFU/cell (MOI) N/R In vitro/In vivo 
Jiang [19] 2010 Bone China English b-FGF AV GFP N/R N/R In vitro/In vivo 
Jin [20] 2003 J Periodontol USA English BMP-7/Noggin AV GFP 200 PFU/cell (MOI) HEK293 In vitro/In vivo 
Jin [21] 2004 Mol Ther USA English PDGF-B /PDGF-A AV Luc 200 PFU/cell (MOI) N/R In vitro/In vivo 
Kanzaki [22] 2006 Gene Ther Japan English RANKL HVJ N/R N/R NIH3T3 In vitro/In vivo 
Kroczek [23] 2010 J Craniomaxillofac Surg Germany 
Netherlands 
English BMP-2 Liposome N/R N/R N/R In vivo 
Kuboki [24] 1999 Arch Oral Biol Japan English LacZ AV N/R N/R HEK293 In vivo 
Lai [25] 2014 J Zhejiang Univ Sci B China English OSX Plasmid GFP N/R N/R In vivo 
Lai [26] 2011 Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 
China English OSX Plasmid N/R N/R N/R In vivo 
Lattanzi [27] 2008 Gene Ther Italy English LMP-3 AV GFP N/R CRE8 In vitro/In vivo 
Li [28] 2010 J Biomed Mater Res A China English BMP-7 AV GFP N/R WEHI 164 In vitro/In vivo 
Li [29] 2010 Zhonghua Yi Xue Za Zhi China Chinese BMP-7 N/R N/R N/R N/R In vivo 
Li [30] 2009 Arch Oral Biol China English Vastatin AAV GFP 5×103, 1×104-5×104 
PFU/cell (MOI) 
HEK293 In vitro/In vivo 
Long [31] 2011 Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 
China English BMP-2 AV LacZ 100 PFU/cell (MOI) N/R In vitro/In vivo 
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Table 1: Summary of essential features of all studies included in the systematic review 
Author Year Journal Country Language Therapeutic 
Gene 
Vector Control Virus Titres 
(Concentration) 
Cell lines for 
generation of 
virus 
Experiment 
design 
Park J [32] 2003 Gene Ther Germany English BMP-2 AV 
Liposome 
LacZ 1-3×1010 PFU/ml 911 helper In vitro/In vivo 
Park S [33] 2015 J Biomed Mater Res A Korea English BMP-2 AV N/R 100 PFU/cell (MOI) HEK293 In vitro/In vivo 
Rabie [34] 2007 Gene Ther China English VEGF AAV GFP N/R HEK293 In vitro/In vivo 
Steinhardt [35] 2008 Tissue Eng Part A Israel/USA English BMP-2 AV LacZ 3000 PFU/cell N/R In vitro/In vivo 
Su [36] 2015 Stem Cell Res Ther China English OPG Lentivirus N/R 1.5×10
6 TU/ml HEK293 In vitro/In vivo 
Sun [37] 2010 Arch Oral Biol China/USA English BMP-2 AV GFP 50 PFU/cell N/R In vitro/In vivo 
Sun [38] 2013 J Oral Maxillofac Surg China English BMP-2 AV N/R N/R HEK293 In vitro/In vivo 
Sun [39] 2014 J Orthop Res China English Runx2 AV GFP 5×109 PFU/ml Runx2 
2×1010 PFU/ml GFP 
HEK293 In vitro/In vivo 
Sun[40] 2007 Shanghai Kou Qiang Yi 
Xue 
China Chinese BMP-2 Plasmid N/R N/R N/R In vivo 
Tan [41] 2009 Cytotherapy China English b-FGF Plasmid GFP N/R N/R In vitro/In vivo 
Tang [42] 2008 Cell Biol Int China English BMP-2 Plasmid N/R N/R N/R In vitro/In vivo 
Tang [43] 2006 Zhonghua Kou Qiang Yi 
Xue Za Zhi 
China Chinese BMP-2 Plasmid N/R N/R N/R In vitro/In vivo 
Wang [44] 2015 Br J Oral Maxillofac Surg China English NGF-β Lentivirus GFP N/R N/R In vivo 
Wei [45] 2013 Stem Cells Dev USA/China English EGFP Retrovirus N/R N/R PG13 In vitro/In vivo 
Wen [46] 2012 Arch Oral Biol China English EGFP Lentivirus N/R N/R 293FT In vitro/In vivo 
Yang [47] 2014 PLoS One USA/China English TSG-6 Lentivirus N/R N/R N/R In vitro/In vivo 
Ye [48] 2006 Shanghai Kou Qiang Yi 
Xue 
China Chinese BMP-2 AV GFP 100 MOI HEK293 In vivo 
Yu [49] 2011 Gene Ther USA English MKP-1 AV LacZ N/R HEK293 In vitro/In vivo 
Zhang [50] 2007 Biomaterials China English BMP-7 AV GFP 2×10
10 particles/ml HEK293 In vitro/In vivo 
Zhang [51] 2009 J Control Release China English BMP-7/PDGF-B AV GFP 2×10
10 particles/ml HEK293 In vitro/In vivo 
Zhang[52] 2015 J Clin Periodontol Switzerland 
China 
English BMP-7/PDGF-B AV N/R 1.4×1010 PFU/ml N/R In vitro/In vivo 
Zhao [53] 2010 Oral Dis China English BMP-2 AV GFP 80 PFU/cell (MOI) N/R In vitro/In vivo 
Zhao [54] 2012 Orthod Craniofac Res China/Japan English OPG HVJ N/R N/R N/R In vivo 
Zhou [55] 2010 Hua Xi Kou Qiang Yi Xue 
Za Zhi 
China Chinese OPG Plasmid N/R N/R N/R In vitro/In vivo 
Zhou[56] 2012 Int J Periodontics 
Restorative Dent 
China English OPG Plasmid N/R N/R N/R In vitro/In vivo 
Zou [57] 2012 PLoS One China English HIF-1α Lentivirus GFP 7 MOI N/R In vitro/In vivo 
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Table 2: Extracted data from included studies with description of disease model and animal model used  
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Abramson 
[1] 
Alveolar bone defect 
with dental implant 
Maxilla 
(bilateral: first 
molars) 
Male Sprague 
Dawley rats 
16 N/R 2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Collagen alone 
Untreated control 
8×1011 particles/ml 
8×1010 particles/ml 
Alden 
[2] 
Alveolar bone defect Mandible 
(bilateral: angle) 
Sprague 
Dawley rats 
13 4 mm 
circular 
Physiological 
saline 
In-vivo 
(local 
injection) 
---------- BMP 2 
BMP 9 
LacZ 
3.75×108 
particles/7.5 µl 
Ashinoff 
[3] 
Distraction Osteogenesis Mandible 
(Right side: body) 
Male Sprague 
Dawley rats 
54 N/R N/R In-vivo 
(local 
injection) 
---------- Untreated control 
BMP2 
LacZ 
1×1010 IFU 
Chang 
[4] 
Periodontal alveolar 
bone defect 
Mandible 
(Buccal plate:1st 
and 2nd molars roots) 
Sprague 
Dawley rats 
144 3×2×1 
mm3 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Collagen alone 
5.5×108 PFU/ml 
5.5×109 PFU/ml 
in 20µl collagen 
Chang 
[5] 
Alveolar bone defect 
with dental implant 
Maxilla 
(Bilateral: first 
molars) 
Male Sprague 
Dawley rats 
100 N/R 2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- High dose 
Low dose 
Luc 
rhPDGF-BB 
Collagen alone 
5.5×108 PFU/ml 
5.5×109 PFU/ml 
Chang 
[6] 
Alveolar bone defect Maxilla 
(Bilateral: 
infraorbital rim) 
Female 
miniature 
swine 
20 3×1.2 
cm2 
Collagen 
Type I 
Ex-vivo ---------- BMP2 
LacZ 
N/R 
Chen 
[7] 
Periodontal Disease Maxilla 
(labial PDL: 
incisors) 
Male Wistar 
rats 
29 N/R Lipid 
bubbles 
In-vivo 
(GAM) 
---------- DNA 
DNA/US 
DNA/NB 
DNA/US/NB 
N/R 
Chen[8] Alveolar bone defect Maxilla 
(Bilateral: anterior) 
Foxhound 
dogs 
N/R 2 cm PDLA In-vivo 
(GAM) 
---------- BMP-4 scaffold  
Autograft 
Scaffold only  
Blank control 
N/R 
Chen[9] Periodontal alveolar 
bone defect 
Maxilla 
(Bilateral: incisors) 
Male New 
Zealand 
White rabbits 
12 15×7×5 
mm3 
PF127 Ex-vivo BMMSCs BMP-2 transfected MSCs/PF127 
Βgal transfected MSCs/PF127 
Untransfected MSCs/PF127 
PF127 only 
50×106cell/ml 
Cirelli 
[10] 
Periodontal Disease Maxilla 
(Bilateral: 
palatal gingival 
tissue between 
molars) 
Male Sprague 
Dawley rats 
45 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
---------- Vehicle 
Pg-LPS 
TNFR:Fc 
TNFR:Fc + Pg-LPS 
1×1011DRP/100ml 
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Table 2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Cao[11] Periodontal Disease Maxilla&Mandible 
(First molars) 
Male 
Wuzhishan 
mini-pigs 
20 5×7×3m
m3 
Physiological 
saline 
Ex-vivo DPSCs DPSCs 
HGF-DPSCs 
DPSCs sheet 
HGF-DPSCs sheet  
Blank control 
1×107cells/0.6 ml 
Dai 
[12] 
Tempromandibular joint 
(Mandibular Condylar 
growth) 
Mandibular 
condyles 
Female 
Sprague 
Dawley rats 
60 N/R N/R Ex-vivo ---------- EGFP 
PBS only 
2×1011 genome 
copies/50 µl 
Dunn 
[13] 
Alveolar bone defect 
with dental implant 
Maxilla 
(First molars) 
Sprague–
Dawley rats 
44 2×1 
mm2 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- Luc 
BMP 7 
2.5×1011 particles 
Hu 
[14] 
Distraction Osteogenesis Mandible 
(Right side) 
Male 
Sprague-
Dawley rats 
44 N/R Physiological 
saline 
Ex-vivo BMMSCs BMP 7 
EGFP-N1 
physiological saline 
1×106 cell/0.15 ml 
Iglesias-
Linares 
[15] 
Orthodontic tooth 
movement 
Maxilla 
(Bilateral:Second 
molars) 
Wistar rats 72 N/R Solution In-vivo 
(local 
injection) 
---------- TM force + PBS (R&L) 
TM force + Corticotomy (R)/TM 
force + Flap surgery(L) 
TM force + RANKL (R)/TM force 
+ Plasmid without RANKL insert 
(L) 
Cortictomy (R)/Flap Surgery (L) 
RANKL (R)/Plasmid without 
RANKL insert (L) 
N/R 
Jiang 
[16] 
Alveolar bone defect Mandible 
(Bilateral) 
Female New 
Zealand 
White rabbits 
14 15×6 
mm2 
NNB Ex-vivo BMMSCs NNB/EGFP-BMP 4 
NNB/EGFP 
NNB/untransfected bMSCs 
NNB alone 
Blank control 
50×106 cell/scaffold 
Jiang 
[17] 
Sinus floor elevation Maxilla 
(Bilateral) 
Male New 
Zealand 
rabbits 
20 13×3×5 
mm3 
β-TCP Ex-vivo BMMSCs β-TCP alone 
Untransduced bMSCs/ β-TCP 
EGFP–bMSCs/ β-TCP 
BMP-2–bMSCs/ β-TCP 
2×107 cell/scaffold 
Jiang 
[18] 
Alveolar bone defect Mandible 
(Ascending ramus) 
Male Fisher 
344 rats 
24 5mm 
circular 
mSS Ex-vivo BMMSCs mSS/bMSCs transduced BMP 2 
mSS/bMSCs transduced LacZ 
mSS/bMSCs 
mSS alone 
2×107 cell/scaffold 
Jiang 
[19] 
Distraction Osteogenesis Mandible 
(Right side: between 
1st premolar and 
mental foramen) 
Male New 
Zealand 
rabbits 
42 N/R Physiological 
saline 
Ex-vivo BMMSCs b-FGF transfected MSCs in 
physiological saline, 
EGFP transfected MSCs in 
physiological saline. 
Physiological saline 
1×107cell/0.15 
ml 
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Table 2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Jin 
[20] 
Periodontal alveolar 
bone defect 
Mandible  
(Bilateral: 
mandibular 1st and 
2nd molar:buccal 
root PDL) 
Lewis rats 25 0.3×0.2 
cm2 
Gelatin 
sponge 
Ex-vivo SDFs GFP control-treated 
Noggin-treated 
BMP 7  
1×106 cell/scaffold 
Jin 
[21] 
Periodontal alveolar 
bone defect 
Mandible 
(Bilateral buccal 
plate of 1st and 2nd 
molars) 
Sprague–Dawley 
rats 
30 0.3×0.2 
cm2 
2.6% 
collagen 
gel 
In-vivo 
(GAM) 
---------- Luc 
PDGF-B 
PDGF-A 
Collagen matrix alone 
2.5×1011 viral 
particles(PN)/ml 
Kanzaki 
[22] 
Orthodontic tooth 
movement 
Maxilla  
(Right 1st molar of 
OF group) 
Male Wistar rats 25 N/R Vector 
solution 
In-vivo 
(local 
injection) 
---------- Control group 
OF group with or without 
RANKL 
Mock group 
N/R 
Kroczek 
[23] 
Distraction Osteogenesis Mandible 
(Right side) 
Female 
Goettingen mini-
pigs 
24 N/R Aqueous 
solution 
Ex-vivo BMMSCs BMP 2 group  
BMP 7 group  
TGF-b group 
IGF 1 group 
Liposome vector group 
No induction group 
4×105cell/dish 
Kuboki 
[24] 
Tempromandibular joint Mandibular 
condyles 
(Bilateral) 
Hartley guinea-
pigs 
16 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
---------- Gene 
Placebo 
Control 
4.8×107 PFU/cell 
Lai 
[25] 
Distraction Osteogenesis Mandible  
(Right side) 
Male New 
Zealand rabbits 
44 N/R Physiol gical 
saline 
Ex-vivo ADSCs transfected ADSCs 
EGFP-N1transfected ADSCs 
physiological saline only 
1×107cell/0.2 
ml 
Lai 
[26] 
Distraction Osteogenesis Mandible  
(Left side: anterior 
to 1st molar) 
Male New 
Zealand rabbits 
44 N/R Physiological 
saline 
Ex-vivo BMMSCs transfected BMMSCs,  
autologous BMMSCs 
physiological saline only 
1×107cell/0.2 
ml 
Lattanzi 
[27] 
Alveolar bone defect Mandible  
(behind the root of 
the incisor) 
Wistar rats 36 5×5 mm2 HA/COL  Ex-vivo SDFs LMP-3 transduced SDF on 
HA/COL 
Untransduced SDF on HA/COL 
HA/COL scaffold without cells 
Control group EGFP 
N/R 
Li 
[28] 
Alveolar bone defect Mandible 
(Bilateral) 
New Zealand 
rabbits 
44 12×8 
mm2 
HA/PA  
 
Ex-vivo BMMSCs Scaffold  seeded with BMP 7 
transduced MSCs 
Scaffolds seeded with 
osteogenically cultured MSCs. 
Pure HA/PA scaffolds  
2×106cell/scaffold 
Li 
[29] 
Periodontal Disease Mandible 
(Bilateral:premolar 
teeth) 
Adult Beagle dogs 5 N/R collagen 
membrane 
Ex-vivo BMMSCs Pure collagen membrane  
Collagen membrane / transfected 
cells Collagen membrane / 
untransfected cells 
1×107 cell/scaffold 
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Table 2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Li [30] Tempromandibular joint Mandibular 
condyles 
(Bilateral) 
Female Sprague–
Dawley rats 
30 N/R N/R In-vivo 
(local 
injection) 
------------ Vastatin 
EGFP 
2×1011 genome 
copies/50µl 
Long 
[31] 
Distraction Osteogenesis Mandible  
(Right side: between 
anterior teeth and 
1st premolar) 
Male Japanese 
rabbits 
36 N/R Physiological 
saline 
Ex-vivo BMMSCs Distraction of 0.8 mm/d for 12 
days. Distraction of 2.4mm/d for 
4 days, with MSCs transfected 
with lacZ  
Distraction of 2.4 mm/d for 4 
days with MSCs transfected with 
BMP-2. 
1×107cell/ ml 
Park J 
[32] 
Alveolar bone defect Mandible 
(Left ramus) 
Wistar rats 56 6mm 
circular 
Collagen 
sponge 
Ex-vivo BMMSCs BMP-2-infected BMSC 
LacZ-infected BMSC 
Untreated BMSC 
Empty collagen sponges 
1×106 cell/scaffold 
Park S 
[33] 
Periodontal alveolar 
bone defect with dental 
implant 
(Peri-implantitis wound) 
Mandible 
(Bilateral: premolars 
and 1st molar) 
Adult Beagle dogs 6 N/R HA/COL 
hydrogel  
Ex-vivo PDLSCs HA with collagen gel (control 
group,) 
HA with collagen gel/ PDLSCs  
HA with collagen 
gel/BMP2/PDLSC  
N/R 
Rabie 
[34] 
Tempromandibular joint  Mandibular 
condyles 
(Bilateral) 
Female Sprague–
Dawley rats 
90 N/R Physiological 
saline 
In-vivo 
(local 
injection) 
------------ VEGF 
EGFP 
PBS  
2×1011 genome 
copies/50µl 
Steinhardt 
[35] 
Alveolar bone defect Mandible  
(Right side) 
NOD/SCID mice N/R 1mm 
circular 
Collagen 
sponge 
Ex-vivo BMMSCs MSC-BMP2 
MSC-lacZ  
Control group (no implant) 
5×106 cell/scaffold 
Su 
[36] 
Alveolar bone defect Mandible 
(Left side: alveolar 
bone of incisors) 
Male New 
Zealand rabbits 
20 5×10×4 
mm3 
β-TCP Ex-vivo PDLSCs Control  
β-TCP  
PDLSCs/β-TCP  
OPG-PDLSCs/β-TCP  
5×106 cell/scaffold 
Sun 
[37] 
Sinus floor elevation Maxilla 
(Bilateral) 
Male New 
Zealand rabbits 
8 13×3×5 
mm3 
OsteoBone Ex-vivo BMMSCs BMP-2-infected BMSC/Scaffold 
EGFP-infected BMSC/Scaffold 
2×107 cell/scaffold 
Sun 
[38] 
Alveolar bone defect Mandible 
(Bilateral) 
Adult New 
Zealand rabbits 
18 10×6 
mm2 
BGC Ex-vivo PDLSCs BMP-2–modified tissue-
engineered bone 
Unmodified tissue-engineered 
bone 
Single BGC graft  
Defects without any implantation  
2×107 cell/scaffold 
Sun  
[39] 
Distraction Osteogenesis Mandible  
(Right side: anterior 
to 1st premolar) 
Female New 
Zealand rabbits 
90 N/R Physiological 
saline 
Ex-vivo ADSCs Runx2 transfected ADSCs  
GFP-transfected ADSCs 
Ovariectomized control 
Sham surgery control 
1×107 cell/ml 
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Table 2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Sun[40] Periodontal alveolar 
bone defect 
Mandible  
(Bilateral: 
premolars) 
Adult beagle dogs 6 5mm Collagen 
sponge 
In-vivo 
(GAM) 
------------ BMP-2 plasmid group 
BMP-2 group 
PBS 
N/R 
Tan 
[41] 
Periodontal Disease Mandible 
(Bilateral: 1st, 2nd 
and 3rd premolars) 
Male beagle dogs 4 5mm 
vertical 
Sodium 
alginate 
Ex-vivo BMMSCs bFGF transfected BMSCs 
Untransfected BMSCs 
2×107 cell 
Tang 
[42] 
Alveolar bone defect Mandible 
(Left ramus) 
Female Sprague 
Dawley rats 
40 4mm 
circular 
CHA Ex-vivo BMMSCs Control groups: empty defect 
CHA/autologous transfected BMP-2 
CHA/untreated autologous BMSCs 
5×106 cell/scaffold 
Tang 
[43] 
Alveolar bone defect Mandible 
(Ramus) 
Female Sprague-
Dawley rats 
24 4mm 
circular 
CHA Ex-vivo BMMSCs Control groups: left untreated 
BMSCs that transfected with BMP-2 
5×109 cell/scaffold 
Wang 
[44] 
Distraction Osteogenesis Mandible 
(Bilateral) 
Male New 
Zealand rabbits 
20 N/R Physiological 
saline 
Ex-vivo BMMSCs MSC transduced with NGF-b 
Control: EGFP 
5×106 cell/0.1ml 
Wei 
[45] 
Tooth restoration/Bio-
Root regeneration 
N/R Inbred miniature 
pigs 
18 N/R HA/TCP Ex-vivo DPSCs 
PDLSCs 
HA/TCP 
Autologous Vc-induced PDLSCs in 
HA/TCP/DPSC 
Allogeneic Vc-induced PDLSCs in 
HA/TCP/DPSC 
1×106 cell/scaffold 
Wen 
[46] 
Periodontal alveolar 
bone defect 
Mandible 
(Right 1st molars) 
Sprague-Dawley 
rats 
6 1×3 
mm2 
Collagen 
gel 
Ex-vivo PDLSCs eGFP transfected PDLSCs 
untransfected PDLSCs 
Empty defect 
5×105 cell 
Yang 
[47] 
Periodontal Disease Maxilla  
(Bilateral: 1st molar) 
Female Sprague–
Dawley rats 
30 N/R systemic: 
culture 
media 
Local: 
Matrigel 
Ex-vivo/ 
In vivo 
(systemic) 
iPSC-
derived 
MSCs 
Healthy control  
Untreated periodontitis  
iPSC-MSCs-treated periodontitis  
iPSC- MSCs/TSG-6-treated 
periodontitis  
5×106 cell/200µl 
media 
L: 1×106 cell/20µl 
gel 
Ye 
[48] 
Central fissures Mandible New Zealand 
rabbits 
45 N/R Bioglass Ex-vivo pOBs BMP-2 transfected POBs/bioglass  
EGFP transfected POBs/bioglass  
Untransfected POBs/bioglass  
Bioglass only  
Blankcontrol  
2×107 cell/scaffold 
Yu 
[49] 
Periodontal Disease Maxilla  
(1st and 2nd molars) 
Male Sprague–
Dawley rats 
51 N/R HEPES In-vivo 
(local 
injection) 
------------ MKP-1 
LacZ 
HEPES- buffered saline 
1×109 PFU 
Zhang 
[50] 
Alveolar bone defect 
with dental implant 
Mandible 
(Bilateral: Premolar 
region) 
Adult hybrid dogs 9 6×5×4 
mm3 
Chitosan/ 
Collagen 
In-vivo 
(GAM) 
PDLSCs Pure scaffold 
Scaffolds with BMP7  
Scaffolds with Easy1 
1×107 cell/scaffold 
Zhang 
[51] 
Alveolar bone defect 
with dental implant 
Mandible  
(Bilateral: Premolar 
region) 
Adult hybrid dogs 6 6×5×4 
mm3 
Chitosan/ 
Collagen 
In-vivo 
(GAM) 
PDLSCs Scaffolds with Easy1: control  
Scaffolds with BMP 7 
Scaffolds with PDGF-B  
Scaffolds with BMP-7/PDGF-B  
1×107 cell/scaffold 
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Table 2: Extracted data from included studies with description of disease model and animal model used 
Author Disease Model Site Animal 
Model 
Sample 
size 
Defect 
size 
Carrier/ 
 Scaffold 
Gene 
Delivery 
route 
Stem cell 
source 
Experimental groups Cell 
concentration 
Zhang [52] Periodontal Disease Maxilla  
(2nd & 3rd premolars) 
Male beagle dogs 5 5×5 
mm2 
MBG/silk 
fibrin  
In-vivo 
(GAM) 
------------ Control non-filled defects 
scaffold alone 
PDGF-B scaffold 
BMP7 scaffold 
PDGF-B + BMP7 scaffold 
5×105 cell/scaffold 
Zhao 
[53] 
Alveolar bone defect Mandible 
(Bilateral: ramus) 
Male Fisher 344 
rats 
11 5mm 
circular 
β-TCP Ex-vivo BMMSCs b-TCP alone 
b-TCP with untreated bMSCs 
b-TCP with bMSCs transduced with 
EGFP 
b-TCP with bMSCs transduced with 
BMP-2 
2×107 cell/scaffold 
Zhao 
[54] 
Orthodontic tooth 
movement 
Maxilla  
(Right 1st molars) 
Male Wister rats 18 N/R Vector 
solution 
In-vivo 
(local 
injection) 
------------ OPG transfection group 
Mock vector transfection group 
Control group 
N/R 
Zhou 
[55] 
Periodontal alveolar 
bone defect 
Mandible 
(Bilateral: 
premolars) 
Male purebred 
beagle dogs 
4 4×4×3 
mm3 
PLGA  Ex-vivo BMMSCs BMSCs/OPG-PLGA 
BMSCS-PLGA 
1×106 cell/scaffold 
Zhou[56] Periodontal alveolar 
bone defect 
Mandible 
(Bilateral: 
premolars) 
Male purebred 
beagle dogs 
4 4x4x3 
mm3 
PLGA Ex-vivo BMMSCs BMSCs/OPG-PLGA 
BMSCS-PLGA 
PLGA 
Negative control: root planing only  
1×106 cell/scaffold 
Zou  
[57] 
Alveolar bone defect 
with dental implant 
Mandible 
(Bilateral: premolars 
region) 
Adult male 
labrador retriever 
dogs 
5 6×5×4 
mm3 
CMPC  Ex-vivo BMMSCs Blank  
CMPC  
CMPC/BMSCs/GFP 
CMPC/BMSCs/HIF 
CMPC/BMSCs/cHIF 
2×105 cell/scaffold 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Abramson [1]  PDGFB demonstrated more mineralized 
tissue at 4 weeks than 2 weeks. Viral 
copies in blood and organs not 
significantly different between treated 
and untreated rats at all time points 
   
Alden [2]    3D CT showed marked osteogenesis and 
bony healing in BMP-2 and BMP-9 
treatment groups while control did not 
show notable healing.  
Slight healing of the defect in control. 
However, BMP-2 and BMP-9 showed 
marked bony regeneration across the defect 
site. BMP-2-treated defect demonstrated 
almost complete regeneration of the 
mandible indistinguishable from the normal 
mandible. 
Ashinoff [3]    Increased radio-density in BMP-2-treated 
animals with increased new bone 
formation compared to control  
 
Chang [4]  Viral vector of PDGFB was detected 
within the first week in DNA and 
gradually decreased to undetectable 
levels after 2 weeks. 
Luc/collagen showed high 
level in animals receiving 
high-dose Luc compared with 
low-dose.  
 Two weeks after surgery, nearly complete 
bone bridging of the alveolar bone in both 
PDGF-B groups whereas limited bridging in 
collagen-only animals. At 35 days, bone had 
completely bridged all of the defect area.  
Chang [5]  Absence of PDGF-B in bloodstream.  µCT showed higher bone volume fraction 
in PDGF-B and rhPDGF-BB groups than 
low dose PDGF-B and Luc groups. 
Bone was noted at coronal margin in Luc 
group and thicker bone trabeculae were 
evident in all PDGF-treated specimens. At 
day 14, near-complete defect fill was noted 
for all PDGF groups 
Chang [6]    3D CT revealed complete repair of defects 
implanted with BMP-2. However, small 
islands of bone formation were observed 
in the βgal. Immunohistochemistry results 
revealed positive staining in BMP-2 cell 
constructs. 
cancellous bone formation at defects 
implanted with BMP-2. Visible bone 
formation was noted at defect site implanted 
with BMP-2 cell constructs while βgal 
control had islands of bone formation with 
variable thickness and marked notching in 
the infraorbital rim.  
Chen [7]   At day 1 after treatments: 
DNA+NB and DNA+US 
treatments were as low as with 
DNA alone treatment. 
Ultrasonication after DNA + NB 
injection significantly increased 
luciferase activity. Rats with 
removed gingivae exhibited weak 
luciferase activity in labial tissues 
of maxillary incisors  
 Histology showed no haemorrhage or 
inflammation, while fluorescence images 
showed EGFP expression mostly confined 
to labial gingival tissues of maxillary 
incisors 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Chen [8]    At week 4, rhBMP-4 and autograft-treated 
groups showed a significant increase in 
bone regeneration when compared with 
the defect-only group and the scaffold 
only groups. No tooth eruption was seen 
at the 4-week time point in any of the four 
groups. New bone could be differentiated 
from grafted bone. By  week 12, the entire 
defect had been filled. 
The difference between new and grafted 
bone could not be seen. All four groups 
exhibited tooth eruption at 12 weeks. 
Chen [9] Showed that the 
adenovirus mediated BMP-
2 gene was positively 
expressed and processed in 
MSCs of the defect. 
  3D CT showed that BMP-2 group had the 
highest mean regenerated bone volume 
and there were no significant differences 
between the other three groups. 
6 weeks, BMP-2 group exhibited greater 
amounts of new bone formation. The newly 
regenerated trabecular bone was covered by 
a thick layer of osteoid and osteoblasts with 
continual bone-forming activity. The β-gal 
group exhibited woven bone formation, 
from the apical aspect of the defect to the 
middle of the root. The PF127 group 
displayed minimal amounts of bone 
formation at the apical third 
Cirelli [10] TNFR:Fc protein 4 weeks 
before Pg-LPS delivery 
showed high level which 
were sustained during 8-
week experimental period 
compared to Pg-LPS, 
vehicle or no treatment. 
High expression of IL-6, IL-10, RANKL 
and OPG observed at 4 weeks in Pg-
LPS-exposed animals, but not in 
TNRF:Fc. 
 2Dand 3D µCT of maxillae showed linear 
bone loss. Significant alveolar bone 
destruction was observed in Pg-LPS group 
continuously over 8 weeks. 
Administration of TNFR:Fc prevented 
linear bone resorption during entire study 
compared with Pg-LPS only treated 
group.  
An intense inflammatory cell infiltrate 
observed in subepithelial connective tissue 
and surrounding alveolar bone of  
periodontia of Pg-LPS- animals but a 
significantly less intense inflammatory 
reaction was observed in TNFR:Fc+Pg- 
LPS animals. Control animals did not show 
evidence of inflammatory cell infiltrates. 
Cao [11] Increased expression of 
HGF in transfected MSCs.  
  3D CT indicated limited bone formation 
in the control group. In contrast, marked 
bone regeneration occurred in the hDPSC, 
HGF-hDPSC, hDPSC sheet and HGF-
hDPSC sheet groups. The heights of 
newly regenerated bone were significantly 
higher in all treatment groups compared 
with control group. The bone volumes in 
all treatment groups were significantly 
larger than the volume in the control 
group. 
At week 12, new periodontal tissue 
regeneration within the periodontal defects 
was significantly less pronounced in the 
control group compared with the 
regeneration in the treatment groups. 
Alveolar bone regeneration was also more 
pronounced in the HGF-hDPSC, hDPSC 
sheet group and HGF-hDPSC sheet group 
than in the control group. The percentages 
of periodontal bone in the hDPSC injection, 
HGF-hDPSC injection, hDPSC sheet, and 
HGFhDPSC sheet groups were significantly 
higher than that of the control group. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Dai [12]  PCR of eGFP in heart, kidney, spleen 
and liver, mRNA was not detected 
reducing the prospects of systemic 
adverse effects. RT-PCR of transgene 
expression in the mandibular condyle 
revealed constant expression throughout 
the experiment. At day 21, there was a 
substantial increase in transgene 
expression. 
   
Dunn [13]   Showed sustained release of the 
gene product. All implants 
displayed the localized nature of 
expression in the near vicinity of 
the oral implants. The gene was 
expressed strongly for the first 
few days with peak expression at 
day 4 then declined by 2–5 
weeks. 
 BMP-7-treated defects displayed tissue 
consistent with early osteoid formation 
throughout the defect area. Ad/Luc group 
exhibited normal bone healing, with most 
specimens showing minimal bone formation 
at the defect borders. At 28 days, bone 
formation was heightened both at the defect 
margins and along the dental implant 
surface in Ad/BMP-7-treated sites. 
Hu [14]  Confirmed transcription of BMP-7 in 
transfected MSCs in contrast with 
negative signal in MSCs transfected 
with N1. 
 Radiodensity of callus in group A at 2 
weeks was greater than in group B which 
was higher than group C. After 6 weeks of 
healing, more mineralization of distraction 
zone was seen in all three groups, but 
group A had greater radiodensity.  
Immunocytochemistry showed BMP-7 
expression in transfected MSCs while 
MSCs transfected with N1 exhibited 
negative signals. Bone regeneration in the 
distraction gaps was intramembranous 
ossification. At 2 weeks, positive signals for 
BMP-7 were found in the distraction zones 
in all three groups. Strong BMP-7 
expression of was observed in group A, 
moderate in group B, and weak in group C. 
At 6 weeks, very weak BMP-7 positive 
staining was seen and a similar pattern and 
intensity was noted among the three groups. 
Iglesias-
Linares [15] 
    TM force groups with corticotomy or 
RANKL transfection showed a larger bone 
resorption area than control groups. 
Transfection group under orthodontic force 
maintained a higher bone resorption rate 
than corticotomy group under force 
throughout the experiment. 
Jiang [16]     No inflammation or giant cell-type reaction 
was observed in any of the groups in 
immunohistochemistry.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Jiang [17]     At week 2, newly formed trabeculae were 
found in the four groups. Just a slight newly 
formed bone was observed in group A; 
however, more bone area was found in 
group B and group C. In group D, a larger 
area of newly formed bone was found not 
only in the periphery but also in the centre 
of the space. At week 8, newly formed bone 
area increased in all four groups. 
Jiang [18] BMSCs transduced with 
BMP-2 produced higher 
levels of BMP-2 during the 
entire culture period as 
compared with LacZ and 
untransduced MSCs using 
ELISA 
Upregulation of collagen type I in MSCs 
transduced with BMP-2. Runx2 showed 
moderate upregulation. Osteopontin 
showed sustained marked upregulation. 
Osteocalcin showed a steep increase. 
Osteogenic markers in LacZ transduced 
bMSCs remained at basal levels. 
 A larger defined radio-opaque new bone 
formation and mineralization was 
observed in BMP-2- transduced bMSCs 
group when compared to the LacZ and 
untransduced groups.  
 
Increased bone formation in BMP-2-
transduced bMSCs implants, less bone 
formation in LacZ or untransduced bMSCs-
seeded scaffolds and no obvious bone 
formation was found in scaffold alone 
defects using histological sections. 
Immunohistochemistry displayed intensive 
BMP-2 staining in both bone matrix and 
surrounding fibroblastic-like tissue for 
BMP-2-transduced bMSCs whereas in LacZ 
bMSCs and untransduced bMSCs groups, 
BMP-2 staining was present but much 
weaker. No obvious positive staining was 
detected in the scaffold alone group. 
Jiang [19]  bFGF was at a highest level at day 7 in 
bFGF transfected MSCs and sustained at 
high level in the next 3 weeks. Negative 
signal of bFGF was detected in MSCs or 
MSCs transfected with EGFP. 
 At 8 weeks, radiodensity of distracted 
callus in group was higher than those in 
groups A and B while radiodensity in 
group B was higher than in group A. µCT 
showed that the lingual cortical bone was 
formed well than the buccal cortical bone 
in all groups. 
Immunohistochemistry showed bFGF 
expressed in bFGF transfected MSCs while 
negative signals in MSCs transfected with 
EGFP. Histology revealed newly formed 
trabeculae in all groups. 
Jin [20]     Expression of BMP-7 and noggin was 
undetectable by 10 and 35 days after surgery 
by immunohistochemistry. Minimal to no 
osteogenesis was seen in GFP and noggin 
groups at early time point. Defects treated 
with BMP-7 demonstrated cartilage and 
limited areas of bone in the majority of the 
defects. At 35 days extensive bone formation 
was seen in most of the defects treated by 
BMP-7 while minimal osteogenesis and 
cementogenesis and lack of fibre insertion 
was noted in GFP and noggin groups. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Jin [21]  PCR showed expression of PDGF-B in 
PDGF-B transduced SDFs but not in 
cells transduced by luc or PDGF-A or 
cells without any adenovirus 
transduction.  
The highest was at day 1 post-
gene delivery and decreased at 
days 4-7. At 14-28 days postgene 
transfer, luciferase decreased 
compared to day 1. 
 Immunostaining was performed at days 3, 
7and 14. In PDGF-B-treated group, greater 
numbers of positively stained cells on the 
surfaces of the alveolar bone and denuded 
tooth roots as well as the tissues 
surrounding the collagen matrix containing 
PDGF-B compared to other treatments at 
both days 3 and 7. At 3 days after treatment, 
no significant evidence of bone or 
cementum formation in any of the treatment 
groups and very few cells invaded into the 
adenovirus collagen implant. 
Kanzaki [22]     No severe inflammations in periodontal 
tissue on repeated local RANKL gene 
transfer. Strong RANKL protein expression 
in the periodontium after 2 or 4 days from 
RANKL gene transfer. Very few RANKL 
protein expressions in the periodontium 
after 6 days from RANKL gene transfer. 
The number of osteoclasts was high at day 2 
after RANKL gene transfer. The number of 
osteoclasts was reduced time dependently. 
Kroczek [23]    Ssome differences between early and late 
period of consolidation in relation to the 
osteoinductive substance applied. The 
central distraction zone had no 
ossification. Induction with TGF-b 
revealed crystallization spots dispersed 
homogenously over the central distraction 
zone. Osteoinduction with BMP-7 showed 
consolidation of the central distraction 
zone after 1 week with a small gap in the 
central distraction zone. In the late 
consolidation period, the gap was bridged 
by fine bone trabeculae. Induction with 
BMP-2 resulted in an accelerated, dense 
new bone formation. 
Lamination of the distracted bone areas 
adjacent to the osteotomy sites with 
longitudinally orientated columns of 
lamellar bone. The bone trabeculae showed 
osteoid deposition and early mineralization 
along their sides. The process of bone 
formation resembled more an 
intramembranous than chondroid 
ossification mode. Induction with TGF-b 
resulted in bone formation similar to one 
without induction. Positive immunostaining 
of BMP-2 was observed in distracted callus 
in all groups. Cellular elements with 
increased BMP-2 expression were found 
both in the distraction zone and in the 
consolidated osseous area close to the 
osteotomy region. A reduced BMP-2 
expression was found in the central 
distraction zones.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author  Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Kuboki [24]  The absence of LacZ in liver, kidney, 
heart, and brain in LacZ- or control 
group. In TMJ of LacZ-injected animals, 
expression of LacZ was detected and not 
detected in the joints of control group. 
  There was no observable difference 
between the virus-injected and the PBS-
injected joints. The frontal section of the 
mandibular joint 1 week after LacZ 
injection clearly showed that articular 
surface-lining cells were stained blue.  
Lai [25]    Radiodensity of distraction areas in group 
A was higher than that in groups B and C 
at Weeks 2 and 6 after the distraction 
procedure. 
Bone cells in the distracted areas were 
stretched along in the direction of the 
distraction. At 2 week, the two fragments of 
mandibles in all groups were filled with 
newly formed bone trabeculae. Similar 
results were seen in groups B and C, but 
much denser and thicker bone trabecules 
were observed in the distracted areas in 
group A than in group B and group C. At 6 
weeks, the distraction gaps of the mandible 
were full of newly generated bone in all 
three groups.  
Lai [26]    Radiograph of a distracted mandible at 2 
weeks showed that callus appeared to be 
greater in group A when compared with 
group B which was higher than group C. 
Bone regeneration in distraction gaps was 
intramembranous ossification. At 2 weeks, 
the new bone trabeculae formation began 
bridging in the 3 groups. More thick and 
dense trabecules were seen in the distraction 
gaps in group A than group B and C. At 6 
weeks, the gaps were filled with newly 
formed bone in all groups. At 2 weeks, 
immunohistochemistry of BSP showed 
areas of fibrous connective tissue within the 
gaps and were mainly detected in the 
cellular components of fibroblast like cells, 
preosteoblasts, and osteoblasts in all 3 
groups. Cells in group A showed greater 
amount and more intense staining for BSP 
within the gaps than group B which is more 
than group C. 
 
 
 
Page 48 of 62
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
7 
 
Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Lattanzi [27]  Efficient LMP-3 expression 24 and 48 h. 
qPCR demonstrated that LMP-3 in 
transduced cells slightly increased in a 
time-dependent manner. 
 All rats treated with LMP-3 transduced 
SDFs showed positive X-rays at 8 and 12 
weeks after surgery. No radiological 
evidences of bone formation could be 
demonstrated in three out of four animals 
at the earliest time point and in animals 
treated with scaffold alone or with non-
transduced cells. 3DµCT revealed the 
successful repair of the defects implanted 
with LMP-3 cell constructs, which 
occurred in a time-related manner until 12 
weeks after implantation. No bone 
formation was observed in the control 
group. 
All rats treated with LMP-3 transduced 
SDFs showed positive histology at 8 and 12 
weeks. No histological evidences of bone 
formation could be demonstrated in three 
out of four animals at the earliest time point 
and in animals treated with scaffold alone or 
with non-transduced cells.  
Li [28]  BMP-7 was expressed in BMP-7 
transfected MSCs while MSCs 
transfected with N1 exhibited negative 
signals. 
 Radiodensity in group A was higher than 
in group B and C. At 8 weeks, increasing 
mineralization in the implants was seen in 
group A than the other two groups. 
Immunocytochemistry showed BMP-7 was 
expressed in BMP-7 transfected MSCs 
while N1 transfected MSCs exhibited 
negative signals. Immunocytochemistry of 
ALP and collagen I in group A was stronger 
than in group B. New bone formation was 
found in the implanted area in all three 
groups. At 4 weeks, the interface zone was 
surrounded by primitive mesenchymal cells 
differentiated into osteoblasts and new bone 
matrix was progressively deposited and 
became ossified. At week 4 and 8, all the 
parameters were significantly higher in 
group A than in group B than in group C. 
However, no significant difference in these 
parameters was found among three groups 
at week 16. 
Li [29]     The percentage of new alveolar area in 
transfected and non-transfected BMSC were 
significantly higher than the control and 
there was also significant difference 
between two experimental groups. The 
percentage of new cementum length in two 
experimental groups was significantly 
higher than the control but there was no 
significant difference between two BMSCs 
groups. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Li [30]  Vastatin was only found  in  the  
experimental group. There were no 
transcripts detectable in the control 
group.   
  Positive signals in immunostaining at day 7 
while absence of signals in control group. 
Expression of Vastatin was the highest on 
day 7, decreased from day 14 to day 60. 
The expression was in the proliferative 
and chondroblast layers on day 7. On day 
14, Vastatin expressed in chondrocyte 
and pre-hypertrophic chondrocyte 
layers. The expression moved to the 
pre-hypertrophic chondrocyte and 
hypertrophic chondrocyte layers on day 
21. On day 30, the expression moved 
deeper  to hypertrophic chondrocyte 
layer. Only minor e xpression could be 
found in the deep hypertrophic 
chondrocyte layer on day 60. 
Long [31] BMP-2 levels were 
significantly higher in 
BMP-2 transfected MSCs 
compared with lacZ–
transfected MSCs 
  The distraction gaps in group B rabbits did 
not show ideal new bone formation at 
week 2 while group A and C showed 
partial. The distraction gap in group A and 
C animals showed more mature new bone 
formation and higher radiopacity at week 
4 compared with week 2. At week 8, 
radiograph of group A and C were almost 
identical to each other. µCT showed little 
new bone formation in the distraction gaps 
of group B animals at week 2. However, 
in groups A and C, new bone tissue was 
gradually mineralized from the centre to 
the margin in the distraction gap. More 
trabecular bone was mineralized at week 4 
in group C than in group A. Groups A and 
C looked similar at week 8. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author  Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Park J [32]     Immunocytochemistry of osteocalcin showed 
mineralization in genetically modified 
BMSC but rarely in control group. In both 
gene transfer groups, the amount of 
osteocalcin increased similarly. At 4 weeks 
endochondral bone formation occurred in the 
gene transfer groups and in the control; 
however, the amount of newly formed bone 
in the control was much less than in 
genetically modified BMSC. Treatment of 
defects with BMP-2-infected BMSC resulted 
in nearly complete bony healing within 4 
weeks after the transplantation.  
Park S [33] BMP-2 expression level in 
the BMP2/ PDLSCs was 
significantly higher than in 
non-transduced PDLSCs. 
BMP-2 expression 
increased for 7 days and 
decreased until day 21. 
  The bone was lost at 4 months after the 
induction of experimental peri-implantitis 
in radiographs. 
The bone labelling experiments 
demonstrated that new bone formation and 
re-osseointegration in the BMP2/PDLSC 
group occurred along the implant surface 
until week 8. PDLSC group showed less 
newly formed bone than BMP2/PDLSC 
group. The control group showed a limited 
amount of new bone formation around the 
peri-implantitis defects. 
Rabie [34] VEGF delivered group was 
higher than those two 
control groups from day 21 
to day 60. VEGF expressed 
from mandibular condyle 
was significantly increased 
from day 14 and lasted 
during the whole time 
periods. On day 30, VEGF 
expression was more than 
in control group. 
the expression of VEGF in condylar 
cartilage at day 7 and the maximum 
level at 21 days consistent with the 
result of in situ hybridization. 
  Immunohistochemistry confirmed increased 
VEGF expression in VEGF delivered 
condyle and positive signal in nearly all 
layers of condyle at day 30. VEGF 
expression was limited to the hypertrophic 
layer in control groups.  
The length and width of the condylar head 
increased significantly. The length of the 
condylar process significantly increased. 
Collagen type II was positive in 
chondroblast and hypertrophic layer. In 
control groups, collagen type II and type X 
positive layer decreased with age. However, 
after VEGF delivery, the collagen type II 
positive layer was significantly increased at 
day 21, compared to eGFP and PBS 
injection.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Steinhardt 
[35] 
 High levels of BMP2 in the cells but the 
protein expression levels were very 
similar. 
 Almost fully regenerated defect after 8 
weeks. Minimal regeneration was 
observed after 8 weeks in control group 
infected with lacZ. 
Masson trichrome staining revealed 
formation of new bone tissue and almost 
complete healing of the defect implanted 
with MSC-hBMP2. Minimal amount of new 
bone tissue was evident but no complete 
regeneration in lacZ or no implant.  
Su [36]  Increased OPG level in hOPG 
transfected cells compared with non-
transfected cells. 
  Toluidine blue staining showed no bone 
regeneration detected at the alveolar bone 
control group. A small amount of new bone 
could be seen in the β-TCP group with some 
osteoid formation in the periphery and 
centre of β-TCP scaffold. PDLSCs/β-TCP 
group showed more new alveolar bone 
formation, with numerous small bone 
trabeculae interconnected with each other. 
Sun [37] High BMP-2 in MSCs 
transduced with BMP-2 as 
compared with EGFP. 
   BMP-2 immunocytochemistry showed high 
staining in BMP-2 infected MSCs than that 
in control and EGFP infected cells. In BMP-
2-MSCs/scaffold and EGFP-MSCs/scaffold, 
more newly formed trabeculae were found 
dose to the parent bony wall and lifted 
membrane. At 4 weeks after implantation, 
newly formed bone area in the entire 
augmented area was larger than that at 2 
weeks. 
Sun [38] High concentration of 
BMP-2 in the supernatant 
of cultured cells. There 
was no BMP-2 detected in 
uninfected cells during the 
entire time course. 
   More new bone tissue was found in the 
peripheral part of the grafted defects than in 
the central part. The central part of the 
grafts showed that the amount of bone in 
groups A and B was significantly larger 
than in group C. In the unfilled controls, 
there was more fibrous connective tissue 
formed in the defects after 12 weeks and no 
full bone healing was found. 
Sun [39]  q-PCR showed the higher expression of 
Runx2 in Runx- transfected ADSCs than 
GFP transfected ADSCs and controls. 
 At week 9, radiograph of Groups A2 and 
D2 showed mature bone formation. µCT 
indicated the formation of new bone in 
Groups A2 and D2 than in the other two 
groups. Little new bone formation was 
observed in the distraction gaps of Groups 
B2 and C2. 
The distraction gaps in specimens from 
Groups A2 and D2 were filled primarily 
with fibrous tissue and tiny trabeculae at 
week 3. By 6 weeks, more new bone tissue 
was formed with thicker and wider 
trabeculae.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Sun [40]     At 8 weeks, a complete osseous healing occurred and dense new periodontal 
ligament fibers rich in blood vessels 
were observed in  BMP-2 group and 
rhBMP-2 group whereas fewer new 
bone occurred and sparse collagen fibers 
aligned irregularly were observed in the 
blank control group. The height of new 
bone and cementum were significantly 
greater in the two experimental group 
than in the blank control group. 
Tan [41]    New bone formation in the two groups but 
the density of the newly formed bone in 
the bFGF-modified BMSC group was 
higher than that in BMSC-alone. µCT 
showed extensive new bone apposition in 
continuity with the trabecular host bone 
structure in the bFGF-modified BMSC 
transplantation group and BMSC-alone 
transplantation group. 
Both groups exhibited periodontal 
regeneration, including newly formed 
cementum, periodontal ligament and bone. 
The newly formed bone and periodontal 
ligament in sites receiving bFGF-modified 
BMSC were greater than those receiving 
BMSC alone.  
Tang [42]    Radiographs confirmed that implanted 
BMSCs expressing BMP-2 promoted 
bone formation.. 
BMP-2 expression was detected by 
immunohistochemistry in transfected cells 
but not in the untreated BMSCs. Bone 
formation was observed on the composites 
seeded with transfected BMSCs expressing 
BMP-2 and the group implanted with CHA 
seeded with untreated BMSCs but the 
negative control implants did not induce 
bone formation. At 4 weeks the bone 
defects that were treated with transfected 
BMSCs showed formation of mature bone 
matrix with a trabecular pattern at the defect 
margin. At week 8, the defect was nearly 
completely closed and the newly formed 
mature bone had a typical trabecular 
pattern. 
Tang [43]     New bone formation was found at the 
margin of the defect treated with the BMSC 
modified by hBMP-2 gene transfer at 4 
weeks and appeared mature 8. However, the 
amount of newly formed bone was much 
less with some adipose tissue at defect 
margins 8 weeks in control group.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Wang [44] Secretion of NGF from the 
transduced MSC which 
increased to day 7. 
   Control group had signs of nerve 
degeneration with few regenerating nerve 
fibres whereas in experimental group there 
were abundant regenerating nerve fibres.  
Wei [45]    Six months after transplantation, bone-like 
tissue formation was observed in HA/TCP 
group with no obvious boundary between 
the newly regenerated tissue and bone as 
well as HA/TCP/ DPSC/PDLSC sheet 
implant formed a hard root structure and a 
clear PDL space was found between the 
implant and surrounding bony tissue. µCT 
demonstrated that there was no obvious 
hard root structure and PDL space in 
HA/TCP group whereas a visible root 
structure and PDL space-like areas in 
HA/TCP/DPSC/PDLSC sheet group. 
PDLSCs sheet had two or three layers and 
uniformly spread as a two dimensional 
tissue structure. Immunostaining for 
vimentin was positive. Fibronectin and type 
I collagen were present in the harvested 
PDLSC sheet.  
Wen [46]  At 7 days, the expression levels of COL-
1 and RUNX2 in PDLSCS were higher 
than those in eGFP-PDLSCs; the 
expression levels of ALP and OPN 
eGFP-PDLSCs were similar to those in 
PDLSCs.  
  6 weeks after surgery new regenerated 
bone, newly formed cementum and 
periodontal ligament were observed in 
group A and B. Strong expression of GFP 
and OPN was observed in the newly formed 
bone and cementum in the experimental 
group. 
Yang [47] The production of 
proinflammatory cytokines 
was also significantly 
decreased in serum 
samples. 
Increased TSG-6 expression in 
transfected iPSC-MSCs whereas low 
TSG-6 expression in untransfected 
iPSC-MSCs. Systemic administration of 
iPSC-MSCs and iPSC-MSCs/ TSG-6 
reduced periodontal inflammation. 
  The infiltration of inflammatory cells in the 
periodontal tissues was markedly decreased 
in iPSC-MSCs/TSG-6 group.  
Ye [48]    Higher bone density was found in the 
rabbit mandibular central fissures of group 
I 4 to 8 weeks after implantation. 
Much more new bony callus in group I than 
in other groups. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Yu [49]    Cells transduced with MKP-1 exhibited 
reduced bone resorption after LPS 
stimulation compared with LacZ or 
HEPES control. 
There were no significant inflammatory 
cells and few multinucleated osteoclasts on 
the alveolar bone surface in the periodontal 
tissues injected with PBS. In contrast, there 
were significantly more inflammatory cells 
more fibroblasts and more multinucleated 
osteoclasts in the periodontal tissues 
injected with LPS. Immunohistological 
staining revealed that MKP-1 was present in 
the periodontal tissues of rats injected with 
MKP-1 but undetectable in control groups 
of rats.  
Zhang [50] The maximum 
concentration of BMP7 in 
the culture media was 
detected after 6–9 days 
incubation and then 
followed by a moderate 
decline. 
Significant differences in expression 
levels of OPN and BSP when HPLCs 
were cultured in BMP7 scaffolds. 
  The new bone formation of Group 2 was 
significantly greater than other groups at 4 
and 8weeks. BMP7 group significantly 
increased the percentage bone defect fill in 
the defects compared to other groups. 
Zhang [51] HPLCs incubated in Group 
3 produced higher level 
PDGF-B and produced 
higher level BMP7 in 
Group 2 during the entire 
culture period. There was 
no significant difference in 
the production of PDGF 
between groups 3 and 4. 
Similar results were noted 
in BMP7 secreted by 
Group 2 and Group 4. 
Osteopontin and Type I collagen values 
of the PDGF-B expressing scaffolds 
were significantly greater than that of 
the control. The significant differences 
were observed in the mRNA expression 
levels of osteopontin, bone sialoprotein 
and Type I collagen when the HPLCs 
were cultured in combination scaffolds 
compared with BMP-7 or PDGF-B 
expressing scaffolds. 
  The new bone formation of the BMP-7 
expressing scaffolds and the combination 
were significantly greater than that of the 
control at 4 and 8 weeks. 
Zhang [52] by 7 days, over fourfold 
significant increases in 
PDGF-B and BMP7 was 
observed. The addition of 
adPDGF-B significantly 
increased cell recruitment 
approximately eight times 
more than control scaffolds 
and over six times higher 
than BMP7 scaffolds. 
In all scaffolds containing BMP7 or 
PDGF-B+BMP7, mRNA levels of each 
gene was significantly increased. The 
scaffolds containing adPDGF-B alone 
was only able to significantly upregulate 
mRNA levels of COL1.  
 Control defects demonstrated little tissue 
formation with regeneration of periodontal 
tissues. Defects filled with scaffolds alone 
regenerated little new periodontal tissues. 
Compared to scaffolds/PDGF-B. In 
contrast, scaffolds containing BMP7 
demonstrated greater new bone formation. 
Scaffolds with PDGF-B and BMP7 
demonstrated qualitative features similar 
to those of native periodontal structures.  
Control defects demonstrated little tissue 
formation with regeneration of periodontal 
tissues below 20% for cementum, alveolar 
bone and PDL. Defects filled with scaffolds 
alone regenerated less new periodontal 
tissues. Scaffolds containing PDGF-B 
demonstrated new formation of PDL. In 
contrast, scaffolds containing BMP7 
demonstrated greater new bone formation. 
Scaffolds with  PDGF-B and BMP7 
demonstrated qualitative features similar to 
those of native periodontal structures.  
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Zhao [53]  OPN and OCN from BMP-2-transduced 
MSCs showed only a slight increase 
relative to GFP-transduced MSCs. At 9 
days of culture, OPN dramatically 
increased in BMP-2-transduced MSCs 
compared with GFP-transduced MSCs. 
 Radiopacities at the defect sites inβ-TCP 
alone group, untreated MSCs ⁄β-TCP 
group and GFP-transduced MSCs ⁄β-TCP 
group. µCT showed that bone formation 
was less for defects filled with untreated 
MSCs ⁄β-TCP and GFP-transduced MSCs 
⁄β-TCP but still advanced when compared 
with the implantation of β-TCP alone. 
Substantial new bone formation was 
observed after 8 weeks in the critical size 
defects which received BMP-2-transduced 
MSCs ⁄β-TCP construct. 
mall amount of irregularly arranged woven 
bone tissue at the centre pores of β-TCP 
scaffold and fibrous connective tissue was 
still frequently observed. In the defects 
filled with implantation of BMP-2-
transduced MSCs ⁄β-TCP construct, mature 
newly formed bone tissue with few fibrous 
connective tissues infiltration was observed 
in the β-TCP pores at both centre and 
marginal area. Bone marrow also largely 
formed accompanied with the bony 
ingrowth. 
Zhao [54]    BMD and BVF were significantly 
increased in the OPG transfection group 
compared to the control and mock groups. 
The amount of ERR in the three groups was 
minimal and no significant differences 
among the three groups at the first two time 
points. By the last day of orthodontic tooth 
movement, the volume of ERR in all three 
groups was significantly increased. After 2 
weeks of retention, the volume of ERR in 
all three groups was significantly decreased 
especially in OPG transfection group. In the 
control and mock groups, there was 
significantly more ERR by the last day of 
retention. Immunohistochemistry showed 
that OPG protein expression was facilitated 
in the periodontium when was injected in 
the OPG transfection group. 
Zhou [55]     After 6 weeks, the height of new alveolar 
bone and cementum and the formation of 
new connective tissue were significantly 
greater in the experimental group than in the 
control groups. 
Zhou [56]    New bone formation was observed in the 
defect. The height of the newly formed 
bone was more than that of the original 
bone crest and there was close fusion 
between the old and new bone. In the cell 
control group and scaffold control group, 
the height of the newly formed bone was 
not as good as that in the experimental 
group. In the negative control, there was 
virtually no new bone formation. 
Immunohistochemistry showed that the 
expression of OPG protein in the BMSCs 
OPG group was higher than that in the 
control group. Significantly more tissue 
regeneration for the scaffolds with BMSCs 
OPG was noted compared with the other 
groups. 
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Table 3: Endpoint results of the main analytical methods used for the experiments 
Author Endpoint results of the main analytical methods 
ELISA PCR Bioluminescence Radiograph (plain or µCT) Histology/Immunohistochemistry 
Zou [57]  HIF-1a mRNA and protein expression 
was upregulated in the target gene 
groups compared with the control group. 
 Scaffolds implanted in the correct position 
and tightly contacted the implant. In the 
HIF-1a expressing groups, new bone 
formation and osseointegration were 
superior to the GFP, CMPC and blank 
groups as measured by bone density and 
the bone contact ratio of dental implants. 
µCT showed that the new bone formation 
in the HIF and cHIF groups was greater 
than that in the other groups at 12 weeks. 
Higher in HIF group than CMPC group, the 
blank group or the GFP group but less than 
the percentage in the cHIF group. BIC in 
each target gene groups was significantly 
higher than the control groups and no 
significant difference was observed between 
the CMPC group and the blank group. 
There were significant differences in bone 
density between the cHIF or HIF group and 
each control group but no significant 
difference was seen among the three control 
groups. 
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Table 4: Categories and grading used to assess the quality of the selected studies 
Item Description  Grade 
1 Title 0 = inaccurate/not concise 
1 = accurate and concise 
2 Abstract 
Summary of the background, research objectives, including details of the species or strain of 
animal used, key methods, principal findings  and conclusions of the study 
0 = clearly inaccurate 
1 = possibly accurate 
2 = clearly accurate 
3 Introduction 
Background-objectives, experimental approach and rationale, relevance to human biology 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
4 Introduction 
Objectives-primary and secondary 
0 = not clear 
1 = clear 
5 Methods 
Ethical statement-nature of the review permission, relevant licenses, national and institutional 
guidelines for the care and use of animals 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
6 Methods 
Study design-number  of experimental and control  groups, any steps taken to minimize  bias 
(i.e., allocation concealment, randomization, blinding) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
7 Methods 
Experimental  procedure-precise details (i.e., how, when, where, why) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
8 Methods 
Experimental animals-species, strain, sex, developmental stage, weight, source of animals 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
9 Methods 
Housing and husbandry-conditions and welfare-related assessment interventions (i.e., type of 
cage, bedding  material,  number of cage companions, light/dark cycle, temperature, access to 
food  and water) 
0 = clearly insufficient 
1 = possibly sufficient 
2 = clearly sufficient 
10 Methods 
Sample size-total number of animals used in each experimental group, details of calculation  
methods 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
11 Methods 
Allocation of animals to experimental groups-randomization or matching, order in which 
animals were treated or assessed 
0 = no 
1 = yes 
12 Methods 
Experimental outcomes-definition of primary and secondary outcomes 
0 = no 
1 = unclear/not complete 
2 = yes 
13 Methods 
Statistical methods-details and unit of analysis 
0 = no 
1 = unclear/not complete 
2 = yes 
14 Results 
Baseline data characteristics and health status of animals 
0 = no 
1 = yes 
15 Results 
Number analysed-absolute  numbers in each group included in each analysis, explanation for 
exclusion 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
16 Results 
Outcomes and estimation-results for each analysis with a measure of precision, as standard 
error or confidence  interval 
0 = no 
1 = unclear/not complete 
2 = yes 
17 Results 
Adverse events-details and notifications for reduction 
0 = no 
1 = unclear/not complete 
2 = yes 
18 Discussion 
Interpretation/scientific implications-study limitations including animal model, implications for 
the 3Rs 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
19 Discussion 
Generalizability/translation-relevance to human biology 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
20 Discussion 
Funding-sources, role of the funders 
0 = clearly inadequate 
1 = possibly adequate 
2 = clearly adequate 
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Table 5: Quality assessment of articles included using ARRIVE guidelines 
Reference Items  
S
c
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 T(36) 
Abramson[1] 1 0 2 1 0 2 0 1 0 2 1 0 0 0 0 1 0 0 0 2 14 0.38 
Alden[2] 1 1 2 1 0 1 1 1 0 2 1 1 0 0 0 2 0 2 2 2 21 0.58 
Ashinoff[3] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 2 2 2 1 1 2 33 0.91 
Chang[4] 1 2 2 1 2 2 2 2 0 2 1 2 2 1 2 1 2 2 2 2 34 0.94 
Chang[5] 1 2 2 1 2 2 2 1 0 2 1 2 2 1 1 1 0 1 1 2 28 0.77 
Chang[6]  1 1 2 1 0 1 1 2 0 2 1 2 2 1 1 2 2 1 1 2 27 0.75 
Chen[7] 1 1 2 1 2 1 1 1 0 2 1 2 2 1 2 1 2 1 1 2 28 0.77 
Chen[8] 1 2 2 1 2 1 1 1 0 1 1 1 2 1 2 2 1 1 1 2 26 0.72 
Chen[9] 1 2 1 1 2 2 2 2 1 1 1 1 0 1 1 2 1 1 1 2 26 0.72 
Cirelli[10] 1 2 2 1 2 2 2 2 1 2 1 2 2 0 1 2 0 1 2 2 31 0.86 
Cao[11] 1 2 1 1 2 2 2 2 0 2 1 1 2 0 2 2 1 1 1 2 28 0.77 
Dai[12] 1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 1 0 1 1 2 26 0.72 
Dunn[13] 1 2 2 1 2 2 2 2 0 2 0 2 2 0 1 1 0 1 1 2 27 0.75 
Hu[14] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 1 2 2 1 1 2 31 0.86 
Iglesias-
Linares[15] 
1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 2 2 2 2 2 31 0.86 
Jiang[16] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Jiang[17] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Jiang[18] 1 2 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Jiang[19] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 2 2 1 1 1 2 31 0.86 
Jin[20] 1 2 2 1 2 2 2 1 0 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Jin[21]  1 2 2 1 0 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Kanzaki[22] 1 2 2 1 2 2 1 1 0 2 1 2 2 1 1 2 2 2 2 2 32 0.88 
Kroczek[23] 1 2 2 1 2 1 2 2 0 2 0 2 2 1 1 2 1 1 1 2 29 0.80 
kuboki[24] 1 1 2 1 2 2 2 1 0 2 1 2 0 0 1 1 2 1 1 2 26 0.72 
Lai[25] 1 1 2 1 2 2 2 1 0 2 1 2 2 1 1 2 2 1 1 2 30 0.83 
Lai[26] 1 1 2 1 2 2 2 2 0 2 1 2 2 1 1 2 2 1 1 2 31 0.86 
Lattanzi[27] 1 1 2 1 2 2 2 1 0 2 1 2 0 1 2 2 1 1 1 2 28 0.77 
Li[28] 1 1 2 1 2 2 1 1 0 2 1 2 2 0 1 2 1 1 1 2 27 0.75 
Li[29] 1 1 2 1 2 2 1 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Li[30] 1 2 2 1 1 2 1 1 0 1 1 1 2 0 0 1 1 1 1 2 22 0.61 
Long[31] 1 1 2 1 2 2 2 2 0 2 1 2 2 0 1 2 2 1 1 2 30 0.83 
Park J[32] 1 2 2 1 0 2 2 1 1 2 1 2 0 0 1 1 1 1 1 2 25 0.69 
Park S[33] 1 2 2 1 2 2 1 1 0 2 1 2 2 0 1 2 1 2 1 2 29 0.80 
Rabie[34] 1 2 2 1 2 1 1 1 0 2 1 2 2 0 1 2 1 1 1 2 27 0.75 
Steinhardt[35] 1 2 2 1 2 1 2 1 0 0 0 2 2 0 1 2 1 1 2 2 25 0.69 
Su[36] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 1 1 1 0 27 0.75 
Sun[37] 1 1 2 1 2 2 2 2 1 2 1 2 2 1 1 2 2 1 1 2 32 0.88 
Sun[38] 1 1 2 1 2 2 2 1 1 2 1 2 2 1 1 1 1 1 2 0 28 0.77 
Sun[39] 1 2 2 1 2 2 1 2 0 2 1 2 2 0 1 2 2 1 1 2 30 0.83 
Sun[40] 1 2 0 0 0 1 1 2 0 2 0 1 2 0 0 2 1 1 0 2 18 0.5 
Tan[41] 1 2 2 1 2 1 1 2 1 2 1 2 2 1 1 2 2 1 2 2 32 0.88 
Tang[42] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 2 1 1 2 30 0.83 
Tang[43] 1 1 2 1 2 1 1 2 0 2 1 2 0 0 1 2 1 1 1 2 25 0.69 
Wang[44] 1 2 2 1 2 2 2 2 0 2 1 2 2 1 1 1 1 1 1 2 30 0.83 
Wei[45] 1 1 2 1 2 2 1 2 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Wen[46] 1 1 2 1 2 2 2 1 1 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Yang[47] 1 1 2 1 2 2 2 1 0 2 1 2 2 0 1 1 1 1 1 2 27 0.75 
Ye[48] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Yu[49] 1 1 2 1 2 2 1 1 1 2 1 2 2 0 1 1 1 1 1 2 27 0.75 
Zhang[50] 1 0 2 1 2 1 1 1 0 2 1 2 2 1 1 2 1 1 1 2 26 0.72 
Zhang[51] 1 0 2 1 2 1 1 1 0 2 1 2 2 1 1 1 1 1 1 2 25 0.69 
Zhang[52] 1 1 2 1 2 2 2 2 1 2 1 2 2 0 1 1 1 1 1 2 28 0.77 
Zhao[53] 1 1 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 29 0.80 
Zhao[54] 1 1 2 1 2 2 1 2 1 2 0 2 2 1 1 2 2 1 2 2 31 0.86 
Zhou[55] 1 1 2 1 2 2 2 1 0 2 1 2 2 0 1 2 1 1 1 2 28 0.77 
Zhou[56] 1 1 2 1 2 2 1 2 0 2 1 2 2 1 2 2 1 1 1 0 27 0.75 
Zou[57] 1 2 2 1 2 2 2 2 0 2 1 2 2 0 1 2 1 1 1 2 30 0.83 
Category score 
(quality 
obtained) 
57 76 108 56 100 100 89 88 16 110 52 105 100 25 61 96 68 60 63 110   
Max category 
score (quality 
expected) 
57 114 114 57 114 114 114 114 114 114 57 114 114 57 114 114 114 114 114 114   
T: Total score for all the 20 items (36 points), Score: score of the items/the total score. 
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Aghaloo Aghaloo, T., Jiang, X., Soo, C., Zhang, Z., Zhang, X., Hu, J., . . . Zhang, X. (2007). A study of the 
role of nell-1 gene modified goat bone marrow stromal cells in promoting new bone formation. Mol 
Ther, 15(10), 1872-1880. 
Ectopic bone 
Aslan Aslan, H., Zilberman, Y., Arbeli, V., Sheyn, D., Matan, Y., Liebergall, M., Gazit, Z. (2006). 
Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue 
regeneration. Tissue Eng, 12(4), 877-889.  
Ectopic bone 
Baum Baum, B. J., Goldsmith, C. M., Hoque, A. T., Wellner, R. B., Baccaglini, L., Ding, C., O'Connell, B. 
C. (2000). Salivary glands as a model for craniofacial applications of gene transfer. Int J Oral 
Maxillofac Surg, 29(3), 163-166. 
Review 
Blessmann Blessmann, M., Al-Dam, A., Hanken, H., Assaf, A. T., Riecke, B., Klatt, J., Grobe, A. (2013). 
Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). J 
Craniomaxillofac Surg, 41(8), 845-849.  
Cancer 
Breitbart Breitbart, A. S., Grande, D. A., Mason, J. M., Barcia, M., James, T., & Grant, R. T. (1999). Gene-
enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced 
retrovirally with the BMP-7 gene. Ann Plast Surg, 42(5), 488-495. 
Bone other 
than OMF 
Cai Cai, J., Zhang, Y., Liu, P., Chen, S., Wu, X., Sun, Y., Pei, D. (2013). Generation of tooth-like 
structures from integration-free human urine induced pluripotent stem cells. Cell Regen (Lond), 
2(1), 6. 
Ectopic bone 
Chan Chan, K. K., Glenny, A. M., Weldon, J. C., Furness, S., Worthington, H. V., & Wakeford, H. (2015). 
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and 
immunotherapy. Cochrane Database Syst Rev, 12, CD010341.  
Cancer 
Chang Chang, S. C., Wei, F. C., Chuang, H., Chen, Y. R., Chen, J. K., Lee, K. C., Lou, J. (2003). Ex vivo 
gene therapy in autologous critical-size craniofacial bone regeneration. Plast Reconstr Surg, 112(7), 
1841-1850.  
Bone other 
than OMF 
Chen Chen, L., & Hu, G. F. (2010). Angiogenin-mediated ribosomal RNA transcription as a molecular 
target for treatment of head and neck squamous cell carcinoma. Oral Oncol, 46(9), 648-653.  
Review 
Chen Chen, R., Chiba, M., Mori, S., Fukumoto, M., & Kodama, T. (2009). Periodontal gene transfer by 
ultrasound and nano/microbubbles. J Dent Res, 88(11), 1008-1013.  
Review 
Chuang Chuang, C. K., Sung, L. Y., Hwang, S. M., Lo, W. H., Chen, H. C., & Hu, Y. C. (2007). Baculovirus 
as a new gene delivery vector for stem cell engineering and bone tissue engineering. Gene Ther, 
14(19), 1417-1424.  
Ectopic bone 
Dai Dai, J., & Rabie, A. B. (2007). Recombinant adeno-associated virus vector hybrids efficiently target 
different skeletal cells. Front Biosci, 12, 4280-4287.  
In vitro 
studies 
Dai Dai, J., & Rabie, A. B. (2007). VEGF: an essential mediator of both angiogenesis and endochondral 
ossification. J Dent Res, 86(10), 937-950. 
Review 
Dai Dai, J., Rabie, A. B., Hagg, U., & Xu, R. (2004). Alternative gene therapy strategies for the repair of 
craniofacial bone defects. Curr Gene Ther, 4(4), 469-485. 
Review 
Dai Dai, J., Wang, X., & Shen, G. (2011). Cotransplantation of autologous bone marrow stromal cells 
and chondrocytes as a novel therapy for reconstruction of condylar cartilage. Med Hypotheses, 
77(1), 132-133. doi: 10.1016/j.mehy.2011.03.045 
Review 
Dehari Dehari, H., Ito, Y., Nakamura, T., Kobune, M., Sasaki, K., Yonekura, N., Hamada, H. (2003). 
Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. 
Cancer Gene Ther, 10(1), 75-85.  
In vitro 
studies 
Du Du, J., Zhou, L., Chen, X., Yan, S., Ke, M., Lu, X., . . . Xiang, A. P. (2012). IFN-gamma-primed 
human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis 
factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol, 44(8), 1305-1314.  
Ectopic bone 
Evans Evans, C. (2014). Using genes to facilitate the endogenous repair and regeneration of orthopaedic 
tissues. Int Orthop, 38(9), 1761-1769.  
Review 
Fan Fan, Y. X., Gu, C. H., Zhang, Y. L., Zhong, B. S., Wang, L. Z., Zhou, Z. R., . . . Wang, F. (2013). 
Oct4 and Sox2 overexpression improves the proliferation and differentiation of bone mesenchymal 
stem cells in Xiaomeishan porcine. Genet Mol Res, 12(4), 6067-6079.  
In vitro 
studies 
Fang Fang, L., Hu, Q., Hua, Z., Li, S., & Dong, W. (2008). Growth inhibition of a tongue squamous cell 
carcinoma cell line (Tca8113) in vitro and in vivo via siRNA-mediated down-regulation of skp2. Int 
J Oral Maxillofac Surg, 37(9), 847-852.  
Ectopic bone 
Ferreira  Ferreira, J. R., Hirsch, M. L., Zhang, L., Park, Y., Samulski, R. J., Hu, W. S., & Ko, C. C. (2013). 
Three-dimensional multipotent progenitor cell aggregates for expansion, osteogenic differentiation 
and 'in vivo' tracing with AAV vector serotype 6. Gene Ther, 20(2), 158-168.  
Bone other 
than OMF 
Fujioka Fujioka, K., Kishida, T., Ejima, A., Yamamoto, K., Fujii, W., Murakami, K., Mazda, O. (2015). 
Inhibition of osteoclastogenesis by osteoblast-like cells genetically engineered to produce 
interleukin-10. Biochem Biophys Res Commun, 456(3), 785-791.  
Ectopic bone 
Gao Gao, Q., Tong, W., Luria, J. S., Wang, Z., Nussenbaum, B., & Krebsbach, P. H. (2010). Effects of 
bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma. 
Int J Oral Maxillofac Surg, 39(3), 266-271.  
Ectopic bone 
Gao Gao, X., Usas, A., Tang, Y., Lu, A., Tan, J., Schneppendahl, J., Huard, J. (2014). A comparison of 
bone regeneration with human mesenchymal stem cells and muscle-derived stem cells and the 
critical role of BMP. Biomaterials, 35(25), 6859-6870.  
Bone other 
than OMF 
Ge Ge, W., Shi, L., Zhou, Y., Liu, Y., Ma, G. E., Jiang, Y., Feng, H. (2011). Inhibition of osteogenic 
differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 
repression of RUNX2-activated transcription. Stem Cells, 29(7), 1112-1125.  
Ectopic bone 
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Harada Harada, K., Supriatno, Kawaguchi, S., Onoue, T., Kawashima, Y., Yoshida, H., & Sato, M. (2005). 
High antitumor activity using intratumoral injection of plasmid DNA with mutant-type p27Kip1 
gene following in vivo electroporation. Oncol Rep, 13(2), 201-206. 
Cancer 
Hattori Hattori, H., Mizutani, H., & Ueda, M. (2002). [Sonic hedgehog]. Clin Calcium, 12(2), 233-237.  Review 
Heikinheimo Heikinheimo, K., Kurppa, K. J., & Elenius, K. (2015). Novel targets for the treatment of 
ameloblastoma. J Dent Res, 94(2), 237-240.  
Review 
Helmrich Helmrich, U., Di Maggio, N., Guven, S., Groppa, E., Melly, L., Largo, R. D., Banfi, A. (2013). 
Osteogenic graft vascularization and bone resorption by VEGF-expressing human mesenchymal 
progenitors. Biomaterials, 34(21), 5025-5035.  
Ectopic bone 
Herberg  Herberg, S., Kondrikova, G., Hussein, K. A., Johnson, M. H., Elsalanty, M. E., Shi, X., Hill, W. D. 
(2015). Mesenchymal stem cell expression of stromal cell-derived factor-1beta augments bone 
formation in a model of local regenerative therapy. J Orthop Res, 33(2), 174-184.  
Bone other 
than OMF 
Hino Hino, S., Kawamata, H., Omotehara, F., Uchida, D., Miwa, Y., Begum, N. M., Fujimori, T. (2002). 
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the 
radiation sensitivity of salivary gland cancer cells. Biochem Biophys Res Commun, 292(4), 957-963.  
In vitro 
studies 
Huang, Huang, C., Tang, M., Yehling, E., & Zhang, X. (2014). Overexpressing sonic hedgehog peptide 
restores periosteal bone formation in a murine bone allograft transplantation model. Mol Ther, 22(2), 
430-439.  
Bone other 
than OMF 
Huang Huang, G., Zheng, Q., Sun, J., Guo, C., Yang, J., Chen, R., . . . Wang, J. (2008). Stabilization of 
cellular properties and differentiation mutilpotential of human mesenchymal stem cells transduced 
with hTERT gene in a long-term culture. J Cell Biochem, 103(4), 1256-1269.  
Ectopic bone 
Kim Kim, N. H., Cha, Y. H., Kim, H. S., Lee, S. E., Huh, J. K., Kim, J. K., Yook, J. I. (2014). A platform 
technique for growth factor delivery with novel mode of action. Biomaterials, 35(37), 9888-9896.  
Bone other 
than OMF 
Kitano Kitano, H., Mamiya, A., Kokubun, S., & Hidai, C. (2012). Efficient nonviral gene therapy with FasL 
and Del1 fragments in mice. J Gene Med, 14(11), 642-650.  
Ectopic bone 
Koc Koc, A., Finkenzeller, G., Elcin, A. E., Stark, G. B., & Elcin, Y. M. (2014). Evaluation of adenoviral 
vascular endothelial growth factor-activated chitosan/hydroxyapatite scaffold for engineering 
vascularized bone tissue using human osteoblasts: In vitro and in vivo studies. J Biomater Appl, 
29(5), 748-760.  
Bone other 
than OMF 
Kurihara Kurihara, Y., Watanabe, Y., Onimatsu, H., Kojima, T., Shirota, T., Hatori, M., Fujiwara, T. (2009). 
Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res, 15(7), 
2335-2343.  
Cancer 
Kyrkanides Kyrkanides, S., Kambylafkas, P., Miller, J. H., Tallents, R. H., & Puzas, J. E. (2007). The cranial 
base in craniofacial development: a gene therapy study. J Dent Res, 86(10), 956-961. 
In vitro 
studies 
Laurencin Laurencin, C. T., Attawia, M. A., Lu, L. Q., Borden, M. D., Lu, H. H., Gorum, W. J., & Lieberman, 
J. R. (2001). Poly(lactide-co-glycolide)/hydroxyapatite delivery of BMP-2-producing cells: a 
regional gene therapy approach to bone regeneration. Biomaterials, 22(11), 1271-1277.  
Bone other 
than OMF 
Lee  Lee, S. Y., Park, H. R., Rhee, J., Park, Y. M., & Kim, S. H. (2013). Therapeutic effect of oncolytic 
adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma. Oncol Res, 20(9), 419-
425.  
In vitro 
studies 
Li Li, C., Shi, F., Yang, D., Wang, J., Jian, X., & Jiang, C. (2012). [Natural killer and cytotoxic T 
lymphocyte-mediated cytotoxicity enhanced by genetic overexpression of MHC class I chain-related 
protein A in oral squamous cell carcinoma: an experimental study in vivo]. Hua Xi Kou Qiang Yi 
Xue Za Zhi, 30(1), 32-35.  
In vitro 
studies 
Li Li, M., Li, Z., Li, J., Jin, L., Jin, C., Han, C., Sun, F. (2015). Enhanced antitumor effect of cisplatin 
in human oral squamous cell carcinoma cells by tumor suppressor GRIM19. Mol Med Rep, 12(6), 
8185-8192. doi: 10.3892/mmr.2015.4423 
Cancer 
Li, Li, S., Yang, X., Wang, P., & Ran, X. (2013). The effects of GLUT1 on the survival of head and 
neck squamous cell carcinoma. Cell Physiol Biochem, 32(3), 624-634.  
Ectopic bone 
Li Li, Y., Li, L. J., Wang, L. J., Zhang, Z., Gao, N., Liang, C. Y., . . . Han, B. (2014). Selective intra-
arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. 
BMC Med, 12, 16.  
Cancer 
Li Li, Y., Tian, W., & Wang, D. (2003). [An experimental study on gene transfection of human 
interleukin-1 receptor antagonist gene into chondrocytes of temporomandibular joint]. Hua Xi Kou 
Qiang Yi Xue Za Zhi, 21(1), 19-21. 
In vitro 
studies 
Liang Liang, Q. X., Liang, Y. C., Xu, Z. Y., Chen, W. L., Xie, H. L., & Zhang, B. (2014). RECK 
overexpression reduces invasive ability in ameloblastoma cells. J Oral Pathol Med, 43(8), 613-618. 
In vitro 
studies 
Liu Liu, J., Xu, L., Li, Y., & Ma, J. (2011). Temporally controlled multiple-gene delivery in scaffolds: A 
promising strategy to enhance bone regeneration. Med Hypotheses, 76(2), 173-175.  
Review 
Liu Liu, S., Chen, P., Hu, M., Tao, Y., Chen, L., Liu, H., . . . Gao, G. (2013). Randomized, controlled 
phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene 
therapy in treatment of oral cancer. Cancer Gene Ther, 20(6), 375-378.  
Cancer 
Liu Liu, X., Huang, H., Wang, J., Wang, C., Wang, M., Zhang, B., & Pan, C. (2011). Dendrimers-
delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. 
Biochem Pharmacol, 82(1), 17-23.  
Ectopic bone 
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Lutz Lutz, R., Park, J., Felszeghy, E., Wiltfang, J., Nkenke, E., & Schlegel, K. A. (2008). Bone 
regeneration after topical BMP-2-gene delivery in circumferential peri-implant bone defects. Clin 
Oral Implants Res, 19(6), 590-599.  
Bone other 
than OMF 
Ma Ma, D., & Mao, T. (2012). [Cell-based approaches to promote bone regeneration in distraction 
osteogenesis]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 26(12), 1512-1515. 
No gene 
therapy 
Matsumoto Matsumoto, G., Kushibiki, T., Kinoshita, Y., Lee, U., Omi, Y., Kubota, E., & Tabata, Y. (2006). 
Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits 
murine squamous cell carcinoma. Cancer Sci, 97(4), 313-321.  
Ectopic bone 
Matsumoto Matsumoto, G., Ohmi, Y., & Shindo, J. (2001). Angiostatin gene therapy inhibits the growth of 
murine squamous cell carcinoma in vivo. Oral Oncol, 37(4), 369-378. 
Ectopic bone 
Matsumoto Matsumoto, G., Omi, Y., Lee, U., Kubota, E., & Tabata, Y. (2011). NK4 gene therapy combined 
with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma. Anticancer Res, 
31(1), 105-111. 
Ectopic bone 
Matsumoto Matsumoto, G., Sasakuri, K., Tsukinoki, K., Ohmi, Y., Lee, U., & Shindo, J. (2002). Growth of 
human squamous cell carcinoma xenografts in mice is inhibited by local angiostatin gene therapy. 
Oral Oncol, 38(6), 543-548. 
Ectopic bone 
Matsumoto Matsumoto, G., Yajima, N., Saito, H., Nakagami, H., Omi, Y., Lee, U., & Kaneda, Y. (2010). Cold 
shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis 
in a mouse model of squamous cell carcinoma. Clin Exp Metastasis, 27(7), 539-547.  
Ectopic bone 
Meshii Meshii, N., Takahashi, G., Okunaga, S., Hamada, M., Iwai, S., Takasu, A., Yura, Y. (2013). 
Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes 
simplex virus. Cancer Gene Ther, 20(9), 493-498.  
Cancer 
Mizuno Mizuno, H., Emi, N., Abe, A., Takahashi, I., Kojima, T., Saito, H., . . . Ueda, M. (1999). Successful 
culture and sustainability in vivo of gene-modified human oral mucosal epithelium. Hum Gene Ther, 
10(5), 825-830.  
Ectopic bone 
Musgrave Musgrave, D. S., Bosch, P., Lee, J. Y., Pelinkovic, D., Ghivizzani, S. C., Whalen, J., . . . Huard, J. 
(2000). Ex vivo gene therapy to produce bone using different cell types. Clin Orthop Relat Res(378), 
290-305. 
Ectopic bone 
Naito Naito, S., Obayashi, S., Sumi, T., Iwai, S., Nakazawa, M., Ikuta, K., & Yura, Y. (2006). 
Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral 
squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther, 13(8), 780-791. 
Cancer 
Nakase Nakase, M., Inui, M., Okumura, K., Kamei, T., Nakamura, S., & Tagawa, T. (2005). p53 gene 
therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther, 
4(4), 625-631.  
Ectopic bone 
Nishikawa Nishikawa, M., Hayashi, Y., Yamamoto, N., Fukui, T., Fukuhara, H., Mitsudo, K., Yoshida, J. 
(2003). Cell death of human oral squamous cell carcinoma cell line induced by herpes simplex virus 
thymidine kinase gene and ganciclovir. Nagoya J Med Sci, 66(3-4), 129-137. 
Ectopic bone 
Okumura Okumura, K., Nakase, M., Nakamura, S., Kamei, T., Inui, M., & Tagawa, T. (2007). Bax gene 
therapy for human osteosarcoma using cationic liposomes in vivo. Oncol Rep, 17(4), 769-773. 
Ectopic bone 
O'Malley O'Malley, B. W., Jr., Li, D., Buckner, A., Duan, L., Woo, S. L., & Pardoll, D. M. (1999). Limitations 
of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope, 109(3), 389-395.  
Cancer 
Omotehara  Omotehara, F., Uchida, D., Hino, S., Begum, N. M., Yoshida, H., Sato, M., & Kawamata, H. (2000). 
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of 
TGF-beta stimulated clone-22. Oncol Rep, 7(4), 737-740. 
Cancer 
Otani Otani, K., Yamahara, K., Ohnishi, S., Obata, H., Kitamura, S., & Nagaya, N. (2009). Nonviral 
delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles. J 
Control Release, 133(2), 146-153.  
In vitro 
studies 
Pan Pan, C. B., Huang, H. Z., Wang, J. G., Hou, J. S., & Li, H. G. (2004). [The inhibitory effect of 
human endostatin gene on tumor growth of tongue squamous cell carcinoma]. Zhonghua Kou Qiang 
Yi Xue Za Zhi, 39(4), 273-276. 
Cancer 
Park Park, J., Lutz, R., Felszeghy, E., Wiltfang, J., Nkenke, E., Neukam, F. W., & Schlegel, K. A. (2007). 
The effect on bone regeneration of a liposomal vector to deliver BMP-2 gene to bone grafts in peri-
implant bone defects. Biomaterials, 28(17), 2772-2782.  
Bone other 
than OMF 
Ren  Ren, M. L., Peng, W., Yang, Z. L., Sun, X. J., Zhang, S. C., Wang, Z. G., & Zhang, B. (2012). 
Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone 
for repairing bone defects in pigs. Cell Transplant, 21(12), 2711-2721.  
Bone other 
than OMF 
Sato Sato, D., Kurihara, Y., Kondo, S., Shirota, T., Urata, Y., Fujiwara, T., & Shintani, S. (2013). 
Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic 
carcinoma cell lines. Oncol Rep, 30(6), 2659-2664.  
Cancer 
Sun Sun, C. X., He, R. G., Cheung, L. K., Zhang, Z. Y., Chen, W. T., Liu, X. K., Chen, S. S. (2002). The 
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Abstract. The aim of this systematic review was to answer the question: What are
the treatments available for bisphosphonate-related osteonecrosis of the jaws
(BRONJ) and their outcomes? A literature search of PubMed, Cochrane Library,
and Web of Science databases was conducted in accordance with the PRISMA
statement, search phrases were (‘jaw osteonecrosis’ OR ‘bisphosphonate-related
osteonecrosis’ OR ‘bisphosphonate osteonecrosis’) AND (‘treatment’ OR
‘outcomes’). Ninety-seven articles published between 2003 and February 2014
were reviewed. The studies reported 4879 cases of BRONJ. The mean age of the
patients was 66.5  4.7 years. The male to female ratio was 1:2. The mean duration
of bisphosphonate (BP) administration was 38.2  15.7 months. The quality of the
publications was good, with some moderate and poor. Minimally invasive surgical
treatment was the treatment most used. Medical treatment was also used.
Adjunctive treatments included laser, growth factors, hyperbaric oxygen and
ozone. The articles provided a broad range of outcome variables to assess the
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heterogeneity was found regarding study design, sample size, and treatment
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J. Kühnisch3, M. Ehrenfeld2, S. Otto2
1Experimental Surgery and Regenerative
Medicine, Ludwig-Maximilians-Universität,
Munich, Germany; 2Department of Oral and
Maxillofacial Surgery, Ludwig-Maximilians-
Universität, Munich, Germany; 3Department
of Conservative Dentistry and Periodontology,
Ludwig-Maximilians-Universität, Munich,
GermanyKey words: bisphosphonates
BRONJ; management; outcomes
risk factors; systematic review.
Accepted for publication 30 January 2015
Available online 26 February 2015ons. Published by Elsevier Ltd. All rights reserved.
Treatment strategies and outcomes of BRONJ 569Bisphosphonates (BPs) are a class of drugs
used across a wide range of disciplines
including endocrinology, oncology, ortho-
paedics, and dentistry.1,2 They are com-
monly prescribed for bone diseases such
as osteoporosis, Paget’s disease of bone,
hypercalcaemia of malignancy, osteolytic
bone metastases, and osteolytic lesions of
multiple myeloma.1,3,4 Their use has
resulted in a statistically significant reduc-
tion in skeletal complications, including
pathological fractures, spinal cord com-
pression, and hypercalcaemia of malig-
nant disease, and has reduced the need
for subsequent radiotherapy or surgery
to bone.5–7
BPs are synthetic analogues of the nat-
urally occurring pyrophosphate molecule.
They are broadly classified on the basis of
whether or not they contain a nitrogen
atom, with nitrogen-containing bispho-
sphonates (N-BPs) being more potent than
non-N-BPs.8 They differ from one another
in the substitution of the active side chains
on their phosphorous–carbon phosphorous
structural backbone.
The mechanism of action of BPs is the
inhibition of bone resorption by suppres-
sing osteoclast activation and inducing
osteoclast apoptosis.9,10 The efficacy of
BPs has been established in several stu-
dies.11–14 However, their use may have
side effects.15 Bisphosphonate-related
osteonecrosis of the jaw (BRONJ) has
been characterized as a main side effect
of BP therapy.16–18 The first descriptions
of BRONJ were reported in 2003.19–21
Since then, numerous reports on the de-
velopment of osteonecrosis of the jaw in
patients treated with BPs have been pub-
lished.22–34
BRONJ lesions may remain silent until
the occurrence of a triggering event, such
as an invasive dental procedure, infection,
or mechanical trauma to the jawbone, as
well as the concomitant use of immuno-
suppressive and chemotherapy drugs.35–37
According to a recent position paper from
the American Association of Oral and
Maxillofacial Surgeons (AAOMS), risk
factors for the development of BRONJ
can be grouped into drug-related, local,
demographic and systematic, genetic, and
preventive.38 The clinical manifestations
of BRONJ vary from necrotic bone expo-
sure (ranging from a few millimetres in
size to larger areas, which can be asymp-
tomatic for weeks, months, or years39),
simple swellings of the soft tissues, and
abscesses, to more complex cases present-
ing with fistulas and diffuse pain.40
There are two major theories regarding
the pathophysiology of BRONJ. One is the
osteoclast-based, ‘inside-out’ theory, inwhich inhibition of osteoclastic activity
and marked suppression of bone turnover,
together with the spread of physiological
micro-damage and possibly local infec-
tion, leads to bone death within the jaw,
with subsequent exposure. As such, the
bone exposure would be a late event. The
second, ‘outside-in’ theory suggests a
break in the oral mucosa leads to ingress
of bacteria and local infection, which,
coupled with poor bone remodelling, leads
to bone death. BRONJ may result from a
combination of these two mechanisms,
and hypovascularity may also play an
important role.41,42 Although there have
been reports relating no obvious co-mor-
bidity factors, it is reasonable to believe
that co-factors play a relevant role in the
development of these lesions.23,43
The management of BRONJ has centred
on efforts to eliminate or reduce the se-
verity of symptoms, to slow or prevent the
progression of disease, and to eradicate
diseased bone.44 There is currently no gold
standard for the treatment of BRONJ.
Several treatment options have been de-
scribed in relation to the AAOMS staging
of BRONJ.45 No agreement on a surgical
versus non-surgical approach to therapy
has been reached in the treatment of
BRONJ.46–49 Some recommendations
focus on prevention and a conservative
approach.19,25,27,50
Treatment strategies include the ad-
ministration of antibiotics, oral antibacte-
rial mouth rinse, cessation of BPs if
possible, pain control, surgical debride-
ment or resection for long-term palliation
of infection and pain,23,50 sequential re-
moval of sequestrum (extensive involve-
ment may necessitate a large area of
debridement to include a segmental man-
dibulectomy and partial maxillectomy23),
mandibular reconstruction with the fibula
flap,51 and covering the exposed areas
with tissue flaps.19 Hyperbaric oxygen
(HBO) therapy, fluorescence-guided
bone resection, and low-intensity laser
therapy have also been studied as thera-
peutic tools.48,52–54
Other treatment modalities that increase
bone wound healing using growth and dif-
ferentiation factors are being studied,55,56
as well as transplantation of intra-lesional
autologous bone marrow stem cells.57
More recently, teriparatide (N-terminal
34-amino acid recombinant human para-
thyroid hormone) has been reported for the
medical treatment of BRONJ.58 Pentoxifyl-
line and a-tocopherol in addition to anti-
microbial therapy has been shown to
decrease the area of bone exposure and
symptoms in BRONJ patients.59 The use
of ozone in combination with antibioticsand surgery for patients with exposed bone
lesions has also been the subject of a clini-
cal investigation and found to resolve pain,
secretions, and halitosis.60
The main objective of this study was to
conduct a systematic review of the liter-
ature to determine the treatment strategies
available for BRONJ, describing the out-
come variables measured for each treat-
ment modality and the success of the
treatment expressed by the outcome.
Materials and methods
The Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses
(PRISMA) guidelines were applied for
this review.61 PRISMA comprises a 27-
item checklist and a four-phase flow dia-
gram that relates to the title, abstract,
introduction, methods, results, and discus-
sion sections of articles, and funding. They
were developed based on recommenda-
tions regarding what should be included
in an accurate and complete report of
systematic reviews and meta-analyses.
The systematic search covered the time
period 2003 (the year of the initial descrip-
tion of BRONJ) to 28 February 2014. All
publications identified in the literature
search were retrieved from online journals
and selected on the basis of the inclusion
criteria.
Inclusion and exclusion criteria
The following inclusion criteria were ap-
plied: (1) academic publications; the re-
view included any published studies
(cross-sectional surveys, cohort, and
case–control studies), clinical trials, case
series, and retrospective studies; (2) pub-
lication in the English language confirm-
ing the diagnosis of BRONJ in accordance
with the AAOMS or American Society of
Bone and Mineral Research (ASBMR)
definitions; (3) studies on humans; (4)
participants of any age and gender with
a clinical diagnosis of BRONJ; (5) any
form of treatment; (6) outcomes variables
should be mentioned in the publication;
(7) outcome of the treatment.
The following exclusion criteria were
applied: (1) single case reports of BRONJ;
(2) experimental laboratory studies; (3)
case series with fewer than five patients;
(4) literature reviews, letters, editorials,
doctoral theses, and abstracts.
Disease definition
The disease definition, as proposed by
AAOMS and ASBMR, includes the per-
sistence of exposed necrotic bone in the
570 Fliefel et al.oral cavity for 8 weeks, despite adequate
treatment, in a patient with current or a
previous history of BP use, without local
evidence of malignancy, and no prior ra-
diotherapy to the affected region.24,40,62,63
A clinical staging system has been pro-
posed to classify patients with established
BRONJ, with appropriate treatment for
each stage (Table 1).24,40,63,64
Electronic database search
Three databases – PubMed, the Cochrane
Library, and Web of Science – were elec-
tronically searched. The heading sequence
(‘jaw osteonecrosis’ OR ‘bisphosphonate-
related osteonecrosis’ OR ‘bisphospho-
nate osteonecrosis’) AND (‘treatment’
OR ‘outcomes’) was searched as text
word. The results of the database searches
were combined and duplicate articles were
excluded. All references were gathered
and screened for eligibility.
In the first round search, abstracts were
reviewed and all articles containing the
key words were retained. Articles that
were not in English were excluded. Com-
plete versions were then obtained for all
articles that that met the inclusion criteria.
In the second round search and evalua-
tion, a manual search was done of the
reference lists of all the articles retained
after the first round for appropriate studies
relevant to the review topic. A search
of the unpublished literature was notTable 1. Staging of and treatment strategies for b
of Oral and Maxillofacial Surgeons (AAOMS).3
BRONJ stage Clinical conditions 
At risk No apparent necrotic 
treated with either ora
Stage 0 No clinical evidence o
clinical findings and s
Stage 1 Exposed and necrotic 
without evidence of in
Stage 2 Exposed and necrotic 
evidenced by pain and 
bone, with or without
Stage 3 Exposed necrotic bone
erythema and one or m
necrotic bone extendin
bone, such as the infe
mandible, or maxillary
resulting in pathologic
oral–antral/oral–nasal 
extending to the inferio
maxillary sinus floor
IV, intravenous; BP, bisphosphonate.performed. Literature reviews and system-
atic reviews were also considered, with the
objective of identifying cases already
reported. All of the articles were read in
full for final selection.
In the third round search, each of the
publications was critically appraised for
assessment of validity, and the following
data were extracted from the accepted
articles and recorded in a standardized
spread sheet: reference and year, study
design, number of patients in the study,
mean age of patients, gender of patients,
location of the lesions, primary cause of
the BRONJ, types of BP used, route
of administration of the BP used, range
of duration of use of BP triggering factors,
co-morbidities, treatment methods, out-
come variables measured, follow-up
period, and outcomes of the different treat-
ments.
Statistical analysis
The duration of BP exposure was defined
as the time in months from the date of first
BP infusion to the last recorded infusion.
A qualitative data analysis was per-
formed with the aim of summarizing the
results of the studies included. The mean
age of patients with osteonecrosis of the jaw
and the ratio of male to female patients
were calculated to determine whether any
particular stratum had a greater predisposi-
tion to develop osteonecrosis of the jawisphosphonate-related osteonecrosis of the jaw (B
8,64
Tre
bone in patients who have been
l or IV bisphosphonates
No 
Pati
f necrotic bone, but non-specific
ymptoms
Sys
med
bone in asymptomatic patients
fection
Ora
Clin
Pati
con
bone associated with infection as
erythema in the region of exposed
 purulent drainage
Sym
Ora
Pain
Sup
irrit
 in patients with pain and
ore of the following: exposed and
g beyond the region of alveolar
rior border and ramus in the
 sinus or zygoma in the maxilla,
al fracture, extraoral fistula, or
communication, or osteolysis
r border of the mandible or to the
Ora
Ant
Deb
reliethan another. The existence of potential risk
factors for osteonecrosis of the jaw was
examined: the mean dose and range, the
duration of treatment, and the proportions
of patients receiving immunosuppressant
therapy (e.g., corticosteroids), with other
comorbidities, and with a history of dental
trauma, infection, or surgical procedures.
The quality of accepted publications
was assessed based on a modification of
the ASBMR,65 by the reporting of 12
parameters for all patients diagnosed with
BRONJ: age, sex, primary cause of the
disease, name of the bisphosphonate used,
duration or treatment, mode of adminis-
tration, affected site, medical history (con-
comitant medications, comorbidities),
triggering factors, treatment, outcome var-
iable measured, and treatment outcome.
The quality of each publication was clas-
sified as good (10–12 variables reported),
moderate (5–9 variables reported), or poor
(1–4 variables reported).
Results
The results of the literature search are
presented in a flow chart, showing study
selection according to the PRISMA state-
ment (2009)61 (Fig. 1). The initial search
strategy yielded 1355 titles/abstracts from
the databases analyzed: 1085 from
PubMed, 235 from Web of Science, and
35 from the Cochrane Library; five addi-
tional articles were identified through aRONJ) according to the American Association
atment strategies
treatment indicated
ent education
temic management, including the use of pain
ication and antibiotics
l anti-bacterial mouth rinse
ical follow-up on a quarterly basis
ent education and review of indications for
tinued BP use
ptomatic treatment with oral antibiotics
l anti-bacterial mouth rinse
 control
erficial debridement to relieve soft tissue
ation
l anti-bacterial mouth rinse
ibiotic therapy and pain control
ridement/surgical resection for prolonged
f of pain and infection
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Fig. 1. Flow chart of the search strategy and study selection used in this systematic review.hand search of the relevant reference lists,
bringing the number of accepted articles to
1360. After title and abstract screening
and/or paper analyses, 300 potentially rel-
evant articles were identified for article
retrieval and full-text review. Two hun-
dred papers were included in the qualita-
tive synthesis and finally 103 papers were
excluded after a preliminary review, due
to non-compliance with the inclusion/ex-
clusion criteria, lack of outcome, not being
related to the proposed research question,
or being irrelevant (Fig. 1).
The remaining 97 articles were included
in the final review. These articles
described 4879 cases of BRONJ. With
regard to the quality of the publications,
79 were classified as good (81.4%), 16
as moderate (16.5%), and two publica-
tions as poor (2.1%). Of the 97 accepted
publications, 35 (36.1%) were case
series,27,49,51,52,59,66–95 3 (3.1%) wereclinical trials,96–98 18 (18.6%) were pro-
spective studies,99–116 37 (38.1%) were
retrospective studies,17,35,44,117–150 and 4
(4.1%) were clinical reports151–154 (Table 2).
Age and gender
A total of 4879 patients were identified
and treated in the 97 publications; the
mean age of these patients was
66.5  4.7 years. In the 4481 cases in
which the sex distribution was reported,
1471 were male patients (32.8%) and 3010
were female patients (67.2%), showing a
female predilection with a female to male
ratio of 2:1 among all reported cases
(Table 3).
BRONJ characteristics
Eighty-nine publications described the site
of BRONJ in 4627 patients receiving BPs;the site was not reported for only eight
publications.59,87,94,95,97,98,111,154 BRONJ
lesions were located most commonly
in the mandible (3011 patients; 65.1%),
followed by the maxilla (1320 patients;
28.5%) or both jaws (296 patients; 6.4%)
(Table 3).
Primary cause of disease
BP therapy was started in 4602 cases for
the following indications: multiple mye-
loma (1434 cases; 31.2%), breast cancer
(1359 cases; 29.5%), osteoporosis (903
cases; 19.6%), prostate cancer (442 cases;
9.6%), metastasis (116 cases; 2.5%), and
other cancers including lung, renal, and
bladder carcinoma (348 cases; 7.6%).
Most patients (60.7%) had multiple
myeloma or metastatic breast cancer
(Table 3).
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Table 2. Summary of the publications included in the systematic review: study design, total number of patients, mean patient age, duration of
administration of bisphosphonates, quality of publications, and treatment modalities.
Reference Study design
Number
of patients
Age,
years
Duration of BP
administration,
months
Quality of
publication Treatment
Thumbigere-Math
2009117
Retrospective 26 64 45.8 Good Medical and minimally
invasive surgery
Thumbigere-Math
2012118
Retrospective 18 60 44.3 Good
Anavi-Lev 201395 CS 52 70.7 40 Good
Holzinger 2013101 Prospective 88 NR NR Moderate
Saussez 2009125 Retrospective 34 62 34.5 Good
Montebugnoli 200749 CS 16 61.2 17.9 Good
Dannemann 200669 CS 14 65 NR Good
Beninati 2013102 Prospective 51 68 41 Good
Alons 2009126 Retrospective 7 66.9 55.2 Good
Lazarovici 200972 CS 101 63.5 48.5 Good
Junquera 200973 CS 21 65.1 25 Good
Stanton 2009128 Retrospective 33 64.5 NR Good
Estilo 2008130 Retrospective 28 NR 34.1 Good
Dimitrakopoulos
2006131
Retrospective 11 61 6 Good
Fortuna 2012104 Prospective 26 68.4 23.3 Good
Abu-Id 2008134 Retrospective 78 65.6 12 Good
Pozzi 2007135 Retrospective 35 70 36 Good
Williamson 2010107 Prospective 40 64 NR Good
Longobardi 200776 CS 18 55 42.3 Good
Wutzl 2012110 Prospective 58 68.3 35.5 Good
O’Ryan 2012144 Retrospective 30 77 52.8 Good
Scoletta 2010113 Prospective 37 68 25.5 Good
Nomura 201389 CS 13 71.2 29.6 Good
Jabbour 201290 CS 14 69 37.5 Good
Mücke 2011100 Prospective 108 68.5 NR Moderate Medical, minimally
invasive and major
surgery
Mortensen 200768 CS 7 66 NR Good
O’Ryan 2009129 Retrospective 59 61.4 NR Good
Elad 2006152 CR 57 62.7 NR Good
Stockmann 2010106 Prospective 50 69.5 31 Good
Ibrahim 200817 Retrospective 8 66.5 14.6 Good
Kim 2012150 Retrospective 21 64.3 30 Good
Yarom 2007127 Retrospective 11 69.7 49.2 Good
Hong 2010139 Retrospective 24 72.1 43.1 Good
Lerman 201344 Retrospective 120 63 36 Good
Maurer 2011138 Retrospective 21 69 47.4 Good
Hansen 2013154 CR 37 NR NR Poor
Hoefert 2011122 Retrospective 47 66.1 41.9 Good Medical
Marx 200527 CS 119 NR NR Good
Van den Wyngaert
2009153
CR 33 58 27 Good
Moretti 2011108 Prospective 34 69.0 39 Good
Alsehimy 2014109 Prospective 96 66.5 NR Good
Lazarovici 201086 CS 27 70 NR Good
Nicolatou-Galitis
2011114
Prospective 63 63.6 37.1 Good
Epstein 201059 CS 6 75 74.6 Good
Vescovi 2011123 Retrospective 567 67.2 NR Good Minimally invasive
surgeryGraziani 2012132 Retrospective 347 67 23 Good
Mercer 2013133 Retrospective 91 69.8 60 Good
Kos 2010136 Retrospective 18 67.0 34.9 Good
Wutzl 200678 CS 17 64.8 32 Good
Ferlito 201294 CS 94 66 24 Moderate
Schubert 2012116 Prospective 258 NR NR Moderate
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Table 2 (Continued )
Reference Study design
Number
of patients
Age,
years
Duration of BP
administration,
months
Quality of
publication Treatment
Rugani 201066 CS 5 75.4 36 Good Laser
Romeo 201167 CS 12 62 NR Moderate
Angiero 2009120 Retrospective 49 69.7 14.8 Good
Stübinger 2009151 CR 8 59.1 53 Good
Vescovi 2014121 Retrospective 63 NR NR Moderate
Vescovi 201270 CS 151 66.6 48.2 Good
Vescovi 200774 CS 19 71 NR Moderate
Manfredi 2011137 Retrospective 25 70.4 55.9 Good
Atalay 2011143 Retrospective 20 55.4 32.4 Good
Scoletta 2010111 Prospective 20 71.3 42.9 Good
Rugani 201381 CS 12 63.9 NR Moderate
Vescovi 2010146 Retrospective 91 67 NR Moderate
Vescovi 200891 CS 28 70.3 NR Moderate
Martins 2012119 Retrospective 22 58.09 24.68 Good
Curi 201171 CS 25 60.7 NR Good Growth factor (PRP or
BMP2)Mozzati 2012140 Retrospective 32 69.7 37 Good
Bocanegra-Perez 2012112 Prospective 8 66.3 1 Good
Coviello 201293 CS 7 75.57 66 Good
Cicciu 201283 CS 20 NR NR Poor
Ripamonti 201196 RCT 10 65 NR Moderate Ozone
Agrillo 200775 CS 58 64 NR Moderate
Ripamonti 201298 RCT 24 62.5 NR Good
Agrillo 201235 Retrospective 131 60 NR Good
Boonyapakorn 2008105 Prospective 22 61.1 NR Good Discontinuation of BP
Urade 2011141 Retrospective 263 68.1 NR Good
Park 201080 CS 5 72.6 79.2 Good
Watters 201388 CS 109 64 NR Good
Wilde 2011145 Retrospective 24 NR NR Good
Chiu 201077 CS 12 69.7 67.2 Good Hyperbaric oxygen
Freiberger 201297 RCT 22 66.1 NR Moderate
Freiberger 200752 CS 16 NR 18 Moderate
Kwon 201282 CS 6 77.5 55.2 Good Teriparatide
Narvaez 201387 CS 7 72 55.2 Good
Kim 2014149 Retrospective 15 77.1 45.6 Good
Pautke 201199 Prospective 15 63.2 44.4 Good Guided debridement
Fleisher 200879 CS 10 NR NR Moderate
Seth 2010124 Retrospective 11 61.3 NR Good Major surgery
Carlson 2009103 Prospective 82 NR NR Moderate
Badros 2006142 Retrospective 22 61 NR Good
Bedogni 2011115 Prospective 30 66 NR Good
Jacobsen 2012147 Retrospective 110 67 NR Good
Voss 2012148 Retrospective 21 68.5 40.1 Good
Hanasono 201392 CS 13 66.6 NR Good
Nocini 200951 CS 7 61 NR Good
Lemound 201285 CS 20 68 34.8 Good
Blus 201384 CS 8 71.3 32 Good
Total 4879 66.5  4.7 38.2  15.7
BP, bisphosphonate; CS, case series; RCT, randomized clinical trial; CR, clinical report; NR, not reported; PRP, platelet-rich plasma; BMP2, bone
morphogenetic protein 2.Characteristics of bisphosphonate
treatment
The bisphosphonate prescribed was spec-
ified for 4118 patients with BRONJ. Over-
all, 2427 (58.9%) patients received
zoledronate, 571 (13.9%) patients re-
ceived pamidronate, 523 (12.7%) patients
received alendronate, 128 (3.1%) patients
received ibandronate, and 469 (11.4%)patients received a combination of BPs
(Table 3).
BP treatment was principally intravenous
(IV) in 3245 patients (83.2%), while 656
patients (16.8%) received oral BPs (Table 3).
Duration of treatment
There was variability in the duration of
BP therapy, which ranged from 1 to 79.2months, with a mean duration of
38.2  15.7 months.
Triggering factors and comorbidities
The most important triggering factors for
the development of BRONJ were de-
scribed for 3198 cases in the articles in-
cluded. Tooth extraction was the principal
cause (1974 patients; 61.7%), followed by
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Table 3. Characteristics of patients diagnosed with BRONJ.
Characteristics Details Number Percentage (%)
Gender Male 1471 32.8
Female 3010 67.2
Location Maxilla 1320 28.5
Mandible 3011 65.1
Both 296 6.4
Primary cause of the
disease
Multiple myeloma 1434 31.2
Breast cancer 1359 29.5
Osteoporosis 903 19.6
Prostate cancer 442 9.6
Other cancers 348 7.6
Metastasis 116 2.5
Type of BP
administered
Zoledronate 2427 58.9
Pamidronate 571 13.9
Alendronate 523 12.7
Ibandronate 128 3.1
Combination 469 11.4
Route of administration
of BP
IV 3245 83.2
Oral 656 16.8
Triggering factors Extraction 1974 61.7
Dental implant 123 3.9
Dental surgery 230 7.2
Periodontal disease 159 5.0
Prosthetic trauma 237 7.4
Spontaneous 475 14.8
Comorbidities Diabetes 298 11.2
Corticosteroids 658 24.6
Hypertension 225 8.4
Thrombosis 108 4.0
Smoking 215 8.0
Chemotherapy 1062 39.7
None 108 4.1
BRONJ, bisphosphonate-related osteonecrosis of the jaws; BP, bisphosphonate; IV, intrave-
nous.trauma from manipulation of dental
implants (123 cases; 3.9%). A history of
dental surgery was reported for 230 patients
(7.2%), periodontal diseases in 159 patients
(5.0%), and prosthesis-induced trauma in
237 patients (7.4%). A large proportion of
BRONJ lesions appeared spontaneously
(475 patients; 14.8%) (Table 3).
With regard to concomitant diseases
and medications, 2674 patients had
comorbidities. Diabetes mellitus was ob-
served in 298 patients (11.2%) and hyper-
tension in 225 patients (8.4%); 1062
(39.7%) patients were under chemothera-
py, 215 (8.0%) patients were smokers, 108
(4.0%) patients had thrombocoagulopa-
thies, 658 (24.6%) were taking corticoste-
roids, and 108 (4.1%) were free from any
concomitant diseases. The incidence of
BRONJ was associated with chemothera-
py (39.7%) of the patients compared to
corticosteroid therapy (24.6%) (Table 3).
Management of osteonecrosis of the jaw
Regarding the management of the BRONJ
lesions, the studies reported discontinuationof BP administration (5.1%) in addition to
treatment by medical therapy (50%) or
minimally invasive surgical therapy
(45.9%); 22.4% of patients underwent ma-
jor surgical procedures, such as segmental
resection of the jaw bones.
Various adjunctive treatments such as
hyperbaric oxygen (HBO) therapy, laser
therapy, ozone therapy, teriparatide, fluores-
cence-guided debridement, treatment with
growth factors (platelet-rich plasma (PRP)
or bone morphogenetic protein 2 (BMP2)),
and ultrasonic therapy were also mentioned.
Medical treatment of BRONJ was
reported in 49 publications17,27,44,49,59,
68,69,72,73,76,80,86,88–90,95,100–102,104–
110,113,114,117,118,122,125–131,134,135,138,139,
141,144,145,150,152–154 and minimally inva-
sive surgical treatment in 44 publications
.17,27,44,49,68,69,72,73,76,78,89,90,94,100–102,104–
107,110,113,116–118,123,125–136,139,141,144,150,
152,154 Major surgical intervention was
reported in 22 publications,17,44,68,92,100,
103,106,115,124,127,129,137–139,141,142,145,147,
148,150,152,154 including the use of surgical
flaps in two publications51,85 and ultrason-
ic therapy in one.84 Laser therapy wasreported in 14 publications,66,67,70,74,81,91,
111,119–121,137,143,146,151
ozone therapy in four
publications,
35,75,96,98 PRP in five publica-
tions,71,93,112,119,140 BMP2 in one,83
HBO in three publications,52,77,97 and ter-
iparatide in three publications.82,87,149
Fluorescence or tetracycline guided de-
bridement was reported in two publica-
tions.79,99
Seven hundred and fifteen patients were
treated by medical and minimally invasive
surgical treatment, 422 patients were trea-
ted by medical, minimally invasive and
major surgical treatment, 286 patients
were treated by medical treatment only,
767 patients were treated by minimally
invasive surgical treatment, 252 patients
were treated by major surgical treatment,
25 patients were treated by guided de-
bridement, 322 patients were treated with
laser therapy, 92 patients were treated with
growth factors, 161 patients were treated
with ozone therapy, 361 patients stopped
BP treatment in addition to other treatment
modalities, 45 patients were treated with
HBO, and 27 patients were treated with
teriparatide (Table 4).
Follow-up and treatment outcomes
After the initial BRONJ treatment, follow-
up periods, which were reported in only 80
publications, ranged from 4 weeks to 50
months, with a mean of 12.9  9.9
months.
Outcome measures
A total of seven outcome variables were
used in the studies. The most frequently
measured outcome was mucosal healing
(47 publications; 48.5%), followed by
bone exposure (30 publications; 30.9%),
pain (31 publications; 31.9%), changes in
signs and symptoms (28 publications;
28.9%), improvement in stage (14 publi-
cations; 14.4%), reduction in lesion size
and number (12 publications; 12.4%), and
finally infection control (seven publica-
tions; 7.2%).
The outcome of the treatment was clas-
sified as (1) complete healing, defined as
complete regrowth of the oral mucosa over
previously exposed bone; (2) partial heal-
ing, defined as either a decrease in lesion
size (largest linear dimension) or the num-
ber of lesions, and/or cessation of pain or
signs of infection; (3) stable disease, de-
fined as no improvement in clinical signs
or symptoms; (4) progressive disease, de-
fined as an increase in the size or number
of lesions, or increased pain and severity
of infection; (5) regressive disease, de-
fined as a decrease in the size or number
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Table 4. Outcome of each treatment modality.
Treatment
Outcome, number of patients (%) Total number
of patients (%)
Complete
healing
Partial
healing
Stable
lesion
Progressive
lesion
Regressive
lesion
Recurrent
lesion
Non-healing
lesion
Medical and minimally
invasive surgery
278 (38.9) 125 (17.5) 94 (13.1) 52 (7.3) 64 (9.0) 5 (0.7) 97 (13.6) 715 (20.6)
Medical, minimally
invasive and major
surgery
169 (40.0) 105 (24.9) 34 (8.1) 19 (4.5) 5 (1.2) 47 (11.1) 43 (10.2) 422 (12.1)
Medical treatment 129 (45.1) 52 (18.2) 23 (8.0) 8 (2.8) 52 (18.2) 20 (7.0) 2 (0.7) 286 (8.2)
Minimally invasive
surgery
301 (39.2) 0 (0) 152 (19.8) 61 (8.0) 231 (30.1) 0 (0) 22 (2.9) 767 (22.1)
Major surgery 207 (82.1) 11 (4.4) 8 (3.2) 5 (2.0) 0 (0) 11 (4.4) 10 (4.0) 252 (7.3)
Guided debridement 12 (48) 10 (40) 0 (0) 1 (4) 0 (0) 0 (0) 2 (8) 25 (0.7)
Laser therapy 146 (45.3) 18 (5.6) 81 (25.2) 5 (1.6) 33 (10.2) 2 (0.6) 37 (11.5) 322 (9.3)
Growth factors 75 (81.5) 2 (2.2) 6 (6.5) 0 (0) 8 (8.7) 1 (1.1) 0 (0) 92 (2.6)
Ozone therapy 93 (57.8) 27 (16.8) 5 (3.1) 0 (0) 28 (17.4) 0 (0) 8 (5.0) 161 (4.6)
Discontinuation of
bisphosphonates
127 (35.2) 27 (7.5) 142 (39.3) 50 (13.9) 3 (0.8) 5 (1.4) 7 (1.9) 361 (10.4)
Hyperbaric oxygen 12 (26.7) 8 (17.8) 2 (4.4) 6 (13.3) 17 (37.8) 0 (0) 0 (0) 45 (1.3)
Teriparatide 22 (81.5) 5 (18.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 27 (0.8)
Total 1571 (45.2) 390 (11.2) 547 (15.7) 207 (6.0) 441 (12.7) 91 (2.6) 228 (6.6) 3475of lesions, or decreased pain and severity
of infection; and (6) negligible or no heal-
ing when there was no sign of improve-
ment.
The outcomes of the treatment modali-
ties of the BRONJ were assessed in 3475
patients. Outcomes of the different treat-
ment modalities were compared (Table 4).
Medical and minimally invasive surgical
treatment
Seven hundred and fifteen patients were
treated by medical and conservative sur-
gical treatment; 278 patients (38.9%)
showed complete healing, 125 (17.5%)
showed partial healing, 94 (13.1%) had
stable lesions, 52 (7.3%) had progressive
lesions, 64 (9.0%) had regressive lesions,
only five (0.7%) had recurrent lesions, and
97 patients (13.6%) had lesions with neg-
ligible or no healing.
Medical, minimally invasive and major
surgical treatment
Four hundred and twenty-two patients were
treated by medical, conservative and surgi-
cal treatment; 169 patients (40.0%) showed
complete healing, 105 (24.9%) showed
partial healing, 34 (8.1%) had stable
lesions, 19 (4.5%) had progressive lesions,
five (1.2%) had regressive lesions, 47
(11.1%) had recurrent lesions, and 43
patients (10.2%) had lesions with negligi-
ble or no healing.Medical treatment only
Two hundred and eighty-six patients were
treated medically; 129 patients (45.1%)
showed complete healing, 52 (18.2%)
showed partial healing, 23 (8.0%) had
stable lesions, eight (2.8%) had progres-
sive lesions, 52 (18.2%) had regressive
lesions, 20 (7.0%) had recurrent lesions,
and two patients (0.7%) had lesions with
negligible or no healing.
Minimally invasive surgical treatment
Seven hundred and seventy-six patients
were treated with conservative surgery;
301 patients (39.2%) showed complete
healing, no patients (0%) showed partial
healing, 152 (19.8%) had stable lesions,
61 (8.0%) had progressive lesions, 231
(30.1%) had regressive lesions, no patients
(0%) had recurrent lesions, and 22 patients
(2.9%) had lesions with negligible or no
healing.
Major surgical treatment
Two hundred and fifty-two patients were
treated with major surgery; 207 patients
(82.1%) showed complete healing, 11
(4.4%) showed partial healing, eight
(3.2%) had stable lesions, five (2.0%)
had progressive lesions, no patients
(0%) had regressive lesions, 11 (4.4%)
had recurrent lesions, and 10 patients
(4.0%) had lesions with negligible or no
healing.Guided debridement
Twenty-five patients were treated with
guided debridement; 12 patients (48%)
showed complete healing, 10 (40%)
showed partial healing, no patients
(0%) had stable lesions, one (4%) had
progressive lesions, no patients (0%)
had regressive lesions, no patients (0%)
had recurrent lesions, and two patients
(8%) had lesions with negligible or no
healing.
Laser treatment
Three hundred and twenty-two patients
were treated with laser therapy; 146
patients (45.3%) showed complete heal-
ing, 18 (5.6%) showed partial healing, 81
(25.2%) had stable lesions, five (1.6%)
had progressive lesions, 33 (10.2%)
had regressive lesions, two (0.6%) had
recurrent lesions, and 37 patients
(11.5%) had lesions with negligible or
no healing.
Growth factor (PRP and BMP2) treatment
Ninety-two patients were treated with
growth factors; 75 patients (81.5%)
showed complete healing, two (2.2%)
showed partial healing, six (6.5%) had
stable lesions, no patients (0%) had pro-
gressive lesions, eight (8.7%) had regres-
sive lesions, one (1.1%) had recurrent
lesions, and no patients (0%) had lesions
with negligible or no healing.
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One hundred and sixty-one patients were
treated with ozone therapy; 93 patients
(57.8%) showed complete healing, 27
(16.8%) showed partial healing, five
(3.1%) had stable lesions, no patients
(0%) had progressive lesions, 28
(17.4%) had regressive lesions, no patients
(0%) had recurrent lesions, and eight
patients (5.0%) had lesions with negligible
or no healing.
Discontinuation of BP treatment in
addition to other treatment modalities
Three hundred and sixty-one patients
stopped BP treatment; 127 patients
(35.2%) showed complete healing, 27
(7.5%) showed partial healing, 142
(39.3%) had stable lesions, 50 (13.9%)Table 5. Summary of treatment modalities and 
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BRONJ, bisphosphonate-related osteonecrosis ofhad progressive lesions, three (0.8%) had
regressive lesions, five (1.4%) had recur-
rent lesions, and seven patients (1.9%) had
lesions with negligible or no healing.
Hyperbaric oxygen treatment
Forty-five patients were treated with
HBO; 12 patients (26.7%) showed com-
plete healing, eight (17.8%) showed par-
tial healing, two (4.4%) had stable lesions,
six (13.3%) had progressive lesions, 17
(37.8%) had regressive lesions, no patients
(0%) had recurrent lesions, and no (0%)
patients had lesions with negligible or no
healing.
Teriparatide treatment
Twenty-seven patients were treated with
teriparatide; 22 patients (81.5%) showedthe outcome variables measured with the mean 
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 the jaws; PRP, platelet-rich plasma; BMP2, bone complete healing, five (18.5%) showed
partial healing, no patients (0%) had stable
lesions, no patients (0%) had progressive
lesions, no patients (0%) had regressive
lesions, no patients (0%) had recurrent
lesions, and no patients (0%) had lesions
with negligible or no healing.
The treatment of BRONJ and the out-
come variables measured with the mean
follow-up of each treatment are summa-
rized in Table 5.
Discussion
The aim of this systematic review was to
summarize the literature concerning
patients receiving BPs, the treatments
of BRONJ, and the outcomes of these
treatments. There was high clinical het-
erogeneity among the studies included,
which is unsurprising given the differingfollow-up of each treatment.
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morphogenetic protein 2; BP, bisphosphonate.
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variations in techniques applied and com-
binations or delivery of interventions. Dif-
ferences in the search periods may explain
the higher prevalence of BRONJ in the
present review.
There are some limitations with re-
spect to the search strategy. It is possible
that eligible studies were missed despite
the extended search. Also, the grey lit-
erature was excluded because basic in-
formation such as authorship, publication
date, and the publishing body cannot be
discerned with certainty. This review did
not include searches of EMBASE, SCO-
PUS, or abstracts from dental, maxillo-
facial, and surgical conferences, which
may also have contributed to an under-
estimation of the number of reported
BRONJ cases. The continuously increas-
ing numbers of BRONJ cases since its
first appearance is apparent in this sys-
tematic review.
The occurrence of BRONJ appears to be
related to the cumulative dose, the dura-
tion of treatment, and the type of BP
used,62,155–158 with a positive correlation
for higher doses, longer durations of ther-
apy, and nitrogen-containing BPs.
Earlier studies reported that the type of
BP may play a role in the development of
BRONJ, particularly the nitrogen-contain-
ing BPs like pamidronate and zoledronate,
with a higher risk for zoledronate followed
by pamidronate.23,27,40,155,156,159–163 The
cumulative hazard of developing BRONJ
is significantly greater with zoledronate
treatment than with pamidronate or pami-
dronate plus zoledronate159,161 due to the
more potent inhibitory effect on the bone
turnover rate and the stronger anti-resorp-
tive activity of zoledronate compared to
pamidronate. Zoledronate is 10–100 times
more potent than pamidronate.164 Consis-
tent with these studies, we noted that most
patients in the publications had received
zoledronate only (58.9%) or pamidronate
only (13.9%), or zoledronate plus pami-
dronate (11.4%).
The mean duration of BP treatment was
38.2  15.7 months; this is a crucial factor
for the development of BRONJ. It has
been suggested that the development of
BRONJ requires a long period of exposur-
e.23 As reported in the literature, the risk of
developing BRONJ is related to the dura-
tion of therapy and the risk appears to be
higher after 3 years of treatment in asso-
ciation with clinical risk factors.48 Recent-
ly, Lo et al.165 reported a higher
prevalence of BRONJ (0.21%) in patients
treated with these drugs for more than 4
years, in comparison with those treated for
less than 2.5 years.Current data suggest that IV BPs are
much more frequently associated with
BRONJ than oral BPs.48,159,166 This has
led to the development of different man-
agement strategies for patients on oral and
IV BPs. This is in accordance with our
search, which showed that 83.2% of
BRONJ lesions developed following IV
BP use. The results confirm data from
other studies indicating that the preva-
lence of BRONJ is much lower in patients
on oral BPs than in patients treated with IV
BPs.167
A greater incidence of BRONJ has been
reported in patients with malignancies,
particularly those with multiple myeloma
and breast cancer.155,159–161 Our results
agree with these reports – BRONJ was
more frequently noted in patients with
multiple myeloma and breast cancer com-
pared with the prostate cancer, lung can-
cer, renal cell carcinoma, and the other
neoplasms group.
With regard to a history of invasive
dental treatment, 61.7% of the patients
had undergone a dental extraction before
the development of BRONJ. This finding
is consistent with the review by Badros
et al., which reported a significant associ-
ation between the occurrence of BRONJ
and age and a history of dental extraction
in patients with multiple myeloma treated
with IV BPs.142 In agreement with pub-
lished reports, tooth extraction in this re-
view was associated with the development
of BRONJ.18,27,156,168–170 According to
the publications in this systematic review,
BRONJ was spontaneous in 14.8% of
cases. Our findings correspond to those
of the authors reporting a higher percent-
age of so-called spontaneous cases, vary-
ing from 14.1% to 60%.18,21,23,30,40,48,70,
88,105,118,123,130,144,171–176 This may be due
to the fact that it is difficult to establish the
initiating factor in some patients.
Correlations between the occurrence of
BRONJ and specific co-medications such
as corticosteroids or chemotherapy have
been discussed.41,167,177,178 These treat-
ments may also increase the vulnerability
of the oral mucosa and reduce its nutritive
supply.27,41,174 Of the patients, 39.7%
were under chemotherapy. Moreover
24.6% used corticosteroids. In fact, corti-
costeroids and some other chemotherapy
medications possess an anti-angiogenic
effect by inhibiting vascular endothelial
growth factor (VEGF) and fibroblast
growth factor (FGF).27,41,174,179
There is considerable discussion in the
literature regarding whether ageing plays a
significant role in the development of
BRONJ. Some studies have found no sta-
tistically significant correlation betweenageing and BRONJ,180,181 whereas others
have included advanced age as a BRONJ
co-factor80,159,182; this could be related to
the physiological effects of ageing, includ-
ing inflammatory issues,183 immune dys-
function,184 a reduction in blood flow and
remodelling ability,185,186 and increased
oxidative stress.187 In fact, these features
are all implicated in the pathogenesis of
BRONJ and could explain why the disease
is not reported in young patients, even
those with other associated risk factors.188
Some authors have reported a positive
correlation between gender and BRONJ.80
It has been speculated that oestrogen ther-
apy may play a role in this correlation,
since hormonal replacement has been as-
sociated with an increased risk of BRONJ
.189 However, there is controversy regard-
ing gender as a BRONJ co-factor. Some
studies have found no statistically signifi-
cant correlation between gender and
BRONJ.159,182 The large proportion of
female patients reported in some stud-
ies1,43,48,80,127,137,190–195 could represent
a coincidence, since women take oral
BPs more frequently than males, especial-
ly because rheumatoid arthritis and osteo-
porosis are more common in women.196 In
accordance with other series reported in
the literature,172 the present review found
a high prevalence of BRONJ among wom-
en (67.2%).
BRONJ affects the mandible more often
than the maxilla. The ratio of mandible to
maxilla involvement found was 2:1. This
could be attributed to the decreased vas-
cularity of the mandible and to the existing
local conditions. This distribution is simi-
lar to that reported by other authors
.113,128,197 Only the mandible and maxilla
appear to be susceptible, highlighting their
unique nature compared with other parts
of the skeleton. The jaws are the only
bones in the human body that are in fre-
quent contact with the outside world and
are subject to repeated micro-trauma
through the presence of teeth and the
forces of mastication; moreover the turn-
over of alveolar bone is 10-fold greater
than that in the long bones.45 BRONJ
occurred more often in the mandible
(59%) than in the maxilla (27%), as also
reported by Marx et al.27 A possible ex-
planation for osteonecrosis, especially in
the mandible, might be the anti-angiogen-
ic effect of BPs198–201 and anatomical and
physiological features of the mandibular
bone that may increase the risk of an
osteonecrotic pathology.202 This action
would result in direct induction of avascu-
lar necrosis of tissue repair and may inter-
rupt the intraosseous circulation and blood
flow in the jaw.30 Furthermore, BPs can
578 Fliefel et al.also inhibit endothelial cell function201
and increase the rate of apoptosis,199 lead-
ing to a decrease in capillary tube forma-
tion.203
The management of BRONJ remains a
controversial topic. Several treatment pro-
tocols have been proposed, but there is no
general consensus with regard to many
crucial questions, such as whether or not
performing surgery is beneficial.67 Some
authors have reported that the discontinu-
ation of BPs for a variable period (1–6
months) before and after interventions
favours the surgical outcome,110,204 em-
phasizing a possible anti-angiogenic effect
on the soft tissues around the necrosis; the
removal of this effect may have a role in
healing. There may also be psychological
aspects. Patients may be stressed by the
idea of taking drugs that could have an
adverse effect on the bones.
Our results show that minimally inva-
sive surgical treatment was the most com-
monly used method for the management of
BRONJ; 767 patients were managed using
sequestrectomy, curettage, debridement,
or smoothening of bone. These results
are in agreement with those of Alons
et al.126 who treated seven patients with
sequestrectomy and curettage of the defect
with a minimum of periosteal deflection.
Mitsimponas et al.205 reported a complete
success rate of 53% in a patient group
using different surgical procedures, in-
cluding bone smoothing, incision and
drainage, ulcer excision, and closure after
debridement. Eckert et al.206 demonstrated
a 58% success rate in 24 operated patients.
The surgical procedures included resec-
tion of the necrotic bone and stable soft
tissue closure. Millesi et al.207 treated 55
patients with sequestrectomy, debride-
ment, or partial resection, with or without
osteosynthesis after 6 months, and found
an overall complete success in 50%.
Carlson and Basile103 reported high
cure rates and improved stages of disease
after surgery. They stated that performing
a segmental resection of the mandible and
partial maxillectomies with the intention
of achieving vital bone margins are of
crucial importance in the management
of BRONJ. According to Otto et al.,208
surgery may be the only curative treatment
in refractory disease. In these studies the
authors favour radical surgery. The obser-
vation of the efficacy of resection for
BRONJ has recently been reported in
the dental literature.115,134
Medical treatment is favoured in the
AAOMS Position Paper, whose authors
state that surgery should be deferred as
long as possible.45 Van den Wyngaert
et al.153 and Scoletta et al.113 have statedthat the medical treatment of BRONJ
leads to mucosal healing in 50% of cases.
However, the healing rate of BRONJ
lesions in the group studied was also sig-
nificantly associated with the stage of
BRONJ at presentation, with lower heal-
ing rates observed for high stages.153
Gomez Font et al., in their BRONJ update,
recommended a long-term antibiotic re-
gime and chlorhexidine 3 or 4 times a day.
Aggressive surgical therapies were not
considered; moreover, inadequate healing
with a lack of mucosal closing was con-
firmed.209
The application of growth factors is also
considered a treatment option because of
improving the soft and hard tissue healing.
Acting like chemotactic agents, they stim-
ulate angiogenesis, migration, prolifera-
tion, and the differentiation of stem cells
from the surrounding mesenchymal tis-
sues into bone-forming cells in the area
of injury.142,210 A new therapy for BRONJ
based on the application of recombinant
human BMP2 (rhBMP2) has been dis-
cussed and shows how growth factor ap-
plication leads to an increase in soft tissue
healing.83 Some studies have reported the
treatment of refractory cases of BRONJ
with bone resection followed by topical
application of PRP55,56,211 in which the
PRP is an autologous concentration of
human platelets and a source of different
protein growth factors. Protein growth
factors such as platelet-derived growth
factor, transforming growth factor beta
(TGF-b), VEGF, and epidermal growth
factor beta are polypeptides released from
the platelets when they are activated and
can induce paracrine effects on stimulated
cells.212–214.
Recurrent BRONJ lesions have been
managed successfully by use of a surgical
laser. Stübinger et al.151 and Vescovi
et al.146 used an Er:YAG laser for bony
debridement. The use of ozone is also
effective on avascular necrosis-related pa-
thologies and acts by stimulating and/or
preserving the endogenous antioxidant
system and by blocking the xanthine/xan-
thine oxidase pathway, active in free radi-
cal synthesis215–217; it also acts by
activating the blood circulation, increas-
ing the number of red blood cells and the
haemoglobin concentration,218 enhancing
diapedesis and phagocytosis, and stimu-
lating the mononuclear phagocytic sys-
tem.218–220
The proposed rationale behind the ben-
eficial effects of HBO therapy in BRONJ
is increased wound healing, a reduction of
oedema and inflammation, stem cell mo-
bilization, and moderation of the suppres-
sion of bone turnover by BPs.221 Recentstudies have revealed that HBO therapy
also generates reactive oxygen species
(ROS) and reactive nitrogen species
(RNS), which affect the signalling process
critical to wound healing.221,222 HBO ther-
apy may also improve inflammation and
infection around necrotic tissues by in-
creasing blood vessels, the oxygen con-
centration, and antibiotic levels in patients
with BRONJ.221,222
Teriparatide, a recombinant human
parathyroid hormone, is an osteo-anabolic
agent that has stimulatory effects on osteo-
blasts and subsequently osteoclasts, and
increases bone turnover by promoting
bone formation with positive balancing
in bone metabolism.223,224 Teriparatide
regulates bone resorption by increasing
osteoclastic activity.225 Therefore, teri-
paratide is known to have rapid and strong
stimulatory effects on bone remodelling,
even in the face of previous exposure to
BPs.226–230 The use of teriparatide on
refractory BRONJ lesions was first de-
scribed by Harper and Fung,231 who ob-
served soft tissue healing in a patient
administered teriparatide for 3 months.
Additionally, in a case study, Ohbayashi
et al.232 demonstrated bone regeneration 6
months after teriparatide therapy in a re-
fractory BRONJ patient. Ma et al.230
showed that teriparatide reverses the in-
hibitory effects of anti-resorptive drugs
such as BPs in vivo. The BPs suppress
osteoclastic activity by inducing apoptosis
of these cells and cause them to detach
from the bone surface.233
Fluorescence-guided bone resection
was introduced as an adjunctive treatment
in the surgical therapy of BRONJ to de-
termine the extent of the surgical debri-
dement.53,234
It is difficult to compare the outcomes of
the different BRONJ therapies for two
mutually non-exclusive reasons: First,
the definition of therapy success has not
been universally defined, and in particular
studies favouring medical therapy regi-
mens often consider maintaining the status
as success. Second, only a few studies
have, to date, compared the therapy out-
comes of medical and surgical treatment
in a controlled clinical manner.49
The key factors for successful treatment
have not yet been identified clearly. There
are several aspects that are likely to influ-
ence the success of surgery and could
cause progression of the disease.66 Com-
paring different studies regarding thera-
peutic success in BRONJ is made difficult
by the different definitions of success.122
Ruggiero and Drew235 considered pres-
ervation of quality of life by controlling
pain, managing infection, and preventing
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as a treatment goal. Taking this into con-
sideration, the relief of symptoms may
very well be a ‘success’ for the oncology
patient.126 Vescovi et al.236 defined ‘clini-
cal success’ as a positive result (e.g.,
transition from a higher stage to a lower
stage, complete mucosal healing), or a
minimum time span of 3 months without
clinical symptoms. With regard to the
definition of BRONJ,167 ‘clinical success’
should principally include the absence of
pain and other symptoms of oral infection,
a lack of oral or cutaneous fistulas, and an
intact mucosal covering over formerly
exposed bone.54
Comparisons between the outcomes of
different therapies are also complicated by
the inclusion of patients taking different
BPs and doing so in an uncontrolled clini-
cal manner.71
The treatment outcome is considered a
success when oral mucosal healing is
maintained without bone exposure or in-
fection and there is acceptable radiograph-
ic healing for a 12-month period after
surgery. Therefore, following patients
for at least 1 year postoperatively may
be indicated to identify the possibility of
recurrence of disease71; this is in accor-
dance with the results of our study, which
showed a mean follow-up period of
12.9  9.9 months.
Data on treatment outcomes of osteo-
necrosis of the jaw in the literature are
vague and scarce. Marx et al.27 reported
that 90% of patients were free of pain
under continuous antibiotic treatment,
but they did not specify the type of re-
sponse (complete response, partial re-
sponse, or non-response). Mavrokokki
et al.156 reported that 70% of patients were
classified as ongoing cases and that 30%
had been resolved, but there were no
details regarding partial response and
non-response. Abu-Id et al.134 recently
published the results of a multicentre
study from Germany, Austria, and
Switzerland based on questionnaires ap-
plied to 78 BRONJ patients. They reported
that 60% of their 78 patients were treated
with minor invasive surgical procedures or
medical treatment with local disinfectants
and antibiotics. The remaining patients
were treated radically by means of bone
resection up to viable bone. Thirty-eight
percent of the patients treated medically
were classified as responsive, as were 86%
of the patients treated radically.
Mucosal coverage is the main goal of
BRONJ treatment in order to prevent sec-
ondary infection. The management of
BRONJ remains controversial, and there
is no definitive standard of care for thisdisease. Non-surgical, conservative, and
minimally invasive treatment regimens
for BRONJ are considered useful to con-
trol the disease, leading to predictable
good results in cases of lower stages of
BRONJ. Further research is indicated par-
ticularly for higher stage BRONJ (refrac-
tory stage 3 lesions). BRONJ may also be
approached with new adjunctive treat-
ments such as ozone therapy, HBO, or
growth factors in order to ensure an opti-
mal patient treatment protocol. The appli-
cation of adjunctive treatments remains
an opinion-based approach rather than
an evidence-based one. Controlled studies
or clinical trials should be performed to
evaluate these adjunctive treatments for
BRONJ patients.
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 Introduction 
 In the current literature, treatment options for 
patients with established medication-related 
osteonecrosis of the jaw differ. While the fi rst 
guidelines focused on preserving the patient’s 
quality of life by controlling pain and secondary 
infection, nowadays there is a trend to a more sur-
gical approach with the aim of complete mucosal 
healing of the lesions [ 1 ,  2 ]. 
 As described in the previous chapters, a 
large variety of treatment modalities have been 
reported including conservative medical man-
agement, various types of surgery, hyperbaric 
 oxygen, and ozone and laser therapy [ 3 – 5 ]. 
In large lesions with pathological fractures, 
reconstruction with vascularized or nonvascu-
larized bone has been described, but remains 
problematic due to poor bone healing and an 
obligatory graft resorption phase, donor site 
morbidity, and infection of foreign material. 
Because bisphosphonates are often administered 
in patients with generalized bone pathologies 
and the molecules not only bind to the jaws, it is 
not unlikely that the transferred bone will either 
be affected by bony metastases or also develop 
osteonecrosis of the jaws [ 6 ,  7 ]. 
 In osteonecrotic lesions, among others, the 
lack of osteogenic precursors and a shortage 
of endothelial progenitor cells (EPCs) cause 
an insuffi cient vascular support, so that safe 
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 Abstract 
 A large variety of treatment options have been proposed for the man-
agement of medication-related osteonecrosis of the jaw in particular for 
osteonecrosis of the jaw due to bisphosphonate intake. More recently, 
regenerative concepts using stem cells from different sources and growth 
factors have been introduced for the treatment of medication-related 
osteonecrosis of the jaws. These new and innovative concepts seem to be 
promising future options in the management of osteonecrosis of the jaws. 
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 alternative therapies are needed to enhance the 
osteogenesis and vasculogenesis [ 8 ,  9 ]. 
 While tissue engineering is the branch that 
brings biology, bioengineering, clinical  sciences, 
and biotechnology together for the purpose of 
generating new tissues and organs and the devel-
opment of biologic substitutes that can restore 
and maintain normal function, a variety of 
approaches are utilized that combine the use of 
morphogens, growth factors, and cytokines, with 
scaffolds and carriers and cells [ 10 – 12 ]. 
 During the last years, the increased interest on 
stem cells allowed the evolution of new horizons 
in treatment perspectives. Stem cells are imma-
ture, undifferentiated cells that can divide and 
multiply for an extended period of time, differ-
entiating into specifi c types of cells and tissues. 
They are defi ned as cells that self-replicate and 
are able to differentiate into at least two different 
cell types, and both criteria must be present for a 
cell to be called a “stem cell” [ 13 ,  14 ]. Embryonic 
stem cells (ESCs), adult stem cells (ASCs), and 
induced pluripotent stem cells (iPSCs) represent 
the three different major types of stem cells [ 15 ]. 
 During embryonic development, embryonic 
stem cells are derived from cells of the inner cell 
mass of the blastocysts. They are pluripotent and 
give rise to all derivatives of the three primary 
germ layers. The most important and poten-
tial use of ESCs is clinically in transplantation 
medicine, where they can be used to develop cell 
replacement therapies [ 13 ,  14 ,  16 ,  17 ]. In con-
trast, iPSCs refer to adult or somatic stem cells 
that have been genetically reprogrammed to 
behave like ESC [ 18 ]. 
 ASCs are multipotent because their potential 
is normally limited to one or more lineages of 
specialized cells [ 16 ]. In addition to bone mar-
row, various tissues have been found to harbor 
mesenchymal stem cell (MSC)-like populations 
including adipose tissues, muscles, tendons, 
dental pulps, periodontal ligaments, umbilical 
cord blood, placenta, periosteum, liver, cartilage, 
synovium, synovial fl uid, spleen, and thymus 
[ 19 – 25 ]. In vitro expanded bone marrow stem 
cells (BMMSCs) may be a rich source of osteo-
genic progenitor cells that are capable of promot-
ing the repair or regeneration of skeletal defects 
when cultured in the presence of dexamethasone, 
inorganic phosphate, and vitamin C. BMMSCs 
can be induced to become osteoblast-like cells 
in vitro and form calcifi ed nodules [ 26 ,  27 ]. 
 Cell-Based Therapy in Craniofacial 
Tissue Engineering 
 The bone is the second most frequently trans-
planted tissue with increasing frequency. 
Reconstruction of craniofacial components is one 
of the most important and intricate objectives in 
stem cell-mediated regenerative medicine [ 28 –
 30 ]. The craniofacial bone has an essential role 
in supporting the adjacent soft tissue, providing 
anchoring for dental structures and providing a 
stable although fl exible framework for craniofa-
cial cartilage structures. Embryologically, most 
craniofacial bones are derived from mesenchy-
mal tissue through membranous ossifi cation [ 31 ]. 
 Facial development, including that of the 
teeth and oral cavity, is a classic act of interac-
tions by stem cells of the epithelium, craniofacial 
mesoderm, and neural crest-derived mesenchyme 
[ 32 ,  33 ]. Cranial neural crest cells (CNC) play 
an important role in development of the teeth, 
alveolar crest, and jaw bone [ 34 ]. Thus, the bio-
logically unique features of cranial neural crest 
cell-derived bone should be considered in the 
etiopathology of antiresorptive drug-induced 
osteonecrosis of the jaw. 
 Stem cell-based strategies are currently a prom-
ising approach in craniofacial bone tissue engi-
neering as they supply suffi cient numbers of cells 
that can not only form bone and associated tissues 
but also maintain bone as it undergoes turnover 
throughout life [ 12 ,  35 ]. Regenerative medicine for 
bone healing has reached the patient in the form 
of cell therapy approaches to treat localized bone 
defects or systemic diseases of the skeleton [ 36 ]. 
 Mesenchymal stem cells (MSCs) have been 
isolated from a variety of mesenchymal tissues, 
and they can differentiate into a wide array of cell 
types, including osteoblasts, chondrocytes, and 
adipocytes. They participate in regeneration of 
injured tissues in different ways. On one hand, they 
directly differentiate into tissue-specifi c cells and 
thus substitute damaged or lost cells. On the other 
hand, they indirectly infl uence  tissue regeneration 
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by secretion of soluble factors. Thirdly, they are 
able to modulate the infl ammatory response. Thus, 
they can promote vascularization, cell prolifera-
tion, and differentiation and modulate infl amma-
tory processes [ 37 ]. 
 As a result of their slower growth rate and the 
absence of telomerase activity in vitro, mesenchy-
mal stem cells (MSCs) are presumed to have a lower 
risk for tumor formation compared with embryonic 
stem cells (ESCs) [ 38 ]. This suggests that mesen-
chymal stem cells may have broader therapeutic 
applications compared to other adult stem cells. 
 Bone marrow-derived mesenchymal stem 
cells (BMMSCs) can be concentrated from bone 
marrow aspirate with different techniques. The 
FICOLL method (synthetic polysaccharide) and 
the BMAC method (bone marrow aspirate con-
centrate) are established methods for mononuclear 
cell concentration from iliac crest aspirate [ 28 ]. 
Percutaneous or intraoperative local administra-
tion of cell suspensions delivers progenitor or 
lineage-committed cells directly to the wound site. 
 Mesenchymal stem cells functional proper-
ties have been proved by several experimental 
and clinical studies using autologous BMMSC 
implants for healing, cell architecture repair, and 
recovery of local blood fl ow on injured and isch-
emic tissues for alveolar ridge augmentation and 
long bone defects [ 39 – 41 ]. 
 Autologous bone marrow or autologous 
 mesenchymal stem cells were successfully 
implanted in a number of patients to enhance 
fracture and osteotomy healing; fi ll bone defects; 
treat pseudarthrosis, bone cysts, and osteonecro-
ses; or enhance spinal fusion [ 37 ]. In a random-
ized controlled trial, it has been shown that the 
new bone formation in sinus lift procedures using 
autologous mesenchymal stem cells in combina-
tion with bovine bone mineral is equivalent to 
autologous bone and bovine bone mineral [ 42 ]. 
 Experimental and Clinical Cell- 
Based Therapy in Medication-
Related Osteonecrosis of the Jaw 
 Several authors have focused on the treatment 
of osteonecrosis of the jaw with mesenchymal 
stem cells. With the ability to induce ectopic bone 
 formation and angiogenesis, MSCs might become 
a promising treatment option for antiresorptive 
drug-induced osteonecrosis of the jaws [ 43 ]. 
 In a mouse model, a mesenchymal stem cell- 
based approach to treat osteonecrosis of the jaw 
was tested. At 2 weeks after tooth extraction, 
ONJ-like wild-type mice receiving intravenous 
infusions with mesenchymal stem cells healed 
with complete soft tissue and bone regeneration at 
the extracted alveolar socket suggesting that cell-
based immunotherapy using T regulatory cells 
(Tregs) or mesenchymal stem cells are promising 
therapeutic strategies to prevent and treat ONJ-
like lesions in wild-type mice. It is discussed that 
cell-based therapy using systemic mesenchymal 
stem cell infusions can prevent or cure antiresorp-
tive drug-induced osteonecrosis of the jaws via 
reestablishment of the immune balance between 
inhibition of T-helper-producing interleukin 17 
cells (th17) and increase in Tregs [ 44 ]. 
 In a swine model, Li et al. reported the treat-
ment of ONJ lesions with allogenic mesenchy-
mal stem cells and concluded to have discovered 
that allogenic mesenchymal stem cell-based 
infusions provide a safe and effective therapeutic 
modality for treating ONJ lesions, which sheds 
light on potential clinical applications for treating 
patients suffering from medication-related osteo-
necrosis of the jaws [ 45 ]. 
 In a case report, Cella et al. published to have 
cured a patient with refractory osteonecrosis of 
the jaw, with autologous mesenchymal stem cells 
that were aspirated from the iliac crest and trans-
planted intralesionally on a gelatin sponge carrier 
after concentration with the FICOLL method. 
This procedure allowed a clinical improve-
ment of symptoms and induced novel ossifi ca-
tion with complete remission from a stage 3 
bisphosphonate- induced osteonecrosis of the jaw 
[ 46 ]. In another case report, Elad et al. presented 
a patient with bisphosphonate-induced osteone-
crosis of the jaw, where bone marrow cells were 
resuspended in saline and injected along the 
mucosal margins of two areas of exposed bone. 
No complications were observed with consider-
able reduction in the size of the alveolar bone 
exposures following the local infi ltration of the 
hematopoietic stem cells. Complete healing of 
the lesion was achieved within a few months 
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of the procedure showing the great potential of 
hematopoietic stem cells to treat osteonecrosis of 
the jaws [ 8 ,  47 ]. 
 In our own experience, a case series of 8 
patients with refractory bisphosphonate- induced 
osteonecrosis of the jaws, the lesions was man-
aged with surgical resection of necrotic bone 
followed by mesenchymal stem cell grafting 
(Fig.  10.1a–j ). Marrow-derived cells were aspi-
rated from the iliac crest and concentrated using 
a chair-side bone marrow concentration proce-
dure (BMAC) to obtain mesenchymal stem cells. 
These MSCs were then grafted into the defect 
with autologous thrombin and a BioGide mem-
brane. In all cases bony edges were rounded, 
and the wound was closed using a three-layer 
 Fig. 10.1  ( a ) Preoperative cone beam CT of a 57-year-
old female patient suffering from bisphosphonate-induced 
osteonecrosis of the jaw in the right mandible after oral 
bisphosphonate treatment for osteoporosis due to rheuma-
toid arthritis and glucocorticoid treatment. ( b ) 
Intraoperative exposure of the osteonecrotic lesion in the 
right mandible. ( c ) Exposure of the inferior alveolar nerve 
after complete removal of the affected bone. ( d ) Puncture 
of the posterior iliac crest for sampling of 50 ml bone mar-
row aspirate. ( e ) Transfer of the bone marrow aspirate into 
the SmartPReP2 centrifuge. ( f ) The suspension is centri-
fuged for 14 min. ( g ) Close-up of the smaller of the two 
chambers of the BMAC™ kit. The white line is composed 
of mononuclear cells including progenitor cells and mes-
enchymal stem cells. ( h ) BMAC is mixed with autologous 
thrombin and inserted under a collagen membrane. ( i ) The 
defect is covered with a multiple layer technique. After 
slitting of the vestibular periosteum, the mobile part is 
quilted under the lingual mucoperiosteal fl ap. ( j ) The 
wound is closed with backstitches and a running suture 
a
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 technique. At 12–15 months follow-up, all 
patients showed satisfactory healing with no 
signs of wound infection, dehiscence, or recur-
rence of osteonecrosis of the jaw. Only one 
patient developed signifi cant complications, that 
of sepsis of unknown origin, 2 months postop-
eratively (unpublished own data).
 Growth Factors in Treatment 
of Medication-Related 
Osteonecrosis of the Jaw 
 Growth factors are soluble-secreted signaling 
polypeptides capable of instructing specifi c cel-
lular responses in a biological environment [ 48 ]. 
The specifi c cellular response triggered by growth 
factor signaling can result in a very wide range of 
cell actions, including cell survival, control over 
migration, differentiation, or proliferation of a 
specifi c subset of cells [ 49 ]. A variety of growth 
factors produced by osteogenic cells, platelets, 
and infl ammatory cells—including bone mor-
phogenetic proteins (BMPs), insulin-like growth 
factors 1 and 2, transforming growth factor-β1 
(TGF-β1), platelet-derived growth factor, and 
fi broblast growth factor 2—are functionally 
involved in bone healing. The bone matrix serves 
as a reservoir for these growth factors [ 50 – 52 ]. 
 Growth factor application to patients suffer-
ing osteonecrosis of the jaws can be considered a 
challenge because of improving the soft and hard 
tissues healing. Acting like chemotactic agents, 
they stimulate angiogenesis, migration, prolif-
eration, and differentiation of stem cells from 
the surrounding mesenchymal tissues into bone- 
forming cells in an area of injury [ 53 ,  54 ]. 
 The discovery of bone morphogenic pro-
teins (BMPs) as osteoinductive factors and the 
subsequent development of commercially avail-
able recombinant forms of BMPs have offered 
the potential to replace traditional grafting tech-
niques with de novo bone formation [ 55 ,  56 ]. 
Bone morphogenetic protein type 2 (BMP-2) 
application substituting the necrotic bone 
removal could be considered a therapeutic option 
for reconstruction of localized bone defects of 
medication-related osteonecrosis of the jaws. 
rhBMP-2 was applied using an absorbable colla-
gen sponge carrier to 20 patients who  underwent 
surgical removal of necrotic bone related to 
bisphosphonate therapy. The collagen was fi xed 
to the soft tissue by an absorbable suture. The 
postoperative controls showed an increase in the 
soft tissue healing and new bone formation of 
the treated sites [ 57 ]. 
 Some researchers have proposed also the 
use of platelet-rich plasma (PRP) in ONJ sur-
gery based on surgical debridement and recon-
struction combined with the use of platelet-rich 
plasma produced from the patient’s autologous 
blood [ 58 – 68 ]. The rationale for the employment 
h i j
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of PRP in patients affected by osteonecrosis of 
the jaws is based on the thesis that the presence 
of growth factors constitutes stimulations for 
bone healing, which is similar to physiologi-
cal healing. The growth factors in platelet-rich 
plasma might accelerate epithelial wound heal-
ing, decrease tissue infl ammation after surgery, 
improve the regeneration of bone and soft tis-
sues, and promote tissue vascularization. The 
additional advantages related to the use of this 
product are its biocompatibility and safety as an 
autologous product [ 69 ,  70 ]. 
 In a prospective study, Scoletta et al. reported 
of only one wound dehiscence after extraction 
of 202 teeth in 63 patients under intravenous 
bisphosphonate treatment. After extraction, the 
sockets were fi lled with scaffold-like autolo-
gous PRP [ 71 ]. In a case series of 25 patients 
with osteonecrotic lesions due to bisphosphonate 
intake, treatment of ONJ with a combination 
of bone resection and platelet-rich plasma was 
found to be an effective therapy that should be 
considered an alternative treatment modality for 
the management of advanced ONJ cases [ 72 ]. 
 Lee et al. also described the successful man-
agement of complications of dental implant 
surgery of 2 patients taking the oral form of 
bisphosphonates, including platelet-rich plasma 
and hyperbaric oxygen [ 60 ]. Several other stud-
ies reported of enhanced mucosal healing of 
patients with ONJ due to bisphosphonate intake 
treated with surgical removal of the exposed 
bone, platelet-rich plasma, and primary closure 
under antibiotic coverage [ 61 – 63 ,  65 ]. 
 Nitrogen-containing bisphosphonates are able 
to inhibit pyrophosphate synthase in the meva-
lonate pathway. The consequently decreased 
synthesis of the metabolite geranylgeraniol is 
believed to largely account for the development 
of bisphosphonate-induced osteonecrosis of the 
jaws. In an in vitro study, Ziebart et al. demon-
strated that geranylgeraniol can rescue the nega-
tive effect of bisphosphonates in human umbilical 
cord vein endothelial cells, fi broblasts, and 
 osteogenic cells [ 73 ]. Geranylgeraniol could lead 
to new treatment strategies for bisphosphonate- 
induced osteonecrosis of the jaws that have to be 
proven in animal studies. 
 Conclusion 
 The implementation of stem cell-based con-
cepts and the use of growth factors are promis-
ing future treatment modalities for patients 
suffering from medication-related osteonecro-
sis of the jaw. 
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6  Pathogenesis of antiresorptive drug-related 
osteonecrosis of the jaw 
RihamFliefel,SvenOtto
1 Introductory questions
In this chapter, three questions are raised and discussed:
•	 Which theories exist for the pathogenesis of antire-
sorptive drug-related osteonecrosis of the jaw 
(ARONJ)?
•	 Why are the jaw bones predominantly affected?
•	 Why can nitrogen-containing bisphosphonates and 
denosumab cause ARONJ?
2 Background
Bones are constantly remodeled through osteoblastic (bone 
formation) and osteoclastic (bone resorption) activity to 
maintain skeletal strength and integrity. However, imbal-
ance between these phenomena affects bone mineral den-
sity leading to such bone disorders as osteoporosis, Paget’s 
disease, myeloma, bone metastases secondary to cancer, as 
well as osteogenesis imperfecta and inflammatory bone loss. 
One of the recent treatments of bone disorders is the use of 
antiresorptive drugs including hormone replacement ther-
apy, selective estrogen receptor modulators, bisphospho-
nates, and denosumab, which reduce the occurrence of bone 
pain, pathological fracture, and spinal cord compression 
[1–4].
Among the antiresorptive drugs, bisphosphonates (BPs) are 
stable analogues of natural inorganic pyrophosphates [5–7]. 
They can be classified into nonnitrogen BPs, which meta-
bolically interfere with adenosine triphosphate-dependent 
(ATP) intracellular pathways, and nitrogen BPs, which in-
hibit farnesyl pyrophosphate synthase [8,9]. Denosumab is 
a new antiresorptive drug with a novel mechanism of action 
[10]. Both denosumab and bisphosphonates target osteoclasts, 
however, their effects on osteoblasts are largely indirect [11].
The mechanisms of action of BPs in bone metabolism are 
complex and multifactorial, altering the osteoclast cytoskel-
eton, stimulating apoptosis, and reducing proton-pump 
expression [12–14]. They interfere with chemotaxis and the 
attachment of osteoclast to bone together with suppressing 
mature osteoclast function by defective intracellular vesicle 
transport, which in turn prevents osteoclasts from forming 
a tight scaling zone or ruffled border required for bone 
resorption [15–17]. In addition, they inhibit recruitment, 
activation, and differentiation of osteoclast precursors [18]. 
The clinical efficacy of BPs rises from their ability to bind 
strongly to bone mineral [7]. The initial clearance of BPs 
occurs through renal excretion or adsorption to bone min-
eral extending over a period of weeks to years [19]. During 
bone resorption, the acidic pH in the resorption lacuna in-
creases the dissociation of BP from bone [20]. This is followed 
by the uptake of the BP most likely by fluid-phase endocy-
tosis [21].
Bone resorption is regulated through what is known as 
RANK/RANKL/OPG pathway [11,22]. The receptor activator 
of nuclear factor kappa-B ligand (RANKL) is a transmem-
brane and soluble protein highly expressed by osteoblasts 
[23,24]; its receptor, receptor activator of nuclear factor 
kappa-B (RANK), is located on the cell membrane of osteo-
clasts and preosteoclasts [24,25]. Increased bone resorption 
results from RANK/RANKL binding, which stimulates the 
formation, activity, and survival of osteoclasts [26]. Osteo-
protegerin (OPG) is a naturally occurring soluble, nonsignal-
ing “decoy receptor” for RANKL. Osteoprotegerin inhibits 
osteoclast activity by binding to RANKL, preventing its 
interaction with RANK [26–28]. Both RANKL and OPG are 
produced by osteoblasts [29].
Denosumab is a fully human monoclonal antibody that was 
developed specifically to interact with the RANK/RANKL/
OPG pathway [7]. By binding to RANKL, it prevents the 
maturation and differentiation of preosteoclasts in the 
extracellular environment and promotes apoptosis of os-
teoclasts [30]. It has several advantages over BPs including 
better tolerability, ease of subcutaneous injection, shorter 
half-life, and reduced incidence of nephrotoxicity, render-
ing it the drug of choice for patients with renal diseases or 
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prostate cancer [31]. In contrast to the BPs, denosumab does 
not become embedded within bone tissue [10,11]. Deno-
sumab is cleared from the bloodstream through the reticu-
loendothelial system, with a half-life of approximately 26 
days without inducing the formation of neutralizing anti-
bodies [32].
Antiresorptive drugs have serveral side effects including 
upper gastrointestinal, where nausea, vomiting, epigastric 
pain, and dyspepsia can occur after oral administration of 
drugs for the treatment of osteoporosis. Subsequently, sev-
eral cases of renal failure were reported following the use 
of intravenous BPs. A possible mechanism of renal toxicity 
was the strong affinity of the BP for metal ions and their 
tendency to form complexes and aggregates with metal ions. 
Nonspecific conjunctivitis is the most common ocular side 
effect of BPs, which usually improves without therapy and 
despite continuing treatment with BPs. Transient hypocal-
caemia with secondary hyperparathyroidism is also a side 
effect of BP administration. There is a possibility of severe 
and sometimes incapacitating bone, joint, and/or muscle 
(musculoskeletal) pain in patients taking BPs [33,34].
3 Theories for the pathogenesis of ARONJ
No potential adverse effect of antiresorptive drugs has caused 
more scientific attention than ARONJ, which ranges in 
severity from painless small areas of exposed bone, to sig-
nificant bone exposure associated with severe pain, seques-
tration, infection, fistula, or jaw fracture [35–38]. The patho-
genesis of the disease is certainly associated with many 
questions regarding the potential mechanisms underlying 
the pathophysiology [22,39,40]. Five main mechanisms have 
also been proposed: 1) impaired remodeling; 2) inhibition 
of angiogenesis; 3) local toxicity; 4) immunomodulation; 
and 5) infections. It is most likely that a combination of 
these facilitate the development of ARONJ [41]. However, 
the most cited theory to explain the mechanism suggests 
that it is caused by cessation of bone remodeling and bone 
turnover by the inhibition of osteoclasts [42]. 
Antiresorptive drug-related osteonecrosis of the jaw most 
commonly occurs in the oral cavity as the jaws are covered 
and protected only by a thin layer of periosteum and epi-
thelium against the multitude of bacteria in the oral cavity 
making it prone for infections. The alveolar bone of the jaws 
is daily remodeled with a high rate of bone turnover, and 
the presence of teeth and gum provides an easy entrance 
for bacterial infection [40, 43]. The oral structures are 
subjected to a wide variety of stresses, which may be phys-
iologic, iatrogenic, or inflammatory. The constant stress leads 
to trauma to the mucosa with exposure of bone [40]. Pro-
longed use of BPs can suppress bone turnover with accu-
mulation of microcracks resulting in decreased biomechan-
ical competence [35,44]. Bisphosphonates cause excessive 
reduction of bone turnover resulting in an increased risk of 
bone necrosis in osseous repair [45, 46]. However, this 
theory failed to explain why exposed necrotic lesions are 
rarely seen in bones other than the jaw. Antiresorptive drug-
related osteonecrosis of the jaw does not appear to occur in 
other conditions associated with reduced bone turnover, 
such as hypoparathyroidism, and in patients with reported 
ARONJ the bone turnover markers were not overly sup-
pressed [47,48]. In patients with breast cancer and bone 
metastases treated with zoledronate or denosumab, bone 
scintigraphy images suggest that the bone turnover of the 
mandible and maxilla is not overly changed when compared 
to other bones [49].
Blood supply may play a role in ARONJ as its reduction 
might lead to delayed wound healing due to the antiangio-
genic effect [50]. Antiresorptive medications may inhibit 
angiogenesis by inhibiting the formation of blood vessels, 
endothelial cells, fibroblast growth factor, and endothelial 
growth factor impairing endothelial cell (EC) functions lead-
ing to altered adhesion and migration. Furthermore, there 
is reduced proliferation, increased apoptosis, and decreased 
capillary-like tube formation in ECs that might cause bone 
necrosis [51–53]. In a study by Wehrhan et al [54], mucoperi-
osteal tissue samples from ARONJ patients under BPs and 
controls were assessed for vascularization with CD31 stain-
ing and neoangiogenesis by CD105. Although there was no 
difference in the vascularization between sample groups, 
there were significantly fewer CD105-positive vessels in 
ARONJ samples suggesting that neoangiogenesis was sup-
pressed in ARONJ patients. Histological evaluation of ARONJ 
tissue revealed decreased p63 gene expression, indicating a 
reduction in basal cell progenitors, and might lead to im-
paired healing of the oral mucosa [55]. Although BPs, beva-
cizumab, and sunitinib all have antiangiogenic effects, the 
effects of denosumab on angiogenesis is largely unknown 
[56–58]. As such, impaired vascularization may play only a 
minor role in the development of ARONJ [59].
Soft-tissue cytotoxicity might also play a role explaining 
why bone is directly exposed to the oral environment through 
teeth and periodontal ligaments [60]. Local infection and 
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blockade of bone resorption with BPs may render it difficult 
for these cells to access the pathogens, allowing the infection 
to persist. The resulting accumulation of bacterial toxins and 
inflammation-generated superoxides will promote bone 
necrosis [68]. The mechanism of ARONJ is highly related to 
immunity and infection rather than being aseptic or avas-
cular in origin [56]. It mostly follows invasive dental proce-
dures, suggesting that ARONJ likely involves a drug-related 
compromise in the bone response to invasive trauma. An-
tiresorptive drug-related osteonecrosis of the jaw often 
manifests after dental extractions but it has to be taken into 
consideration that the majority of those extractions are per-
formed due to dental infections, especially apical and peri-
odontal infections. For a direct in vivo mechanism to be 
identified, it is yet unclear whether invasive trauma by itself 
is sufficient to precipitate ARONJ in individuals treated with 
antiresorptive drugs [36,48]. Polymicrobial infection and 
periodontal disease are very likely to contribute to the de-
velopment of ARONJ as a biofilm-associated infection. Filleul 
et al [72] found out that actinomyces were present in 70% 
of all cases. Thumbigere-Math et al [73] found actinomyces-
like microorganisms in all bone specimens of patients during 
microbiological examination. In animal models treated with 
BPs, bacterial infection was sufficient enough to cause ARONJ 
[36]. Sterile inflammation alone in the soft tissues surround-
ing the jaw seems insufficient to induce ARONJ [74]. 
Treatment with antibiotics in animal models [75] and mu-
coperiosteal coverage on the day of tooth extraction in a rat 
model prevented the development of ARONJ [76].
The presence of the infectious component in ARONJ seems 
to be the most dangerous aspect. Oral pathogens should be 
prevented from reaching the bone surface, and optimum 
oral hygiene is essential. The current regimens, which con-
sist of oral antiseptics and antibiotics, are not always suc-
cessful. Ideally, treatment aims to eradicate the underlying 
infection, prevent secondary infection, stop the disease 
process, and control symptoms [77]. Traumatic intervention 
should be avoided, but where it must be undertaken, strict 
adherence is necessary. The proposed sequence of events 
in the development of ARONJ with infection could justify 
temporary discontinuation of the drug to allow recovery of 
macrophage production and function [78]. A potential scheme 
for the pathogenesis of ARONJ taking together the above 
mentioned aspects but stressing the role of local infections 
is illustrated in Fig 6-1. Infection might also be the initiating 
event for ARONJ in patients receiving denosumab as there 
is also a strong remodeling suppression and therefore only 
limited capacity to deal with odontogenic infections.
tooth extraction could result in the release of BPs into the 
local tissues. Provided that the local concentration of drugs 
is high enough, the proliferation of adjacent epithelial cells 
could be inhibited and thus slow down the healing of the 
breached mucosal barrier [61]. However, soft-tissue toxicity 
has not been reported with denosumab. Use of BPs was 
explored on a variety of cells, including gastrointestinal cells, 
cervical epithelial cells, renal cells, prostate epithelial cells, 
and oral mucosal cells [40]. Antiresorptive drugs also act on 
immunity, resulting in impairment of myeloid cell function 
[62,63], and dendritic cell [64] and T-cell upregulation [65]. 
They increase the antigenicity of cancer cells as targets and 
increase adaptive immunity. This impairment of local im-
munity with an infectious tendency may be a key element 
in ARONJ [41].
4 Special properties of jaw bones
Infection and periodontal disease are critical factors 
associated with ARONJ. However, controversy exists as to 
whether: 1) BP inhibition of bone remodeling results in 
necrosis with subsequent infection or 2) the direct toxic 
effects of BPs on the oral mucosa allow for invasion of oral 
pathogens causing infection with subsequent necrosis [66,
67]. Among all the bones, the jaw seems to be the most 
liable to bacterial infection since mucosa covering the al-
veolar bone is very thin and vulnerable and teeth easily 
become a pathway for bacteria from the outside into the 
bone. After administration, BPs accumulate in the bone and 
during physiological remodeling, osteocytes are exposed to 
BPs in bone [68]. Bisphosphonates bind to bone at neutral 
pH and are released from bone in an acidic milieu; thus, pH 
and infections might play an important role in the patho-
genesis of ARONJ. This physiologic mechanism takes place 
in the resorption lacunas during bone resorption, where 
acid pH increases the dissociation between BP and hydroxy-
apatite. To date, this well-known feature has usually not 
been brought into connection to the pathogenesis of ARONJ, 
but may prove to be the missing part in the multifactorial 
puzzle [69,70].
Aghaloo et al [71] found that necrosis of the alveolar bones 
developed after the placement of a wire ligature around the 
crown of a maxillary molar in a rat periodontal disease 
model. The results showed that periodontitis, which is pre-
sumably infection-related, can trigger osteonecrosis. When 
periodontitis occurs, inflammatory cells are recruited to the 
sites to eliminate the causative pathogens. However, the 
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Fig 6-1 Potential scheme for the pathogenesis of ARONJ.
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5 Conclusion
While various theories for the etiology of ARONJ are 
discussed, there is more and more data supporting the im-
portant role of local infections. Consequently, the jaw bones, 
especially in areas with dentoalveolar infections and surger-
ies, are mainly affected. The similarities and potential dif-
ferences between ARONJ lesions caused by BPs and deno-
sumab still have to be elucidated.
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